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Abstract
Human axillary odour is formed by the action of Corynebacteria or Stephyloccui
bacteria on odourless axilla sections. Several groups have identified axillary odorants,
including 3-methyl-2-hexanoic acid (3M2H) and 3-hydroxy-3-methyl-hexenoic acid
(HMHA), and how they are pre-formed and bound to amino acid conjugates.
However, there is currently a lack of LC-MS methodologies and no reported NMR
methods, that are required to further identify the non-volatile constituents, which
would provide further information to allow understanding of the underlying
physiological biochemistry of malodour.
This work has incorporated a three-pronged approach. Firstly, a global strategy,
through the use of NMR and LC-MS, provided a complementary unbiased overview
of the metabolite composition. Metabolites were identified based on acquired
standards, accurate mass and through the use of in-house or online databases.
Furthermore, spectra of biological samples are inherently complex, thus, requiring a
multivariate data analysis (MVDA) approach to extract the latent chemical
information in the data. Secondly, semi-targeted LC-MS/MS methodologies has been
used to identify metabolites with a common structural core (i.e. odour precursors) and
provide structural information for the reliable identification of known and unknown
metabolites. Finally, a targeted LC-MSIMS method provided an increase in
specificity and sensitivity to accurately quantify known metabolites of interest (odour
precursors).
Initially, all methodologies were developed through the use of either an artificial
sweat matrix (global strategy) or through the use of synthetic standards (semi-targeted
or targeted strategy). The sample complexity was then increased by applying the
methodologies to an ASG5 apocrine cell line, in order to provide further knowledge
into apocrine cell metabolism and to identify whether there could be any potential
male or female differences due to differences in circulating hormones. Changes in the
cell metabolism were identified, and both the NMR and LC-MS data could
differentiate between control, tamoxifen- and J3-estradiol-treated. However, it is
difficult to attribute these changes to specific pathways, as these hormones or the
vehicle used (ethanol) are likely to produce a ripple effect across the cell's
metabolism. Nonetheless, NMR spectroscopy quantified 25 metabolites with lactate
being the most abundant at 19.1 mM, while HILIC-MS could detect a range of lipids,
nucleotides, amino acids, fatty acids and vitamins.
The methodologies were then applied to human apocrine sweat collected from six
volunteers across five days. NMR spectroscopy was able to identify 25 and quantify
19 metabolites, with lactate being the most abundant at 13.2 mM. LC-MS/MS readily
identified 12 amino acid conjugates with HMHA being the most abundant.
Furthermore, a possible 20 unidentified conjugates were detected (LC-MSIMS semi-
targeted methodologies) as well as putatively identifying 473 metabolites (LC-MS
global methodologies). MVDA techniques such as principal component analysis
(PCA) illustrated that intra-individual variation was greater than inter-individual
variation, as well as secretions from both the left and right arm being consistent with
one another. Moreover, MVDA illustrated the complementary nature of both NMR
and MS, as the data acquired with the two types of instrumentation showed the same
trends, even though these trends were based on different subsets of metabolites.
The work presented herein, has successfully used a number of analytical technologies
to investigate metabolite content of human apocrine sweat. It has been shown that a
number of complementary techniques and multivariate analysis can provide a
valuable insight into the underlying physiology of malodour.
This work was funded by BBSRC and Unilever (Port Sunlight, UK).
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Chapter 1
1 Introduction
1.1 Metabolomics
Metabolomics is the global study of all the naturally occurring low molecular weight
molecules, called metabolites, in biological samples such as cells, biofluids (e.g. urine
and blood) or tissues. These low molecular weight molecules, which make up the
'metabolome', are derived from the interaction of the genome with its environment
and are not merely the end products of gene expression, but also form part of the
metabolic status of a biological system.
When 'metabonomics' was first introduced it was defined as "the quantitative
measurement of the time related multi-parametric metabolic response of living
systems to pathophysiological stimuli or genetic modification" (Nicholson et al.,
1999). Whereas metabolomics has been described as "a comprehensive and
quantitative analysis of all metabolites" (Fiehn, 200 I). These terms are often used
interchangeably, although groups adhering to these definitions tend to adopt the use of
'metabolomics' to discuss work on simple cell systems and intracellular metabolite
concentrations and 'metabonomics' for the analysis of products of non-enzymatic
reactions which interact with and influence metabolite formation (Daykin and
Wulfert, 2006). However, it will be up to the reader to distinguish between those
definitions. Both terms claim superiority, though ultimately it will be left for the user
community to decide. The term metabolomics will be employed here with the
realization that either term may be used interchangeably.
As the definition of the metabolome above suggest, in a metabolomics experiment the
ultimate goal would be to capture and quantify all the metabolites in a cellular system
simultaneously without pre-selecting a specific pathway. However, metabolites
consist of a diverse set of chemical (molecular weight, polarity, solubility) and
physical (volatility) properties. Moreover, the metabolome extends over a wide
concentration range, which is estimated to be between 7-9 magnitudes of
concentration (pM-mM) (Dunn and Ellis, 2005). This diversity means that no one
analytical technique is capable for all investigations. Thus, a number of strategies are
employed, as listed below, with nuclear magnetic resonance (NMR) and mass
spectrometry (MS) coupled to chromatography, being the most prevalent analytical
techniques (Dunn et aI., 20 11b): -
• Metabolomics, initially defined as the comprehensive analysis of the entire
metabolome. The term is now used to describe one or more of the strategies
defined below.
• Metabolite profiling, the holistic study of the metabolite complement of a
biological system, often employing multiple analytical platforms, to
encompass a wide coverage of the metabolome.
• Metabolic footprinting, analysis of the extra-cellular metabolome which is
composed of metabolites consumed/not consumed from the environment or
metabolites secreted from the intra-cellular volume.
• Metabolite target analysis, quantitative analysis of a small number of
metabolites related to a specific metabolic reaction or pathway, for example; a
particular enzyme system that would be affected by abiotic or biotic
perturbation.
Whilst these strategies are not universally accepted, they are continuously evolving.
Hence, there can be overlap in their definitions; however, the above classification
illustrates the options available for monitoring the metabolome (Dunn and Ellis, 2005;
Hollywood et al., 2006).
Although metabolomics is complementary with transcriptomics and proteomics, it
also has certain advantages. In particular, the metabolome is further downstream from
gene to function, thus, any change in cell physiology (resulting from gene deletion or
over expression) are amplified through the hierarchy of the transcriptome and
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proteome (Goodacre et al., 2004). It is also important to highlight those factors other
than gene expression or single nucleotide polymorphisms, which can affect the
system biology view of an organism; environmental factors such as diet, age, sex,
ethnicity, lifestyle, and microfloral populations all have large influences and these
factors need to be deconvolved (Lindon et al., 2004). Hence, metabolic fluxes are not
just regulated by gene expression but by both post-transcriptional and post-
translational modifications and as such, the metabolome can be considered closer to
the phenotype (Hollywood et al., 2006).
Metabolomics has already been widely employed in the study of toxic insult (Lindon
et al., 2003b; Nicholson et al., 2002), the study of disease and disease models
(Brindle et al., 2002), as a means of discovering novel biomarkers for early disease
detection or providing new drug targets as well as providing insights into the disease
process itself. Furthermore, metabolomics is increasingly being applied to the study of
healthy individuals (e.g. HUSERMET project'), which aims to provide a metabolic
'reference map' of the normal population against which data from other studies can be
drawn against. Currently, the samples most commonly analysed are plasma (Daykin
et al., 2002; Lenz et al., 2003; Nicholson et al., 1983; Zelena et al., 2009) and urine
(Connor et al., 2004; Daykin et al., 2005; Gika et al., 2007), which are considered to
be readily accessible and minimally invasive. However, analysis has been performed
on other biofluids such as cerebrospinal fluid (Holmes et al., 2006; Sweatman et al.,
1993), seminal fluid (Lynch et al., 1994; Spraul et al., 1994b), saliva (Takeda et al.,
2009), and eccrine sweat (Harker et al., 2006) as well as tissues and tissue extracts
(Dunn et al., 2011a; Xu et al., 2009).
1.2 Application of Techniques
The first requirement for metabolomics analysis is to have techniques available that
are as comprehensive as possible. This is especially important, as metabolites are
heterogeneous in nature, thus, isolating and measuring them all together ('true
metabolomics') is extremely difficult. For practical reasons this is never achieved,
hence, most metabolomic studies are really 'metabolic profiling' of a subset of
I http://www.husermet.org/
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chemical classes (Kell, 2004). Indeed, specific platforms are not a prerequisite for
metabolomic studies, so in theory, any technique capable of generating
comprehensive data in a relatively short time frame can be used as a powerful means
of generating multivariate metabolic data (Robertson, 2005). Thus, the choice of
analytical tool is based on the level of chemical information required and the
appropriate time frame in which the data must be obtained. However, one must
remember that there will be introductions of chemical bias with respect to the method,
which are highlighted in Table 1.1.
Table 1.1 Consideration for metabolomics analysis. Reproduced with modifications (Hollywood et al.,
2006).
Consideration Approach Comments
Chemical information MS
NMR
Chromatography
(GC, HPLC, eE)
FT-IR, Raman
Chemical bias GC-MS
LC-MS
NMR FT-IR, Raman
Speed Chromatography
(GC, HPLC, CE)
NMR
ESI-MS
FT-IR
MSn will provide some structural information. FT-
fCR-MS can generate empirical formulae for mlz
<500.
Gives detailed structural information, particularly
using 2-D NMR of isolated metabolites.
On its own will not generally lead to metabolite
identification. However, coupled with MS and NMR
is very powerful for analyte identification.
Provides limited structural information, but useful
for identification of functional groups.
Solvent extraction bias: non-polar versus polar
analytes. Need for chemical derivatization.
Solvent bias means it is usually more applicable to
polar compounds (HILlC) or non-polar compounds
(reverse phase CI8 or C8 columns).
Biased by concentration, available functional groups
and where they resonate in the spectrum.
Very useful for separation but typically takes 30
min.
Few minutes to hours. Depends on the strength of
the magnet, sensitivity can be improved with cryo-
probes.
1-3 min flow-injection (direct infusion) mode.
10-60 s.
The two most information-rich techniques that otTer atom-specific molecular
structural information are MS and NMR. The resolution, sensitivity and selectivity of
MS based techniques can be enhanced through coupling to gas chromatography (GC)
or liquid chromatography (Le). Furthermore, hyphenating individual systems, LC-
NMR-MS, can maximise the information obtained, since the NMR will yield
structural information and the MS can determine the mass of each component.
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NMR spectroscopy has some specific advantages in the area of metabolomics over
other analytical methods discussed in Table 1.1 and these are highlighted in Table 1.2.
This is typically the case in regards to analysing biofluids, as it is rapid, non-
destructive, requires little or no sample preparation and uses small sample sizes. NMR
is based on the fact that nuclei such as 1H, 13C and 31P can exist at different energy
levels due to the differences in nuclear spin, which can be measured by applying an
external magnetic field. This means a comprehensive profile of metabolite signals can
be produced without the need for pre-selection of measurement parameters or the use
of separation or derivatisation procedures (Lindon et al., 2004). Thus, the sample is
left unperturbed, allowing rapid analysis of many biochemical molecules
simultaneously. Moreover, the non-destructive nature of NMR is particularly useful
when further analysis is required for identification of unknown metabolites or when
using hyphenated techniques such as LC-NMR-MS (Corcoran and Spraul, 2003);
unlike LC-MS where the sample is destroyed after analysis and derivatisation and
optimisation procedures can often be expensive and time consuming. More recently,
the technique of magic-angle spinning, where the samples are spun rapidly at 54.70
relative to the applied magnetic field has opened up the possibility of applying
metabolomics to tissue samples (Lindon et al., 2009; Sitter et al., 2009). This would
serve as a tool for linking biofluid changes to the mechanism of action in target
tissues, particularly when products of metabolism dominate changes in the biofluids
(Robertson, 2005). Further technological advances that have improved the resolution
and sensitivity of NMR includes the introduction of cryogenically cooled probes
whereby the magnet is super-cooled with cryogenic liquid. This enables the thermal
noise of the system to be reduced, thereby, improving the signal-to-noise ratio by
approximately four fold (Robosky et af., 2007). This also enables smaller sample
volumes to be measured or allows measurements of fixed sample concentrations with
a weaker magnetic field strength, which will be more commercially affordable
(Kovacs et af., 2005). In comparison, MS also offers a number of advantages as
highlighted in Table 1.3. These include an increase in sensitivity and when
hyphenated with LC, can detect hundreds or thousands of metabolite features in a
given sample as well as providing metabolite identification. Nonetheless, one thing is
clear, these two complementary approaches (MS and NMR) will provide information
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on different sets of metabolites, and integration of both techniques will provide a
more comprehensive characterisation.
Table 1.2 Summary of the main features of IH NMR Spectroscopy. Reproduced with modifications
(Daykin and Wulfert, 2006).
Feature Comments
Selectivity
Non-invasive
Speed
Sample volumes
Sample preparation
Dynamic information
Structural information
Reproducibility
Sensitivity
No need for pre-selection of analytical conditions based on the chemical
properties of the analyte, or postulation of the metabolites affected by a
disease toxicological process.
NMR spectroscopy is non-invasive, non-destructive and non-equilibrium
perturbing, thus, allowing subsequent analysis of a sample with other
techniques.
A typical single IH NMR biofluid spectrum is obtainable in <10 minutes,
thus, can allow> 100 samples/day.
With standard NMR tubes, a total volume of 600 III is required for routine
spectroscopy, or 5 III for micro-volume NMR probe.
Minimal sample preparation for 'global' metabolite profiling. Only the
addition of deuterium oxide is required for analysis. However, with complex
components (biofluids) physical separation maybe used to simplify spectra.
Information can be obtained on dynamic biochemical processes in complex
matrices and molecular interactions such as protein-ligand binding.
Data provides qualitative structural information that can also be quantitative
with addition of internal standards at known concentrations.
NMR spectroscopy is an inherently reproducible analytical method.
Inherently insensitive technique, realistically detection limits remain in the
uM levels for complex samples such as biofluids, though this is improving
with cryoprobes and increased field strength magnets.
Feature
Table 1.3 Summary of the main features ofLC-MS.
Comments
Selectivity
Invasive
Speed
Sample volumes
Sample preparation
Dynamic information
Dynamic range
Structural information
Identification
Reproducibility
Sensitivity
Size and cost
Dependent on the column, polar compounds (HILlC) and non-polar
compound (CISor Cs).
Biological fluids (minimally invasive) or tissue samples need to be collected
prior to analysis. The sample is destroyed upon analysis.
LC-MS typically around 30 min per sample, though, DIMS -1-3 min per
sample.
Typically 5 IIIper injection.
Derivatisation generally not needed. Requires sample extraction, followed by
evaporation (overnight) before reconstitution. Also, pooled samples are
required to generate QC samples for quality assurance. Targeted
methodologies generally require the addition of internal standards.
Post-translational modifications and single nucleotide polymorph isms in
proteome analysis, structure elucidation, metal complex and disulphide bond
interactions.
Depending on mass analyser, can be between 104_106orders of magnitude.
Depending on the mass analyser, can provide fragmentation profiles as well as
empirical formula. Data can be both qualitative and quantitative.
LC-MS libraries are not as robust as GC libraries, thus, can be complex.
Dependent on sample matrix, typically 120 injections per new column.
Typically sub picomole concentrations when using targeted methodologies.
Relatively small and cheaper to maintain (ca. NMR).
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1.3 NMR Background and Theory
Since the introduction ofNMR spectroscopy by Rabi and Breit (Breit and Rabi, 1931;
Rabi, 1937) and its further development by Bloch and Purcell (Bloch et al., 1946),
NMR spectroscopy has become an invaluable tool for chemists and structural
biologists and has increasingly been used in metabolic profiling over the last two
decades.
NMR spectroscopy is based on the magnetic properties of the atomic nuclei. Many
nuclei (most commonly IH, "c, 19F and 31p) possess a property described as spin,
which makes the nuclei behave like magnets, i.e. possesses a nuclear magnetic
moment (P) described by the magnetogyric ratio (l') for each particular nucleus. The
nuclear spin is quanti sed and is described by the nuclear spin quantum number I,
which has values of 0, ~, 1, 1~, etc. in units of h/Ix, where h is the Plancks constant.
The actual value of the spin depends on the atomic number and mass number of the
nucleus. However, only atoms with odd mass numbers, for example; IH, will be
considered.
A nucleus of spin 1 has 21 + 1 possible energy levels, which are defined by the
magnetic quantum number mi, which has values of -I, -I + 1,... , 1- 1, I, i.e. for a
nucleus of spin ~, m, = +~ or -~. There is no difference in energy between nuclei
spinning in different directions. However, in the presence of an external magnetic
field (Bo), the magnetic dipoles align with or against the external magnetic field
resulting in an energy difference between m, = +~ and -~ spin states (see Figure 1.1).
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E2 (Opposed to the external
magnetic field)
El (Aligned with theextemal
magnetic field)
Figure 1.1 Schematic representing the splitting of nuclear spin states in the presence of an external
magnetic field.
The energy of this interaction is proportional to J.I. and Bo and is explained in Equation
1.1.
Equation 1.1
The difference between these energy levels increase with an increase in Bi: The
relative distribution of these populations is described by Boltzmann distribution
(Equation 1.2)
Equation 1.2
where N is the fraction of the population of nuclei in each energy state, T is the
temperature, and k = Boltzmann constant (1.38x 10-23 J k-I). The majority of the spins
occupy the lower level, resulting in a weak net magnetisation aligned along the axis of
Bo. It is this weak net magnetisation that is measured in NMR spectroscopy. The net
magnetisation will start to precess around the direction of the Bo (also termed as the z-
axis) at the Larmor frequency (vo) as depicted in Figure 1.2.
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Figure 1.2 Schematic to illustrate precessional orbit. The vector ~ of the magnetic moment precesses
in a static field with the Larmor frequency Vo about the direction of the magnetic vector Bo.
A particular nucleus eH, "c etc.) resonates at a characteristic frequency, i.e absorbs
radio frequencies (RF) within a certain range, for example: IH resonance frequency is
100 MHz. By applying RF pulses (also termed BI) 900 to the z-axis at exactly the
frequency of the nucleus, the net magnetisation can be flipped from the z-axis into the
x-y plane, thereby creating an observable signal. Once the RF pulse is removed, the
perturbed spin system will begin to relax back towards its equilibrium condition in the
z-axis. The emissions from the net magnetisation decay are recorded by the
spectrometer as a function of time in the form of free induction decay (FlO). The
signal is then Fourier transformed to obtain the spectrum in the frequency domain.
For a more detailed description of NMR spectroscopy, a number of books are
available (Abraham et al., 1988; Claridge, 2008; Keeler, 2010).
1.3.1 ID IH NMR Spectroscopy
ID IH NMR spectrum contains chemical shift and J-coupling information for each
proton in a molecule, which are indicative of the chemical environment (i.e. number
of spin active neighbours, connecting bonds and geometrical relationships) and is
independent of the applied field strength. Interpretation of this information is used for
structural identification of compounds.
9
The chemical shift is a combination of the Bo and the magnetic field at the nucleus;
with the difference between these two termed nuclear shielding. Each chemical
environment will precess at a slightly different frequency, giving rise to different
signals in the spectrum, with an increase in chemical shift values resulting from more
electronegative groups. Typically, chemical shift is always measured against a
suitable reference, often trimethylsilyl [2,2,3,3-2H41 propionate (TSP, cS = 0), and is
defined as: -
y -y
s: sample reference 106( )
u= x wm
oscillator frequency (Hz)
Equation 1.3
Where Vreference and Vsample are the resonant frequency of their respective nuclei. This
definition allows the resonance frequency of a signal to be expressed independently of
the field strength. The chemical shift is expressed in parts per million (ppm) with the
range being dependent on the nucleus being monitored, for example: 1H NMR range
-10 ppm.
J-coupling is the peak splitting pattern between adjacent nuclear spins due to the
influence of bonding electrons or two nuclei in close proximity in which they interact
with the spin-state of its neighbour. This is governed by the n number of equivalent
coupled nuclei, each of spin 1= Y2, where the multiplicity of the signal will be split n
+ 1 times. The relative intensities of split peaks will be governed by Pascal's triangle,
for example: a triplet has intensities of 1 : (I + I) : I, and a quartet has intensities of I
: (1 + 2) : (2 + I) : 1. The distance between each of the signals is measured in Hertz.
1.3.2 2D NMR Spectroscopy
Biological samples produce complex IH NMR spectra, often with heavily overlapping
peaks in 3-4.5 ppm region. Thus, 2D NMR experiments (Table 1.4) can be used to
increase spectral dispersion in the second dimension, allowing separation of
overlapping peaks. Furthermore, 2D NMR experiments can be used to provide
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unequivocal identification by obtaining information from correlations between
homonuclear eH-IH) and heteronuclear (IH_13C) coupling.
In comparison to 1D 1H NMR spectra, where the signal is obtained as a function of
time, 2D NMR spectra, the signal is recorded as a function of two time variables,
denoted as FI and F2, with the resulting data Fourier transformed twice to yield a
spectrum which is a function of two frequency variables. 2D data acquisition can be
considered as an extension of aID NMR experiment. Initially, the sample is excited
by an external magnetic field, which is allowed to evolve for a specific duration, Fl.
Further pulses then excite the nuclei, which is known as the mixing time, transferring
the excitation to another nucleus, where the FID is recorded as function of F2 for each
value of Fl. The data is presented as a contour plot, where the interactions of the
nuclei during the mixing time will result in diagonal cross- peaks arising from through
bond (scalar) or through space (dipolar) interactions.
Table 1.4 Summary of NMR experiments, which can be useful for assigning peaks in the 'H NMR
spectra of complex mixtures (Aue et al., 1976; Bax and Davis, 1985; Braunschweiler and Ernst, 1983;
Cloarec et al., 2005; Lindon et al., 1996; Nagayama et al., 1980; Pullen et al., 1995).
Correlation Spectroscopy
The simplest type of 20 NMR experiment. It is used to establish
connectivity between protons in a molecule or help simplify a(COSY)
spectrum of a complex mixture.
Total Correlation Spectroscopy Similar to COSY, but in theory gives a total correlation of all
(TOCSY) protons in an unbroken spin system.
Takes advantage of the multicolinearity of the intensity variables
Statistical Total Correlation in a set 'H NMR spectra to generate a pseudo-2D NMR spectrum
Spectroscopy (STOCSY) that displays the correlation among the intensities of various
peaks across the whole sample.
J-Resolved Spectroscopy Used to establish the multiplicity of peaks in regions of heavy
(J-Res) spectral overlap (particularly useful for sugars).
IH_IlC Heteronuclear Single Used to establish correlation between l3C chemical shifts and 'H
Quantum Coherence chemical shifts of compounds and hence lead to identification of
Spectroscopy (HSQC) compounds.
Used to simplify NMR spectra by physical separation and
HPLC-NMR-MS provide simultaneous mass spectra in the same chromatographic
run. In theory it can be less labour intensive than off-line
separation followed by NMR.
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1.4 Mass Spectrometry
Mass spectrometry was developed over a century ago by Thompson and Aston, which
has been recently reviewed (Griffiths, 1997). In the period since, many advances have
been observed into what it is today, a highly sensitive tool that is capable of analysing
small and large molecules. The basis of a mass spectrometer is the measurement of an
ion's mass-to-charge ratio (mlz). A mass spectrometer is made up of three main
separate systems: the ion source, the mass analyser and the detector. Ions are
generated by inducing either the loss or the gain of a charge from a neutral species.
Once formed, the ions are electrostatically directed into the spectrometer where they
can be separated according their mlz and finally detected. The result of ionisation, ion
separation and detection is a mass spectrum that can provide molecular weight and
structural information. For a more detailed description of MS, a number of books are
available (Hoffmann and Stroobant, 2001; McMaster, 2005; Siuzdak, 1996).
1.4.1 Electrospray Ionisation
Electrospray ionisation (ESI) is the most common ionisation method used in LC-MS
analysis for the production of gaseous ions from a liquid solution and has been
described in several reviews (Gabelica and De Pauw, 2005; Gaskell, 1997; Kebarle
and Verkerk, 2009). However, a number of other ionisation modes can be employed,
such as electron impact (GC-MS), chemical ionisation (GC-MS) and APC! (LC-MS),
with the latter two being less frequently used.
ESI is considered as a soft ionisation technique that results in little fragmentation and
is generally suited to metabolites of high polarity. The Electrospray can be considered
as a fine spray of highly charged droplets, which is generated by applying a strong
electric field (typically +4 kV in positive ion mode and -4 kV in negative ion mode)
under atmospheric conditions to the capillary tip, in which the eluent passes through.
Assuming a positive potential is applied to the capillary tip, positive ions will
accumulate at the tip to form a 'Taylor cone' which continuously produces positively
charged droplets that are directed towards a counter electrode of lower potential, as
depicted in Figure 1.3. Heated dry gas (typically nitrogen) is also injected coaxially in
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order to promote solvent evaporation. As the solvent evaporates, the droplets reduce
in size, resulting in an increase in charge density on the droplets surface. This
continues until the so called 'Rayleigh limit', where 'Coulomb fission' occurs,
resulting from the mutual repulsion between like charges exceeding the surface
tension of the droplet. As the evaporation proceeds, the progeny droplets also undergo
fission, which is repeated until a singly or multiply charged ion is produced, which is
then directed into the MS. Two models have been suggested for the generation of gas-
phased ions: the ion evaporation mechanism proposed by Iribarne and Thomson
(Thomson and Iribame, 1979) and the charged residue mechanism proposed by Dole
(Dole et aI., 1968). Though the ESI mechanism is still in debate, it is generally
accepted that small ions are produced from the ion evaporation mechanism and larger
molecules such as globular proteins are produced via the charged residue mechanism
(Gabelica and De Pauw, 2005).
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Redutlion
Electrons
High Voltage
PO'IYer Supply
droplet
fission at
Rayleigh
limit
formation of
desolvated ions
by further droplet
fission and/or
ion evaporation
Figure 1.3 Schematic representation of the generation of an electrospray and droplet formation in
positive mode (modified from www.waters.corn).
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1.4.2 Mass Analysers
Mass analysers scan or select ions over a particular mass range. The key feature of all
mass analysers is their measurement of mlz, which for a protonated molecule can be
described as: -
mlz = [M + nH] / nH
Where
mlz - mass to charge ratio
M - molecular mass
nH - number of protons
However, other species such as sodium, ammonium or potassium adducts can also
form. Furthermore, if the ion is multiply charged then the mlz will be significantly
less than the actual mass. Multiple charging and the formation of adducts can yield
many peaks that correspond to the same metabolite, which can make data analysis
complex. Mass analysers have variations in their capabilities, such as accuracy,
dynamic range and resolution, as summarised in Table 1.5. The resolution of a mass
analyser is defined as the ability to distinguish between ions of different mlz ratios.
Thus, greater resolution corresponds directly to the increased ability to differentiate
ions (Siuzdak, 1996). The most common definition for resolution is given by: -
Resolution = M / ~M
where M and ~ correspond to mlz and full width half maximum (FWHM)
respectively. For example, an mlz of 500 and FWHM of one will have a resolution
equal to 500. High resolution mass analysers allow separation of an ion's individual
isotopes rather than a weighted average of all isotopes of each constituent element of
the molecule, thereby, producing narrow peaks allowing more accurate determination
of its position. Thus, the resolving power of the mass analyser to a certain extent
determines the accuracy of the instrument.
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1.4.3 Quadrupole
Quadrupole mass analysers comprise four parallel rods with a fixed direct current
(which can be positive or negative) and a superimposed radio-frequency (RF)
potential being applied on opposing rods. The field on the quadrupoles functions as a
mass filter by determining which ions are allowed to reach the detector. Ions entering
this region will oscillate depending on their mlz ratio and depending on the applied
radio frequency, only ions of a particular mlz will pass through. All other ions will
have an unstable flight, causing the ions to be lost via contact with the rods.
1.4.4 Ion Trap
An ion trap analyser can conceptually be considered as a quadrupole bent on itself in
order to form a closed loop, consisting of a ring electrode and two ellipsoid end caps
that form a chamber. Ions with different masses entering the chamber are trapped
together by an electric field and selectively expelled according to their mass by
increasing the voltage on the ring electrode. There is a finite volume and capacity for
the ions which limits the dynamic range, especially when analysing complex matrices.
Furthermore, MSIMS fragmentation experiments are limited; for example, neutral
loss scanning or precursor ion scanning cannot be conducted due to the ion trap being
time-dependent rather than space-dependent, like quadrupoles. However, due to the
structural similarities to quadrupoles, they are often hybridised (often called linear ion
traps) to incorporate the functionalities of both, allowing on-the-fly experiments
which would not be possible with either alone.
1.4.5 Time-of-Flight
Time-of-flight (TOF) is based on accelerating a set of ions to the detector
(predetermined distance) with the same amount of kinetic energy, whereby the
resulting velocity is characteristic of their mlz ratio. The smaller ions reach the
detector first because of their greater velocity. More recent TOF instruments are
combined with reflectors and ion pushers to further improve mass accuracy and
resolution.
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1.4.6 Orbital Trap
The orbitrap is a mass analyser that dynamically traps ions in an electric field formed
between a central spindle electrode and two bell-shaped outer barrel electrodes (Hu et
a!., 2005; Makarov, 2000). Electrostatic and centrifugal forces cause the ions to
oscillate in both the axial and radial directions. The axial frequency is used to derive
the mlz ratio because it is independent of the initial properties of the ions. The time
domain transients are detected by the outer electrodes and converted to mass spectra
through Fourier transformation. The orbitrap provides a higher mass resolution than
most time-of-flight instruments (-10 000) and approaches that of FTleR (-100 000),
to ensure higher mass accuracy and to enable confident discrimination between co-
eluting, isobaric compounds in complex mixtures. The orbitrap analyser has also been
coupled to a linear ion trap, allowing high resolution spectra while simultaneously
conducting data-dependent MS/MS in the ion trap to aid identification of unknown
metabolites (Hogenboom et a!., 2009) as MSn alone is not adequate for metabolite
identification. A limited number of studies have reported the use of linear ion orbitrap
in metabolomic analysis of microbes (Herebian et al., 2009b), plants (Herebian et al.,
2009a), and animals (Dunn et al., 2008; Zhang et al., 2009).
1.4.7 Hybrid Instruments
The power of a given mass analyser can be increased by coupling to it another of the
same or different type to obtain desirable performance characteristics. For example,
QTOF or a hybrid quadrupole linear ion trap (QqQLit) (also referred to as QTRAP)
mass spectrometer systems have special advantages in MS/MS studies, such as
providing structural elucidation of metabolites. In the case of the QTOF. accurate
mass measurements in the TOF can be performed on precursor or product ions. The
QTRAP has the standard configuration of a QQQ mass spectrometer; however, Q3
can be operated as a linear ion trap on demand. This enables a number of scan
functions; product ion scanning, precursor ion scanning (PI), natural loss scanning,
and multiple reaction monitoring (MRM) as depicted in Figure 1.4. In addition to
these scan functions common to a QQQ; the linear ion trap also includes Enhanced
18
MS (EMS), Enhanced Product Ion (EPI), MS3, Enhanced Resolution (ER), Enhanced
Multiply Charged (EMC), and Time Delay Fragmentation.
Selected Reaction Monitoring
1- II-EEl I -~ I
Selected Selected
Precursor mlz Fragment mIz
Product Ion Scan
I-II-€II/I
ScannedSelected mIz
Precursor Ion Scan
Scanned Selected mlz
Neutral loss Ion Scan
Selected mIz = a Scanned mlz = x-a
Figure 1.4Main MSIMS scan functions offered in tandem mass spectrometry.
The definitions of these scans are as follows: MRM (also referred to as single reaction
monitoring (SRM)) consists of monitoring a fragmentation reaction, in which Ql and
Q3 are focused on selected masses. PI scanning consists of selecting a common
fragment to monitor in order to determine the precursor ions. All the precursor ions
that produce ions with the selected fragment mass in Q3 will be detected. EPI is
generally coupled to an information dependent acquisition (IDA) function, whereby if
the detected analyte signal meets a certain criteria (i.e. signal intensity), Ions
transmitted to Q3 are accumulated and scanned out to produce full ion spectra.
19
1.5 Multivariate Data Analysis
Multivariate analysis (MVA) can be broadly thought of as the application of
mathematical and statistical methods for the aid of pattern recognition (PR) in
chemical numerical data (Lindon et aI., 2004; Robertson, 2005). Metabolomics data,
by definition, is multivariate since there are multiple measurements per sample, which
typically exhibit correlated traits. Thus, MVA or PR is necessary for the investigation
of such data (for example, spectra obtained from IH NMR spectroscopy or mass
spectrometry), due to the fact that visual interpretation is impractical and the user will
often miss the correlations between measurements, which will greatly reduce the
amount of information that can be extracted from the dataset. Currently, the PR
strategies typically pursued in metabolomics fall under the heading of 'unsupervised'
and 'supervised', in order to generate the models depicted in Figure 1.5. Indeed, the
general aim of PR is to classify an object or predict the origin of an object, based on
the inherent patterns in a set of experimental measurements or descriptors in a way
that will allow biological interpretation (Lindon et aI., 2004; Lindon et aI., 2003a).
Like other 'ernie' data, patterns provide one level of information, but the spectra can
be drilled down to obtain the identification of individual components within the
sample mixture (Robertson, 2005). Thus, MVA is an essential tool for investigating
such data. However, there are obvious cost implications in terms of instrument time
and 'man-hours' for the analysis of the data obtained. Though, through computational
advancement in both hardware and software, these methods can now be achieved in a
reasonable time frame.
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As mentioned previously, metabolomics data are essentially multivariate. Thus, the
starting point for data analysis is a single matrix N x D, where N is the number of
samples (either biological or technical replicates) and D is the number of metabolites
or variables. In the case of NMR data, the variables are often the chemical shift
values, while for MS data this is most commonly represented as mlz. Each
independent variable may be regarded as constituting a different dimension, thus, for
n variables, the object resides at a unique position in n-dimensional hyperspace
(Goodacre et aI., 2007). Thus, the underlying theme of MVA is simplification or
dimensionality reduction, for example, from several hundreds of peaks to a few
coefficients, thereby facilitating in the aid of visualization of inherent patterns within
the data. This may be achieved by unsupervised dimensionality reduction (through the
use of projections), clustering (identifying groups of points which are similar to each),
and supervised pattern recognition or machine learning (where knowledge about class
membership is used to help discriminate between groups). It is beyond the scope of
this thesis to describe in detail all the available methods on multivariate analysis;
however, the following resources will provide a good overview (Beebe et al., 1998;
Duda et al., 2001; Everitt, 1993; Hastie et al., 2001).
1.5.1 Pre-processing of Data
Data pre-processing is arguably the most important stage of data analysis as the
quality of any model produced will solely depend on the quality of the data presented
(Daykin and Wulfert, 2006), i.e. garbage in, garbage out. The data initially collected
by the analytical instrumentation is classed as raw data, which then can be exported in
multiple different computer readable formats (generally for compatibility) before the
pre-processing can be performed. The first stage of pre-processing is to reduce the file
size, through reduction in data complexity, in order to make analysis less
computationally extensive as well as presenting the data in a format suitable for a
range of software packages such as SIMCA P (Umetrics, Umea), The second stage is
to remove or reduce any inaccuracies so that a single metabolite is reported as one
feature. In terms of NMR data, one method would be to use integrals of a specific
spectral peak. However, this is not only computational intensive, it can also be
detrimental to the production of useful multivariate models because of any slight
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variation of peak chemical shifts which can be brought about via changes in pH or
ionic strength between samples. For example, citrate is particularly sensitive to these
changes and whilst these shifts pose little problem by eye, from a data analysis
perspective, if a certain peak is not consistently being expressed in the same position,
the model will interpret the change as a different metabolite, making the model
redundant. However, calculating the peak areas within specified segments, commonly
referred to as 'bucketing' or 'binning' (Holmes et al., 1997; Spraul et al., 1994a), into
bin widths of 0.04 ppm is a common tactic to solve this problem, as illustrated in
Figure 1.6. This approach is adequate in most cases, though, it can be rather crude, as
subtle metabolic differences between groups of data may be lost. For this reason,
several authors prefer to align peaks with genetic algorithms, especially for high-
resolution NMR data. Thus, a number of approaches have been proposed for this
(Forshed et al., 2003; Kassidas et al., 1998; Lee and Woodruff, 2004; Stoyanova et
al., 2004; Vogels et al., 1993). However, these are generally not feasible in
metabolomic studies since the spectra can show either the complete loss of some
peaks or appearance of new peaks. MS based data are generally converted from a 3D
matrix of time vs mass vs intensity, to a matrix of chromatographic peaks (with
associated retention time and accurate mass) and peak area. This deconvolution can
be achieved either by using the manufacture's proprietary software (e.g. MarkerLynx
supplied by Waters and SIEVE supplied by Thermo Scientific), or converting the raw
data to produce a text-based file known as NetCDF (network common data format)
(Rew and Davis, 1990), in order to use open-source software such as XCMS,
Metalign, MZmine, MathDAMP (Baran et al., 2006; Katajamaa and Oresic, 2005;
Lommen, 2009; Nordstrom et al., 2006).
A B
4.50 3.50 BD 1.50
Figure 1.6 An example of A NMR spectrum B segmented spectrum after bucketing to a width ofO.04
ppm. Own data obtained from the analysis of human apocrine sweat.
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1.5.2 Data Pre-treatment Methods
Different pre-treatment methods can be used for generate MYA models, which can
affect the level of biological information obtained. The two main methods currently
used in metabolomics studies are mean centring and unit variance scaling (also known
as auto scaling) (Eriksson et al., 2001). Mean centring focuses on the differences in
the data and not the similarities by removing the offset from the data to zero, instead
of around the mean of each metabolite concentration. However, this can bias the
model to the metabolites that are higher in concentration. Unit variance compares
metabolites based on correlations, as all metabolites have a standard deviation of one
(i.e. become equally important). Thus, large peaks that dominate the spectra are
treated as equally as small peaks. However, this can have undesirable effects as the
baseline noise is inflated. These data pre-treatment methods, as well as other less
common scaling and transformation methods are described further by van den Berg
(van den Berg et aI., 2006).
1.5.3 Principal Component Analysis
Probably one of the oldest and most used techniques of multivariate analysis is PCA,
which allows the expression of most of the variance within the data set in a small
number of factors or principal components (PCs). This is achieved by transforming
the original set of variables into a new set of uncorrelated variables called PCs. These
new variables are created from linear combinations of the initial descriptors with
appropriate weighted coefficients. Indeed, this reduces the dimensionality of the data
set while accounting for as much variation as possible. The properties of the PCs are
such that each PC is orthogonal (uncorrelated) to each other and that each successive
PC explains the largest variation of the data set not accounted for by the previous
PCs. Thus, this will remove any 'noise' since after the first few PC, the axes will be
due to random noise in the data set. Hence, the first few PCs will describe most of the
variation, but the number is dependent upon the application e.g. for clinical
applications you may use many more. Plotting two PCs summarises the observations
in K-space by projecting each variable along each PC. The co-ordinate values on this
plane are called scores, hence, plotting the projected configuration is known as a score
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plot. Observations which are close to one another are similar in composition, whereas
observations which are at opposite sides are significantly different. In order to
determine which variables are influential or how the variables are correlated, a
loading plot is used. The loadings define the orientation of the PC plane with respect
to the original variables. Thus, variables which are inversely correlated are positioned
in opposite sides of the plot and the distance from the origin represents how
influential each variable is on the model.
1.5.4 Partial Least Squares Regression
There are a large number of supervised methods (i.e. class membership of the samples
are included in the calculation). One of the most popular is PLS (Partial Least
Squares), which is commonly used to determine whether a relationship exists between
two matrices, X and Y. The X matrix usually comprises of spectral or
chromatographic data, while, the Y matrix contains quantitative values for those
samples (a priori knowledge), for example, concentration, drug dosage or storage
time (Lindon et al., 2006; Trygg et al., 2007). These relationships are derived through
the use of latent variables of the original matrix X (known as the predictor variable)
and the observed vector Y (known as the response variable), which are acquired by an
iterative procedure. These latent variables are used to create linear combinations of
columns (X and Y) so that their covariance is maximised. When the first latent vector
is found, it is subtracted from both X and Y and repeated until X's components tend
to a zero value (Wold et al., 1999). The resulting model can then be used to predict
the analyte concentrations or examine the influence of time on a data set from the
spectra of a new sample.
1.5.5 Principal Component Discriminant Analysis
PC-DA can be considered when more than two Y variables are being compared at any
one time. It has the ability to summarise metabolite differentiation between-group
variability, while overlooking within-group variation. Initially, the mean spectra for
each class are calculated as per PCA, in order to construct significant limits for each
specified class. Then the individual spectra, from each class, are projected onto the
2S
PCA model, illustrating how close individual samples are to their respective means.
However, unlike PLS, classification and prediction performance can only be
qualitatively measured.
1.6 Identification of Components
Identification of individual metabolites from the obtained data is not always
mandatory, while in other studies it is a critical part for the biological interpretation.
For commonly analyzed biosamples, such as blood and urine, this can be achieved by
comparison with spectral databases (see Table 5.2 on page 155), literature, and two-
dimensional NMR spectroscopy. Moreover, for MS based approaches, a workflow
summarised in Figure 1.7, can be followed in order to reduce the number of initial hits
from databases in order to putatively identify unknown endogenous metabolites
which can then be later confirmed by spiking the sample with internal standards.
Nonetheless, for other samples, which are less well reported, these avenues of
investigation will not result in positive metabolite identification. In this case,
separation techniques such as LC-NMR-MS are required to gain full structural
information. LC-NMR-MS can allow unequivocal identification of metabolites where
neither LC-NMR nor LC-MS alone could generate all the necessary information.
Once identified, the information can be stored in a database for future reference.
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Initial Candidates • • • • • • • • •• • • • • • • •
• • • • • • •
Limitto biological compounds
(C, H, 0, N, Sand P)
'Biological' databases • • • • •• • • • • • •
Search by mass
Potential biological matches • • • • • • •
•
Limitto retention time matches
Highly probable matches • • • •• •
Rank by fragmentation matches
Most probable matches • • ••
Ranking of most probable matches
•
•
•
•
Figure 1.7 Summary of the proposed workflow for reducing potential matches from databases
searches.
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1.7 Sweat Gland Biology
Skin is regarded as the most versatile organ of the human body (Wilke et aI., 2007)
and accounts for 12-15% of body weight (Gallagher et al., 2008). A vast amount of
research has been published on the different roles, either from a barrier function or as
a first-line immune response system (Menon and Kligman, 2009). However, relatively
few studies have focussed on sweat glands or their biology even though regulation of
core body temperature by sweating is a fundamental process for survival. Constant
core body temperatures above 40°C result in protein denaturation and cell death,
resulting in multiple organ failure. Hence, the most useful purpose of the sweating
mechanism is to down-regulate the body core temperature by releasing thermal
energy through the evaporation of water from the skin surface.
The nervous system ultimately governs the rate of perspiration to meet the
requirement of the body and therefore production increases in proportion to the level
of environmental stress and metabolic rate. This process is regarded as
thermoregulatory sweating and involves eccrine glands, which are distributed over the
whole body surface. Since thermoregulatory sweating serves as a system for
temperature reduction, failure in this system will therefore lead to hyperthermia and
death (Wilke et aI., 2007). The onset of thermal sweating is caused when the sum of
the internal body temperature has a 10-fold increase over the mean skin temperature,
i.e. the internal temperature increases by a significant amount to what is experienced
on the surface. It is also important to note that sweating can be affected by many
internal factors such as gender, physical fitness, menstrual cycle and circadian rhythm
as well as external factors like humidity. Thus, the sweating rate can vary from each
individual. The onset of sweating can also arise from emotional stress (emotional
sweating) or through the consumption of highly spicy food (gustatory sweating). The
former is caused by a physical reaction to emotive stimuli, for example; anxiety, fear
or pain, and can occur over the whole body but are mainly confined to the palms,
soles, and axillary region (Allen et aI., 1973; Eisenach et aI., 2005). Thus, in this
instance, sweating occurs independently of ambient temperature and decreases during
relaxation (Wilke et al., 2007). However, emotional sweating does not occur until the
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onset of puberty, which leads to the assumption that apocrine and apoeccrine sweat
glands are involved, as these glands become functional during this development stage
(Lonsdale-Eccles et al., 2003). Gustatory sweating on the other hand is the direct or
indirect thermal effect of ingestion of certain foods (e.g. hot and spicy substances) and
is confined to the face, scalp, and neck. Its onset is usually triggered within a few
seconds of food entering the mouth, rarely by smelling of food and is not triggered
through food reaching the stomach, chewing inert substances, or thought of food
(Bloor, 1969; Bronshvag, 1978). Ingestion of food also causes an increase in
metabolism, which leads to an increase in body temperature and the onset of thermal
sweating.
1.7.1 Sweat Glands
Sweat glands are cutaneous appendages like hair follicles or sebaceous glands,
forming tiny coiled tubes embedded in the dermis or subcutaneous fat. They contain
myoepithelial cells, which, when contracted, squeeze the gland to discharge the
accumulated secretions via the duct to the outer skin surface. Glands are characterised
through their morphology or by their mode of secretion. For example: sweat glands
secrete eccrine (secretion is released from the cell as a liquid without disintegration)
or apocrine (secretion occurs via pinch off of outer cell parts) (Lonsdale-Eccles et al.,
2003; Wilke et al., 2007). Through this distinction there are said to be two types of
sweat glands: eccrine (also known as merocrine sweat glands) and apocrine glands.
The morphology of the eccrine and apocrine sweat glands is depicted in Figure 1.8,
whereby, the green (Oil stained) and red (Nileblue stained) outlines the coil cellular
boundaries and nuclei respectively. While immunolabelling with MFG, a marker for
eccrine glands, or COlS, a marker for apocrine glands, is also shown. Wilke and co-
workers have reported a number of other antibodies that can also be used to
differentiate between eccrine and apocrine glands in order to describe their structural
diversity (Wilke et al., 2006). The apocrine gland coil is -800 urn in diameter (ca. to
eccrine gland coil -500-700 urn), with an outer and internal tubule diameter of -200
urn and -100 urn respectively. The duct and secretary coil is a very short straight tube
(ca. to eccrine duct which is generally a corkscrew channel -2000 urn in length) and
is located near to the hair follicle. The secretary cells consist of a single layer of
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columnar shaped cells situated near to the basal membrane. In companson, the
eccrine outer and internal tubule diameter is -120 urn and -40 urn respectively.
Sato and co-workers reported the existence of a third type of sweat gland which could
not be classified as either eccrine or apocrine gland and showed characteristics of
both, hence, it was termed the 'apoeccrine' gland (also known as mixed-type gland)
(Sato et al., 1987). It is questionable however, as to whether this third type of sweat
gland exists. Recently, Bovell and co-workers (Bovell et al., 2007) investigated the
axillary skin of ten volunteers, and tried to identify apoeccrine glands by a means of
serial sectioning histology and immunofluorescence using CD 15, CD44, SI 00 and
HMFG-I antibodies. They concluded that no evidence of apoeccrine glands was
found either by histology or by immunofluorescence. Thus, the lack of distinct
features does not comply with the definition proposed by Sato (Sato et al., 1987). To
the author's knowledge, this work has not been repeated, thus, to overcome this
controversy further investigations are needed on normhydrotic and hyperhidrotic
patients, in addition to the effects of dissection on glandular appearance, to reveal if
there really is a 'third' type of sweat gland.
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AIntemalDiameter
30-40 urn
Outer Diam eter
60-120 um
Internal Diameter
IO-20f,lm
OuterDiameter
50-80 urn
c Diameter
500-700 urn
B
Outer Diameter
280 urn
IntemalDiameter
80-100~m
Outer Diameter
120-200 prn
D
Figure 1.8 Upper: Schematic diagram of A eccrine gland B apocrine gland showing both a cross-
section of the coil and duct. Lower: Correlative microscopy of C eccrine coil D apocrine coil.
Myoepithelial cells (M), Intracellular canaliculi (IC), Nuclei (N), and desmosomal contacts (D).
Reproduced with modifications (Weiner and Hellmann, 1960; Wilke et al., 2008).
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1.7.2 Chemical Composition of Eccrine Sweat
Excreted sweat can vary in composition and electrolyte concentration depending on
the secretary and reabsorptive properties at the coil and duct, respectively. When
sweat is initially formed in the secretary coil it is near iso-osmotic (Sato et al., 1987),
and following excretion the sweat is relatively hypo-osmotic and acidic (Patterson et
aI., 2000). This change in sweat osmolality and acidity can vary between skin regions
(Sato and Dobson, 1970), as it is reliant on the functional capacity of the sweat gland,
which is ultimately governed by the ductal transport processes. From an analytical
perspective this adds further complexity to the study of human sweat as variation in
sweat composition can vary significantly within an individual.
Sweat is primarily composed of water (99%), and is therefore well suited for
evaporative cooling. A diverse array of organic and inorganic compounds can be
found in sweat, many of which are found in plasma but at much lower concentrations
(Harker et al., 2006), thus, sweat glands appear to selectively secrete some substances
and retain others (Robinson and Robinson, 1954). There are approximately 61
compounds reported in eccrine sweat with varying concentrations reported in the
literature (see Table 1.6). To the author's knowledge, there is no reported literature on
electrolytes and ionic constituents, or their respective concentrations in apocrine
sweat. However, it is likely they would be of similar magnitude. Furthermore, it is
important to establish chemical composition of eccrine sweat as this could provide
useful information in identifying components present in apocrine sweat, which will be
discussed in further detail later (see Section 1.7.5).
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Table 1.6 Median values of eccrine sweat constituents. Reproduced with modifications (Harvey et al.,
2010; Stefaniak and Harvey, 2006).
Components Molecular Formula Median (min and max) concentration (M)
Electrolytes
Sodium
Chloride
Calcium
Potassium
Magnesium
Phosphate
cr
3.1 xl 0-2 (1.1 x I 0-4- 3.9xl 0-1)
2.3xlO-2 (1.7xI0-s - 2.8xI0-1)
5.2xI0-3 (4.7xlO-6 - 1.5xlO-2)
6.1xlO-3 (6.7xlO-6 - 3.8xI0-2)
8.2xlO-s (7.4xlO-8 - 3.8xlO-3)
3.1xI0-4 (2.3xI0-s - l.lxlO-3)
Inorganic Ions
Ammonium
Bicarbonate
S.2xlO-3 (4.7xI0-4 - 2.SxI0-2)
3.0xlO-3 (2.6xlO-4 - 2.0xlO-2)
Ionic Species
Sulfate
Sulfur
Fluoride
Phosphorous
Bromine
Cadmium
Copper
Iodide
Iron
Lead
Manganese
Nickel
Zinc
SO/-
S
F
P
Br
Cd
Cu
4.2xlO-4 (7.0xlO-s - 2.0xlO-3)
2.3xI0-3 (2.2xI0-4 - 2.3xlO-3)
1.lxlO-s (S.8xI0-8 - 9.SxlO-s)
1.3xlO-s (2.2xI0-8- l.SxlO-3)
2.3xlO-6 (4.4xlO-9 - 6.3xlO-6)
1.8xlO-8 (1.2xI0-8 - 2.3xlO-8)
9.4xlO-7 (l.3xlO-8 - 1.2x10-3)
7.1xlO-8 (7.9xI0-11 -7.SxI0-s)
9.8xI0-6 (1.SxlO-8 - l.lxI0-3)
1.2x10-7 (3.SxlO-9 - 2.0xlO-7)
1.1xl 0-6 (1.1x 10-9 - l.3x 10-3)
4.2xlO-7 (1.7xI0-9 - 8.3xlO-7)
1.3x10-s (1.4xI0-8 - 2.3xlO-s)
Fe
Pb
Mn
Ni
Zn
Amino acids
Alanine
Valine
Leucine
Isoleucine
Phenylaline
Glycine
Threonine
Tyrosine
Aspartic acid
Glutamic acid
Histidine
Lysine
C3H7NOz
CsHllNOz
C~13NOz
C6HI3N02
C9HIIN02
C2HsNOz
C4H9N03
C9HIIN03
C4H7N04
CsH9N04
C6H9N30z
C~14Nz02
3.6xlO-4 (NA)
2.SxlO-4 (l.3xI0-4 - 3.8xlO-4)
2.1xl0-4 (9.1xI0-s - 3.2xl0-4)
1.7x10-4 (7.6xI0-s - 2.8xI0-4)
1.3x10-4 (6.1xlO-s - 2.1xlO-4)
3.9xI0-4 (NA)
4.5xlO-4 (1.4xI0-4 - 7.6xI0-4)
1.7x10-4 (6.6xlO-s - 3.0xI0-4)
3.4xl0-4 (NA)
3.7xI0-4 (NA)
S.2xI0-4 (2.7xI0-4 - l.3xlO-2)
i.sxnr' (9.6xlO-s - 2.2xI0-3)
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Table 1.6continued
Components Molecular Formula Median (min and max) concentration (M)
Arginine C6HI4N40Z
CIIHlzNzOz
C4H9N30Z
CsHlzNzOz
C6H13N303
C7H7NOz
Tryptophan
Creatine
Ornithine
Citrulline
p-Aminobenzoic acid
Hydroxy/Keto Acids
Pyruvic acid
Lactic acid
Fatty Acids
Acetic acid CZH40Z
C3~OZ
C4HsOz
C4H80Z
CsHIOOz
C6H1ZOZ
Propionic acid
Butyric acid
Isobutyic acid
Isovaleric acid
Hexanoic acid
Carbohydrates
Dehydroascorbic acid
Glucose
Amino Ketones
Urea
Creatinine
Purines and Purine Derivatives
Uric acid CS~N403
Vitamins
Choline CSHI4NO
Ascorbic acid C~806
Inositol C~1206
Nicotinic acid C6HsNOz
Pantothenic acid C9HI7NOs
Pyridoxine C8H11N03
Riboflavin C17HzoN406
Folic acid CI9HI9N706
Thiamine C1zH17CIN4OS
7.8xlO-4 (3.3xlO-4 - 4.4xlO-3)
s.s-io' (2.0xlO-s - 9.1xlO-5)
1.5xlO-5 (NA)
1.5xlO-4 (NA)
4.0xl0-4 (NA)
7.1xlO-8 (5.8xlO-9 - 1.8xI0-z)
1.8x 10-4 (1.0x 10-7 - l.Ox 10-3)
1.4xlO-2 (3.7xlO-3 - 5.0xlO-2)
I.3xlO-4 (5.9xI0-S - 4.2xlO-4)
3.5xlO-6 (1.2xlO-6 - 7.4xlO-6)
2.4xlO-6 (5.0xI0-7 - 6.0xlO-6)
8.0xlO-7 (NA)
l.IxlO-6 (2.0xlO-7 - 4.5xlO-6)
9.0xlO-7 (2.0xlO-7 - 3.5xI0-6)
l.IxlO-S (7.6xI0-9 - 8.6xlO-4)
1.7xlO-4 (5.6xlO-6 - 2.2xlO-3)
1.0x 10-2 (1.8x 10-3 - 4.6x IO-z)
8.4xlO-s (8.8xlO-6 - 2.0xlO-3)
5.9xlO-5 (4.2xI0-6 - 4.8xlO-3)
2.6xlO-5 (6.8xlO-7 - 1.5xlO-4)
1.0xlO-s (l.1xlO-7 - 3.6xlO-s)
1.6xlO-6 (8.3xI0-7 - 1.2)
4.lxlO-1 (1.4xlO-7 - 3.7)
I.3xlO-1 (6.8xI0-s - 3.6)
1.0xlO-s (2.4xI0-9 - 5.0xlO-3)
2.0xlO-2 (1.3xlO-s - 8.0xlO-I)
1.6xlO-8 (1.2xI0-8 - 2.0xlO-s)
5.0xlO-3 (4.5xI0-9 -5)
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The major cations (Na+, K+, Ca2+, Mg2+) and anions rcr, ro,", HC03) located in
sweat are similar to that found in plasma. The most concentrated solute in sweat is
NaCI, which ranges from 5 mM to as high as 148 mM (Robinson and Robinson,
1954). Any salt depletion produced by sweating can cause heat cramps and fatigue
resulting from the reduction in extracellular fluid volumes due to the reduction in
tonicity. Furthermore, a relationship between sweat Na+ concentration and pH has
been reported, whereby, the greater the concentration of Na+ the greater the pH
(Kaiser et al., 1974). Hence there is considerable variation in the observed pH of
sweat. In the literature, the observed pH ranges from 2.1-8.2 (median 5.3) for eccrine
sweat (Stefaniak and Harvey, 2006), which has been found to be more acidic than that
of apocrine sweat (Robinson and Robinson, 1954).
Potassium concentration tends to be lower than that of sodium or chloride averaging
approximately 4.5 mM. It has been reported by Locke (Locke et al., 1951), that
potassium concentration varies inversely with sodium concentration and that the ratio
of NaIK varies directly with sodium concentration. While Patterson and co-workers
reported a positive relationship between lactate and K+ concentration (Patterson et al.,
2000).
Lactic acid and pyruvate have both been measured in sweat secretion, values of which
range from 4-40 mM and 0.1-0.8 mM, respectively (Robinson and Robinson, 1954),
of which, both substances are more concentrated than that of blood or urine. Despite
lactate being present in high concentrations, little attention has been made to its
functioning role within the sweat gland. It has been suggested that lactic acid may
come from the blood for a regulatory purpose in preventing an excess accumulation of
blood and tissue lactate (Robinson and Robinson, 1954). However, it is debatable as
to whether lactate present in sweat is derived from blood lactate. Others have
suggested that lactate is produced from the gland's metabolism (Gordon et al., 1971;
Sato and Dobson, 1971; Weiner and Vanheyningen, 1952). In the literature, it is
currently unclear as to why there is such a varied concentration range in both lactate
and pyruvate with respect to changes in temperature, sweating rate, sweating duration
and acclimatisation, although these factors have been studied in regards to sodium and
chloride concentration of sweat. Nonetheless, there have been a few studies
highlighting an inverse relationship between lactate concentration and exercise
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intensity (Lamont, 1987; Meyer et al., 2007). Although, this relationship is likely be
due to a dilution effect resulting from the increase in sweat secretion (Buono et al.;
Green et al., 2004).
Nitrogenous constituents of sweat vary in concentration when compared to blood
plasma. For example: ammonia is typically 100 times more concentrated in sweat;
urea is about twice as concentrated in sweat; amino acid concentrations are similar or
slightly lower than in plasma, although the concentrations of individual amino acids
may differ; and both uric acid and creatinine are more dilute in sweat. Typical
nitrogen concentrations of sweat reported in the literature vary from 0.5-8 mM (Sato
et al., 1989). Other amino acids, including cysteine, methionine, proline, and serine
have also been detected in eccrine sweat, however, their quantitative concentration
have not been reported (Coltman et al., 1966; Liappis and Hungerla, 1972; Stefaniak
and Harvey, 2006).
1.7.3 Axillary Malodour Formation
The human body generates a variety of different odours, for example; scalp, hair
mouth, axilla, foot, and general skin surface all possess characteristic odours. Of all
the human scents, axillary odour is probably the most powerful and easily
recognisable (Hasegawa et al., 2004).
Axillary odours possess a distinctive malodorous scent communally called "body
odour" which originates from the axilla regions. These regions contain a dense
arrangement of apocrine, eccrine, sebaceous, and apoeccrine glands (see Table 1.7 for
an overview between the differences of the glands), and volatile substances
evaporating from these areas make a key contribution to human body odour (Zeng et
al., 1996a). This has been examined and discussed from an analytical, biological and
a behavioural-physiology point of view (Hasegawa et al., 2004). Although. in today's
society, body odour is deemed unpleasant, several studies have illustrated that axilla
odour may contain chemical signals that affect the menstrual cycle (Natsch et al.,
2004), or that it may be involved in mate selection depending on the major
histocompatibility complex (MHC)-allele (Natsch et al., 2004). Axillary secretions
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are an ideal source of pheromones, thus, are generally secreted into areas that often
contain hair that can greatly increase the surface area for dispersion and aid in
volatilization. Hence, axilla is a focal point for a multi-billion-dollar consumer
product industry since the general consensus in today's society is to eliminate or mask
these body odours (Gautschi et al., 2007; Wysocki and Preti, 2004).
Table 1.7 Difference between eccrine, apocrine and apo-eccrine sweat glands. Reproduced with
modifications (Lonsdale-Eccles et al., 2003; Sato et al., 1989).
Eccrine A~ocrine A~o-eccrine
Age of onset of gland Birth Adolescence Adolescence
activity
Distribution of sweat Whole body- Axilla, breast and labia Hair-bearing area of
glands excluding auditory axilla
canal, clitoris and labia
minora
Stimulation Cholinergic » Cholinergic = Cholinergic>
Adrenergic Adrenergic Adrenergic
Gland size Small Large Variable
Location of secretary Mid-dermis Deep-dermis/fat Deep-dermis
coil
Duct Long - connecting Short - connecting to Long - connecting
directly to skin surface hair follicle directly to skin surface
Cell type Secretary (clear), dark Columnar secretary Dilated segments
and myoepithelial cell, myoepithelial resemble apocrine
gland and non-dilated
resemble eccrine
glands
Sweat secretion rate Continuous - high Transient and Continuous - very high
output intermittent - low output
volume
Gland product Water fluid Turbid fluid - protein Water fluid
rich
The ultimate source of axillary odour is apocrine sweat, which, when initially secreted
is both sterile and odourless (Leyden et af., 1981), and since the pioneering work of
Shelly et al. (Shelley et al., 1953), it is known that the action of skin bacteria is
needed to generate the odoriferous components from the non-smelling molecules
present within these secretions. Indeed, the axilla is a skin region supporting a dense
bacterial population (-106 cells cm"), which are dominated by two genera
Staphylococcus and Corynebacteria (Austin and Ellis, 2003; Natsch et al., 2003),
both of which are best adapted for the conversion of fresh apocrine sweat to the
'classic male locker room smell' (Troccaz et al., 2004).
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Most individuals carry a flora that is dominated by either one of these two genera;
however, strong correlations between high populations of Corynebacteria and strong
axillary odour formation have been found. For example, certain strains of
Corynebacteria have been associated with the clinical condition of plantar
bromidrosis (acute offensive body odour) (Troccaz et aI., 2004). Thus,
Corynebacteria and certain Staphylococci possess all the enzymatic machinery
required to carry out biochemical conversions of proteins, lipids and steroids into
odorous components (Natsch et al., 2004; Troccaz et al., 2004). As practical
consequence of these findings, the cosmetic industry introduced halogenated
antibacterials and aluminium preparations for reducing bacterial populations as their
main active ingredient in deodorants over the last 40 years (Gautschi et al., 2007;
Natsch et al., 2003). Considerable progress has been made since these initial
observations, in terms of identifying odorous compounds, however, there has been
less attention to the biochemistry of axillary odour formation. Hence there is only a
limited amount of literature available regarding the structures of precursors isolated
from axilla secretions, and no specific bacterial enzymes capable of generating these
precursors have been isolated.
1.7.4 Chemical Nature of Body Malodour
The composition of sweat odour comprises of four principle components. First, a
steroidal fraction comprising of four pungent steroids, 5a.-androst-I6-en-3-one,
androsta-4,16-dien-3-one, and their respective alcohols, 5a.-androst-I6-en-3a.-ol and
androsta-4,16-dien-3a.-ol. It has only been recently that the identities of these volatile
steroids precursors present in apocrine sweat have been identified (Austin and Ellis,
2003). From their discoveries, Austin and Ellis proposed a new metabolic map
(Scheme 1.1) of the biotransformations needed to generate odourous components
from non-odourous precursors. They also illustrated that no single bacterium isolated
was capable of carrying out the full complement of enzymatic transformations,
thereby, generating a blend of 16-androstenes. Furthermore, the overall ability of
Corynebacteria to biotransform odourous steroids from androsta -5,I6-dien-3a.-ol is
low (Austin and Ellis, 2003).
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3-Hydroxy Androsten-6-one Androstadienedione
i6HSD i6HSD
"octSh octShOH OH
Androstenediol 6-hydroxy Androstadienone
octSh
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6-hydroxy androstenone
Androstenediol
t Hydroxylase/dehydrogenase t Hydroxylase/dehydrogenase t Hydroxylascldehydrogenase t Hydroxylase/dehydrogenaseand hydratase acitvity and hydratase acitviry aod hydratase acitvity and hydratase acitvity
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Androstadienol Androstadienone Androstenone Androstenol
~ l-ene DH ~ l-ene DH ~ l-ene DH ~ l-ene DH
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Androstatrienol Androstatrienone Androstadienone Androstadienol
I Hydroxylase/dehydrogenase
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Scheme 1.1 Simplified schematic of the biotransformation of 16-androstenes by Corynebacteria (A)
axillary isolates. It is important to note that no single isolate is capable of carrying out all the enzymatic
reactions to produce all the steroidal malodour components. Key: HSD (hydroxysteroid
dehydrogenase) and DH (dehydrogenase). Reproduced with modifications (Austin and Ellis, 2003).
Secondly, volatile fatty acids (VFAs) can be formed by the action of bacteria,
typically Corynebacterium species (Figure 1.9). However, the Corynebacterium
genus can be split into two groups depending on their ability to metabolise lipids,
specifically free fatty acids (FFA). These groups have been named as
Corynebacterium (A) and (B), where the latter are unable to utilise FFA as a carbon
source (Austin and Ellis, 2003). Furthermore, the former, sub-group A, lack the
ability to fully catabolise long chain fatty acids (LCFAs), and instead only partial
degradation products are formed (C6-11 acids). For example, methyl-branched fatty
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acids such as isostearic acid (heterogeneous C16-18branched and unbranched fatty
acids) are metabolised into a range of highly odourous 2-methyl-C6_14fatty acids
(Troccaz et al., 2004).
Glycerol
LacticAcid
Staphylococci
I Ski! Lipil I
~eb'deria U\)
~
~---_/(A)BranchedAmilo Acns
Figure 1.9 Formation of VFA by Corynebacteria and Staphylococci. Reproduced with modifications
from (James et al., 2004).
Thirdly, the predominant olfactory contributor in axillary sweat, (E)-3-methylhex-2-
enoic acid (3M2H), is described as being the key odour component and was first
presented by Zeng and co-workers (Zeng et al., 1992; Zeng et al., 1991). This
compound had initially been found in the sweat of schizophrenic patients (Smith et
al., 1969) until Gordon and co-workers (Gordon et al., 1973) showed that 3M2H was
detectable in both normal population and schizophrenics, indicating there was no
special relationship between 3M2H and schizophrenia (Akutsu et al., 2006). In a later
study, Spielmen and co-workers (Spielman et al., 1995) illustrated that 3M2H was
non-covalently associated with two proteins, which have been designated as apocrine
secretion odour-binding proteins 1 and 2 CASOB1,45 kDa, and ASOB2, 26 kDa). The
ASOB2 protein was identified as apolipoprotein D (apoD), a member of the lipocalin
family of carrier proteins (James et al., 2004; Zeng et al., 1996a). However, Natsch
and co-workers (Natsch et al., 2003) produced a contradictory study, whereby, 3M2H
and the chemically related 3-hydroxy-3-methylhexanoic acid CHMHA), are instead
non-covalently bound to the carrier protein in the form of glutamine conjugates and
40
are released by the action of corynebacterial N-acylglutamine aminoacylase (Scheme
1.2). It was then postulated that once cleaved from the glutamine conjugate, the acids
might be able to associate non-covalently with apoD (James et al., 2004). More
recently, Martin and co-workers described the relationship between axillary odorants
and the ABCC J J gene (Martin et a/., 20 I0). They reported that individuals who were
AA homozygotic for single nucleotide polymorphism (SNP), 538G-+A, leading to a
G180R substitution, were found to have a significantly smaller amount of axillary
odorants to those from AG and GG phenotypes. ABCC J J gene has also been
previously shown to function in the auditory canal, where, 538G-+A SNP is
associated with dry white ear wax phenotype that is predominant in Asians (80-95%)
and rare in Africans or Europeans (0-3%) (Yoshiura et al., 2006). This same SNP
predominates in the Asian population, which nearly leads to a complete loss of typical
body odour. The ABCCll protein is expressed and localised in the apocrine sweat
gland and appears to have an essential role in the secretion or formation of glutamine
precursors. Furthermore, the work presented by Martin et al (20 I0) is similar to the
work present by Jacoby et aI, where they reported the concentration of ASOB2 to be
low or undetectable in Asians, compared to non-Asian subjects, where it was readily
detected (Jacoby et al., 2004). Thus, the relationship between ASOB2 and ABCCll
protein and their regulation of odour production still needs to be assessed.
~C02H
ZirI.:dependent amiIDacylase
from Corynebacterium Ax20
(AMRE)
Scheme 1.2 Release of sweat acids from glutamine. Reproduced from (Gautschi et aI., 2007).
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Finally, sulfanylalkanols, sulfur containing thiols; have also been shown to have a key
role in the perception of sweat malodour, possessing a sweat/onion-like character.
This is derived from the action of pyridoxal phosphate-dependent ~-lyase activity
(probably related to cystathionine ~-lyase) upon secreted sulfur-containing amino
acids (Scheme 1.3) (Natsch et al., 2003; Troccaz et aI., 2004). However, this has been
proposed without data on the structure of the secreted precursor or isolation of the
bacterial enzyme, as structure elucidation has proven to be more complex.
Furthermore, certain bacteria have been associated with ~-elimination activity for
cysteine S-conjugates, primarily through the action of lipase, ~-cystathionase (an
enzyme involved in methionine biosynthesis), y-cystathionase, tryptophanase (a
transaminase) and ~-lyases (again involved in methionine biosynthesis, whereby they
cleave the intermediate (S)-cystathionine) (Natsch et al., 2004; Troccaz et al., 2004).
In addition, sulfanylalkanols were recently found to be bound to the Cys-Gly
dipeptide in axilla secretions (Natsch et aI., 2006).
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OH H NH2
~N~S OH
o 0 ~ f}-Lyasefrom Staphylococcus
1
~,~ ~U,
djpeptidase ~
OH
NH2 »:"
HO~S OH /
o ~ Cystathionine- p-lyase from
'I Corynebacteriwn Ax20
Scheme 1.3 Release of sulfanylalkanols from the Cys-Gly precursors Reproduced from (Gautschi et
al.,2007).
1.7.5 Natural Precursors/Apocrine Sweat Composition
Many years after the work of Shelley and co-workers (Shelley et al., 1953), only
speculations with respect to the chemical nature of apocrine sweat precursors were
available. However, over the last decade a few authors have started to tackle this gap
within the literature, mainly due to the analytical and computational advances, which
enable the correct identification of these metabolites. Appendix A illustrates the full
spectrum of compounds currently extracted from apocrine sweat (Natsch et aI., 2006;
Natsch et al., 2004; Troccaz et al., 2004), while known odour precursors are
summarised in Table 1.8.
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It has been speculated that body odour formation arises from common metabolic
pathways of skin microflora and therefore is a by-product of bacterial metabolism that
utilises these sweat secretions, which are essentially the by-products of the body's
metabolism. Examples of bacterial metabolism include the catabolism of L-leucine
into isovaleric acid (3-methylbutanoic acid) and the formation of short acids by the
incomplete degradation of skin lipids (Natsch et al., 2003). However, the recently
identified glutamine conjugate (3M2H-Gln) is somewhat contradictory. Thus, it is
more likely that these compounds are synthesised specifically to exert their action
once secreted in the axilla region rather than just being a by-product of metabolism.
The actual benefit of being secreted in precursor form instead of direct secretion of
the acids could be many fold. For instance, the use of a precursor would lead to a
controlled release and make the chemical signal longer lasting. More of a
physiological approach would suggest that transporting low molecular weight acids is
more achievable when they are in a water-soluble precursor form (Natsch et al.,
2003). This would indicate co-evolution between skin micro flora and humans, since
the bacteria have adapted their enzymes to recognise the precursor structure of axilla
secretions.
The work produced by Natsch (Natsch et al., 2003) has illustrated that the
aminoacylase is unique, whereby, it is very selective for the Gin residue but has a
very broad substrate specificity regarding the acyl part. This would readily lend itself
to being more malleable to other Gin-containing precursor structures. Furthermore,
they confirmed the findings of Zeng's group (Zeng et al., 1991), that other branched
amino acids are also present in axilla secretions. Although, it was highlighted that
further investigations would be needed to identify if these too are linked to Gln-
conjugates.
Thiols and methylsulfanyl metabolites, in which sulfur is derived from the
glutathione, have been identified in secretion products of xenobiotics. Typically,
glutathione--{S)-conjugates undergo enzymatic hydrolysis to yield Cys-(S)-
conjugates, firstly, by the cleavage of the y-glutamyl moiety via y-glutamyl trans-
peptidase and then followed by the action of a carboxypeptidase (Starkenmann et al.,
2005). The formation of volatile sulfur compounds from Cys-(S)-conjugates have
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been described in wine, passion fruit, Allium species and have been described as the
substrates for p-Iyase. Starkenmann group also postulated that the production of the
Cys-(S)-conjugate takes place before excretion of the sweat onto the skin surface.
Furthermore, this group speculated that the formation of 3-methy-3-sulfanlhexan-l-ol,
3-sulfanylhexan-I-ol, and 2-methyl-3-sulfanylbutan-l-ol are produced through their
Cys-G Iy-(S )-con jugates precursors.
Currently, there is lack of comprehensive analytical approaches to measuring the
complex biochemicals excreted in apocrine sweat. Thus, this study exploits a range of
LC-MS platforms and NMR techniques, coupled with a modem metabolomics
approach, to provide further information in understanding the underlying
physiological biochemistry of malodour. Global profiling via LC-MS, using high
mass accuracy instrumentation such as QTOF or an orbitrap, and NMR will provide
complementary metabolite information (Lanza et al., 20 10; Lenz et al., 2004;
Williams et al., 2005a). This approach is typically used when biological knowledge is
limited. A large number of metabolites are detected without a priori information,
thereby, increasing the complexity of the data and as a result does not provide
automatic chemical identification. Metabolite identification is currently one area that
requires significant development, typically with LC-MS data. In comparison to NMR
data, metabolite identification is less complex due to NMR databases being relatively
well defined. The information obtained, coupled to MY A techniques, aims to identify
inter- and intra-individual differences as well as providing further knowledge into the
chemical composition of apocrine sweat. Targeted or semi-targeted LC-MS will
provide information about metabolites of interest (either monitoring for specific
metabolites using unique MRMs or a survey analysis for the same class of metabolites
such as odour precursors). These strategies require the use of QQQ mass
spectrometers which provide greater specificity compared to that of a QTOF or
orbitrap spectrometers. The data obtained is often less complex then data obtained
from global methodologies. Furthermore, targeted methodologies provide an increase
in sensitivity (readily detecting sub picomolar concentrations) and provide
quantitative information when using internal standards. Thus, the targeted
methodologies will be able to screen for known odour precursors, while the semi-
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targeted methodology using PI scanning provides the ability to screen for known and
unknown odour precursors present in human apocrine sweat.
1.8 Aims of the Thesis
The overall aim of this project is to develop analytical methods that will ultimately
allow the composition of axillary malodour to be identified, with particular reference
to identifying new odour precursors. The project aims to achieve this by: -
• Developing and optimising, bothNMR and Le-MS methodologies for the
global analysis of human apocrine sweat secretions
• Developing and optimising mass spectrometry methodology for the analysis of
conjugated fatty acids and thiols present in human apocrine sweat secretions
• Assessing inter-subject variability
• Assessing intra-individual differences between secretion obtained from the left
and right arm
• Providing further knowledge to the chemical composition of human apocrine
sweat
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Chapter 2
2 Development of 'n NMR Spectroscopy Methodology for the
Metabolomic Analysis of Apocrine Sweat
2.1 Introduction
NMR spectroscopy is one of the major technologies for metabolic profiling (Griffin,
2006; Lindon and Nicholson, 2008) due to its ability in providing comprehensive
chemical information about unknown metabolites as well as providing information on
a variety of dynamic processes, such as protein ligand binding (Liu et al., 1997; Luo
et al., 1999; Medek et al., 2000; Pellecchia et al., 2002). Moreover, NMR
spectroscopy benefits from being a specific and yet a non-selective technique (i.e.
independent of the chemical properties of the metabolites being analysed). This
means each observable resonance is specific to a particular metabolite, thereby, aiding
identification of individual constituents. Moreover, the same observable nuclei (i.e. all
iH) have the same sensitivity, thus, in theory absolute concentration of metabolites
can be determined when measured with an internal standard (e.g. TSP). The majority
of biological samples analysed by NMR spectroscopy are measured in solution state,
however, intact tissue samples using high resolution magic angle spinning (HR-MAS)
can also be analysed (Sitter et aI., 2009). In addition, NMR requires minimal sample
preparation, with only the addition of deuterated solvents such as 020 or COCb to
provide a frequency lock of the magnetic field as well as being non-destructive
allowing several analyses to be conducted on the same sample. Currently, no NMR-
based study to date has attempted to qualitatively and quantitatively profile
endogenous metabolites present in human apocrine sweat. Thus, NMR spectroscopy
could provide a powerful tool for the analysis of human apocrine sweat. However,
apocrine sweat is secreted in low volumes, typically 5 Ill, with the majority of the
metabolites present being lower concentrations than those found in plasma. Thus,
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NMR methodologies need to be developed in order to compensate for the restricted
sample volumes.
Over the last 50 years, the field of NMR has developed a sophisticated array of
experimental capabilities (Braun and Berger, 2004). For example, ID NOESYPRI D
pulse sequence provides good solvent suppression while a ID 1H Carr-Purcell-
Meiboom-Gill (CPMG) pulse sequence (Meiboom and Gill, 1958) can be used to
reduce signals from large macromolecules such as phospholipids triglycerides and
lipoproteins which give rise to broad signals while retaining those from smaller
molecules such as amino acids and carbohydrates (Foxall et aI., 1993; Harker et aI.,
2006; Nicholson et aI., 1995). However, compared to other common spectroscopic
methods of molecular characterisation, NMR is by far the least sensitive as shown in
Table 2.1 (Lacey et al., 1999).
Table 2.1 Limit of detection for common analytical techniques (Lacey et al., 1999).
Method LOO (mol)
Fluorescence 10-18 _ 10-23
Mass Spectrometry 10-13 - 10-21
Electrochemical 10-15 - 10-19
Radiochemical 10-14_10-19
UV-Vis absorbance 10-13 - 10-16
NMR 10-9 - 10-11
NMR insensitivity stems from the fact that the energy levels of transitions are
narrowly separated. Maxwell-Boltzmann statistics dictates that the population
differences between the upper and lower energy states represents only a tiny fraction
«0.01 %) of the nuclear spins from the total number of molecules (Lacey et aI.,
1999). Thus, NMR spectroscopy can only detect and quantify metabolites present in
relatively high concentrations, whereby, 20-40 metabolites are typically detected in
tissues (Griffin et al., 200 I), 20-30 and 30-100 metabolites detected in blood plasma
(Brindle et al., 2002) and urine samples respectively (Connor et aI., 2004).
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Historically, the need for relatively large sample volumes was dictated by the low
sensitivity of the NMR instrument. However, modem advances in technology have
brought about higher field strength magnets and a steady improvement of NMR
probes, which have increased the overall sensitivity of the method (Eisenreich and
Bacher, 2007; Schlotterbeck et al., 2006). For instance, ultra high field NMR
spectrometers (up to 900 MHz) and cryogenically cooled detector coils are available
(Wishart, 2008). Nevertheless, analysis of micro volume samples, e.g. natural section
of body fluid (apocrine sweat), still remains challenging (Schlotterbeck et al., 2002).
The introduction of cryogenically cooled probes offers an increase in sensitivity by a
factor of three to four compared to conventional probes by super cooling the receiver
coil and preamplifiers to 25 K or below, resulting in a reduction of the thermal noise
(Schroeder and Gronquist, 2006; Spraul et al., 2003). However, the spectral
dispersion of each signal remains the same (Schroeder and Gronquist, 2006).
Nonetheless, in terms of cost implication, the cryoprobe offers considerable
advantage over installing higher-field spectrometers, for example; 900 MHz only
offers an increase in sensitivity by a factor of two as compared to at 600 MHz,
therefore the increase in sensitivity is only modest in comparison (Rinaldi, 2004).
The simplest and cheapest approach to increasing the signal-to-noise without
acquiring more expensive higher-field strength magnets or changing the RF coil is to
use small sample tubes to decrease the volume required for acquisition. Typically, a
total volume of 600 J.11is required for sample acquisition when using 5 mm OD NMR
tubes, as this volume is enough to 'fill' the coil of the probe so the field homogeneity
will not be disturbed. Specially designed tubes such as capillary tubes or spherical
inserts can be used to limit the sample volume to just the volume of the receiver coil,
while a Shigemi tube compensates for less volume by using 020 matched glass. Thus,
the aim of this chapter was to evaluate different NMR field strengths (400 and 500
MHz), probes (5 mm quattro nucleus probe (QNP), I mm micro-volume triple
resonance inverse probe (TXI), and 5 mm TXI cryoprobe) and NMR tubes (e.g.
standard tubes, Shigemi tubes, capillary tubes) in order to find the optimum analytical
set-up which will ultimately be applied to the analyse of apocrine sweat which
typically have 5 III sample size volume.
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2.2 Aims
• To create an artificial sweat matrix suitable for method development.
• Establish suitable NMR methodology to provide the optimum sensitivity for
the analysis of low sample volumes, which, will be later used for the analysis
of apocrine sweat.
• Use multivariate analysis to determine whether any correlation exists between
the storage lengths of the artificial sweat matrix.
2.3 Materials and Methods
2.3.1 Chemicals
Creatine, 020, pyruvate, and trimethylsilyl [2,2,3,3/H4] propionate (TSP), was
purchased from Fisher Scientific (Loughborough, UK). Citric acid, lactic acid
ornithine, and potassium phosphate were purchased from Sigma Aldrich (Poole, UK).
Creatinine was purchased from Alfa Aesor (Heysham, UK). Neocate was purchased
from SHS International Ltd (Liverpool, UK). Neocate is composed of dried glucose
syrup, non-hydrogenated coconut oil, high oleic sunflower oil, refined vegetable oils
(canola, sunflower), arginine, aspartate, leucine, lysine acetate, glutamine, calcium
phosphate dibasic, proline, valine, emulsifier (E472c), tripotassium citrate, isoleucine,
glycine, threonine, tyrosine, phenylalanine, serine, histidine, alanine, cystine,
tryptophan, sodium chloride, methionine, magnesium aspartate, high arachidonic
single cell vegetable oil, choline bitartrate, magnesium chloride, tricalcium citrate,
ascorbic acid, potassium chloride, myo-inositol, high docosahexaenoic acid single cell
vegetable oil, taurine, ferrous sulphate, zinc sulphate, carnitine, nicotinamide, OL-
alpha tocopheryl acetate, calcium O-pantothenate, antioxidants (E304, E307 and
E306), manganese sulphate, copper sulphate, vitamin A acetate, pyridoxine
hydrochloride, thiamine hydrochloride, riboflavin, potassium iodide, folic acid,
chromium chloride, sodium molybdate, vitamin K 1, O-biotin, sodium selenite,
vitamin 03 and cyanocobalamin.
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2.3.2 Sample Preparation
Apocrine sweat is a complex mixture with a wide range of metabolite concentration
with different chemical properties. This diversity together with limited sample
availability creates an analytical challenge when developing analytical methodologies.
Thus, an artificial sweat matrix was developed for the purpose of developing
analytical methodologies and was not intended to replicate apocrine secretions per se.
An artificial sweat model (see Table 2.2) was proposed through personal
communication with Dr Mark Harker (Unilever). However, due to the complex nature
of blood plasma, the premise of the artificial sweat matrix was based on an amino
acid hypoallergenic infant formula from Neocate (www.neocate.co.uk). The use of
the Neocate as a biological matrix meant that the full quantitative composition of all
the components were known (see www.neocate.co.uk/aaa neocatel15999-
ingredients.html) compared to a biological matrix from blood plasma, which is
considerably more complex. Thus, Neocate provided a suitable matrix that was well-
defined (in comparison with blood plasma), protein free (allowing comparative
evaluation of the metabolites without complication from protein binding) and contains
both low molecular weight metabolites and lipids. Additional metabolites that have
been reported in eccrine sweat were also added. Each metabolite (see Table 2.3) was
individually weighed out and spiked into the Neocate to create the desired
concentration and made up to I ml with phosphate buffer (pH 6, 0.1 M). For storage
purposes, the stock solution was then aliquoted into smaller sample volumes of 40 J.LI
and stored at either -20°C or 4°C until required.
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Table 2.2 Artificial apocrine secretion model initially proposed for method development through
collaboration with Unilever.
Ingredient Level in ug/ml
Cholesterol
Cholesterol esters
Wax esters (lanolin)
Squalene
Glycerides (tristearin)
Fatty acids (stearic acid)
Lysozyme
ApoD
Zn -o-glycoprotein
Amino acids/conjugates
Glutamine conjugate
Cysteine conjugate
Carbohydrate (glucose)
Androsterone sulphate
Dehydroepiandrosterone sulphate
Synthetic plasma with phosphate buffer (pH 6)
18.75
0.25
0.9
0.005
2.5
2.5
40,000
5,000
5,000
10,000
Estimate 5
Estimate 5
1000
5
5
To Iml
Table 2.3 Artificial sweat matrix composition used for NMR method development. The amount of
Neocate used was based on the amino acid content to reflect that of the apocrine secretion model
above.
Metabolite Level in m~/ml Reference
Ornithine 0.017 (Coltman et al., 1966; Liappis and Hungerla.H,
1972)
Creatinine 0.061 (Fukumoto et al., 1988; Mosher, 1933;
Stjohnlyburn, 1956)
Creatine 0.0079 (Stjohnlyburn, 1956)
Pyruvate 0.086 (Jin et al., 200 I)
Citric acid 0.068 (Leake, 1922)
Lactic acid 3.90 (Mosher, 1933; Patterson et al., 2000;
Stjohnlyburn, 1956; Weiner and Vanheyningen,
1952)
Neocate powder 61.48
Nutritional summary of Neocate
Protein equivalent 7.92
Total amino acids 9.53
Carbohydrates 33.12
Sugars 3.01
Fat 14.14
As saturates 5.16
Monounsaturates 5.53
Polyunsaturates 2.77
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2.3.3 IHNMR Spectroscopy
The preparation of the artificial sweat mixture for IH NMR analyses varied depending
on the type of NMR tubes being utilised. 5 J..11of the actual amount of artificial sweat
used remained constant, while the amount of 020 containing a primary reference
standard, trimethylsilyl [2,2,3,3,- 2H4]propionate (TSP, -7.6 mM) varied as follows: -
• Standard 5 mm OD NMR tubes, 650 J..1l020.
• Shigemi tube, 300 J.lI020
• Capillary NMR tubes, 180 J..11020
• Spherical insert, 10 J..11020
• 1mm Micro-volume probe, 3 J..1l020
IH NMR spectra were acquired on a Bruker Avance 400 spectrometer, operating at
400.13 MHz IH observation frequency and equipped with a quadruple resonance eH,
BC, 31p, 19F) QNP probe with an internal probe temperature of 298 K, a TXI I mm
micro-volume probe equipped with Z-gradient with a internal probe temperature of
298 K and a Bruker ORX-500 spectrometer, operating at 500.18 MHz IH observation
frequency, equipped with a triple resonance (IH, 13e, 15N) cryogenically cooled TXI
probe with an internal probe temperature of 303 K.
Spectra were acquired using a conventional solvent presaturation pulse sequence for
solvent suppression based on the start of the NOSEY pulse sequence [RO-900-tl-90° -
tm-90° -acquire free induction decay], where 90° represents a non-selective 90° RF
pulse, RO is a relaxation delay of 1.5 s during which the water peak was selectively
irradiated, and tl corresponds to a fixed interval of 3 us. Typically, 256 transients
were collected into 32 K data points with a spectral width of 8000 Hz. Prior to Fourier
Transform, exponential line broadening of 0.3 Hz was applied to FIOs which were
zero-filled by a factor of 2. All spectra were manually corrected for phase and
baseline distortions within TopSpin TM 2.1 (Bruker Analytische GmbH, Germany) and
chemical shifts referenced to TSP standard at 00.00 ppm.
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2.3.4 Spectral analysis and metabolite quantification
Relative quantification of each identified metabolite peak was achieved by integration
of IH NMR peaks using Bruker AMIX program. IH NMR can be used to analyse the
relative concentrations of different metabolites because the area under each resonance
is directly proportional to the number of nuclei giving rise to that resonance.
Resonances from these metabolites were integrated along with those from the internal
standard, TSP. The amount of each metabolite was then calculated in mmollL using
Equation 2.1 and then converted from molar concentration to mg/L afterwards.
Equation 2.1
where
m = Metabolite
s = Standard
= Peak area integral
N = Number of protons
C = Concentration
2.3.5 Data Pre-Processing
The IH NMR spectra were reduced into consecutive integrated spectral regions of
widths 0.04 ppm using AMIX software (Analysis of MIXtures, Bruker), also referred
to as "bucketing". The region M.50-5.18, surrounding the water resonance was
excluded from the analysis in order to remove the effects of variations in the
suppression of the water resonance. The resulting data matrix was exported into
Microsoft Excel 2007 and block-normalised by calculating the intensity of each
bucketed spectral region as a percentage of the total spectral area, in order to
minimise the effects of any concentration differences between samples.
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2.3.6 Partial Least Squares Regression (PLS)
PLS regression was carried out using SIMCA-P version 11 (Umetrics, Umea,
Sweden) in order to determine the covariance between the NMR profiles and the
observed storage time. PLS regression is a well established technique for modeling
biochemical data and has been thoroughly described and explained by Geladi and
Kowalski (Geladi and Kowalski, 1986). PLS builds a regressive model by
maximizing the covariance between a set of variables X and a dependent variable y
and it thus called a supervised method. The model is then used to predict values of y
for a given set of X variables. The number of latent variables (LV) used to predict y is
determined using cross-validation where the sample set is divided into a number of
segments which in turn are excluded before re-entering into the model in order to
estimate the prediction error. The optimal number of LV's used in the prediction
model is chosen when the least error in prediction is observed. To evaluate the models
performance, a random sub-set cross-validation was used where two thirds of the
samples were used to create a training set and a third used as a test set.
2.4 Results and Discussion
The basic premise underlying the development was to obtain the highest possible SIN
ratio from a limited sample volume (5 Ill). This enhancement was also coupled with
the desire to be cost effective and user-friendly. It has been well documented that
decreasing the sample concentration by half requires quadrupling the number of
transients to maintain a given SIN (Martin and Hadden, 1999). It was on this basis
that the comparison between 5mm OD NMR tubes, 1.7 mm capillary NMR tube,
Shigemi tube as well as the use of the 1 mm NMR micro-volume probe on a 400 MHz
spectrometer and 500 MHz with a cryro-probe was conducted. This study compared
the results obtained from IHNMR spectra of artificial sweat matrix.
A typical 400 MHz 1H NMR spectrum of the artificial sweat mixture is given in
Figure 2.1. At this stage, all peak assignments are tentative, based on comparison
against spectra of authentic reference standards contained in a spectral database.
Verification of these peak assignments will require the acquisition of 20 NMR
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spectra such as correlation spectra (COSY), total correlation spectra (TOCSY) and J-
Resolved spectra (J-Res). However, due the composition of the artificial sweat matrix
being well defined this was not necessary.
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Figure 2.1 Typical 400 MHz 'H NMR spectrum of artificial sweat mixture obtained using 1 mm
micro-volume probe. The metabolites are tentatively assigned. Spectra were acquired using a standard
1D NOESYPRESAT sequence where ns = 256 scans.
2.4.1 Signal-to-Noise-Ratio
In NMR, the SIN is typically defined as the ratio of the height of any given peak in an
NMR spectrum divided by two times the root mean-square of the noise floor (Lacey
et aI., 1999). The sensitivity of an NMR experiment is governed by the properties of
the probe for a given field strength and sample concentration. Other parameters such
as the number of transients (ns) and total acquisition time (tacq) can affect spectral
results since the SIN ratio is proportional to the square root of the number of spectra
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accumulated. Thus, the SIN ratio of a single scan can be increased by a factor of two
by acquiring four scans, resulting in a four-fold increase in acquisition time.
Similarly, the same SIN ratio may be obtained in one fourth of the time by doubling
the sample concentration (Abraham et al., 1988).
Table 2.4 highlights the mass sensitivity of the 5 mm QNP probe with the use of
either capillary, Shigemi, and conventional 5 mm OD NMR tubes compared to that of
a conventional 5 mm TXI cryo-probe and 1mm micro-volume TXI probe.
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From a practical point of view, the conventional NMR tubes (OD 5 mm) which are
filled to a total volume of 600 ul, are user-friendly and with the use of the cryo-probe
offer considerable advantage over the same tubes used on the 400 MHz spectrometer.
The simplest approach to potentially increasing the SIN without having to upgrade the
field strength or probe design is to use smaller sample tubes (which may feature
deuterium matched glass) or tube inserts to decrease the total volume required for an
experiment. In theory, if the sample volume is decreased by a factor of four then the
concentration can be increased by a factor of four, however, the number of spins (1H
of each atom) detected remains constant (Lacey et al., 1999).
The Shigemi tubes (which have a total volume of 300 ul) are expensive and difficult
to handle, and unlike the options available above, automation is not possible and
therefore labour intensive and for this reason these were only acquired on the 400
MHz spectrometer. The results obtained are illustrated in Table 2.4. The use of
solvent susceptibility matched shigemi tube should improve solvent suppression, RF
homogeneity and overall performance resulting in a two-three fold increase in
sensitivity (Schroeder and Gronquist, 2006). As illustrated in Table 2.4, the general
increase observed was two to three-fold when compared to standard S mm OD NMR
tubes. However, due to the expense and labour intensive nature of preparing the
samples for acquisition this method was not considered as a viable option.
The capillary NMR tubes (OD 2.S mm, L 178 mm) reduced the total volume required
to 180 ul, However, as illustrated in Table 2.4, only offered a marginal increase in
sensitivity over the conventional NMR tubes and proved to be less sensitive when
acquired on the 500 MHz equipped with a cryo-probe. The lack of increase in
sensitivity could be related to the fill factor as the RF field can be inhomogeneous
with space, which is determined by the probe design (Jahnke, 1996). Since the
capillary tube is further away from the B, field, compared to the standard tubes, the
accuracy of the NMR measurements therefore diminishes causing line-broadening
effects and reducing the overall sensitivity.
Alternatively, the sample can be contained in a spherical microcell bulb as depicted in
Figure 2.2, reducing the volume to 18 ,..il (www.wilmad-labglass.com/group/20IS).
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The PTFE holder holds the microcell within the standard 5 mm OD NMR tube, and
the positioning rod allows one to insert and remove the assembly from the tube. Both
the PTFE holder and positioning rod are reusable while the inserts are intended for
one time use. It must be stressed that locating the active region of the RF coil is not a
trivial task. Moreover, shimming the sample is also difficult due to the air/glass
interface within the NMR coil, resulting, in inhomogeneity of the sample, which again
contributes to further line broadening effects. As a result, no useful data could be
attained from using this method.
Positioning Rodn Assembly prior toU removal of rod
Spherical insert
T
50mm
1
5 A
Figure 2.2 Schematic diagram of the 5 mm micro-cell assembly.
Micro-volume probes allow samples as small as 5 III to be handled successfully;
however, quantitative transfer of a sample this small from the container to the NMR
tube is still problematic. This is especially true when dealing with rare samples (e.g.
sweat) rather than a diluted stock solution, although this problem could be minimised
via the use of robotics. Another consideration, which would not be problematic for
larger volume sizes, is the rate of moisture sorption. With the sample handling
problems aside, there are additional advantages to using a micro-volume probes. For
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example, signals from solvent impurities are much less prominent and 'solvent noise'
from electrically conductive solvents (salt containing solutions) is reduced (Martin
and Hadden, 1999). Another advantage of using small volumes is the reduction in the
amount of expensive deuterated solvents (Schlotterbeck et aI., 2002) as well as the
reduction in data acquisition time.
The results obtained are illustrated in Table 2.4. The comparative performance in the
study demonstrates that the 1 mm micro-volume probe offered at least a 5-8 fold
performance advantage over data acquired with a 5 mm OD NMR tube and offered a
similar SIN ratio of the standard NMR tubes acquired with 500 MHz equipped with a
cryo-probe. Thereby, using small sample volumes without the need for diluting the
sample, offered a considerable advantage in sensitivity over the other techniques
examined. Compared to the 5 mm tubes, the mean enhancement of 7.8 represents a
decrease in data acquisition time of 60.84 (7.82) or the ability to perform an
experiment in the same amount of time with 12.8% (117.8) of the sample mass.
The SIN value is directly proportional to the active volume of the probe (Yobs) for a
concentration-limited samples. Thus, if an NMR tube is placed in the probe which has
a two-fold decrease in its inner diameter; Yobs is decreased four-fold, as well as the
concentration sensitivity. Thus, to maximise the SIN, the tubes with the largest Yobs
(up to the maximum allowed by the probe) should be used, but at the expense of using
additional sample. While a reduction in the diameter of the receiver coil increases the
SIN ratio (Schroeder and Gronquist, 2006), a reduction in coil diameter inevitably
results in a decrease in the sample volume, thus, micro-volume probes will only
provide a sensitivity advantage where the mass-limited sample is fully soluble in the
smaller volume. However, for concentration-limited samples, micro-volume probes
will offer no competitive advantage as the small probe will accommodate less of the
sample compared to that of conventional probes.
Cryogenic probes substantially increase the SIN ratio as shown in Table 2.4. In
general these probes offer an advantage when the sample concentration is low, 20 or
3D experiments are required due to the low intrinsic sensitivity, and when the
experiment time needs to be reduced.
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2.4.2 Application with Mass Limited Samples
The spectra depicted in Figure 2.3 clearly show the power of reducing the sample
volume size for metabolite identification. Using the 1 mm micro-volume probe we
have been able to acquire IH NMR spectra from a limited sample volume of 5 ,..rl
which has comparable sensitivity to that of the 500 MHz equipped with a cryo-probe.
Tryptophan
Phenylalanine1TY'7ine Tyrore
l_____jL
Histidine
A
o
1..3 8.2 8.1 1.0 7.1 7.1 7.7 7.1 7.$ 7.4 7.3 7.2 7.1 7.0 1.1 ppm
Figure 2.3 Spectra comparison of the artificial sweat matrix obtained from A 5 mm OD NMR tube
acquired on a 500 MHz equipped with a cryo-probe. B-E acquired on a 400 MHz spectrometer with B
5 mm OD NMR tube C Shigemi tube D capillary tube E micro-volume probe.
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The limit of detection (LOO) and limit of quantification (LOQ) are defined as being 3
or 10 times the intensity of the noise respectively (Olson et al., 1998). This is shown
in Table 2.5 and was calculated by using Equation 2.1, substituting L; for the average
noise intensity as previously reported (Savage et al., 2011). The concentration LOOs
are in the low mg/ml range which may seem high, they correspond to nanomole
amounts of sample, which is consistent with previous reports (Olson et al., 1998). The
ability to acquire high resolution spectra with 5 III samples with improved mass
sensitivity can further increase NMR popularity to biological applications in cases
were only a limited volume of biotluid is available. The reduced volume also has the
added advantage of reducing the background noise, as there is a smaller signal from
the residual protonated solvent which is less detrimental to the quality of the spectrum
obtained. Furthermore, there is a reduction of the "solvent noise" arising from
electrically conductive solvents such as salt containing solutions. This has been
shown by Olson and co-workers, where they reported a reduction in the SIN of <10%
from a 30 mM sucrose concentration in the presence of 500 mM KCI (Olson et al.,
2004). An additional advantage of small-volume NMR probes is the reduction in the
amount of expensive deuterated solvents (often by two orders of magnitudes).
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2.4.3 The Application of PLS Regression to Determine the Stability of Artificial
Sweat Mixture during Storage
There were no obvious differences between the NMR spectra of the artificial sweat
mixture acquired at varying storage time points when analysed by visual inspection.
Thus, applying multivariate techniques through the use of projections will provide
useful analysis to determine the relationship between multitudes of signals detected in
the NMR spectrum over the storage period of one month. PCA is purely used as a
visualisation method to highlight any major trends in the data (i.e. any variation in the
NMR profiles) but gives no information how this is related to the amount of time
being stored either at 4°C or -20°C. In comparison, PLS allows correlation with
external variables to be evaluated in order to determine whether any correlation exists
between the NMR profiles (X) and the storage period (y). To test the predictive power
of the model, the data set was split into a training set containing the majority of the
samples and a test set containing approximately one third of data. This equated to
randomly removing whole days, because data included from replicate measurements
in the training set will bias the model towards a better fit. To validate the predictions,
five iterations were produced for both storage conditions to gain an accurate
representation of the models in order to obtain stable prediction errors. In order to
evaluate the performance of the predicative models the Root Mean Square Error
(RMSE) in combination with the correlation coefficient (r) are used as a measure.
RMSE is defined as follows:
RMSE = ~I(ypred - Yref )2
N
Equation 2.2
where ypredis the predicted value, Yrefis the measured value, and N is the number of
samples. RMSEE is the root mean square error of the observations/training set and
RMSECV is the root mean square error of cross validation which evaluates the
stability of the current data set. If the model is good the RMSEE and RMSECV
should be quite similar.
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Three samples were omitted from both storage models due to poor NMR spectral
quality. Leave one out internal cross validation of the training sets indicated two
latent variables (LV) was optimal for the 4"C storage and one latent variable was
optimal for the -20CC storage. The results from using five random subset cross
validation procedures for both storage conditions are summarized in Table 2.6, while
a representative model from both storage conditions are depicted in Figure 2.4, where
the predicted versus observed values (days) are plotted for both the training set and
test set.
Table 2.6 Performance of PLS regression models from the artificial sweat matrix stored at 4°C and
-20°C. IH NMR spectra as X variable and storage day as y variable. Mean values are calculated from
five iterations.
Condition LV' RIX~eumt RIY~eum~b !t~eumr RMSEEd RMSECV" R ~lIIIi"i~
f
R ;J;;millill
f
4°C 2 0.27 ± 0.02 0.87 ± 0.02 0.49 ± 0.15 2.94 ± 0.4 55.52 ± 73.22 0.44 ± 0.17 0.93 ± 0.01
-20°C 0.18 ± 0.02 0.74 ± 0.09 0.54±0.16 3.77 ± 1.04 8.35 ± 3.31 0.61 ± 0.2 0.86 ± 0.05
-20°C ~no da~ O~ 0.18 ± 0.03 0.71 ± 0.1 0.4 ± 0.26 3.85 ± 0.85 10.94 ± 5.06 0.37 ± 0.27 0.84 ± 0.06
a LV = Number oflatent variables
b RI (X or Y)eum =Cumulative fraction of Sum of Squares (SS) of all the X's or Y's explained after each extracted component
C Qleum = The cumulative QI for the extracted components
d RMSEE = Root mean square error of the fit for observations in the work set
e RMSECV = Root mean square error of cross validation of the prediction set
f R = Correlation coefficient
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Figure 2.4 PLS derived relationship between observed and predicted storage day using IH NMR
spectra of the artificial sweat matrix. A and B PLS models from the artificial sweat stored at 4°C, C
and D are the PLS models from the artificial sweat stored at -20°C. The predicted values of the test set
are plotted against the observed storage day to visualise the predictive power of each model.
The results of the PLS models produced average R2X(cum) and R2Y(cum) values of
0.27 and 0.87 respectively and Q2(cum) was 0.49 for the 4°C storage condition and
R2X(cum) and R2Y(cum) values ofO.18 and 0.74 respectively and Q2(cum) was 0.54
for the -20°C storage condition. Generally, R2X(cum), R2Y(cum) and Q2 values
should be well balanced as any differences larger than 0.2 indicate the presence of
irrelevant model terms or a few outlying data points (Eriksson et al., 200 I). Together
with a correlation coefficient (r) of 0.44 and RMSECV 55 days for the 4°C storage
and r 0.54 and RMSECV 8 days for -20°C storage shows there is weak linear
correlation between NMR profile and the number of days in storage and poor
prediction ability for both models. A large standard deviation error of RMSECV
indicates that the models are not stable. Furthermore, the r value of 0.9 and 0.44 for
the 4°C storage condition and r 0.86 and 0.61 for the -20°C storage condition for the
training set and predictive set respectively, indicate the model could be over fitted as
these values are unbalanced. From this, it can be concluded that both storage
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conditions don't significantly change over a course of a month and that any alterations
in sample composition are likely to be random. Moreover, models with day 0 being
omitted from the training set for the -20ce storage condition were produced to see if
freezing the samples had an effect. As illustrated in Table 2.6, these models are
similar and therefore can be concluded that freezing had minimal effect.
2.5 Conclusion
The aim of this chapter was to create an artificial sweat matrix, designed to broadly
replicate apocrine gland secretions, in order to develop NMR methodology which will
be suitable for the analysis of low sample volumes. The comparative performance
assessment described in this study demonstrate that the I mm micro-volume probe
offers an - 5.3 fold performance advantage over data acquired for the same mass
limited sample using specialist tubes with a 5 mm sample probe. Furthermore, the
micro-volume probe offers a similar enhancement to that offered from a 500 MHz
instrument equipped with a cryoprobe. However, in terms of maintenance and cost, it
is more viable to use the micro-volume probe. NMR spectroscopy-based studies on
the whole are typically robust and reproducible and differences in solvent suppression
are generally minor when compared to the effects caused by biological change. The
stability study showed that there was minimal change over the storage of one month
in both the samples stored at 4ce and -20ce. Thus, when comparing the
reproducibility and sensitivity of different methods, storage conditions can be
removed as an interfering factor. The high sensitivity offered by the 1 mm micro-
volume probe opens many new potential avenues of investigation of limited volumes,
weights, and low cell counts in biological sample, e.g. rodent CSF (Griffin et al.,
2002), urine and serum (Grimes and O'Connell, 2011) or apocrine sweat.
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Chapter 3
3 Development of Mass Spectrometry Methods for the Analysis of
Key Metabolites in Apocrine Sweat
3.1 Introduction
Mass spectrometry is a mature and well established analytical technique which can be
applied with or without chromatographic separation before detection. MS can offer a
number of advantages over other analytical techniques, including increase in
sensitivity, chemical identification capabilities via accurate mass measurements or
mass spectrum interpretation, as well as the ability to quantitatively detect hundreds
of metabolites in a given sample when combined with chromatography. In
comparison to NMR spectroscopy, samples physically interact with the instrument
which can change the response over short to medium periods oftime, highlighting the
importance of QC samples, as well as being destructive to the sample.
The analysis of apocrine sweat in the literature is predominantly focused on odour
content, thus, the analytical strategies commonly used are GC-MS or variations of this
(e.g. headspace analysis), which will be able to describe the volatile organic
compounds that are present in apocrine sweat (Gower et al., 1997; Natsch et al.,
2006; Penn et al., 2007). However, these studies are mostly intended to characterise
malodour rather than individual odour per se. Although the components of sweat have
been studied, there is comparatively little attention to the biochemistry of axillary
odour formation. Consequently there is limited literature available regarding the
chemical structures of odour precursors isolated from axilla secretions, and no
specific bacterial enzymes capable of recognising these precursors have been isolated.
Furthermore, estimates for inter-individual variability or intra-individual consistency
as well as the identities of individual odour need to be addressed.
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A range of MS-based methods have been developed over recent years to undertake
metabolic profiling of biological tissues, and the major approaches are summarised
here.
3.1.1 Direct Injection Mass Spectrometry (DIMS)
The analysis of metabolite profiles from crude samples or sample extracts by DIMS
can be performed in 1-3 min, providing a rapid, high throughput method, capable of
screening up to 1000 samples per day (Rashed et al., 1997). The samples can be
introduced into the MS either through the use of the HPLC system (Kaderbhai et al.,
2003) or infused with syringe pumps (Goodacre et al., 2002), resulting in one mass
spectrum per sample, which is used for sample classification. Direct injection can
avoid the disadvantages of LC system; noise levels, retention time shifts and high
variability in signal intensities (Boemsen et al., 2005). However, it is not without its
pitfalls, as analysis is susceptible to ion suppression effects that arise from the
competitive ionization with other compounds within the matrix. For example, the
types of interference that can occur during acquisition are typically from ionic
compounds such as salts, charged organic compounds, organic acids/bases, and
hydrophobic compounds. However, through the use of a nano electrospray setup,
these effects can be reduced due to the increase in ionization efficiency (Bedair and
Sumner, 2008). Definitive metabolite identification is also a limitation with this
technique due to the inability to distinguish between isomeric compounds.
3.1.2 Reverse Phase High Performance Liquid Chromatography Mass
Spectrometry (RP-HPLC-MS)
MS based metabolomics are predominantly linked with GC (Fiehn et al., 2000;
Welthagen et al., 2005), HPLC (ldborg-Bjorkman et al., 2003; lander et al., 2004;
Plumb et al., 2002), or CE (Baidoo et al., 2008; Sato et al., 2004; Soga et al., 2003),
which can overcome many of the drawbacks of DIMS such as; increasing sensitivity
due to reduction in background noise, reducing ion suppression caused by co-eluting
compounds, and reducing isobaric interferences. For metabolomic purposes, HPLC-
MS separations have primarily relied on using reversed-phase (RP) chromatography
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coupled to electrospray ionization (ESI) in both positive and negative mode to obtain
a comprehensive metabolic profile (Lenz and Wilson, 2007). RP-HPLC columns are
composed of a non-polar stationary phase, typically silica, which has been modified
with dimethylchlorosilane, containing a bulky alkyl group such as C IsH37or CsH 17 to
form the hydrophobic surface and an aqueous polar mobile phase. Thus, RP-HPLC
separations are suitable for compounds of medium and low polarity, while more polar
compounds (e.g. amino acids and sugars), are not well retained and non-polar
compounds (e.g. lipids) are difficult to elute. These limitations can be partially
overcome through the use of graphitized carbon columns (Tornkvist et al., 2004), pre-
column derivatization or through the use of ion-paring agents (e.g. perfluorinated
carboxylic acids). Such approaches have not found widespread use because of
practical difficulties in applying to biological extracts. Thus, these polar and ionic
metabolites have traditionally been under represented in metabolomic studies.
HPLC-MS is capable of moderate to high throughput analysis with a reasonable
dynamic range. However, unlike IH NMR spectroscopy, HPLC-MS is chemically
biased, as compounds need to be ionized in order to be detected as well as the column
chemistry being selective to certain chemical species (typically non-polar metabolites,
including lipids for RP-HPLC). Moreover, HPLC methods involve several parameters
that need to be checked and validated such as sample handling, mobile phase
composition, column chemistry, and gradient, which can be a time consuming
process.
3.1.3 Hydrophilic Interaction Liquid Chromatography (HILIC)
An alternative technique for the separation of polar compounds is hydrophilic
interaction liquid chromatography (HILlC), which was first introduced by Alpert for
the separation of peptides, nucleic acids and other polar compounds (Alpert, 1990)
and later used by Strege for drug research (Strege, 1998). HILIC is analogous to
normal phase chromatography in that it utilizes a hydrophilic stationary phase,
allowing the retention of polar analytes (Cubbon et al., 2007). However, unlike
normal phase, HILIC allows the use of aqueous/polar organic solvents, which are
more compatible with ESI-MS system. In contrast to RP-HPLC, gradient elution
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begins with low-polarity organic solvent and elutes polar analytes by increasing the
polar aqueous content. However, the exact retention mechanism for HILlC is still
open to debate within the scientific community. Alpert (Alpert, 1990) suggests that
compounds are partitioned between a polar organic mobile phase and the water-
enriched layer of the mobile phase that is partially immobilized on the polar stationary
phase. Others have reported that separation is mainly governed by polar-polar
interactions i.e., hydrogen bonding which depend on the acidity or basicity of the
solutes, electrostatic interactions, dipole-dipole interactions, which rely on the dipole
moments and polarizabilities of molecules (Wang et al., 2008; Yoshida, 2004). In a
recent review, Hemstrom and Irgum (Hemstrom and Irgum, 2006) considered the
contribution from both the partitioning and adsorption processes and found that they
fit better with the Synder-Soczewinski adsorption model (Snyder and Poppe, 1980)
than the partitioning model (Wang et ai., 2008). The advantages of HILlC have been
summarised (McCalley, 2007) as:
• Good retention of polar and ionic compounds compared to RP-HPLC.
• The order of elution of solutes is generally the opposite of that found in RP-
HPLC, thereby, providing an alternative selectivity.
• Higher flow rates are possible due to the high organic content of typical
mobile phases.
• ESI-MS sensitivity is enhanced in comparison to normal phase due to the high
organic content in the mobile phase and the high efficiency of spraying and
desolvation techniques.
• Good peak shape can be obtained for bases.
In HILlC mode, the mobile phase generally consists of between 5 and 50% water
(Alpert, 1990), however, the composition is dependent on the polarity of both the
stationary phases and the analytes to be separated. The water content must be low
enough to achieve separation, but high enough for the mobile phase to dissolve the
analytes and elute them in a reasonable timeframe. Typically, the more polar the
stationary phase and the analyte, the higher the water content is needed for separation.
The polar organic solvent of choice is generally acetonitrile (Churms, 1996) but other
mixtures such as water-methanol (Valette et al., 2004), dichloromethane-methanol
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(Herbreteau et aI., 1992), isopropanol (Li and Huang, 2004), and ethanol have been
used (Nguyen and Schug, 2008). Various hydrophilic columns have been employed in
the Hille mode, depending on the specific applications. Typically, non bonded silica
columns, polar-bonded silica phases have been employed in the literature. These
include aminopropylamide-, poly(succinimide)-, diol-, cyanopropyl-, and
sulfoalkylbetaine silica phases. The properties of these stationary phases have been
discussed in a recent review by Hemstrom and Irgum (Hemstrom and Irgum, 2006).
Hll.rC has shown promise in bioanalytical applications for a wide variety of polar and
hydrophilic compounds which are summarised in Table 3.1. Generally, in Hille
mode, acetonitrile is used as the organic component with the addition of ammonium
acetate, typically 5-20 mM, in addition to having long analysis times, typically 30
mm.
To date no study has attempted to qualitatively and quantitatively determine the
profile of human apocrine sweat. Thus, two additional MS analytical approaches will
be developed to provide complementary information to the NMR data. Firstly, a
global fingerprint of metabolites of medium to high polarity and secondly, identify
specific odour precursors in a qualitative and quantitative manner. Moreover, the
targeted based method will allow more definitive identification of unknown odour
precursors, as although accurate mass can be obtained in the global methodology, this
information does not provide any hits in biological databases such as HMDB or Lipid
Maps. The former method will be optimised with an artificial sweat matrix and the
complexity will then be increased using more representative biological sample (see
chapter 4). The latter method will be developed with available standards.
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3.1.4 Analytical Strategies for Profiling Apocrine Sweat Metabolites
The following information was taken into account when developing methods in this
chapter.
Global approach
In using DIMS or HPLC-MS in a comprehensive global approach, the intention is to
measure as many of the small molecule components as possible in the sample. With
regards to HPLC-MS, this intention puts large demands on the applied
chromatographic separation capability. The stationary phase will also influence, in
terms of retention properties of metabolites, the range of different chemical properties
of the separated metabolites. Although the fingerprint regions would likely look
different on different stationary phases, they are not expected to have a higher
information content. Thus, the approach taken herein is to obtain a method that is
capable of separating a range of polar compound in under 30 min.
Gin, Cys and Cys-Gly -conjugate profiling
The general structures of the odour precursors all contain one of three common
moieties (see Appendix A); Gin, Cys or a Cys-Gly residue, an example of which is
depicted in Figure 3.1. Thus, a precursor ion scanning method was developed which
would be later used to screen actual apocrine gland secretions in order to help identify
all the amino acid conjugates present, including unknowns, in a single run without
making prior assumptions of identity.
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Gin Conjugates: -
;
:H
N,
o X
X= Fatty acid residue
Gin Conjugates Examples: -
H,N
N-a-4-methyl-2-oxopent-anoyl- L-g lutamine N-a-4-ethyl-hept-anoyl- L-glutamine
H,N
N-a-4-hydroxyphenyl-acetyl- L-glutamine N-a-4-ethyl-oct-anoyl- L-glutamine
Figure 3.1 An example of common glutamine conjugates.
Specific targeted analysis of odour precursors
In a targeted approach, the main aim is to identify and quantify specific compounds of
interest. As a consequence, the standard route of method development is to find the
optimum chromatographic conditions to separate representative standards from one
another as well as from matrix interferences. However, compromises will have to be
made for the eluent composition to ensure sufficient analysis times, optimum peak
capacity, and the stability of the sample profiles, in addition to the MS parameters, as
one set of conditions is unlikely to suit all compounds.
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3.1.5 Aims
• To establish an analytical method that would be capable of detecting
and identifying a broad range of metabolites present in human apocrine
sweat, either by DIMS or LC-MS.
• To establish an analytical method capable of identifying odour
precursors from a common structure.
• To establish an analytical method to specifically identify odour
precursors in human apocrine sweat using MRM analysis coupled with
full product ion spectra.
3.2 Material and Methods
3.2.1 Chemicals
HPLC grade acetonitrile (far UV), methanol, ammonium formate, and glucose were
purchased from Fisher Scientific UK Ltd (Loughborough, UK). HPLC grade water
was obtained from a Millipore Milli-Q Gradient purification system (Bedford, MA).
Formic acid, ammonium hydroxide, cholesterol, and stearic acid was obtained from
Sigma Aldrich (Poole, UK) and stored at 4°C. Ammonium acetate was of ACS grade
and tristearine from Fluka. L-alanine, L-valine, L-leucine, L-isoleucine, L-proline, L-
methionine, L-phenylalanine, L-tryptophan, L-glycine, L-serine, L-threonine, L-
cysteine, L-tyrosine, L-asparagine, L-glutamine, L-aspartic acid, L-glutamic acid, L-
histidine, L-lysine, L-arginine were sourced from Sigma-Aldrich at a purity of 99%.
Lanolin was sourced from Alfa Aesar (Heysham, UK). 3-methylhex-2-enoyl-L-
glutamine (3M2H-Gln), N-a-3-hydroxy-3-methylhex-2-enoyl-L-glutamine (HMHA-
GIn), S-[ 1-(2-hydroxy-I-methylethyl)-ethyl]-L-cysteine (2M3H-Cys) and S-[ 1-(2-
hydroxyethyl)-l-methylbutyl]-L-cysteine-glycine (3M3SH-Cys-Gly) were supplied
by Dr Mark Harker (Unilever R&D, Bebington, UK).
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3.2.2 LC-MS Columns
The CI8 Synergi Hydro-RP 80A, (4 ).lm, 150 x 2 mm) was purchased from
Phenomenex (Macclesfield, UK). An Atlantis CI8 column (3 um, 100 x 2.1 mm) was
purchased from Waters (Manchester, UK). A ZIC-HILIC (5 ).lm, 150 x 2.1 mm)
column along with a guard column (20 x 2.1 mm) was purchased from SeQuant
(Umea, Sweden). All columns were equilibrated with mobile phase prior to use and
washed as per manufacturer recommendations.
3.2.3 Sample Preparation
Apocrine secretion is a turbid fluid that is complex in nature, containing a wide range
of compounds such as proteins, lipids and steroids (Labows et aI., 1979). The
secretion of this fluid from the apocrine gland is transient and intermittent, with only
low volume being produced. Obtaining this fluid from human volunteers is very
costly, thus, an artificial sweat matrix was developed for the purpose of developing
analytical methodologies, as depicted in Table 3.2, and not intended to replicate
apocrine sweat secretions but to have chemical characteristics in common. Blood
plasma (human venous blood collected from the Nottingham University Hospital and
placed into vials containing lithium heparin as an anticoagulant) was used as the
underlying matrix for the artificial sweat matrix, due to the plasma containing
common metabolites, in particular the non-polar species like cholesterol, glycerides
and fatty acids. The proteins present in the blood plasma were removed by
precipitation, using a 3: 1 acetonitrile before the addition of amino acids standards.
Furthermore, the use of blood plasma as the matrix overcomes the difficulties of
dissolving polar and non-polar components into a solution, due to many of the
components being present in blood plasma. An amino acid standard mixture
containing all the amino acids listed in Section 3.2.1 was also separately prepared at a
concentration 40 ug/ml.
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Table 3.2 Artificial apocrine secretion matrix used for method development.
Ingredient Level in JJ.gIml Ingredient Level in JJ.gfml
Plasma 500 III Threonine 40
Alanine 40 Cysteine 40
Valine 40 Tyrosine 40
Leucine 40 Asparagine 40
Isoleucine 40 Glutamine 40
Proline 40 Aspartic acid 40
Methionine 40 Glutamic acid 40
Pheny lalanine 40 Histidine 40
Tryptophan 40 Lysine 40
Glycine 40 Arginine 40
Serine 40
3.2.4 Global Profiling by LC-QTOF-MS
All experiments were conducted on a Shimadzu LC system (lOAD VP) equipped with
two Shimadzu binary pumps (LC-lOAD), a vacuum degasser, a cooled autosampler
(SIL-HTc) and a column oven (Shimadzu, Columbia, MD, USA). The HPLC system
was coupled to a Waters QTOF Premier system (Water MS Technologies,
Manchester, UK) equipped with an electro spray source operating in positive ion
mode. The source temperature was set to 125°C with a cone gas flow of 56 I/h, a
desolvation gas temperature of 350°C and a desolvation gas flow of 400 l/h. A
capillary voltage and a cone voltage were set to 3.0 kV and 25 V, respectively. The
MCP detector voltage was set to 1850 V. The QTOF acquisition rate was set to 0.3 s
with a 0.01 s interscan delay. Tune page was used to regulate the sample cone
voltage. Argon was employed as the collision gas at a flow rate of 0.4 ml/min. The
mass spectrometer was mass calibrated prior to use with sodium formate (0.05 M
sodium hydroxide and 0.5% formic acid in 90:10 2-propanol:water v/v) between m/z
50-1000 with a residual error <I.79x 10.4 amu.
A 5 ,..1.1 aliquot of artificial sweat mixture was injected onto a SeQuant ZIc'l!)-HILIC
column, 150 x 2.1 mm (5 J.Lm particle size) along with a guard column (20 x 2.1 mm)
operated at 25°C, with all the eluent from the LC column being directly transferred
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into the ion source of the MS without post-column splitting. The final optimised
mobile phase contained [A] 10 mM ammonium acetate and 90% acetonitrile at pH 5
and [B] 10 mM ammonium acetate. The gradient duration was 25 min at a flow rate
of 250 ul/min, From the start to 2.5 min [A] was kept constant at 100% and linearly
decreased to 50% in 7.5 mins and held constant for 3.5 mins. Finally, at the end of a
gradient an 11.5 min re-equilibration period was employed. The mass spectrometric
data was collected in full scan mode from mlz 50 to 1000 from 0-25 min.
3.2.4.1 Preliminary Development Work for LC-QTOF-MS
A range of different HPLC columns and mobile phase conditions were used during
the method development and are listed below. The final optimised LC-QTOF-MS
method is noted above (Section 3.2.4).
Initial Column Selection Conditions
CIS Synergi Hydro-RP 80A, (4 f.U11, 150 x 2 mm): - Mobile phase [A] consisted of
100% water and 0.1% formic acid [B] acetonitrile and 0.1% formic acid. The gradient
duration was 10 min at a flow rate of 250 ul/rnin as follows: an isocratic stage of 0%
[A] for 2 min, followed by a linear raise to 50% [A] in 8 min.
ZIC-HILIC column (5 f.U11, 150 x 2.1 mm): - Mobile phase [A] consisted of 90%
acetonitrile and 5 mM ammonium acetate [B] 5 mM ammonium acetate, pH 6.2. The
gradient duration was 10 min at a flow rate of 250 ul/rnin as follows: an isocratic
stage of 0% [B] for 2 min, followed by a linear raise to 60% [B] in 8 min, and at 10
min decreased back to the initial 0% [B] for 5 min to re-equilibrate the column.
Isocratic Elution
Mobile phase consisted of 80% acetonitrile and 10-30 mM ammonium acetate, pH 5
or 70-90% acetonitrile and 20 mM ammonium acetate, pH 5. The elution duration
was 50 min at a flow rate of 250 Ill/min.
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Effect of Ionic Strength
Mobile phase [A] consisted of 100% acetonitrile or 100% acetonitrile and 0.1%
formic acid [B] IO-SOmM ammonium acetate, pH 5. The gradient duration was 40
min at a flow rate of 250 ul/min as follows: an isocratic stage of 5% [8] for 6 min,
followed by a linear raise to 40% [8] in 14 min, further linear rise to 60% [8] in 10
min and at 30.0 min decreased back to the initial 5% [8] for 10 min to re-equilibrate
the column.
Mobile phase [A] consisted of90% acetonitrile and 0.5 mM ammonium acetate, pH 5
[8] 60% acetonitrile and I-lO mM ammonium acetate, pH 5. The gradient duration
was 45 min at a flow rate of 250 ul/min as follows: 5% [8] and increasing linearly to
60% over a period of 2S.5 min, further increase to 95% [8] in 5 min and at 34 min
decreased back to the initial 5% [8] for 10min to re-equilibrate the column.
Effect of pH
Mobile phase [A] consisted of95% acetonitrile and 10 mM ammonium acetate [8] 10
mM ammonium acetate. The pH was varied in both mobile phases between 4-S. The
gradient duration was 40 min at a flow rate of 250 ul/min as follows: an isocratic
stage of 0% [8] for 6 min, followed by a linear raise to 35% [8] in 14 min, a further
linear rise to 55% [B] in 10 min and at 30.0 min decreased back to the initial 0% [8]
for 10 min to re-equilibrate the column.
3.2.5 Global Profiling by Direct Injection Mass Spectrometry
Direct injection mass spectrometry was acquired with the same MS conditions and
setting as noted in Section 3.2.4. The HPLC system was used to load 5 J.llof the
sample into the LC sample loop using LC solvents (50:50 v/v mixture of acetonitrile
and water containing 0.1% formic acid) and pumped from 100-500 ul/min for one
min. All the eluent directly transferred into the ion source of the MS. Three blanks
were run between each sample to reduce any carry over from the HPLC-tubing.
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3.2.6 Targeted Profiling by LC-MSIMS
Analysis was conducted on a Shimadzu LC system (lOAD VP) equipped with two
Shimadzu binary pumps (LC-l OAD), a vacuum degasser, a cooled autosampler (SIL-
HTc) and a column oven (Shimadzu, Columbia, MD, USA). The HPLC system was
coupled to a Applied Biosystems 4000 QTRAP® (QqQLit) hybrid triple quadrupole
linear ion trap (Foster City, CA, USA) equipped with a TurboIon electro spray source
operating in positive ion mode.
3.2.6.1 Optimisation of compound dependent parameters for MRM Analysis
Analyses were performed using multiple reaction monitoring (MRM) for 3M2H-Oln
(C12H20N204,MW: 256.14), HMHA-Oln (C12H22N205, MW: 274.15), 2M3H-Cys
(CgH17N03S, MW: 207.09) and 3M3SH-Cys-Oly (C12H24N204S,MW: 292.15). The
optimisation of the precursor to product ion dissociation was performed by infusion
into the MS of separate standard solutions (10 ug/ml) in 50:50 v/v of[A]/[B] mobile
phase (see below) for each analyte at a flow rate of lOlli/min. The probe capillary
voltage (IS) was optimised at 5000 V; temperature of the turbo gas (TEM) 350°C;
nebulizer gas (OSI), auxiliary gas (OS2), curtain gas (CUR) were set to 20, 10, and
10, respectively (arbitrary values). Nitrogen was used for collisionally induced
dissociation (CID). Optimal declustering potential (DP) and collision energy (CE)
values were then used for the determination of 14 MRM transitions, each representing
an individual odour precursor (see Table 3.4). Each transition was performed with a
25 ms dwell time. DP and CE voltages for those conjugate precursors for which
standards were unavailable, were predicted from those obtained from a closely related
standard. The mass spectrometer was also set to use the information dependent
acquisition (IDA) function, where the instrument utilises an MRM as survey scan to
trigger a consecutive enhanced product ion (EPI) scan (MS/MS) for structural
confirmation (Figure 3.2). IDA criteria were set to select those MRM transitions
above a signal intensity of 5000 counts. Dynamic exclusion was set to 15 sec. Full
product ion spectral data as well as retention times of each of the standards were used
for structural and peak identification, respectively.
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Figure 3.2 Schematic of the IDA driven acquisition procedure.
3.2.6.2 Conjugate Profiling using Precursor Ion Scanning
y
Based on the evidence in the literature and available standards, GIn, Cys, and Cys-Gly
conjugates, all fragmented under CID to produce their respected amino acid residue,
mlz 147, 179 and 105 respectively. Thus, these ions were chosen as the signature
product ions for the precursor ion scan. Subsequent ion trap scans were triggered
when the threshold of the precursor ion scan reached 2x 104 counts. Each precursor
ion scan ranged from mlz 200-400 over a scan time of 1.2 sand EPI MS/MS spectra
were obtained over a range mlz 50-400 by ramping DP and CE from 25-35 V and 15-
30 eV respectively. The quadrupoles were set to unit resolution with the mass range
covering the range of analytes expected. PI scan was used as a filter to select
candidates of interest on-the-fly, once the selection criteria are satisfied, mass spectra
are obtained by fixing the first quadrupole (Q 1) for the mlz of the pseudomolecular
ion which is then passed through to a collision cell and scanned through the
appropriate mass range in Q3. The mass accuracy of the spectra obtained is based on
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the limitations of the quadrupole. However, such error can be corrected for by the use
of EPI scan that follows each survey scan. When EPI spectra are collected, Q3 is
acting as a linear ion trap rather than being scanned out, thus, ions are stored for a
predetermined amount of time before being expelled and recorded.
3.2.6.3 Chromatographic conditions
A 5 III aliquot of each standard was injected onto a Atlantis CI8 column (3 urn, 100 x
2.1 mm) operated at 40°C, with all the eluent from the LC column being directly
transferred into the ion source of the MS without post column splitting. The elution
solvents were [A] water containing 0.1% formic acid and [8] methanol containing
0.1 % formic acid. The gradient profile started at 15% [8] (0.5 min), increased to 90%
(6 min) and maintained at 90% [8] for 5 min.
3.2.7 MSD for Fragmentation Confirmation
Fragmentation confirmation was performed with a LTQ Velos dual pressure linear ion
trap (Thermo, Hemel Hempstead, U.K.). The analyses on the Velos instrument were
performed using heated electrospray ionization (h-ESI) in positive mode at sheath,
auxiliary and sweep gas flows of 5, I and 0.2 respectively (arbitrary units). The
capillary and source heater temperatures were set to 240 and 40°C respectively. The
ion spray voltage was adjusted to 2.5 kV. Analysis of the 2M3H-Cys, 3M3SH-Cys-
Gly, HMHA-Gln, and 3M2H-Gln standards at 10 ug/ml were carried out by direct
infusion at a flow rate 5 Ill/min into the ion source as well as the mobile phase flow
rate of 250 Ill/min to produce a stable signal.
3.2.8 Data Analysis
QTOF - Results obtained from LC-MS were analyzed by the Micromass MarkerLynx
v4.l application manager (Waters, UK); the retention time (tr) and mlz data pair for
each peak were detected by the software.
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QTRAP - Results obtained from LC-MS/MS analysis were processed by Analyst
vI.4 (Applied Biosystems).
3.3 Results and Discussion
The strategy undertaken for method development was three-fold. Firstly, a method
was developed that would be capable of identifying metabolites on a global scale (to
complement the NMR data) either via DIMS or LC-MS. This global approach was
initially developed with the use of an artificial sweat matrix with qualitative
assessments being made in order to highlight optimum conditions for further
investigation. The optimum conditions would then be further tested by increasing the
complexity of the sample to that of apocrine sweat produced from cell lines (see
chapter four) in addition to being more representative of the actual sample type under
investigation. Secondly, a LC-MSIMS method was developed that was capable of
specifically screening for known and unknown odour precursors by exploiting their
common structural similarities. Finally, a LC-MSIMS method was developed that can
qualitatively and quantitatively identify known odour precursors.
3.3.1 Direct Injection Mass Spectrometry
DIMS provided a sensitive high throughput method without chromatographic
separation, with the speed of analysis usually less than 5 min. A typical DIMS mass
spectrum of the amino acids present in the artificial sweat matrix is depicted in Figure
3.3. It is evident that a broad range of metabolites can be readily detected, including
all the amino acids as well as lipophilic metabolites. The higher mass ranges (i.e. lipid
content) are the most intense metabolites detected. Furthermore, when analysing
amino acid standards in the artificial sweat matrix, ion suppression was observed
across all analytes, in particular alanine, glycine, serine, cysteine, tyrosine,
asparagine, and glutamic acid. Ion suppression effects (also known as matrix effect
(King et aI., 2000)) can be viewed as a competition for ionisation between molecules
that have simultaneously been introduced into the MS source. The ion suppression
effect has a dramatic effect on the reproducibility between samples as depicted in
Figure 3.4, in which the average coefficient of variation (CV) for the amino acids
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present in the pseudo sweat mixture 43.9%. In contrast to LC-MS, the CV is expected
to be less than 15% for an optimised method (FDA, 2001). Furthermore, in-source
fragmentation could be observed for leucine/isoleucine and valine, which could be
tentatively assigned to the product ions mlz 86 and mlz 72 respectively. This
fragmentation is due to the loss of H20 and CO leading to immonium ions [Imr = [R-
CH=NH2t, where R is the residue of the amino acids (Petritis et aI., 2000; Qu et al.,
2002). Conversely, this approach would allow a variety of metabolites (e.g. lipids and
organic acids) to be detected in one brief analysis and have been used in microbial
(Goodacre et al., 1999; Vaidyanathan et al., 2002) and plant (Goodacre et aI., 2003;
Mauri and Pietta, 2000) studies.
However, this approach cannot distinguish between isomeric compounds such as
leucine/isoleucine. In order to distinguish between isomers and reduce ion
suppression effects, separation through chromatographic means will need to be in
place. Moreover, analytical separation would result in an increase in sensitivity and
MS data quality due to the reduction in background noise.
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In conclusion, this approach would allow information-rich ESI-MS spectra from
human apocrine samples to be generated without the need for chromatographic
separation. However, the poor precision reported from this methodology suggests this
method is suited to more of a screening approach rather than a quantitative method.
The absence of chromatographic separation can be detrimental to mass accuracy
arising from peak overlap with monisotopic differences of less than 0.025 Da (Dunn
and Ellis, 2005) as well reducing the overall sensitivity arising from competitive
ionisation (Mas et al., 2007; Villas-Boas et al., 2005). Furthermore, structural isomers
have the same monisotopic mass and would require LC-MS to be detected separately.
In addition, the classification of in-source fragmentation or adduct formation is
complicated. In the literature, application of DIMS is mainly focused in the microbial
(Castrillo et al., 2003) and plant areas (Overy et al., 2005), and when used in disease
diagnostics, a MSIMS approach is taken (Rashed, 2001). Thus, this approach will no
longer be pursued as it is not suitable to provide adequate identification of unknowns.
3.3.2 Global Profiling: IllLIC-QTOF
As previously mentioned, the majority of the work published on apocrine sweat is
predominately GC-MS based, focussing on volatile fatty acids (VFA). The limited
LC-work that has been published is based on RP-HPLC systems (Emter and Natsch,
2008; Martin et al., 2010; Natsch et ai., 2003; Troccaz et ai., 2009) leading to large
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knowledge of non-polar metabolites. Thus, this work focuses on the developing a
global method for the analysis of the more polar metabolites that are typically not
well retained on a CIS column. Systematic changes to the column, mobile phases,
gradients, flow rates, and total analysis times were made in order to optimise the
separation of the more polar compounds present in the pseudo sweat mixture.
3.3.2.1 Column Selection
Column selection depends largely on prior knowledge on the type of analyte, i.e.
range of target compounds of interest. Thus, to evaluate the retention of polar
metabolites in order to identify which type of column would be most suited for
development, the amino acids content in the artificial sweat matrix were used. Amino
acids represent a diverse range of polarities, thus, covering an adequate polarity range
suitable for a global method development of polar to medium polar metabolites
(Table 3.3). Initially, two columns were evaluated; a ZIC-HILIC column (5 urn, 150 x
2.1 mm) and a CIS Synergi Hydro-RP 80A, (4 urn, 150 x 2 mm) to identify which
would be most suited for this application. The initial results obtained are illustrated in
Table 3.3. The amino acids were poorly retained on the CIS column, with the
exception of Leu, lie, Phe Try, and Tyr due to these particular analytes being more
hydrophobic in nature. In comparison, the HILlC column was able to retain all the
amino acids, which typically eluted around 5-8 min. The elution order from the
HILlC column was generally from least polar to polar, which is opposite of traditional
RP-LC. However, the basic amino acids, His, Lys, and Arg, were relatively less
retained on the HILlC compared to the polar, non-polar or acidic amino acids, which
eluted around 2-3 min. Thus, from this preliminary study, the CIS column will be
omitted from further development due to poor retention of the amino acids, while the
HILlC column will be subjected to further development.
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3.3.2.2 Solvent and Buffer Selection
Reviews of the relevant literature (Table 3.1) revealed that acetonitrile was the most
effective solvent for the separation of polar/semi-polar compounds using HILlC;
hence, mobile phase method development was based on this solvent (Alpert, 1990;
Alpert et al., 1993; Olsen, 2001; Schlichtherle-Cerny et al., 2003; Valette et al.,
2004).
The buffers typically used for HILIC are either ammonium acetate or formate (5-20
mM) due to their compatibility with MS, solubility in high organic solvent and pH
range from 3-8. Initially, binary solvent systems were evaluated as this overcomes
some of the difficulties associated with retention time shifts due to column
equilibration. The acetonitrile content or ammonium acetate concentration was
separately altered between 70-90% and 10-30 mM respectively. As depicted in Figure
3.5 A, the organic content had a profound effect on retention, with increasing organic
content resulting in longer retention of all amino acids, which is consistent with the
literature (Guo and Gaiki, 2005; McCalley, 2010; Novakova et al., 2008). Separation
could be achieved with the use of high organic content, however, this would result in
a long analytical run time (>40 min) due to the basic amino acids being well retained,
which is considered unfavourable. In comparison, the change in salt concentration
slightly increased the retention of all except the basic amino acids (Figure 3.5 B). A
binary solvent system is not desirable, thus, a gradient profile was sought after in
order to reduce the overall analytical runtime.
The effect of ionic strength and pH were then independently investigated through the
use of gradient elution conditions. Initially, the ammonium acetate was varied
between 1-80 mM as depicted in Figure 3.6 A-C. High salt concentrations resulted in
a marginal increase in retention across all the amino acids, except the basic amino
acid residues, His, Lys, and Arg, which decreased in retention. This observed effect is
consistent with the HILIC mechanism (Bicker et al., 2008; Lammerhofer et al., 2008;
Wu et al., 2008) and the current literature (McCalley, 2010; Novakova et al., 2008).
The increase in salt concentration potentionally reduces the electrostatic repulsion,
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since the sulfonate groups on the sulfobetaine stationary phase are negatively charged
and prevent the carboxyl groups from interacting with the positively charged
quaternary amine groups located closer to the silica surface (Guo et al., 2007). Thus,
as the salt concentration increases, the retention of basic compounds on the negatively
charged sites are reduced, while the repulsion of acidic compounds from the same
sites is reduced, thereby increasing the retention of the acidic metabolites.
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Figure 3.5 Effect of A increasing organic content B salt concentration on amino acid retention time in
a binary solvent system.
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The effect of the mobile phase pH on the RP-HPLC is known to have a significant
effect on the retention properties due to changes in the ionisation properties of the
analyte. For example, a weak acid with a pKa value - 3 will be ionised at two pH
units above or non-ionised two pH below, which will increase or decrease the
retention respectively. Further changes in greater than two pH units either side of the
pKa values will have minimal effect on retention because the ionisation of the analyte
will remain unchanged (Snyder et al., 1988). The effect of pH on HILIC separation
was therefore investigated between pH 4-8, by altering stock salt concentration before
mixing with acetonitrile. The absolute pH of the mobile phase was not directly
measured and would presumably deviate from that of the stock solution (Barbosa and
Sanznebot, 1994). Figure 3.6 D summarise the effect of altering pH on the HILIC
retention of amino acids. The pKa values of the amino acids are summarised in Table
3.3. The COOH group and NH3 group of all the amino acids will be ionised between
pH 3-8. Only the ionisation state of the Asp, Glu, and His side chain will change
under the experimental pH conditions. As depicted in Figure 3.7 D, the retention time
essentially remained unchanged, with all the amino acids behaving in similar way.
Thus, it is likely that the ion exchange effect is contributing to the overall retention,
thereby, masking any pH effect. This is similar to Guo and co-workers (Guo and
Gaiki, 2005) were they illustrated that pH had a minimal effect on retention when
analysing salicylic acid, cytosine and cytidine, however, the retention of aspirin
gradually decreased when reducing the pH.
The effect of ionic strength and pH on the peak width (FWHH), which is an
indication of peak sharpness and, in general, an indication of column efficiency, is
depicted in Figure 3.7. A change in pH was shown to have a marginal effect on
FWHH. When the pH was increased to 6.5, FWHH tended to get broader across all
the amino acids. In contrast to the salt concentration, peak width remained relatively
constant, except in Figure 3.7 A, in which an increase in salt concentration reduced
FWHH. This is likely due to the pH of the mobile phase under these conditions,
which would be more basic as formic acid was not added to mobile phase [A].
It was concluded from these studies that 10 mM ammonium acetate at pH 5 would be
the optimum conditions. Lower buffer concentrations are more favourable for MS
detection and an acidic pH value resulted in an increase in peak efficiency. Figure 3.8
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A and B represents extracted ion chromatograms of the amino acids standards and
amino acids from artificial sweat matrix on a ZIC-HILIC column obtained from the
optimum conditions, which ultimately will be used for the analysis of apocrine gland
secretions. Not all peaks were fully resolved or contain a Gaussian peak shape (i.e.
good chromatographic peak shapes). The basic amino acids, typically in the artificial
sweat matrix, were more difficult to detect. This is most likely due to the poor peak
shapes eluting over a longer periods of time and ion suppression effects from co-
eluting metabolites. However, overall a good compromise between the broad ranges
of polarities have been achieved within a 25 min runtime.
105
6.7
8.5
9.4 ."',nu,~
">~
.Vallnf"
.~I.: 11.2 • leuci~/~o'e
~
• P(oIin~12.1
• Melhionirw
• Pheny'.'anin.
• Tryptophan
14.8
• GIycif1e
Seci~
• Threonine
• Cystein~
B TyrO$ln~
• Aspar,s n
.Glutamin~
Asparlk tldd
• Glutamic add
Hrslldl
lvs~
Ar,if""
9.~
">~
.~I.:
~
12.1
Figure 3.8 3D extracted ion chromatogram of A amino standards B amino standards present in the
pseudo sweat mixture.
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In summary, the HILle method shows a good alternative in providing retention of
polar metabolites compared to that of RP-HPLC. In contrast to the nature of and
amount of organic modifier, both the investigated ranges of salt concentration and pH
were found to have little effect compared to the amount of water present. This
indicates considerable stability of the elution conditions for this stationary phase,
which is desirable for retention time stability in metabolomics analysis.
3.3.3 Targeted LC-MSIMS
By employing the QTRAP® instrument and exploiting its unique scan capabilities
(Hager, 2002; Hager and Le Blanc, 2003) it was possible to devise an analytical
strategy capable of obtaining quantitative and qualitative data of metabolites in
complex matrices as well as specifically tailoring for the survey of common structural
moieties. The survey scans are generally based on pre-defined selection criteria of
either a common precursor ion or a common natural loss which is processed "on-the-
fly" in order to determine the pseudomolecular ion from a single injection. Once the
selection criteria are satisfied, an enhanced product ion (EP}) scan is triggered to
produce spectra which give full structural information. An enhanced resolution (ER)
scan can also be trigged before acquisition of the EPI scan, in order to confirm the mlz
value of the unknown pseudomolecular ion. However, when analysing complex
mixture, the pseudomolecular ion might not be the most intense peak during that scan
cycle resulting in the wrong ion being selected for EP} scan, thus, this function was
removed. Nonetheless, three types of scans can be generated in a single cycle time
that is very much lower than conventional triple-quadrupole (Q-q-Q) mass
spectrometers and when the QTRAP® is switched to operate as an ion trap, higher
quality spectra are obtained compared to that of a conventional Q-q-Q mass
spectrometers.
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3.3.3.1 Optimization of the Declustering Potential and Collision Energy
The MRM optimisation procedure involves a sequence of experiments where the
voltages of the various ion optics parameters (i.e. DP and CE) are ramped to
determine the maximum signal intensity for each ion. The optimum DP for each
standard was obtained by direct infusion while systematically increasing the DP from
o to 120 V. Optimum values for each of the standards were around 30 V. The CE was
ramped between 5 and 100 V with the intensity of the amino acid product ion mlz 147
(GIn), mlz 105 (Cys) and mlz 179 (Cys-Gly) being plotted with each of the standards
producing a similar maximum of around 20 V as summarised in Table 3.4.
Table 3.4 Retention times and optimised declustering potential and collision energies for the odour
precursor standards.
Standard Retention Precursor Product Declustering Collision
Time ~minl Ion ~mlz~ Ion ~mlz~ Potential U:~ Ener~ ~eVl
2M3H-Cys 3.2 208.1 105.1 40 20
3M3SH-Cys-G1y 4.9 293.1 179.1 30 20
HMHA-G1n 5.2 275.1 147.1 30 25
3M2H-Gln 6.5 257.1 147.1 30 20
3.3.3.2 LC-MSIMS Analysis of Odour Precursor Standard Compounds
MS Production Fragmentation
MSIMS transitions were generated as a result of the selective determination of the
pseudomolecular ion and the most abundant product ion for each available amino acid
conjugate standard. The literature is currently limited with respect to MRM analysis
of odour precursors, and the LC-MS work that has been published is focused on
single ion monitoring (SIM) (Troccaz et al., 2009), with the majority of published
work being with GC-MS. For the odour precursors for which there are no standards
available, theoretical transitions were used based on fragmentation patterns from
standards. Any co-eluting compounds were detected by defining a time in which the
transition was excluded (dynamic exclusion) after acquiring the EPI scan. Figure 3.9
shows the EPI spectra of the four standards while their respective chromatographic
separation is depicted in Figure 3.10. Source-dependent parameters optimised for
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MRM remain the same for EPI scans. However, the OP and CE were ramped during
the EPI scan cycle from 25-45 V and 15-30 V respectively. This was in order to
obtain full fragmentation profiles of each standard to aid identification. It was
experimentally observed that the mass accuracy of the EPI scan was usually within
either 0.2 or 0.1 amu of the expected value. These EPI spectra are helpful in the
confirmation of structural identification of amino acid conjugates in a complex
biological sample. To my knowledge, this is the first work that presents full product
ion spectra of any of the amino acid conjugates.
The elucidation of fragmentation mechanisms was not the main aim of this project,
hence, fragmentation confirmation was only carried out on the available standards
with the use of the MSn. Confirmation of the fragmentation behaviour will provide
additional information which will be later used when analysing data obtained from the
PI survey scanning methodology. The 2M3H-Cys conjugate (mlz 208) contained
fragments mlz 191, 105, and 87 (see Figure 3.9 A). The fragment at mlz 191 is
consistent with a loss of OH, and mlz 105 is interpreted as cysteine residue [M+H-
NH3f which can be further broken down to form mlz 87 [105-H20] as well as coming
from 2-methyl-3-sulfanylbutan-l-ol with the loss of H2S (mlz 34). The collisionally
activated dissociation of the amino acid [M+Hf ions have been observed by other
ionisation methods and the mechanisms of their formation has been explained
(Biemann and McCloskey, 1962; Bouchonnet et aI., 1992; Oookeran et al., 1996;
Kulik and Heerma, 1988; Petritis et aI., 2000).
The 3M2H-Gln conjugate (mlz 257) contained fragments mlz 240, 147, 129 and III
(see Figure 3.9 B). The fragment at mlz 240 was consistent with the loss of OH and
can further fragmented to produce fragments of mlz 130 and I II which are interpreted
as the loss of glutamine [M+H-NH3t and 3-methylhex-2-enoic acid respectively. The
peak at mlz 147 is considered as glutamine residue [M+Hf and can further be
fragmented to produce an mlz 130 through a loss of NH3. The peak at 129 is also
interpreted as glutamine residue [M+H-H20] + and in tum can be further fragmented
to form mlz 83 [lm-NH3t.
The 3M3SH-Cys-Gly conjugate (mlz 293) contained fragments mlz 179, 162, 144,
and 116 (see Figure 3.9 C). The fragment at mlz 179 was consistent with the loss of
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Cys-Gly residue. The fragment of mlz 162 and 144 was consistent with the loss OH
and a combined loss of OH from NH3 respectively, from the Cys-Gly residue. The
peak at mlz 116 is considered as the 3M3SH with the loss ofH2S (mlz 34).
The HMHA-Gln conjugate (mlz 275) contained fragments of mlz 257,240, 147, 130,
and 111 (see Figure 3.9 D). The fragment of mlz 257 and 240 is consistent with a loss
of OH and a combined loss of OH and NH3 from 3M2H and Gin respectively. The
peak at mlz 147 and 130 is considered as glutamine residue [M+Ht and [M+H-NH3t
respectively.
110
o:r
o
K
~~o
o
:r
-JI--------i
o !~
~------------------------~
i
!i~: .....
! i
o 1·fl!,-
o i
~----j~
! J J J J J J J J J
....0 • ~ ~ ~ • M ~ _
ocb·.._,
o
:~}
~------------~~
Q
-"~-.-.---_---_ .._-----_
! ~! ~ ! ~ ! ~ ! J
~ ~ • ~ M ~ ~ _ _ ~
od,·~,
LC-MS/MS Analysis of the Conjugates
The analytical method was initially optimised with four odour precursors (3M2H-Gln,
HMHA-Gln, 2M3H-Cys and 3M3SH-Cys-Gly) which were purchased via custom
synthesis from Unilever (Bebington, UK). The chromatographic method was initially
modified from the work published by Troccaz and co-workers (Troccaz et al., 2009).
The racemic odour precursors were prepared at a concentration of 1 ug/ml and
injected on to the HPLC column, while the MS was in MRM mode. Figure 3.10
shows a typical extracted ion chromatogram of the optimal chromatographic
conditions, with an elution profile of 2M3H-Cys conjugate (3.2 min), 3M3SH-Cys-
Gly conjugate (4.9 min), HMHA-Gln conjugate (5.2 min) and 3M2H-Gln conjugate
(6.5 min). The diastereoisomers of Cys conjugate at 3.2 min showed peak splitting
which previously have been reported to co-elute (Troccaz et al., 2009). This was
confirmed by full MSIMS product ion scanning, which produced identical
fragmentation patterns. Modifying the pH of the mobile phase affected the intensity of
each standard with minimal effect on the peak splitting of the 2M3H-Cys conjugate.
Experiments comparing methanol and acetonitrile as the organic mobile phases
resulted in methanol providing improved retention of the 2M3H-Cys conjugate.
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Figure 3.10 Extracted ion chromatogram of 1) 2M3H-Cys 2) 3M3SH-Cys-Gly 3) HMHA-Gln 4)
3M2H-Gln conjugate reference standards containing 1 ug/ml of each precursor.
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3.3.3.3 LC-MSIMS profiling of Odour Precursors using Precursor Ion Survey
Scan
As depicted in Figure 3.11 - Figure 3.13, the PI scanning approach was able to detect
each of the standards at the correct retention time compared with the verified LC-
MSIMS targeted analysis and were positively identified using the EPI spectra. As
noted previously in Section 3.3.3.2, 2M3H-Cys conjugate has a double peak (see
Figure 3.11), where each peak produces similar EPI spectra as previously mentioned.
Figure 3.12 also shows a double peak in the extracted ion chromatogram; both peaks
produce a similar EPI spectrum suggesting that one peak may arise from an impurity
present in the synthetic standard. The EPI spectra obtained from PI scanning were
similar to that produced in the targeted MS/MS approach (see Figure 3.9), thereby,
allowing identification of odour precursors without making assumptions of their
absolute identity. Nonetheless, there were limitations to this scanning method. The
EPI threshold was set higher than that of the LC-MSIMS method by an order of
magnitude. This was to allow high quality spectra to be obtained at the expense of
detecting conjugates at a low concentration range as well as limiting false positives.
Furthermore, this method is not as sensitive as MRM analysis by at least one order of
magnitude. This is due to compromises in the CE and DP being made in order to
cover a range of metabolites, longer scan times (s instead of ms) resulting in fewer
data points across anyone peak, and an increase in background ions. However, any
peaks of interested that have been detected can be added to the MRM methodology in
order to increase the sensitivity.
In summary, the precursor ion scan coupled with full product ion spectra has the
potential to identify common structural moieties of the odour precursors in order to
identify possible new conjugates in biological extracts. Once new compounds have
been identified by the precursor ion approach, then precursor and product ion can be
used to monitor for these new conjugates in a biological extract.
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Figure 3.11 Extracted ion chromatogram of 2M3H-Cys (mlz 208) and EPI spectrum of the peak at 3.2
min from an EPI triggered PI scan of mlz 105. Both peaks produce similar EPI spectra.
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Figure 3.12 Extracted ion chromatogram of3M2H-Gln (mlz 257) and EPI spectrum of the peak at 6.5
min from an EPI triggered PI scan of mlz 147.
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Figure 3.13 Extracted ion chromatogram of 3M3SH-Cys-Gly (mlz 293) and EPI spectrum of the peak
at 5.1 min from an EPI triggered PI scan of mlz 179.
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3.4 Conclusions
The choice of analytical methodology to pursue is highly dependent on the level of
chemical information required about the metabolites of interest as highlighted in
Table 3.5. Currently, there is no one analytical technique, i.e. 'gold standard', capable
of providing all the information required for analysis of apocrine sweat samples.
Thus, a range of methods have been developed to provide complementary information
on metabolites in apocrine sweat samples.
The LC-MS(MS) methodologies developed herein represent a significant step forward
in providing identification for the full range of metabolites present in apocrine sweat
samples as a whole, as well as specifically identifying and quantifying odour
precursors. Although there is a large body of literature on the analysis of apocrine
sweat, these are predominantly GC-MS based methods providing identities of only
the volatile components present. To my knowledge there has been no global or MRM
LC-MS work published to date, adding to the uniqueness of the present work. The
DIMS approach did provide quick analysis times; however, the data obtained would
be too complex and insufficient in providing metabolite identification, thus, will no
longer be pursued.
The LC-MS(MS) methodologies have been developed using artificial sweat mixture
or standard precursors. These methods will be further tested on samples that are more
representative of that of apocrine sweat, which will be discussed in the following
chapter.
Overall, the global MS method will provide complementary information to that of the
NMR data, and with the use of a high mass accuracy instrument, empirical formula
and tentative identification can be found. The MRM and precursor ion scanning-IDA-
EPI approach carried out in this chapter provides informative product ion spectra
which will provide a useful tool for structural confirmation. Furthermore, by
monitoring for common structural moieties, the semi-targeted method is no longer
restricted to the availability of standards.
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Table 3.5 Summary of the analytical conditions that have been developed.
Global Profiling Broad-profiling Semiffargeted
HILlC-MS LC-MSIMS
NMR DIMS for profiling polar for amino acid
metabolites conjugates
Gives detailed Qualitative and not
structural Characteristic
information, quantitative. High mass accuracy fragment-ionChemical particularly Inability to (5-10 ppm) for information that isInformation
using 2-D NMR distinguish between empirical formulae related to chemical
of isolated isomeric generation structure
metabolites compounds
These methods
have little
chemical bias Solvent bias means Solvent bias means Bias to the
Chemical Bias (high cone it is usually more it is usually more analytes of interest
metabolites) and applicable to polar applicable to polar i.e. odour
can be used compounds compounds precursors
directly on the
sample
Speed 25 min 3 min 25 min 18 min
Reequilibration, Reequilibration,
Minimal Matrix and Ion
temperature and temperature and
number of number of
Reproducibility variation «5% suppression effects injections can all injections can all
RSD) vary cause cause
chromatographic chromatographic
variation variation
Sample Size 8 ~I 5 JlI 5 JlI 5 JlI
Limit of Low JlM <JlM <JlM <JlM
Detection concentrations concentrations concentrations concentrations
non-biased High sensitivity,detector, non-
invasive, highly Rapid screen of average to high High sensitivity,
Advantages reproducible, metabolites, chromatographic structural
relatively easy to minimal sample resolution, information
identify clean up empirical formula
metabolites generation
Identification of Ion suppression
Lower Matrix effects, unknown is labour effects, more
Disadvantages sensitivity than identification of intensive, limited costly than NMR,
metabolites require structural requires a prioryMS
MSIMS information, more knowledge of
costly than NMR analytes
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Chapter 4
4 Application of IH NMR Spectroscopy and LC-MS to an In- Vitro
Model of Apocrine Sweat Produced from ASG5 Cell Lines
4.1 Introduction
Apocrine glands secrete a turbid fluid comprised of water, electrolytes, fatty acids,
steroids, lipids, proteins and nitrogen metabolites such as ammonium and urea
(Gower et al., 1986; Zernecke et al., 2010). When exposed to micro-flora populations
present on the skin, the lipidic solutes, including steroids and short chain fatty acids,
are transformed to malodorous compounds. Apocrine sweat is produced in low
volumes, typically less than 5 ~I, and secreted into the hair follicle, after which, there
is a lag time of 24-48 h before further apocrine sweat can be produced. Apocrine
sweat is both difficult to collect and very costly. Hence, a practical way of
investigating apocrine secretions is to use a long-term proliferating ASG5 cell line
(Burry et al., 2008), that closely mimic the function of an apocrine gland in situ. The
development of such an in vitro model has potential benefits not only in providing a
suitable matrix for future method development, but potentially in assisting in the
identification of transport secretary mechanisms, screening of malodorous compounds
and determining effective concentrations of metabolites present.
The morphology of the ASG5 apocrine cell line are depicted in Figure 4.1, whereby,
microvilli (M) and apical blebs (A) are present at the luminal membrane, as well as
secretary granules (S) being present throughout the cytoplasm. The typical pinching
off (mode of secretion) is also observed (Figure 4.1 B and C). This data is comparable
to apocrine secretary morphology in vivo (Montagna et al., 1953).
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Figure 4.1 Ultrastructure of an ASG5 apocrine cell using 200 hexagonal copper grids for transmission
electron microscopy. Microvilli (M), apical blebs (A), secretary granules (S) and empty vesicles (V).
Reproduced from (Burry et al., 2008).
Apocrine glands do not begin to function until puberty, thus, it is thought that
androgens (sex steroid hormones) play some part in the regulation of apocrine gland
activity due to the presence of androgen receptors (Beier et ai., 2005; Labrie, 1991).
This is further supported by the fact that cholesterol biosynthesis is upregulated in the
presence of androgens (Heemers et al., 2003), which could be used as a precursor for
the production of volatile steroids (Cowley and Brooksbank, 1991; Grosser et ai.,
2000). The ASG5 cell line possesses the genes required for androgen and estrogen
synthesis, in addition to necessary ~ receptors required to mediate the response.
Furthermore, the AGS5 cell line expresses the ABCCll gene, as well as the apoD,
which is known to be associated with cellular secretary processes (Martin et al., 2010;
Spielman et ai., 1998; Spielman et ai., 1995; Zeng et al., 1996b). The ASG5 cell line
possesses the GG phenotype (538G-A SNP), that is associated with wet ear wax
type (Yoshiura et al., 2006) and increased levels of axillary odour. The ASG5 cell line
also retains many of the steroidogenic features present in vivo secretions as depicted
in Figure 4.2 (Burry et al., 2008). Thus, production of malodorous compounds and
odour precursors, as well as cell proliferation, would be expected to be compromised
by compounds known to interfere with the androgen pathway. Such compounds
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include, but are not limited to tamoxifen (estrogen receptor antagonist) or p-estradiol
(E2).
0HO_'?~
"s"'o ~
0
Dehydroepiandrosterone sulphate
~STS
0 OH
Hoe 1713HSD HO.cif_____.
Dehydroepiandrosterone Androstenediol
~3j3DH
~3I3DH
0 OH
o~
17j3HSD
o~
_____.
Androstenedione Testosterone
~ARO ~ARO
0 OH
~
1713HSD
~
_____.
110 HO
Estrone Estradiol
SRD5A
_____.
Dihydrotestosterone
~ 1713HSD
Androstanediol
Figure 4.2 Schematic of the steroid synthesis pathway present in ASG5 apocrine cell lines. Key: STS
(steroid sulphatase), HSD (hydroxysteroid dehydrogenase), DH (dehydrogenase), ARO (aromatase)
and SRD5A (5a-reductase). Reproduced with modifications (Burry et aI., 2008).
4.1.1 Metabolite Extraction from ASG5 cells
Prior to analysis with the methodologies developed in chapters two and three, the
cellular metabolites have to be extracted. Ideally, the extraction method should extract
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the largest number of metabolites, be nonselective, nondestructive or modify
metabolites through chemical or physical means (Maharjan and Ferenci, 2003).
However, there is no ideal technique to simultaneously extract all classes of
metabolites, due to their high variability in the chemical and physical properties, thus,
a variety of extraction methods have been developed. For example, perchloric acid is
widely used to precipitate proteins and extract hydrophilic metabolites. Although
advantageous for extracting amines, acidic treatment can have detrimental effects on
the structural stability of metabolites (Lin et al., 2007) and can directly interfere with
analytical methods. Polar organic solvents (methanol, ethanol or acetonitrile) on the
other hand, are typically mixed with water to extract hydrophilic metabolites, while
chloroform is used to extract hydrophobic metabolites (Lin et al., 2007). Given that
the optimal extraction method will be essential in metabolome studies, several
protocols have been developed with varying levels of success. The commonly used
methods involve hot (90°C) ethanol (Tweeddale et al., 1998), hot (70°C) methanol
(Shryock et al., 1986), cold (-40°C) methanol, perchloric acid (Shryock et al., 1986),
alkali (KOH) (Gonzalez et al., 1997), and methanol/chloroform (Dekoning and
Vandam, 1992). There have been several studies comparing the different types of
extraction methods (see (Faijes et al., 2007; Lin et al., 2007)). Maharjan and co-
workers (Maharjan and Ferenci, 2003) considered the problems associated with the
different extraction protocols and concluded that the cold methanol protocol has
distinct advantages over the other methodologies. Since the extraction is carried out at
-40°C, stability and enzyme quenching minimise any metabolite transformations.
Moreover, this method has all the advantages of hot methanol or ethanol protocols;
denaturing and precipitating proteins and polysaccharides, no salts are added, easy to
evaporate or concentrate extracts and minimal effect on pH.
At present, there is limited research available with regards to the use of ASG5 cell
lines in metabolomic studies. The work that has been presented focuses on GC-MS as
the primary analytical tool for the analysis of metabolites present in the ASG5 cell
lines (Burry et al., 2008). For the first time, NMR or Le-MS methodologies will be
applied to analyse the metabolic composition the ASG5 apocrine cell lines. The
developed analytical methodologies in both chapter two and three will have the
potential to provide further insight into the apocrine cellular metabolism, as well as
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identifying if male and female apocrine glands have the potential to behave
differently due to the differences in circulating hormones. The use of applying
multiple analytical platforms for metabolomic profiling of biological samples is
gaining precedence (Hodson et al., 2007; Lanza et al., 20 I0; Lenz et al., 2004; Lenz
et al., 2007; Williams et al., 2005a), as it provides a better strategy for covering,
detecting and identifying metabolites than relying on any single technique alone.
4.1.2 Aims
• Evaluate the analytical methodologies developed in chapters two and three by
identifying whether each technique can discriminate between tamoxifen
(estrogen receptor antagonist) or p-estradiol treated cell lines.
• Identify metabolites in IH NMR spectra which could be used as a reference for
identifying metabolites from human axillary secretions.
4.2 Material and Methods
4.2.1 Sample Preparation
4.2.1.1 Cell Culture
Cell culture and preparation of cell pellets was undertaken by Dr Mark Harker and
co-workers at Unilever (Port Sunlight, UK). Initially, a long-term proliferating cell
line derived from axillary apocrine glands (ASG5) was generated as described
previously (Burry et al., 2008). ASG5 cells passage number 47 or 48 were grown in
15 ml Mammary Epithelial Growth Medium (MEGM), supplemented with 10 nglml
EGF, 10 ug/ml insulin, 0.5 ug/rnl hydrocortisone, 30 ug/ml bovine pituitary extract,
50 ug/ml gentamicin and 50 ng/ml amphotericin, under incubation in a 95% air / 5%
CO2 humidified incubator at 37°C, the medium was changed every three days. After
four or five days the cultured cells (n=5) were treated with tamoxifen (TAM) in
ethanol (2.7 nM), p-estradiol (E2) in ethanol (10 nM), vehicle (ethanol) or left
untreated for three days prior to harvest. Harvesting was performed using trypsin
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0.25% solution (incubation time 8 min, 37°C). The resultant cell suspension was
centrifuged (2000 rpm, 7 min) with the supernatant being discarded. The pellet was
re-suspended in 1 ml fresh medium and transferred to 1.5 ml eppendorf tubes. The
cells were centrifuged in a microfuge at 6000 rpm for 5 min and the supernatant
discarded. The pellets were stored at -80°C.
4.2.1.2 Cell Extraction
The cells were extracted with an equal volume of cold (-20°C) absolute methanol.
After vortexing (30 s), the tube was transferred into a dry ice bath for 30 min and
subsequently thawed in an ice bath for 10 min. Centrifugation (13,000 rpm, 10 min)
was carried out and the supernatant was collected. The cell pellet was subjected to a
second extraction with 50% v/v cold (_20DC) methanol, and the first and second
extracts were combined. The pooled supernatants were evaporated to dryness with a
centrifugal concentrator (-4 h) and then re-suspended in 20 III of water. Each sample
was aliquoted as follows: 5 III aliquots into I mm NMR tubes with the addition of 3
III deuterated potassium phosphate buffer (pH* 6.0, 0.1 M) containing TSP (7.6 mM),
10 III aliquots into MS vials with the addition of 85% acetonitrile, and the remaining 5
III was pooled together in order to create QC samples with the addition of 85%
acetonitrile.
4.2.2 IHNMR Spectroscopy
Development of the methodology for the analysis of human apocrine gland sweat
secretions is discussed in chapter two (Section 2.3.3). In summary, spectra were
acquired on a Bruker Avance 400 spectrometer, operating at 400.13 MHz IH
observation frequency equipped with a I mm TXI micro-volume with an internal
probe temperature of 298 K and with 256 transients being collected. All spectra were
manually corrected for phase and baseline distortions using TopSpin TM 2.1 (Bruker
GmbH,Germany) and chemical shifts referenced to TSP standard at 80.00 ppm.
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4.2.3 2D NMR Spectroscopy
To aid spectral assignment, 20 IH_IH COSY spectra were measured with solvent
presaturation pulse sequence on each sample. Acquition and processing parameters
for the COSY spectra included a relaxation decay of 1.86 s, a spectral width in FI and
F2 of 5995.2 Hz, 2 k time domain points, 128 Fl increments, 64 transients per
increment and qsine apodization in F1 and F2.
4.2.4 HILIC-QTOF-MS
HILIC-QTOF-MS was used for a global profiling approach as previously described in
chapter three (Section 3.2.4). In summary, data was acquired mlz 80-1000 in positive
ion mode over 25 min.
4.2.5 Targeted LC-MSIMS
RP-HPLC-MSIMS was used to specifically target amino acid conjugates as
previously described in chapter three (Section 3.2.6). This method was only
conducted on the QC samples due to the limitation in sample volumes.
4.2.6 Quantification of Artificial Apocrine Sweat Metabolites by INMR
Spectroscopy
Quantification was carried out as previously described in chapter two (Section 2.3.4).
4.2.7 NMR Spectral Data Reduction
Pre-processing of NMR spectra was carried out as previously described in chapter
two (Section 2.3.5).
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4.2.8 HILIC-QTOF-MS Data Pre-Processing
LC-MS data were prepared for multivariate data analysis using Micromass
MarkerLynx Application Manager (Version 4.0, Waters, UK). MarkerLynx
incorporates an ApekTrack-peak detection algorithm which allows detection and
retention time alignment of the peaks eluting in each chromatogram. The data were
combined into a single data matrix by aligning peaks with the same mass/retention
time pair together from each data file in the dataset, along with their associated
intensities. Only peaks between 1.5 min to 14 min retention times were included in
the final data matrix and the intensity of each ion was normalised to the samples total
signal intensity.
4.2.9 Multivariate Data Analysis
Umetrics SIMCA-P version 11 was used for multivariate data analysis. Two types of
scaling were used, mean-centring (subtracting the calculated average of a variable
from the data so that the mean for each variable is 0) and mean-centring followed by
autoscaling (division of each variable by the standard deviation for that variable). The
use of mean-centred but not autoscaled data in basic multivariate analyses such as
PCA, often results in an emphasis on perturbation of the metabolites that are present
in high concentrations, whereas autoscaled data standardise the variance of each
variable to one, thus, is more sensitive to changes in the levels of minor metabolites as
each variable has an equal weight. For the purpose of illustrating the results of this
study, autoscaling of the data is reported.
Principal component analysis was used for initial visualization of both the IH NMR
spectra and mass spectral data. PCA is a well-established method for the
interpretation of chemical data that has been thoroughly described previously (e.g.
(Massart and Kaufman, 1983)). PCA reduces the dimensionality of a dataset, which
has a large number of variables, while describing as much variation within the data as
possible. The results of PCA are discussed in terms of component score vectors
(observation coordinate along a PC) and loading vectors (direction coefficient of a
PC).
124
Supervised analysis using principal components discriminant analysis (PC-OA)
(Coolen et al., 2008; Harker et al., 2006; Hoogerbrugge et al., 1983) was then used to
maximise separation between the sample groups. PC-OA was preferred over other
options such as PLS-OA because it is more suitable for multi-class clustering, such as
in this study, whereas PLS-OA is more suitable for cases where there are two classes.
4.2.10 Compound Identification
Metabolite identification via HILIC-MS is based on accurately measuring
pseudomolecular ions to determine their mlz or chemical formula in order to extract
potential structures from databases. In order to calculate the most likely and
chemically correct formula, rules need to be followed and adhered to in order to
constrain thousands of possible candidates. A set of rules for this purpose has been
published (Kind and Fiehn, 2007) and these have been used to aid compound
identification from MS data in this chapter: -
• Apply heuristic restrictions for number of elements during formula generation
(e.g. 12Cat 1000 Da follows 1000/12 = 83 maximum limit for a hypothetical
molecule that consists exclusively of carbon)
• Nitrogen rule (odd nominal mass implies odd number ofN)
• Perform isotopic pattern filter
• PerformHIC ratio check (hydrogen/carbon ratio >0.125 and <3)
• Perform NOPS ratio check (N (0-1.3), 0 (0-1.2), P (0-0.3), and SIC (0-0.8)
ratios)
• Perform heuristic HNOPS probability check (H, N, 0, P,SIC high probability
ratios)
A list of freely and commercially accessible online databases are summarised in
chapter five (Table 5.2). The main databases used in this chapter were biological
databases such as HMOB and Lipid Maps.
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4.3 Results and Discussion
4.3.1 IH NMR Spectra of In-Vitro Model of Apocrine Sweat
Figure 4.3 shows a typical 400 MHz IH NMR comparative spectra for each apocrine
cell extract, acquired using only 5 ~l of extract and increasing the method sensitivity
by use of a Imm micro-volume probe. The spectrum depicted clearly illustrates the
power of the miniaturized probe when there is only a limited volume of the biofluid
available. The mass sensitivity per sample quantity is inversely proportional to the
diameter, thus, enhancement of the probe can be approximated since SIN cc lI(coil
diameter) (Olson et al., 1998; Peck et al., 1995). This equated to a -5.3-fold increase
compared to conventional 5 mm NMR probes, thus, providing a similar performance
to that seen on a 500 MHz spectrometer equipped with a cryo-probe (data not shown).
This increase in sensitivity enabled 29 metabolites to be readily identified, with 25
being quantified. Many of the resonances have been assigned by comparison with
existing literature (Harker et al., 2006; Lindon et al., 2000; Nicholson et al., 1995) in
combination with an in-house spectral database and confirmed by IH_IH 20 COSY.
These assignments are tabulated (Table 4.1), together with typical concentrations of
metabolites found in the control samples. The most abundant metabolites detected
were lactic acid and several amino acids including glycine, alanine, and tyrosine, with
the former being present at concentrations of 19.1 ± 10.8 mM and the latter ranging
from 1.6 - 3.6 mM. Any high variability in the concentration, e.g. lactate; is likely
due to overlapping peaks, e.g. CH2 lipid peaks, during the integration process. In
order to minimise the error, multiple resonances of the same metabolite were
averaged where possible. The reported concentrations are consistent with
observations made previously following the NMR spectroscopic analysis of eccrine
sweat (Harker et al., 2006).
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A
Sugars (Predominantly Glucose) and Alpha-CH
of Amino Acids
Arginine
Lysine
Lactate
~
Lactate
).,:g
Glycine
~ ..
~
Leucine
Isoleucine
Valine
1
B Possibly NMN or Niacin
Possibly NMN or Niacin
Uracil
1Phenylalanine Adenosine orj_TYI~::M::Isine Adenos.ine\nucleotid9 .1,-l, ~ [l, POSSibl~Fumarate
Uracil
Figure 4.3 400-MHz ID IHNMR comparative spectra of an ASG5 cell extract acquired using a 1 mm
TXI NMR probe, A 0 0.5-4.5 region and B 05-9.2 region. Key, blue (TAM), red (E2), Green (Eth), and
purple (Unt).
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Table 4.1 Relative concentrations of identified metabolites from AGS5 cell extract determined by
NMR spectroscopy equipped with 1 mm micro-volume probe. No correction for differences in T I
relaxation.
Chemical Shift (PPM) Assignment Metabolite Typical Concentration (mM)
0.89 (m) CH3 Lipid
0.92 (t) o-CH3 Isoleucine 2.4± 1.4(0.9-3.8)
0.99 (d)
~-CH3
0.96 (t) I)-CH3 Leucine 3.6 ± 2.1 (1.3 - 5.5)
1.72 (m) CH2
3.72 (m) a-CH
0.98 (d) CH3 Valine 1.6 ± 0.9 (0.5 - 2.4)
1.03 (d) CH3
2.26 (m) P-CH
3.59 (d)" a-CH
l.18 (d) CH3 3-p-hydroxybutyrate 0.2 ± 0.1 (0.04 - 0.4)
2.28 (ABX)" CH2
1.30 (m) CHz Lipid
1.33 (d) CH3 Lactate 19.1 ± 10.8 (6.6 - 28.6)
4.11 (q) CH
1.48 (d) CH3 Alanine 2.6 ± 1.5 (0.9 - 4.1)
1.48 (m)" "(-CHz Lysine 4.2 ± 2.2 (1.7 - 6.2)
1.73 (m) s-en,
1.90 (m) P-CH2
3.04 (t)" £-CH2
1.92 (s) CH3 Acetate 0.6 ± 0.4 (0.2 - 0.9)
2.07 (s) CH3 Acetamide" 3.6 ± 1.7 (1.8 - 5.1)
2.03 (m) "(-CHz Proline 1.7 ± 1 (0.5 - 2.5)
2.36 (m)"
~-CHz
3.35 (m) 8-CHz
3.43 (m) 8-CHz
4.15 (m)" a-CH
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Table 4. J continued
Chemical Shift (PPM) Assignment Metabolite Typical Concentration (mM)
2.07 (m)"
~-CH2 Glutamate 3.3±2(1.l-5)
2.35(m) 'Y-CH2
3.77 (m)" a-CH
2.15 (m)"
~-CH2 Glutamine 3.4 ± 2 (1.2 - 5.1)
2.46 (m) 'Y-CHz
3.77 (d)" a-CH
2.51 (AB)a
~CH2 Citrate 1.1 ± 0.7 (0.3 - 1.8)
2.65 (AB)" ~CHz
2.68 (ABX)"
~-CHz Aspartate 0.8 ± 0.5 (0.2 - 1.4)
2.82 (ABX)
~-CHz
3.90 (ABX)a a-CH
3.04 (s) CH3 Creatine 1.3 ± 0.7 (0.5 - 1.9)
3.93 (s) CHz
3.20 (s) N(CH3)3 Choline 0.8 ± 0.5 (0.3 - 1.2)
3.51 (m) NCH2
4.05 (m) OCHz
3.28 (t)" H5 Myo-inositol
3.53 (dd)" HIIH3
3.63 (dd)" H41H6
4.06 (t)" H2
Residual methanol
3.36 (s) from the extraction
procedure
3.31 (ABX) CH2 Tyrptophan"
3.49 (ABX) CHz
4.06 (ABX) CH
7.21 (t) C5H
7.29 (t) C6H
7.33 (s) C2H
7.55 (d) C7H
7.74 (d) C4H
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Table 4.1 continued
Chemical Shift (PPM) Assignment Metabolite
3.41 (m) C-H4 Glucose
3.48 (t) C-H3
3.53 (dd) C-H2
3.73 (dd) C-H6'
3.85 (m) C-H6
3.90 (dd)" C-H6
5.24 (d) C-HI
Typical Concentration (mM)
0.4 ± 0.2 (0.2 - 0.5)
3.56 (s) CH2 Glycine 3.7 ± 2.3 (1.2 - 5.9)
3.59 a-CH Threonine 3.2 ± 1.8 (1.1 - 5)
4.26 (m) ~-CH
3.85 (dd)" a-CH Serine 3.7 ± 2.3 (I.I - 5.8)
3.95 (dd)"
~-CH2
4.00 (dd)"
~-CH2
5.32 (m) -HC=CH- Lipid 0.2 ± 0.2 (0.1 - 0.6)
5.80 (d) CH Uracil" 0.5 ± 0.4 (0.1 - 0.9)
7.54 (d) CH
6.90 (d) H3/H5 Tyrosine 0.6 ± 0.4 (0.2 - I)
7.19 (d) H21H6
7.33 (m) H21H6 Pheny lalanine 0.7 ± 0.5 (0.2 - 1.1)
7.39(m) H4
7.43 (m) HlH5
8.46 (s) CH Formate 0.2±0.1 (0.1-0.3)
"Partially obscured resonances
'Tentatively assigned
'Below limit of quantification
Multiplicity is indicated as s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet
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4.3.2 Le-Mass Spectrometry Analysis of In-Vitro Model of Apocrine Sweat
Figure 4.4 shows comparative 2-D LC-MS maps (horizontal axis: retention time,
vertical axis: mlz) for each of the ASG5 cell extracts using HILIC- TOF-MS. More
than 1000 features were detected in this sample during a 25 min acquisition period,
highlighting both the sensitivity of the technique and the complexity of the sample.
However, it should be noted that not all these features may be represented as
individual compounds due to fragmentation or adducts during the ionisation process.
As with the NMR data, visual inspection would be tedious, inefficient and prone to
subjective error. Thus, examination of the data was carried out through the use of
multivariate analysis.
Both the global approach (HILIC-MS) and the targeted (RP-LC-MS/MS) approach
proved to be unsuccessful in detecting known odour precursors in apocrine secretions,
including 3M2H-Gln. However, a previous report using the ASG5 cell lines have
reported the ability to detect 3M2H-Gln using GC-MS and a different extraction
procedure (Burry et al., 2008). Thus, it is likely that the cold methanol extraction used
herein, did not extract these metabolites or that the presence was not represented in all
sample classes, resulting in being diluted down in the QC samples, thereby, being
below the limit of detection. Furthermore, none of the androgens in Figure 4.2 were
detected. Androstanediol (C19H3202 mlz 331.2039 [M+K]) produced a possible hit
with a potassium adduct, which had a retention time of 3.75 min and an associated
mass error of 5.2 ppm. However, this is likely to be a false positive due to the other
androgens not being detected as well not detecting the psudomolecular ion or any
other adducts. Cholesterol and squalene, which have been detected previously (Burry
et al., 2008), were also not detected. As mentioned previously, it likely that these
metabolites were not extracted with the cold methanol procedure or that they eluted
off the column in the void volume. However, 275 metabolites were putatively
identified such as phospholipids, glycerolipids, fatty acids and amino acids (see
Appendix B). This is in line with previous reports (Burry et al., 2008), and further
supports that the evidence that the ASG5 cell line mimics the functions of an apocrine
gland. However, false positives are always found, though could be significantly
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reduced by acquiring fragmentation spectra (MS/MS or MSn) and comparing it to an
authentic standard or to an insilico derived fragmentation mass spectra (Wolf et al.,
2010).
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Figure 4.4 Two dimensional mass versus retention 'map' obtained from QTOF-HILIC-MS analysis of
ASG5 cell extract of A TAM, B E2, C Eth and D Unt. Typically, over 1000 features can be detected in
15 min.
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4.3.3 Multivariate Data Analysis
Both the NMR and LC-MS data were initially analysed with PCA to obtain a global
unbiased view and to find the systemic metabolic changes between each of the
treatments. UV scaling was used for all the models presented in this section, as
compared to mean centred data, all metabolites become equally important. PCA
scores plots of the IH NMR spectral data and HILIC-MS spectra are depicted in
Figure 4.5 A and B, which explains 54.2% (PCI vs PC2 vs PC3) and 54.8% (PCI vs
PC2) of the total variation, respectively.
PCA of the NMR data showed separation of the treatment groups split across three
PCs, and therefore supervised clustering was performed via PC-DA to ease
visualisation and interpretation of the data. PC-DA model employs a priori
knowledge relating to group information in order to construct the model. Due to the
limited sample size, PC-DA models were initially constructed on the average
response to the different cell treatments. The original data were then projected onto
the model in order to determine the predictability of the model. The clustering of
samples shown in Figure 4.6 is consistent with that of the LC-MS data, with the
samples clustering according to the different treatments; however, ethanol and
tamoxifen treated were clustered together across all discriminant axes, regardless of
the analytical method. Thus, TAM can be considered as having no additional effect to
that of the vehicle or any effect incurred by the TAM is masked by the effect of the
vehicle. The first discriminant axis is mainly responsible for explaining the difference
between treatments with the E2 inhibitor. In a similar way, the second discriminant
axis is important for explaining the difference between untreated and TAM and
ethanol treated cells. It can be seen in Figure 4.5 and Figure 4.6 that the E2 treated
and control groups can be easily distinguished using both PCA and PC-DA, thus,
demonstrating a clear influence that hormones have on the metabolic composition of
apocrine sweat in vitro, as well as highlighting the complementary nature of both
analytical methodologies.
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Figure 4.5 PCA scores plot (UV scaled) obtained from A IHNMR spectra and B HILlC MS data from
the analysis of ASGS apocrine cell lines treated with tamoxifen, p-estradiol and ethanol (n=S).
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Figure 4.6 PC-DA score plot (UV-scaled) obtained from IH NMR spectra from the analysis of ASG5
apocrine cell lines treated with tamoxifen, p-estradiol and ethanol (n=5).
Determining the regions of interest between the different treatments is extremely
difficult as there is an abundance of information from both methodologies. The NMR
data showed a clear distinction between E2 and TAM, ethanol, and untreated groups,
while the difference between untreated and TAM and ethanol were more subtle. In the
case of IH NMR the metabolites responsible for clustering of the E2 group include
glucose, acetate, and p-hydroxybutyrate whilst the TAM and ethanol treated samples
are characterised by lactate, myo-inositol and unknown metabolites that are putatively
identified as nucleotides or nucleotide derivatives. Untreated cells are grouped by
other amino acids such as valine, leucine and isoleucine as well as lipids peaks and
formate. Table 4.2 summarises the main fmdings, where changes were supported by
the PC-DA generated loading plot of the NMR data. The perturbations in metabolite
profiles highlighted here show that the cells react differently to different levels of
circulating hormones.
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Table 4.2 Key changes in the endogenous metabolites responsible for defining the hormonal treatment
observed using PC-DA. The mean normalised bucketed values are reported.
Tentative Assignment TamoxifenBuckets
x±SD
Untreated
4.68 ± 0.21
p-Estradiol Ethanol
Lactate
Trp/Myo Inositol
Unkown
Phe/Ser
Creatine/A. A possibly Tyr
A.A possibly Asp
Sugar possibly Glucose
Unkown possibly A. A
Glucose
Myo inositol
Proline
Myo inositol! A. A possibly
Pro
A.A possibly Tyr
A.A possibly Phe
Creatine/ A.A possibly Lys
A.A probably Asn
Lipid
Unknown possibly
Methylamine
Glutamine
Glutamic acid
Unknown possibly
acetamide
Lipid (CH2)n
P-hydroxybutyrate
Leu/lie/val
4.14,4.1, 1.38,
1.34, 1.3
4.06
4.02
3.98
3.94
3.9
3.86,3.82
3.78
3.74,3.7,3.68,
3.5,3.46,3.42,
3.38
3.62,3.54
3.34,2.02
3.3
3.18
3.14
3.02
2.98
2.94,2.9
2.54
2.46,2.18,2.14
2.38,2.34
2.06
1.26,1.22
1.18
1.02,0.98,0.94,
0.9
0.86,0.82
4.60 ± 0.42
0.70 ± 0.05
0.69 ± 0.08
1.05 ± 0.14
1.23 ± 0.39
3.36 ± 0.33
0.89 ± 0.11
3.12±0.14
0.65 ± 0.13
1.19 ± 0.09
0.90 ± 0.23
2.01 ± 1.13
4.13 ± 1.35
1.79± 1.02
1.93 ± 0.70
1.75±0.21
1.93 ± 0.57
0.53 ± 0.05
1.31 ± 0.06
0.70 ± 0.07
3.14±0.71
0.33 ± 0.07
0.27 ± 0.13
1.29 ± 0.09
0.09 ± 0.03
3.56 ± 0.82
0.61 ± 0.14
0.65 ± 0.05
0.97±0.16
1.18 ± 0.21
3.49 ± 0.32
1.30 ± 0.49
3.14±0.19
1.13 ± 0.38
1.10 ± 0.10
0.83 ± 0.21
2.01 ± 0.89
3.67 ± 0.67
1.75 ± 1.03
1.85 ± 0.63
1.71 ± 0.14
1.89 ± 0.55
0.55 ± 0.03
1.06 ± 0.07
0.83 ± 0.09
3.46 ± 0.58
1.00 ± 0.43
1.21 ± 1.11
1.13 ± 0.11
0.40±0.16
5.26 ± 0.75
0.97 ± 0.11
0.88 ± 0.04
1.51 ± 0.17
1.06 ± 0.09
2.99 ± 0.23
1.06 ± 0.19
2.46 ± 0.21
0.71 ± 0.07
1.62 ± 0.20
0.66 ± 0.09
1.37 ± 0.61
3.78 ± 0.55
2.41 ± 1.30
1.27 ± 0.38
1.57 ± 0.23
1.81 ± 0.47
0.37 ± 0.06
0.95 ± 0.06
0.55 ± 0.08
2.86 ± 0.10
0.33 ± 0.07
0.37 ± 0.11
1.13 ± 0.07
0.11 ± 0.03
0.92 ± 0.08
0.8 ±O.II
1.39 ± 0.11
1.01 ± 0.07
3.31 ± 0.25
1.00 ± 0.09
2.76±0.15
0.68 ± 0.07
1.56 ± 0.11
0.69 ± 0.03
1.22 ± 0.19
4.6 ± 0.74
2.10 ± 0.77
1.37 ± 0.29
1.64 ± 0.15
1.96 ± 0.24
0.47 ± 0.03
1.02 ± 0.05
0.65 ± 0.05
2.86 ± 0.31
0.32 ± 0.05
0.38 ± 0.18
1.13 ± 0.03
0.11 ± 0.02
TAM has a complex pharmacology as it is a selective estrogen receptor modulator
which can prevent estrogen from stimulating growth as well as possessing agonistic
effects such as the induction of calcium signalling (Zhang et al., 2000) and
influencing bone and lipid metabolism (Love et al., 1992; Riggs and Hartmann,
2003). TAM has been shown to increase intracellular triglycerides (Hozumi et al.,
1998) and disrupts fatty acid metabolism (Lelliott et al., 2005). Furthermore, TAM
can affect the lipoprotein concentrations by reducing levels LDL-cholesterol due to
increasing LDL receptor activity (Bruning et al., 1988; Powles et al., 1989; Walsh et
al., 1991). However, with the data presented it is difficult to state whether they agree
with the current literature as cholesterol compounds and their derivatives were not
detected. Lactate dehydrogenase, which catalyzes the conversion of pyruvate into
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lactate, has been shown to increase with E2 (Thomas et aI., 1989). However, the data
presented contradicts these findings, although, it does agree with the fact that TAM
has no effect on lactate production. TAM (C26H29NO;mlz 372.2327 [M+HD is known
to be metabolised into N-desmethyltamoxifen (C2sH27NO;mlz 358.2170 [M+HD and
4-hydroxytamoxifen (C26H29N02;mlz 388.2276 [M+H]), where oxidation of these
primary metabolites results in formation of 4-hydroxy-N-desmethyltamoxifen
(endoxifen; C2sH27N02;mlz 374.2119 [M+HD by hepatic cytochrome P450s (Desta
et al., 2004; Hoskins et al., 2009). These metabolites along with E2 (C18H2402;mlz
273.1854 [M+HD were not identified in the samples prior to MVA. In comparison to
the NMR data analysis, TAM and E2 were considered to be below the limit of
detection. It is important to remove any drug metabolites to avoid miss-interpretation
of the data, as the models produced would predominately describe the variation
between the different drugs and their corresponding metabolites.
The principle ions contributing to the PCA grouping from HILIC-MS data were, mlz
447.3474,289.1790,461.3638, 312.3637, 368.4240, 312.3637, 284.3296, 256.2993
and 228.2674 which were shown to be only present in the E2 group. The untreated
group were grouped due to the lipid content (e.g. glycerophosphocholines) whilst
those at mlz 247.0581, 405.0090 152.0561 and 229.1538 were more prevalent in the
TAM and ethanol treated samples. Furthermore, the phospholipids content is
generally lower in concentration with TAM treatment when compared against the E2
treated cells, while nucleotide metabolites were shown to be elevated in the TAM
treated cells. Molecular mass, postulated elemental composition and chromatographic
retention time data for the ions relating to the differences are given in Table 4.3.
However, as with tentative assignments for the ions responsible for distinguishing
between the different treatments, these metabolites are as yet unidentified despite
searches of available databases using the accurate masses and atomic compositions.
Further investigations, such as metabolite isolation via fraction collection which
would then be subjected to further NMR and MS analysis, would be required in an
attempt to characterise and identify these compounds. Moreover, a continuing
problem with the confirmation of the identity of many compounds is the lack of
authenticated standards to provide unequivocal structures, thus, calculating the correct
empirical formula is essential (Kind and Fiehn, 2007). Many of the changes observed
are also unlikely to be directly relevant to apocrine sweat. There will be many
138
changes caused by the addition of ethanol and other disruptions caused by hormone
interactions which will produce a rippling effect across intracellular metabolism.
Nonetheless, the analytical methodologies used can reveal many of these global
changes. However, it is more difficult to attribute these changes to specific pathways,
but not impossible since many of the steroid hormone effects are characterised.
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4.4 Conclusions
A IH NMR and HILIC-MS based metabolomics approach was used to investigate the
effect of adding hormonal drugs to an ASG5 apocrine cell lines. Both analytical
methods produced high quality data in which untreated and the E2 treated cells could
clearly be differentiated from the TAM and ethanol treated cells when coupled with
MYA techniques. Furthermore, it was observed that TAM and ethanol could not be
differentiated, thus, concluded that TAM produced no additional effect to that of the
ethanol-treated cells. The differences in the metabolic profile between the different
hormonal treatments observed both by IH NMR spectroscopy and HlLlC-MS were
based on different sets of markers. Thus, this illustrates the complementary nature of
the two analytical methodologies and demonstrates the potential value of applying
both techniques to analyse biological samples.
Definitive identification of metabolites is a very challenging aspect of metabolomics
for both NMR spectroscopy and LC-MS. Identification of metabolites detected by
NMR was aided by the large body of information already available on human
biological fluids. Thus, the information provided herein will provide a good base for
the identification of apocrine sweat in vivo. In comparison, the available data for
metabolite identification by LC-MS is less extensive and the identity of most of the
metabolites contributing to the different treatments is currently unknown. However, a
number of putative identifications (either metabolite ID or elemental composition)
were achieved by relying on the mass accuracy of the QTOF system.
Limited conclusions could be drawn on the effect of hormonal drugs on the ASG5
cells; nevertheless, this is vastly more than is currently available in the literature.
Currently, the ASG5 cells are not well characterised, thus, it is unknown whether
TAM or E2 (as well as any other chemical mediators) will effect cell proliferation or
have an effect on the androgen pathway . TAM would not be expected to interfere
with androgen pathway directly since it inhibits the estrogen receptor, which is down
stream of androgen synthesis. However, it is unsure whether the inhibition of the
receptor may invoke a feedback response. Nonetheless, there is clear difference in the
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cellular metabolism between the different hormone treatments which suggest that
apocrine cells from males and females might behave differently due to the different
levels of circulating hormones.
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Chapter 5
5 Metabolomic Investigations of Human Axillary Secretions
5.1 Introduction
The human axilla region is populated with two classes of sweat glands: the eccrine
glands, which produce a watery secretion in response to heat, and the apocrine glands,
which produce micro-droplets of a viscous secretion in response to emotional stress.
The characteristic axillary odour (commonly referred to as "body odour") is generated
when bacteria, predominately of the Corynebacteria and Staphylococci genera
(Leyden et al., 1981; Shehadeh and Kiligman, 1963), on the skin surface interact with
apocrine secretions (Shelley et aI., 1953). The main contributors to axillary odour are
unsaturated or hydroxylated branched fatty acids, (E)-3-methyl-2-hexenoic acid
(3M2H) and 3-hydroxy-3-methyl-hexanoic acid (HMHA), with the former being the
key component (Zeng et al., 1991); sulfanylalkanols, particularly 3-methyl-3-
sulfanylhexan-l-ol (3M3SH) (Gautschi et al., 2007; Hasegawa et al., 2004; Natsch et
al., 2004; Troccaz et al., 2004); and the odoriferous steroids, 5a-androst-16-en-3-one
and 5a-androst-16-en-3a-ol (Bird and Gower, 1981; Claus and Alsing, 1976). The
precursor of the odorant acids have been shown to be secreted as glutamine
conjugates, that are then cleaved specifically by a bacterial Zn-dependent Na-acyl-
glutamine-aminoacylase (N-AGA) from Corynebacteria Ax20 (Natsch et aI., 2006;
Natsch et aI., 2003). Sulfanylalkanols have been shown to be secreted as either a
cysteine-IS) or cysteine-glycine-CS) conjugate, which are then cleaved by the
sequential action of a bacterial dipeptidase and a cysteine ~-lyase (Emter and Natsch,
2008; Starkenmann et al., 2005). There is evidence that odoriferous steroids are
formed from nonodoriferous steroid precursors, conjugated to a sulphate or
glucuronic acid (Froebe et al., 1990), as a result of bacterial metabolism (Decreau et
al., 2003; Gower et al., 1997; Labows et aI., 1979).
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These latest findings confirm the importance of bacterial activity and sweat odour
precursors for the generation of body odours. It is commonly known that gender,
ethnicity, emotional, physiological, and environmental factors may influence
individual odours (Akutsu et al., 2006; Dixon et al., 2007; Penn et al., 2007; Troccaz
et al., 2009). Furthermore, several studies have concluded that individuals have a
distinct odour type, which may be used for mate selection (Wedekind and Furi, 1997;
Wedekind et al., 1995) as well as individual or kin recognition (Weisfeld et al., 2003).
Thus it is suggested that an individual's odour profile is partly determined by their
major histocompatibility complex (also known as human leucocyte antigen region)
(Roberts et al., 2005), however, the underlying mechanism is currently unknown
(Natsch et aI., 20 10). Furthermore, MHC-dependent odour discrimination and mating
preference have been presented in mice (Yamazaki et al., 2000; Yamazaki et al.,
1976), reptiles (Olsson et al., 2003), birds (Freeman-Gallant et al., 2003) and fish
(Reusch et al., 2001), where MHC-dissimilarity may help to maximise the frequency
of MHC-heterozygotes in their offspring, providing increasing resistance to disease
and prevent inbreeding (Penn and Potts, 1999).
To date, the literature has limited information on the importance of skin bacteria or
sweat composition in generating the characteristic axillary odour from an individual.
Furthermore, most studies only consider the volatile composition or odour perception
without considering their origin (i.e. left or right side) or do not specify whether
samples come from one axilla or are pooled together from one individual or several
donors. Side related differences have seldom been assessed in humans, and what has
been reported is often contradictory. Bird and Gower found that high level of
androstenone correlated with the handedness, except for one individual (Bird and
Gower, 1982). Ferdenzi and co-workers reported that the left and right axillary are
perceptually equivalent when sampling the general population, with only a significant
difference in the left axilla in left-handed people (Ferdenzi et al., 2009). However,
they stated that this difference is likely to be attributed to the perception of female
raters who did not use hormone-based contraception and who were likely to be in the
fertile phase of their cycle (Ferdenzi et al., 2009). This is consistent with the idea that
there is increased awareness of stimuli between mating and fertilisation issues at the
time of ovulation (Lundstrom et aI., 2006).
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Axillary secretions and odours are of both a biological and commercial importance.
Studies have shown that odours contain chemical cues that can affect an individual's
mood (Jacob et al., 2002; Preti et al., 2003), brain activity (Jacob et al., 2001; Savic et
al., 2001), or even alter length and timing of the human menstrual cycle (McClintock,
1978). In addition, the nature and biogenesis of these odorants that contribute to ones
'volatile metabolome', is a focus of a multibillion-pound consumer cosmetic industry,
which seeks new products to counteract either odour production or perception.
In summary, the literature on apocrine sweat composition is biased towards the
volatile components, thus, this chapter will use the methodologies developed in
chapter two and three to provide further identification of the non-volatile components,
through the use of in-house metabolite libraries and external databases. Particular
emphasis will be on the odour precursors as these are considered key metabolites for
odour production. Furthermore, pattern recognition techniques will be used to analyse
the spectral data obtained from six volunteers, with each underarm collected
separately, across five days in order to determine the inter-day or inter-individual
variation.
5.2 Aims
• To identify metabolites present in human apocrine sweat, with emphasis on
odour precursors, using NMR spectroscopy, HILIC-MS (QTOF) and LC-
MSIMS (QTRAP) methodologies developed in chapters two and three.
• UPLC-Orbitrap-MS method initially developed by Dr Catherine Ortori will
also be applied to the analysis of human apocrine sweat.
• To assess inter-subject variability in the measured profiles of odour precursors
in apocrine sweat.
• To determine whether there are any intra-individual differences in the odour
precursors measured in apocrine sweat from the left and right arm.
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5.3 Materials and Methods
5.3.1 Chemicals
MS grade caffeine, sodium dodecyl sulfate, and sodium taurocholate were purchased
from Sigma Aldrich (Poole, UK). Mass spec grade Ultramark 1621 and MRFA
tetrapeptide was purchased from ABCR GmbH & Co. KG (Karlsruhe, Germany) and
Research Plus Inc (Barnegat, NJ) respectively.
5.3.2 LC-MS Column
A Zorbax RRHO Eclipse Plus CIS column (1.8 urn, 2.1 x 150 mm) was purchased
from Agilent Technologies (Cheshire, UK). The column was equilibrated with mobile
phase prior to use and washed as per manufacture recommendations.
5.3.3 Collection of Odourless Axillary Secretions
The collection of human apocrine secretions was carried out by Dr Mark Harker
(Unilever, Port Sunlight) as follows: The axillae of six male volunteers who had a
controlled wash in their underarms on the morning of day one with subsequent
collections on morning of days two to five from both underarms, which were
collected separately (right and left). After each collection their underarms were
washed again. Thus, each collection point represents a 24 h time point between
samples during the course of the week-long test. Both underarms were sampled using
a Teflon cup and stick. The Teflon cup was placed on the skin in the underarm whilst
panelists lay down with their arm raised. 1.5 ml water was applied to the buffer cup
and the water was stirred with the Teflon stick for 60 s. This water was then collected
using a pipette and stored on ice. This process was repeated and the two fractions
were pooled. This process was then repeated for the other underarm. The two samples
for each panelist were treated separately. The samples were spun at 14 OOOxgfor 5
min to remove dead skin and bacteria. Samples were maintained at 4DC after
collection until storage when they were kept at -80DC.
149
5.3.4 Sample Preparation
All samples were evaporated to dryness with a centrifugal evaporator (25°C, 2 h) and
then re-suspended in 20 IIIwater. Each sample was aliquoted as follows: 5 III aliquots
into I mm NMR tubes with the addition of 3 IIIdeuterated phosphate buffer (pH * 6.0,
0.1 M) containing TSP (7.6 mM), 10 III aliquots into MS vials with the addition of
85% acetonitrile, and the remaining 5 III was pooled together in order to create QC
samples with the addition of 85% acetonitrile for LC-MS analysis.
5.3.5 IH NMR Spectroscopy for the Global Profiling of Axillary Secretions
Development of the methodology for the analysis of human apocrine gland sweat
secretions is discussed in chapter two (Section 2.3.3). In summary, spectra were
acquired on a Bruker Avance 400 spectrometer, operating at 400.13 MHz 1H
observation frequency equipped with a 1 mm TXI micro-volume probe with an
internal probe temperature of 298 K and with 256 transients being collected. All
spectra were manually corrected for phase and baseline distortions using TopSpin TM
2.1 (Bruker GmbH,Germany) and chemical shifts referenced to TSP standard at ~O.OO
ppm.
5.3.6 2D NMR Spectroscopy
To aid spectral assignment, 20 IH_IH COSY spectra were measured with solvent
presaturation pulse sequence on each sample. Acquisition and processing parameters
for the COSY spectra included a relaxation decay of 1.86 s, a spectra width in FI and
F2 of 5995.2 Hz, 2 k time domain points, 128 FI increments, 64 transients per
increment and qsine apodization in F I and F2.
150
5.3.7 HILIC-QTOF-MS for the Global Profiling of Axillary Secretions
HILlC-QTOF-MS was used for a global profiling approach as previously described in
chapter three (Section 3.2.4). In summary, data was acquired mlz 80-1000 in positive
ion mode over 25 min.
5.3.8 UPLC-Orbitrap-MS for the Global Profiling of Axillary Secretions
In addition to using the HILIC-QTOF-MS developed specifically for the project, a
benchtop Orbitrap mass spectrometer (Thermo Scientific Exactive), was used as
another approach for global profiling. The orbitrap mass analyser has a higher
resolution than that of most time-of-flight instruments (-10 000) and approaches that
of FTICR (-100 000) to ensure high mass accuracy and to enable confident
discrimination between co-eluting, isobaric compounds in complex samples. Such
applications require mass accuracy of less than 5 ppm. Furthermore, the Exactive is
capable of higher scan speeds and polarity switching without sacrificing mass
accuracy. Thus, positive and negative spectra can be obtained in a single run.
All experiments were conducted on an Accela U-HPLC system equipped with
quaternary pumps coupled to an Exactive orbitrap mass spectrometer (all from
Thermo Scientific, Hemel Hempstead, UK), controlled by Xcalibur 2.1 software. The
instrument was equipped with an ESI probe and was operated in positive-negative
polarity switching mode. The spray voltage was set to 3 kV or -3 kV for positive or
negative ion mode respectively. The sheath gas, auxiliary and sweep gas flows were
set to 70, 40, and 2 respectively (arbitrary units) and the capillary temperature was set
to 350°C. The instrument was operated in full scan mode from mlz 100-1000 and
from mlz 50-200. This was in order to maintain mass accuracy at the high mlz end. It
is a known limitation of the instrument where the last mass ~ 20 x first mass. The
mass spectrometer was calibrated according to the manufacturer's guidelines prior to
use with either caffeine, MRFA tetrapeptide (Met-Arg-Phe-Ala), and Ultramark 1621
or sodium dodecyl sulfate, sodium taurocholate, and Ultramark 1621 in an
acenonitrile:methanol:water solution containing 1% acetic acid for positive and
negative mode respectively.
151
A 5 III aliquot of apocrine sweat mixture was injected onto a Zorbax RRHO Eclipse
Plus CI8 column (1.8 11mparticle size, 2.1 x 150 mm) operated at 40°C, with all the
eluent from the LC column being directly transferred into the ion source of the MS
without post column splitting. The eluent solvents were [A] water with 0.1% formic
acid and [8] acetonitrile and 0.1% formic acid. The gradient duration was 16 min and
was based on an in-house method developed by Dr Catharine Ortori and is
summarised in Table 5.1 below.
Table 5.1 LC-MSfMS conditions for the analysis of apocrine sweat secretions. Mobile phase [A] water
+ 0.1% formic acid and [8] acetonitrile + 0.1% formic acid.
Time (min) Parameter [8] Flow rate el/min
o
4
7
12
13
16
10
22
99
99
10
10
300
300
300
450
600
450
5.3.9 Conjugate Profiling using RP-HPLC-MSIMS
RP-HPLC-MS was used as a survey scanning method to detect amino acid conjugates
without making prior assumption of identity as previously described in chapter three
(Section 3.2.6). The precursor ion survey scanning method was split into two
analytical replicates instead of three due to the limited sample volume. The Gin (mlz
147) and Cys (mlz 105) containing conjugates were monitored together within the
same acquisition, while the Cys-Gly conjugate (mlz 179) were monitored separately.
Thus, it must be noted that EPI spectra would only be available for the most intense
ion, i.e. if Gin and a Cys conjugate co-eluted, EPI spectra will only be produced for
the most concentrated metabolite.
5.3.10 Targeted Profiling using RP-HPLC-MSIMS
RP-HPLC-MSIMS was used to specifically target amino acid conjugates as
previously described in chapter three (Section 3.2.6).
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5.3.11 Data Analysis
Methodology for the pre-processing and subsequent data-analysis of the NMR,
HILIC-MS and Q-TRAP data were carried out as discussed previously in chapter two
(Section 2.3.5), chapter three (Section 3.2.8) and chapter four (Section 4.2.8). For the
Exactive work, the raw data was analysed using Sieve version 1.0 (Thermo Scientific,
UK); this application manager integrates peaks in the UPLC-MS data by using
ChromAlign TM peak detection.
The ion intensities for each peak detected are then exported to Microsoft Excel 2007
to be normalised, within each sample, to the sum of the peak intensities of that
sample. The resulting normalised peak intensities are then exported in to SIMCA P
and analysed as discussed in chapter four (Section 4.2.9).
5.3.12 Compound Identification by LC-MS
Metabolite identification via LC-MS is based on two computational methods:
matching MSIMS fragment patterns to spectral libraries or accurately measuring
pseudomolecular ion to determine their mlz or chemical formula in order to extract
potential structures from databases. In order to calculate the most likely and
chemically correct formula, rules need to be followed and adhered to in order to
constrain thousands of possible candidates. This work flow is discussed in chapter
four (Section 4.2.10) and a recent review (Kind and Fiehn, 2007).
There are currently a range of freely and commercially accessible online databases, as
summarised in Table 5.2. These databases can be searched by name, mass or structure
and some have additional information, like MS fragmentation or metabolic pathways,
which may provide further assistance with metabolite identification. The main
databases used in this study were the biological databases such as HMDB or Lipid
Maps, as these are specific to metabolites that have been reported in human biological
samples. However, synthesized authentic standards are necessary for ultimate
confirmation of an unknown metabolite identity. The confirmation of a metabolite's
identity is not trivial and can be considered the most challenging and time consuming
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process in metabolomics. Hence, the level of evidence in supporting a proposed
metabolite identity is indicated by a one to three star rating for ease of interpretation
in this chapter; one star, putative identification, two stars has common fragmentations
ions to that of what would be expected, and three stars confirmed with a standard.
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Name
Table 5.2 Some commonly used metabolomic databases used for metabolite identification.
Content
Compound specific databases
PubChem
HMDB
Lipid Maps
KNApSAcK
MMD
Drugbank
ChemSpider
Reference databases
NIST08
GMD
METLIN
MassBank
MS2T
MMCD
Fiehn GC-MS Database
Pathway specific databases
KEGG
BioCyc
EcoCyc
MetaCyc
HumanCyc
Reactome
Chemical compounds and structures, links to Entrez databases,
bioactivity data from high throughput screening programs
A comprehensive database >7900 human metabolites obtained from
NMR, GC-MS and MSIMS
Structure and annotations of >I0,000 biological lipids in human
and other mammals
A cross-species metabolite database of>28,500 compounds mostly
from plants and microorganisms
A knowledgebase of 42,687 endogenous and exogenous
metabolites
Drug, drug targets, physicochemical, clinical, and pharmacological
properties, links to other databases, 3D and chemical structure
ChemSpider is an aggregated database of organic molecules
containing more than 20 million compounds from many different
providers. At present the database contains information from such
diverse sources as a marine natural products database, ACD-Labs
chemical databases, the EPAs DSSTox databases and from a series
of chemical vendors
A commerical library of >220,000 El mass spectra from> 190,000
pure chemical compounds
Mass spectra and retention indices of known plant metabolites
analysed by GC-MS
A database of LC-MS, LC-MSIMS, and LC-FTMS mass spectra of
matabolites from human and microbial species. It contains >25,000
structures, including more than 8000 di and tripeptides.
A high resolution MSIMS spectral database for standard chemical
substances. More than 30,000 spectra from > 1900 different
compounds are available
A MSIMS spectral tag library of phytochemical compounds
A NMR and LC-MS spectral library of metabolite standards. It
contains approximately >20,000 metabolite entries and
experimental spectral data on >600 compounds
This library contains data on 713 compounds (name, structure, CAS
ID, other links) for which GCIMS data (spectra and retention
indices) have been collected by the Fiehn laboratory
A composite database consisting of collections of pathway maps,
genes, organisms, enzymes and ligands (metabolites, drugs and
other small molecules)
A collection of 1004 pathway/genome databases of organisms with
completely or partially sequenced genomes
A scientific database of Escherichia coli K-12 MG 1655
A database of nonredundant, experimentally elucidated metabolic
pathways on > I ,600 pathways from >2000 different organisms
A human metabolic pathway and human genome database on
28,783 genes, their products and the metabolic reactions and
pathways they catalyze
A database of human metabolic pathways and biological processess
involving small metabolites, biomolecules and their
reactions/interactions. Reactome has data and pathway diagrams for
>2700 proteins, 2800 reactions and 860 pathways for humans
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5.4 Results and Discussion
5.4.1 Identification of Small Molecule Components of Human Apocrine Sweat
5.4.1.1 Global Analysis using IH NMR Spectroscopy
To my knowledge, this is the first report of applying NMR spectroscopy to the global
profiling of human apocrine sweat. The results obtained in the present study confirm
that NMR based metabolomics can be successfully applied to the metabolic profiling
of apocrine gland sweat. A typical 400 MHz IH NMR spectrum of human apocrine
sweat acquired using a 1 mm micro-volume probe is depicted in Figure 5.1. The
increased sensitivity obtained from using a micro-volume probe has allowed 25
metabolites to be identified. Many resonances have been assigned by comparison with
existing literature (Harker et aI., 2006; Lindon et al., 2000; Nicholson et aI., 1995) in
combination with an in-house spectral database and are tabulated (Table 5.3), together
with concentrations of metabolites found in a typical sample. The major classes of
metabolites identified included TCA cycle intermediates (e.g. citric acid, formic acid),
ketone bodies (3-hydroxybutyrate), energy metabolites (creatinine, lactate), amino
acids and nucleotide derivatives. Lactic acid was found to be the most abundant
metabolite, which is consistent with observations made previously following
spectroscopic analysis of human eccrine sweat (Harker et al., 2006). A number of
unassignable compounds or tenatively assignable compounds were also observed. In
particular, the chemical shifts downfield (aromatic region) are presumed to be
nucleotides or nucleotide derivatives. Furthermore, from the 20 1n-'H COSY spectra,
it was shown that the doublets observed at 6.41 ppm are coupled with doublets at 7.32
ppm, indicating an AX spin system.
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Figure 5.1 Typical400 MHz 'H NMR spectrum of human apocrine sweat obtained using I mm micro-
volume probe. Some metabolites are tentatively assigned. Spectra were acquired using a standard
noesy preset pulse sequence with 256 scans.
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Table 5.3 Peaks assigned to metabolites in apocrine sweat and experimentally determined
concentrations. No corrections for difference in TI relaxation have been made.
0.90 (t)8
Chemical Shift Assignment Metabolite
n-hydroxy-n-butyrate"
Typical Concentration (mM)
0.92 (t)
0.99 (d)
0.96 (t)
1.72 (m) CH2
3.72 (m) a-CH
0.98 (d)
1.03 (d)
2.26 (m)
3.59 (d)
1.14 (d)
1.18 (d)
CH3
CH3
f3-CH
a-CH
2.28 (ABX) CH2
1.26 (s)
1.33 (d)
4.11 (q)
1.48 (d)
1.48 (m)
1.73 (m)
1.90 (m)
3.04 (t)
1.56 (m)
1.86 (m)
3.13 (t)
3.74 (t)
1.92(s)
2.03 (m)
2.36 (m)"
3.35 (m)
3.43 (m)
4.15 (m)"
y-CH2
5-CHz
f3-CH2
&-CHz
y-CHz
f3-CHz
a-CHz
a-CHz
y-CHz
f3-CH2
5-CHz
8-CHz
a-CH
Isoleucine
Leucine
Valine
lsobutyrate''
3-f3-hydroxybutyrateb
ce-hydroxyisobutyrate''
Lactate
Alanine
Lysine
Citrullene''
Acetate
Proline
1.9 ± I (0.9 - 3.8)
1.2 ± 0.6 (0.7 - 2.1)
0.9 ± 0.3 (0.5 - 1.4)
0.2 ± 0.1 (0.1 - 0.5)
1.8 ± 1 (0.9 - 3.4)
13.2 ± 13.8 (2.4 - 44.8)
2.4 ± 1.1 (1.2 - 4.2)
1.9 ± 0.8 (0.9 - 3.1)
158
Table 5.3 continued
Chemical Shift Assignment Metabolite Typical Concentration (mM)
2.07 (m)" ~-CH2 Glutamate 6.8 ± 3.7 (3 - 12.8)
2.35 (m) y-CH2
2.15 (m)' ~-CH2 Glutamine 2.2 ± 1.4 (0.9 - 4.1)
2.46 (m) y-CH2
2.51 (AB)" ~CH2 Citrate
2.65 (AB)' ~CH2
2.68 (ABX) ~-CH2 Aspartate 0.2±0.1 (0.1-0.4)
2.82 (ABX) ~-CH2
3.90 (ABX) a-CH
3.04 (s) CH) Creatine 0.2 ± 0.1 (0.1 - 0.5)
4.02 (s) CH2
3.31 (ABX) CH2 Tyrptophan 0.5 ± 0.4 (0.1 - 1)
3.49 (ABX) CH2
4.06 (ABX) CH
7.21 (t) C5H
7.29 (t) C6H
7.33 (s) C2H
7.55 (d) C7H
7.74 (d) C4H
3.56 (s) CH2 Glycine 3.2 ± 1.5 (1.5 - 5.9)
3.59 a-CH Threonine 1.7 ± 0.9 (0.7 - 3.1)
4.26 (m) ~-CH
3.85 (dd) a-CH Serine 3.7 ± 1.8 (1.7 - 6.4)
3.95 (dd)
~-CH2
4.00 (dd)
~-CH2
6.90 (d) H31H5 Tyrosine 0.4 ± 0.2 (0.2 - 0.7)
7.19(d) H21H6
7.33 (m) H21H6 Phenylalanine 0.3 ± 0.1 (0.2 - 0.5)
7.39 (m) H4
7.43 (m) HlH5
8.46 (s) CH Formate 0.6 ± 0.4 (0.2 - 1.4)
'Partially obscured resonances, bTentatively assigned
Multiplicity is indicated as s = singlet, d = doublet, t = triplet, q = quartet, m =multiplet
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5.4.1.2 Global Analysis using High Mass Accuracy Le-MS (HILIC and CIS)
HILIC methodology was developed to identify and characterise the aqueous fraction
of apocrine sweat secretions, as discussed in chapter 3. Figure 5.2 shows a 20 LC-MS
map (horizontal axis: retention time, vertical axis: mlz) for a typical QC sample
acquired in positive ESI mode. A total of 580 peaks were detected with an average
cumulative variation of 103% across all QC samples. This variation is considered to
be large; indicating the method was not performing as expected. Only 37 metabolites
had a CV of less than 25%. Altering the processing parameters, such as minimum
peak intensity, to that of a higher value, e.g. 600 counts, the number of extracted
peaks dropped to 190 metabolites with an average CV of 91.5%. This error also
incorporates any error or inconsistencies from peak integration during the pre-
processing stage. Therefore, it is considered that there was a sensitivity detection
issue with the instrument which would cause this high CV error. Nonetheless,
valuable information can still be obtained from this data set in regards to the presence
of amino acid conjugates.
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Figure S.2 Two dimensional mass versus retention 'map' (mlz 80-1000) obtained from QTOF-HILlC-
MS analysis of a human apocrine sweat sample. In this typical chromatogram, -580 ions can be
detected in 15 min.
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An 'in-house' metabolomic method, previously developed in our group, using a RP-
UPLC C18 column coupled to an Orbitrap-MS was used for analysis of semi-
polar/non-polar fraction. A typical total ion chromatogram obtained from a
representative QC apocrine sweat sample is depicted in Figure 5.3 for both positive
and negative ESI mode. The initial pre-processing of the UPLC-MS data using Sieve,
extracted 1359 peaks with an average CV of 36% and 988 peaks with an average CV
of 23%, across all QC samples in positive and negative mode respectively. Using the
information gathered from the literature about the composition of human apocrine
sweat (see Appendix A), putative identification of the odour precursors are
summarised Table 5.4, while putative identification of known metabolites previously
reported in apocrine sweat are summarised in Table 5.5.
Identification of the amino acid conjugates was based on using the accuracy of the
instrument in order to extract the individual peaks from the TIC. In total, nine amino
acid conjugates were shown to be detected with both the HILlC-QTOF and UPLC-
Orbitrap methodologies, with 3M2H-Gln and HMHA-Gln being the most abundant
conjugates detected. N-a-9-hydroxy- non-anoyl- L-glutamine, N-a-3-hydroxy-3-
methyl oct anoyl- L-glutamine and N-a-3-hydroxy-4-methyloct anoyl- L-glutamine
(where each metabolite has a corresponding mlz 303.1927) all produce one
chromatographic peak at 7.12 min, thus, no further identification is possible. 3M3SH-
Cys-Gly was detected with the HILIC methodology, however, was marginally above
the limit of detection. S-[ 1-(2-hydroxyethyl)-butyl]-L-cysteinylglycine (mlz
279.1379) produced two chromatographic peaks at 6.07 min and 8.53 min. The mass
error at 6.07 min is 20.42 ppm, thus, is likely the Na+ adduct of 3M2H-Gln, while the
peak at 8.53 min is marginally above the limit of detection in the HILIC method.
Furthermore, S-[ 1-(2-hydroxyethyl)-butyl]-L-cysteinylglycine produced several
chromatographic peaks (ranging from 1.39-12.89 min) from the UPLC C18 method in
negative mode only. Again, all the representative peaks were only marginally above
the limit of detection, with the most intense peak eluting at 11.29 min, thus, no
retention time can be reliably obtained.
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Figure 5.3 UPLC-MS total ion chromatogram acquired in A positive mode B negative mode, of a
representative human apocrine sweat sample.
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Table 5.5 Tentative identities of known compounds previously reported in apocrine sweat.
Positive mode Nelative mode
Comt:0und Name Formula Detected mI: Della !t:t:m! Actual RT Detected mI: Della !t:t:m! Actual RT
a-Pinene ClOHI6 137.1327 1.78 7.16
(4-Hydroxypheny1jacetic acid C,lhO, 153.0548 1.33 8.23
Geranial CIOH160 153.1274 0.32 740
Geraniol CIOH"O 155.1433 1.93 7.16
Isopropylacetophenone CllHl40 163.1120 1.58 7.94
2-Phenylethyl acetate CIOH12O, 165.0912 Ll8 9.17
Eugenol CIOH12O, 165.0912 Ll8 9.17
Isoeugenol CIOH12O, 165.0912 Ll8 9.17
Jasmone C11H1.O 165.1276 Ll3 7.35
(Z)-4-Methylnon-3-enoic acid CIOH'I02 17U381 0.79 10.37
(E)-4-Methylnon-3-enoic acid CIOH"O, 17U381 0.79 10.37
9-Decenoic acid ClOH1,O, 17U381 0.79 10.37
Octanedioic acid (suheric acid) C,Hl404 175.0964 -D.72 9.88
E-Cinnamyl acetate C11H1,O, 177.0913 1.79 8.04
10-Undecenoic acid C11H20O, 185.1539 1.34 7.35
2-Hexyl 2-pentenoate C11H20O, 185.1539 1.34 7.35
l-Dodecene C1,H" 186.2219 1.27 8.59
Citronellol acetate C12H"O, 199.1695 0.97 8.82
Famesene C1,H" 205.1954 1.59 12.26
Pentyl salicylate C1,H1.O, 209.1175 1.15 8.23
Methyl trans-jasmonate C1,H1,O, 21U331 0.95 6.78
Cyclotetradecane CI4H" 214.2532 1.37 7.65
1-Tetradecene CI4H" 214.2532 1.37 7.65
N.N-Dimethyl-I-dodecylamine Cl4H'lN 214.2532 1.37 7.65
l-Hexenyl salicylate CnHI6O] 22UI72 -D.OI 907
Tetradecanal CI4H"O 230.2481 Ll6 7.69
2-Tetradecanone CI4H"O 230.2481 Ll6 7.69
2-Phenylundecane C17H" 233.2269 2.17 12.22
3-Phenylundecane C1,H" 233.2269 2.17 12.22
4-Phenylundecane C17H" 233.2269 2.17 12.22
5-Phenylundecane C17H" 233.2269 2.17 12.22
6-Phenylundecane C17H" 233.2269 2.17 12.22
2-Pentadecanone C1,HwO 244.2639 1.61 7.65 225.2216 -3.30 9.99
9-Hexadecenoic acid C1.H,oO, 255.2321 1.08 7.97 253.2168 -1.94 10.25
a Hexadecadienol C1.H,oO 256.2639 1.54 7.62
Hexadecanal C1.H"O 258.2795 1.55 7.59
2-Hexadecanone C1.H"O 258.2795 1.55 7.59
2-Phenyldodecane C1,Hw 264.2688 0.73 12.22
5-Phenyldodecane C1,H30 264.2688 0.73 12.22
6-Phenyldodecane C1.H30 264.2688 0.73 12.22
9-Heptadecenoic acid C17H"O, 269.2480 1.67 8.13 267.2325 -153 10.68
7-Hexadecenoic acid methyl ester C17H"O, 269.2480 1.67 8.13 267.2325 -1.53 10.68
9-Hexadecenoic acid methyl ester C17H"O, 269.2480 1.67 8.13 267.2325 -153 10.68
Androsta-4, 16-dien-3-one C1.H,.O 271.2060 Ll8 7.85
Androsta- 5, l S-dien- 3-on. C.H.O 271.2060 Ll8 7.85
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Table 5.5 continued
CompoUDd Name Formula
Positive mode Neeative mode
Detected mi. Delta (ppm) Actual RT Detected mi. Delta (ppm) Actual RT
5a-Androst-16-en-3-one
Androsta-4, 16-dien-3a-ol
So-Androsta-S. 16-dien-3Jl-ol
Androsta-5, 16-dien-3a-ol
Hexadecanoic acid
Methyl 9-methyltetradecanoate
Pentadecanoic acid methyl ester
Ethyl tetradecanoate
Oleic acid
I-Nonadecene
Heptadecanoic acid
2-Methylhexadecanoic acid
Hexadecanoic acid methyl ester
Ethyl pentadecanoate
5a-Dihydrotestosterone
Dodecyl benzoate
Cyclopentanetridecanoic acid methyl ester
Octadecanoic acid
Heptadecanoic acid methylester
Ethyl hexadecanoate
Dodecyl hexanoate
Decyl octanoate
Tridecy I benzoate
Isooctanedioldibutyrate
Hexadecanoic acid isopropyl ester
Ethyl heptadecanoate
Propanedioic acid dimethyl ester
Methyl N,N-diethylthiocarbamate
10-Methyltridecanoic acid
Tetradecanoic acid
Dodecanoic acid
Tridecanoic acid methyl ester
9-Pentadecenoic acid
Pentadecanoic acid
n -Methyltetradecanoic acid
Tetradecanoic acid methyl ester
Isopropyl dodecanoate
2-Ethylhexyl salicylate
Dodecyloctanoate
17-0xo-5-androsten-3a-yl sulfate
17-Oxo-5a-androstan-3a-yl sulfate
C19H2.O
CI,H"O
CI,H"O
CI9H2,O
CI,H,,02
CI,H'202
CI,H'202
CI,H3202
CI.H"O,
CI,Hn
C17H,.O,
C17H,.02
C17H,.02
C17HJ402
CI,H"O,
CI,H,002
CI,H"O,
CI.H,,02
CI.H"O,
CI.H"O,
CI.H"O,
CI.H"O,
C,.H"O,
CI.H300,
CI,H3IO,
Cl9HlI02
C,H,O,
C,H13NOS
CI,H"O,
CI,H"O,
CI,H"O,
CI4H,,02
CI,H"O,
CI,H300,
CI,H,.O,
CI,H,oO,
CI,H300,
CI,H"O,
C,oH.oo,
CI,H280,S
CI,H"O,S
273.2216
273.2216
273.2216
273.2216
274.2744
274.2744
274.2744
274.2744
283.2634
284.331S
288.2901
288.2901
288.2901
288.2901
291.2319
291.2319
297.2791
302.3059
302.3059
302.3059
302.3059
302.3059
30S.2480
309.2035
316.3215
316.3215
1.08
1.08
1.08
1.08
1.31
1.31
1.31
1.31
0.96
1.18
1.26
1.26
1.26
1.26
0.26
0.26
0.93
1.73
1.73
1.73
1.73
1.73
1.57
-O.S5
1.57
1.S7
7.40
7.40
7.40
7.40
7.46
7.46
7.46
7.46
8.33
8.46
7.6S
7.65
7.65
7.65
9.S6
9.56
8.56
7.82
7.82
7.82
7.82
7.82
7.51
9.81
8.01
8.01
255.2324
255.2324
255.2324
255.2324
281.2482
269.2482
269.2482
269.2482
269.2482
295.2636
283.2639
283.2639
283.2639
283.2639
283.2639
285.2068
1140087
146.0642
227.2011
227.2011
227.2011
227.2011
239.2011
241.2168
241.2168
241.2168
241.2168
249.1492
311.2955
367.1580
369.1736
-2.14
-2.14
-2.14
-2.14
-1.55
-1.50
-1.50
-1.50
-1.50
-2.28
-1.41
-1.41
-1.41
-1.41
-1.41
-1.21
1.92
-2.15
-2.66
-2.66
-2.66
-2.66
-2.33
-2.29
-2.29
-2.29
-2.29
-1.80
-0.17
-1.30
-1.53
10.94
10.94
10.94
10.94
1110
11.29
11.29
11.29
11.29
11.69
12.18
12.18
12.18
12.18
12.18
7.09
8.97
6.44
10.03
10.03
10.03
10.03
9.86
10.45
10.45
10.45
10.45
9.35
9.38
7.86
7.38
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The associated error with respect to the tentative identities reported in Table 5.5 are
generally less than 2 ppm, however, would need to be confirmed by authenticated
standards. Moreover, the metabolites that were detected in both positive and negative
mode report different retention times, thus, it is likely that another unknown
metabolite has the same mlz ratio. No further identification can be made from the data
collected.
The high mass accuracy «5 ppm) of the Exactive instrument was exploited in order
to use the accurate masses of parent ions for databases searches (see Section 5.3.12)
in order to find tentative identities to the known unknown' metabolites. The result of
these searches are summarised in Appendix C, in which 473 metabolites were
putatively identified. This generally works well when the composition of biological
fluid is well characterised (i.e. plasma). However, when analysing biological fluids
where the composition is poorly known (i.e. apocrine sweat), highly variable or
limited information is only available. As a result, only -21 % of the total extracted
data from Sieve produced any potential matches. Furthermore, each of the searched
mlz often produced several possible metabolites hits. This can be reduced by
including restriction on the elemental composition i.e. C, H, 0, N, Sand P,
hydrogen/carbon ratios, heuristic chemical structure and bonding rules and isotopic
abundances, as discussed in Tobias Kind and Oliver Fiehn (Kind and Fiehn, 2007).
However, the volume of unknown unknowns3 highlight the fact that LC-MS
metabolite databases are currently lagging behind NMR and GC-MS, which is a view
echoed by others (Williams et al., 2005b). One approach in providing identities of
these unknown unknowns is to use hyphenated techniques e.g. LC-NMR-MS.
5.4.1.3 Semi-Targeted analysis using Le-MS Survey Scanning
As mentioned previously, precursor ion survey scan coupled with EPI spectra has the
potential to identify common structural moieties, such as amino acid conjugates. This
2 Known unknown corresponds to metabolites that are known, but have not been formally identified in
a biological mixture.
3 Unknown unknown corresponds to metabolites that are truly novel and have never been identified
before.
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is achieved by monitoring for a specific fragment; Gin (mlz 147), Cys (mlz 105), and
Cys-Gly (mlz 179). Using precursor ion survey scan coupled with full product ion
spectra, a number of known and unknown amino acid conjugates were detected. In
order to provide tentative assignments to the unknowns, where standards were not
available, a simple set of rules were followed. Firstly, the amino acid moiety is
known, thus, the FA fragment can be calculated as the remainder of the mlz ratio.
Secondly, from the literature (Appendix A) it is also known that the FA fragment
contains no more than four oxygen elements, with the majority of reported structures
containing two or three, and generally no nitrogen elements, thereby, eliminating a
number of possible empirical formula. Finally, the chromatographic retention gives
additional information on the polarity of the molecule. Since RP-LC is employed, it
would be expected that shorter acyl chains would elute faster than longer acyl chains
due to fewer interactions with stationary phase. Moreover, the increase in unsaturation
results in reduced retention due to the cis double bonds reducing the overall surface
area that can interact with the stationary phase.
Gin conjugates
HMHA-Gln and 3M2H-Gln eluted at 5.2, and 6.5 min respectively. These amino acid
conjugates were identified on the basis of retention time and EPI spectra compared to
reference standards, as illustrated in Figure 5.16 and Figure 5.17. Furthermore, a
number of analytes were tentatively identified as Gin conjugates. Standards were not
available to confirm identification for these unknowns. However, it is known that the
Gin conjugates fragments into mlz 147, which can further fragment into mlz 130.
Thus, this information can provide additional confidence that the detected unknowns
are actually an amino acid conjugate and not another unknown metabolite that also
produces a fragment of mlz 147. Table 5.6 summarises the main finding, with the
evidence to support the identities given below.
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There are four potential matches where the pseudomolecular ion corresponds to an
amino acid conjugate that has been reported in the literature (see Appendix A).
Firstly, unknown mlz 289, which has three chromatographic peaks at retention times
of 6.2, 6.5, and 8.5 min (Figure 5.18). The FA fragment is expected to have an mlz
142 which is likely to have the formula of CgH1S02• There are four ions of mlz 289
that have been reported in the literature; N-a-3-hydroxy-4-methylhept anoyl- L-
glutamine, N-a-3-hydroxy- 3-methylhept-anoyl- L-glutamine, N-a-3-hydroxy-oct-
anoyl- L-glutamine, and N-a-8-hydroxy-oct-anoyl- L-glutamine (Natsch et al., 2006).
The former two conjugates would be considered the most likely candidates for the
retention time of 6.2 and 6.5 min with N-a-3-hydroxy-4-methylhept anoyl- L-
glutamine being slightly more retained. Where, N-a-3-hydroxy-oct-anoyl- L-
glutamine would be the most likely candidate for the peak that elutes at 8.5 min.
Secondly, unknown mlz 303 has a retention time of 7.1 min (Figure 5.19). The FA
fragment is expected to have an mlz 156 which is likely to have the formula of
C9H1702• There are four ions of mlz 303 that have been reported in the literature; N-a-
3-hydroxy-3-methyloct anoyl- L-glutamine, N-a-3-hydroxy-4-methyloct anoyl- L-
glutamine, N-alpha-7-carboxy-hept-anoyl- L-glutamine, and N-a-9-hydroxy- non-
anoyl- L-glutamine (Natsch et al., 2006). Out of these reported metabolites, it would
be expected the former two would be most likely candidate as the later two would be
considered to be more polar. On closer inspection of the extracted precursor ion
chromatogram, there are two closely eluting peaks which further suggest that N-a-3-
hydroxy-3-methyloct anoyl- L-glutamine and N-a-3-hydroxy-4-methyloct anoyl- L-
glutamine, with the later eluting later, as the most probable candidate.
Thirdly, unknown mlz 285 has a retention time of 7.5 min (Figure 5.20). The FA
fragment is expected to have an mlz 138 which is likely to have the formula of
C9H1SO. There is only one reported match in the literature, thus, is tentatively
assigned as N-a4-methyl-3-oct-enoyl- L-glutamine, with the FA being (E)-4-
Methyloct-3-enoic acid (Natsch et al., 2006).
Finally, unknown mlz 301 eluted at 8.1 min (Figure 5.21). The FA fragment is
expected to have an mlz 154 which is likely to have the formula of CIOH190. There is
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one reported match in the literature, thus, is tentatively assigned as N-a-4-ethyl-oct-
anoyl- L-glutamine, with the FA being 4-ethyloctanoic acid (Natsch et al., 2006).
There were also a number of possible conjugates that have no potential match within
the reported literature. However, the calculated FA fragments in most cases do match
VFA that has been detected in apocrine sweat from the literature (see Appendix A).
These are all summarised in below.
• Unknown mlz 271 has a retention time of 6.9 min (Figure 5.22). The FA
fragment is expected to have an mlz 124 which is likely to have the formula of
CgH130.
• Unknown mlz 317 has a retention time of 7.7 min (Figure 5.23). The FA
fragment is expected to have an mlz 170 which is likely to have the formula of
CIOHI902•
• Unknown mlz 299 has a retention time of 7.9 min (Figure 5.24). The FA
fragment is expected to have an mlz 152 which is likely to have the formula of
CIOH170 or C9H1302.
• Unknown mlz 313 has a retention time of 8.2 min (Figure 5.25). The FA
fragment is expected to have an mlz 166 which is likely to have the formula of
CIOH1502 or C11H190.
• Unknown mlz 329 has a retention time of 8.7 min (Figure 5.26). The FA
fragment is expected to have an mlz 182 which is likely to have the formula of
C12H230 or CIIHI902
• Unknown mlz 357 has a retention time of 9.07 min (Figure 5.27). The FA
fragment is expected to have an mlz 210 which is likely to have the formula of
C14H270 or C13H2302.
Unknown mlz 311 has a retention time of 1.40 min (Figure 5.28). The FA fragment is
expected to have an mlz 165 which is likely to have the formula of C IOH1302.
However, with this size fragment you would expect the analyte to elute a lot later.
Also, there is no mlz 130 peak present. Thus, it is likely that this metabolite is a false
positive.
171
Unknown mlz 206 has a retention time of 4.1 min (Figure 5.29). The FA fragment is
expected to have an mlz 59 which is likely to have the formula of C3HgO.Again there
is no peak at mlz 130, thus, expected to be a false positive.
Cys or Cys-Gly conjugates
2M3H-Cys and 3M3SH-Cys-Gly eluted at 3.2 and 5.08 min respectively. These
amino acid conjugates were identified on the basis of retention time and EPI spectra
compared to reference standard, as illustrated in Figure 5.30 and Figure 5.31.
Furthermore, a number of analytes were tentatively identified as Cys-Gly conjugates.
Standards were not available to confirm identification for these unknowns, thus,
tentative assignment was based upon characteristic product ions observed in the EPI
spectra of the 3M3SH-Cys-Gly conjugate. It is known from the 3M3SH-Cys-Gly
standard that the fragmentation pattern produces common product ions of mlz 179,
162, and 144 which are characteristic fragments of the Cys-Gly residue. Thus, it is
reasonable to suggest that any other Cys-Gly conjugate would contain the same
product ions. Table 5.6 summarises the main finding, with the evidence to support the
identities given below.
There are two potential matches where an unknown pseudomolecular ion corresponds
to an amino acid conjugate previously reported in the literature (see Appendix A).
Firstly, an unknown mlz 265 eluted at 1.65 min (Figure 5.32). The FA fragment is
expected to have an m/z 86 which is likely to have the formula of CSH110. If this
fragment is a thiol then it could be tentatively assigned to 3-sulfanylpentan-l-ol or 2-
methyl-3-sulfanylbutan-I-ol. Secondly, an unknown mlz 279 has a retention time of
3.3 min (Figure 5.33). The FA fragment is expected to have an mlz lOOwhich is
likely to have the formula of C6H130. This thiol containing compound could be
tentatively assigned to 3-sulfanylhexan-l-ol. Another addition of CH2 group would
result in 3M3SH-Cys-Gly conjugate which elutes at 5.08 min (Figure 5.31). The
addition of each CH2 group would result in a stronger retention due to the metabolite
becoming less polar. This chromatographic behaviour is consistent with other
metabolites that have been reported on RP systems, for example; homoserine lactones
had a predictable increase in retention with increasing acyl chain length (Ortori et al.,
2007).
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There were also a number of possible conjugates that have no potential match within
the reported literature. However, the assumption would be that the non-amino acid
fragment would presumably be a thiol.
• Unknown mlz 313 has a retention time of 5.13 min (Figure 5.34). The FA
fragment is expected to have an mlz 134 which is likely to have the formula of
C9HllO. The increase in retention due to increasing the carbon length is offset
by the presence of double bonds, which reduce the retention time compared to
their corresponding linear isomers, due to the overall surface area being
reduced.
• Unknownmlz 307,309, and 310 has a retention time of5.37, 6.8, and 6.9 min
respectively. As depicted in Figure 5.35, Figure 5.36 and Figure 5.37, these
unknown metabolites have fragments higher than the pseudomolecular ion.
This could be a result of being multiple charged, where that resultant
fragments also fragments into common product ions being monitored. The
resolution of this work is not sufficient to be able to distinguish multiple
charged species by using isotope distribution of CI2/Cl3. However, for a
doubly charged species you would expect the isotope cluster to be half an amu
apart (Hoffmann and Stroobant, 2001). The FA fragment is expected to have
an mlz -128 which is likely to have a formula ofCgH160.
• Unknown mlz 365 has a retention time of 6.6 min (Figure 5.38). The FA
fragment is expected to have an m/z 186 which is likely to have the formula of
CI2H270.
• Unknown mlz 358 has a retention time of 6.8 min (Figure 5.39). The FA
fragment is expected to have an m/z 186 which is likely to have the formula of
C12H2oO.
• Unknown mlz 375 has a retention time of 7.6 min (Figure 5.40). The FA
fragment is expected to have an mlz 196 which is likely to have the formula of
Cl3H250.
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• Unknown mlz 295 has a retention time of 9.5 min (Figure 5.41). The FA
fragment is expected to have an mlz 196 which is likely to have the formula of
C7H170.
5.4.1.4 RP-LC-MSIMS Multiple Reaction Monitoring for Targeted Analysis of
Odour Precursors in Human Apocrine Sweat Secretions
Targeted MRM analysis requires prior knowledge of the metabolites of interest.
Ideally, the CE and DP need to be optimised for each metabolite in order to obtain
maximum sensitivity for the transition which is being monitored. However, due to the
limited availability of standards, this could not be optimised for all the amino acid
conjugates that have been reported in the literature (see Appendix A). Since all the
reported odour precursors have a common structure (amino acid moiety), it is
reasonable to suggest that these reported amino acid conjugates would fragment in a
similar way, thereby, leaving the amino acid residue to be monitored. In comparison
to precursor ion survey scanning, this approach is considered to be more sensitive, as
the spectrometer is no longer scanning, since Q1 and Q3 are fixed, thus, allowing the
spectrometer to monitor the precursor and fragment ions over longer times (Hoffmann
and Stroobant, 2001).
As previously stated, 14 mass transitions were monitored for the analysis of odour
precursors present in human apocrine sweat samples. This was based on predictions
of the MRM transition, for all the reported amino acid conjugates in literature, to
which standards were not available. A representative total ion chromatogram is
depicted in Figure 5.4. A number of analytes were tentatively identified as amino acid
conjugates as summarised in Table 5.7. As mentioned previously, standards were not
available to confirm identification for these unknowns.
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Figure S.4 HPLC-MSIMS total ion chromatogram of a representative human apocrine sweat sample in
MRMmode.
Table S.7 Summary of the potential odour precursors identified in human apocrine sweat by LC-
MSIMS using MRM.
m/z % Peak Area Retention Tentative Identity ConfidenceTime (min)
Gin conjugates
257/147 11.40 6.5 N-a-3-methylhex-2-enoyl-L-glutamine • • •
275/147 72.08 5.2 N-a-3-hydroxy-3-methylhexanoyl- L-glutamine • • •
289/147 5.39 6.5 N-a-3-hydroxy-4-methylhept anoyl- L-glutamine • •
303/147 1.28 7.3 N-a-3-hydroxy-3-methyloct anoyl- L-glutamine • •
285/147 1.97 7.5 N-a-4-methyl-3-oct-enoyl- L-glutamine • •
3011147 0.52 8.2 N-a-4-ethyl-oct-anoyl- L-glutamine • •
287/147 0.30 7.9 N-a-4-ethyl-hept-anoyl- L-glutamine **
259/147 0.36 6.6 N-a-3-methyl-2-oxopent-anoyl- L-glutamine
Cys or Cys-Gly conjugates
208/105 0.37 3.2 S-[I-(2-hydroxy-l-methylethyl)-ethyl]-L-cysteine ***
293/179 6.21 5.1 S-[ 1-(2-hydroxyethyl)-I-methylbutyl]-L-cysteinylglycine ***
279/179 0.03 4.7 S-[ 1-(2-hydroxyethy lj-butyl]- L-cysteiny Iglycine • •
236/105 0.10 5.4 S-ll-(2-hydroxyethyl)-I-methylbutyl]-L-cystein
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2M3H-Cys, 3M3SH-Cys-Gly, HMHA-Gln and 3M2H-Gln have retention times of
3.2, 5.0, 5.2, and 6.5 min respectively. These conjugates were identified on the basis
of retention time and EPI spectra compared to reference standards, as noted above.
While screening for the known amino acid conjugates from the literature in MRM
mode, potentially, three additional conjugates were also detected that were not
detected/present in the PI scanning mode. Firstly, the transition mlz 287/147 resulted
in a peak that eluted at 7.9 min (Figure 5.5). This has been tentatively assigned to N-
a-4-ethyl-hept-anoyl- L-glutamine which was also detected with the UPLC-Orbitrap-
MS (Table 5.4). Secondly, the transition mlz 259/147 resulted in a peak that eluted at
6.6 min (Figure 5.6 A). This has been tentatively assigned to N-a-3-methyl-2-
oxopent-anoyl- L-glutamine. Finally, the transition mlz 236/105 resulted in a peak that
eluted at 5.4 min (Figure 5.6 B). This has been tentatively assigned to N-a-3-methyl-
2-oxopent-anoyl- L-glutamine. EPI spectra were not obtained for the latter two
metabolites, due to the low concentration, thus, no further evidence can suggest if
these metabolite are amino acid conjugates. Evidence for the tentative identification
of mlz 289, 303, 285, 301 and 279 were discussed above. Furthermore, it is also
evident that the two most intense peaks are HMHA-Gln and 3M2H-Gln conjugates.
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Figure 5.5 Extracted ion chromatogram from the MRM transition mlz 287/147 and EPI spectrum of the peak
at 7.6 min.
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spectra were obtained for these metabolites.
Summary of identification of small molecules compounds of human apocrine sweat.
To my knowledge, this is the first time NMR spectroscopy has been applied to human
axillary secretions in which 25 metabolites were readily identified and quantified.
Furthermore, identification of metabolites detected by NMR was aided by the large
body of information already available on human biological fluids. While the detection
of biomarkers was facile in regards to the LC-MS methodologies, the process of
identification however is more demanding, due in part to the limited database
available. Both global methodologies were able to detect 9 amino acid conjugates
which were confirmed by a targeted MSIMS approach. The precursor ion survey
scanning approach has successfully identified four amino acid conjugates present the
human apocrine sweat secretions, for which standards were available and tentatively
identified 26 other amino acid conjugates. Further identification of these unknown
metabolites is not possible with the data presented here; all that can be hypothesized
is that these are likely to be a GIn, Cys, or Cys-Gly conjugate. There is no evidence in
the literature to support the presence or identity of these analytes. Moreover, this
method is not selective towards the detection of amino acid conjugates alone due to
prevalence of other endogenous metabolites which could produce similar fragments,
thereby highlighting the limitations of this methodology.
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5.4.2 Study of Temporal, Inter- and Intra-Individual Differences in Human
Axillary Secretions
5.4.2.1 Inter- and Intra-Individual Differences
Visual comparison of this type of data, from both NMR spectroscopy and LC-MS
data-sets could be performed, however, such analysis would be tedious, inefficient
and prone to subjective error. Thus, multivariate analysis such as PCA (unsupervised)
and PC-DA (supervised) were applied to all the NMR and global LC-MS (QTOF and
Exactive) data-sets obtained from the apocrine sweat samples. Both mean centred and
UV scaling lead to a similar degree of separation between the six classes, thus, only
UV scaled models will be shown as a representative example. The PCA model (UV
scaled) obtained from the NMR data resulted in R2X (cum) of 0.354 using two PCs,
where PC 1 and 2 explained 21.3% and 14.1% of the total variation, respectively, as
depicted in Figure 5.7. The HlLIC-MS PCA model (UV scaled) resulted in R2X
(cum) of 0.275 using two PCs, where PCI and 2 explained 17.8% and 9.6% of the
total variation, respectively, as depicted in Figure 5.8. PCA model (UV scaled)
obtained from the Exactive data in positive mode resulted in R2X (cum) of 0.467
using two PCs, where PCI and 2 explained 29.3% and 17.4% of the total variation,
respectively. The negative mode PCA model (UV scaled) resulted in R2X (cum) of
0.554 using two PCs, where PCI and 2 explained 35.6% and 19.7% of the total
variation, respectively, as depicted in Figure 5.9.
These global methodologies provided complementary information to one another as
inter-person variation is clearly evident across all PCA models. As would be
expected, PC-DA further improved the separation between each individual (data not
shown). It is also evident that the clustering between the intra-individual variations in
the PCA model obtained from the negative electro spray data are more closely defined
compared to that of the NMR or MS positive mode data. This is likely to be due to the
main differences between groups being metabolites that are only observed in negative
mode.
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The ten amino acid conjugates that were identified or tentatively identified
confidently (indicated with two or more stars in Table 5.7) also provided
complementary evidence to the global methodologies. Figure 5.10 illustrates the inter-
volunteer variation across day one, which is a representative example across all days.
The inter-person variation of the amino acid conjugates is consistent with other
biological fluids, due to variation in genetic profiles as well as environmental life
styles. However, it is evident that HMHA-Gln conjugate (mlz 275) is the most
dominant peak, which is consistent across all volunteers, while 2M3H-Cys conjugate
(mlz 208) is predominantly weak. 3M2H-Gln conjugate (mlz 257) remains relatively
consistent across all samples, with slightly more produced for volunteer two. 3M3SH-
Cys-Gly conjugate (mlz 293) was the most variable between each volunteer, with a
higher concentration produced in volunteer two compared to the least produced in
volunteer five.
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Figure 5_7 PCA score plot (UV scaled) of human apocrine sweat samples analysed by NMR
spectroscopy of six healthy male volunteers (left and right axillae measured separately) across four
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Figure 5.8 PCA score plot (UV scaled) of human apocrine sweat samples analysed by HlLIC-MS of
six healthy male volunteers (left and right axillae measured separately) across four days. Key:-
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5.4.2.2 Inter-Day Differences
To assess whether there is any inter-day variation from sample collection or to
identify whether the sweat produced is constant across the four days; the data was
mean centred per individual. This effectively minimises the dominant inter-person
variation from the model, so only intra-person variation or time trends will influence
the separation in the model. Both mean centring per person and UV scaling per person
lead to a similar degree of separation between the four classes for all analytical
methodologies, thus, only UV scaled models from NMR and Le-MS will be shown as
a representative example. The peA models from the first two pes account for 26.6%
and 44.8% of the total variation, obtained from the NMR and Exactive data
respectively. peA of the apocrine sweat profiles did not display intrinsic clustering
related to sample collection as depicted in Figure 5.11.
The ten amino acid conjugates (indicated with two or more stars in Table 5.7) were
selected in order to identify the degree of inter-day variation across all volunteers. As
depicted in Figure 5.12, there is little difference between the 24 h time points of
sample collection. This is consistent with the above finding from both the global
NMR and MS data as well as the work published by Leydon and co-workers (Leyden
et al., 1981). However, intra-volunteer difference across each day was observed for
all amino acid conjugates. A representative example is shown in Figure 5.13,
highlighting a gross inter-day effect for all amino acid conjugates. This gross effect
was observed for all volunteers, however, the actual inter-day levels varied between
each volunteer. Thus, the observed change is attributed to a concentration effect
arising from how the sample was collected or how much sweat was secreted rather
than inter-day effect, as the relative proportions remain consistent across all
metabolites.
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Figure 5.11 PCA scores plot (UV scaled per person) of human apocrine sweat samples analysed by A
NMR spectroscopy B UPLC-MS negative mode, of six healthy male volunteers (left and right axillae
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Figure 5.12 Pie charts illustrating the average inter-day variation of the targeted amino acid conjugates
(LC-MSIMS), with each day representing a 24 h time point.
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Figure 5.13 Summarises the intra-day variation of each amino acid conjugate, with each day
representing a 24 h time point, obtained from volunteer one.
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5.4.2.3 Left and Right Arm Differences
To assess whether there are any side related differences between the left and right
axilla, the data was mean centred per person as discussed previously (Section 5.4.2.2).
Both mean centring per person and UV scaled per person lead to a similar degree of
separation between the two classes for all analytical methodologies, thus, only UV
scaled models from NMR and LC-MS will be shown as a representative example. The
PCA models from the first two PCs account for 26.6% and 44.8% of the total
variation obtained from the NMR and Exactive data respectively. PCA of the apocrine
sweat profiles did not display any side related differences as depicted in Figure 5.14.
Furthermore, the data obtained from the targeted analysis was consistent with the
above finding from both the global NMR and LC-MS data, as depicted in Figure 5.15.
All identified amino acid conjugates (indicated with two or more stars in Table 5.7)
were secreted in equal quantities in both the left and right ann across each day.
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Figure 5.14 PCA scores plot (UV scaled per person) of human apocrine sweat samples analysed by A
NMR spectroscopy B UPLC-MS negative mode of six healthy male volunteers (left and right axillae
measured separately) across four days. Coloured to highlight the difference between left (red) and right
(black) axilla.
187
left arm Rightarm • 208.2/105.1
.257.1/147.1
.275.1/147..1
.293.1/179..1
.289.1/147..1
.285.2/147.1
.301.2/147.1
.279.1/179..1
303.2/147..1
.287.1/147.1
Figure 5.15 Pie chart illustrating the relative difference between the left and right arm across all
volunteers.
Summary
All the analytical methodologies were capable of detecting inter-individual
differences in the axillary sweat metabolic profile. Furthermore, each technique
(NMR, LC-MS, and LC-MSIMS) showed that there was minimal inter-day variation
and that the composition of the apocrine sweat produced from left and right axilla was
consistent with one another. Thus, all techniques used herein provided
complementary information, as discrimination by IH NMR and LC-MS was based on
different sets of markers, especially in the case of the targeted approach were only ten
metabolites were selected for analysis.
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Figure 5.16 Extracted ion chromatogram of mlz 275 and EPI spectrum of the peak at 5.2 min from an EPI
triggered PI scan of mlz 147.
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Figure 5.17 Extracted ion chromatogram of mlz 257 and EPI spectrum of the peak at 6.4 min from an EPI
triggered PI scan of mlz 147.
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Figure 5.18 Extracted ion chromatogram of mlz 289 and EPI spectrum of the peak at 6.5 min from an EPI
triggered PI scan of mlz 147.
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Figure 5.19 Extracted ion chromatogram of mlz 303 and EPI spectrum of the peak at 7.1 min from an EPI
triggered PI scan of mlz 147.
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Figure 5.20 Extracted ion chromatogram of mlz 285 and EPI spectrum of the peak at 7.5 min from an EPI
triggered PI scan of mlz 147.
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Figure 5.21 Extracted ion chromatogram of mlz 301 and EPI spectrum of the peak at 8.1 min from an EPI
triggered PI scan of mlz 147.
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Figure 5.22 Extracted ion chromatogram of m/z 271 and EPI spectrum of the peak at 6.9 min from an EPI
triggered PI scan of m/z 147.
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Figure 5.23 Extracted ion chromatogram of m/z 317 and EPI spectrum of the peak at 7.6 min from an EPI
triggered PI scan of m/z 147.
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Figure 5.24 Extracted ion chromatogram of m/z 299 and EPI spectrum of the peak at 7.9 min from an EPI
triggered PI scan of m/z 147.
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Figure 5.25 Extracted ion chromatogram of mlz 313 and EP] spectrum of the peak at 8.2 min from an EP]
triggered P] scan of mlz 147.
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Figure 5.26 Extracted ion chromatogram of mlz 329 and EP] spectrum of the peak at 8.7 min from an EP]
triggered P] scan of mlz 147.
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Figure 5.27 Extracted ion chromatogram of mlz 357 and EP] spectrum of the peak at 9.0 min from an EP]
triggered PI scan of mlz 147.
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Figure 5.28 Extracted ion chromatogram of mlz 311 and EPI spectrum of the peak at 1.4 min from an EPI
triggered PI scan of mlz 147.
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Figure 5.29 Extracted ion chromatogram of mlz 206 and EPI spectrum of the peak at 4.1 min from an EPI
triggered PI scan of mlz 147.
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Cys or Cys-Gly conjugates
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Figure 5.30 Extracted ion chromatogram of m/z 208 and EP) spectrum of the peak at 3.2 min from an EP)
triggered P) scan of m/z 105.
117.7 510 2.9oe
'.10.7 2Ioe
~.611
1.0007
2.4te
9.000e
~ :!oil
8.000e 2006
§. 7000e Uo.! 'li0ii
I6000e I1....5.000e 1.206
• . oooe '.006
3.000e '.Ooe
6.0015
118.0
~ OllIe
• . 005
l000e
2.0015
0.00
, ,
, : 3 • 5 6 7 8 • 10 11 12 '3 1. 15 11n.._
'120
'79.0
213.'
Figure 5.31 Extracted ion chromatogram ofm/z 293 and EP) spectrum of the peak at 5.1 min from an EP)
triggered P) scan of m/z l 79.
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Figure 5.32 Extracted ion chromatogram of m/z 265 and EP) spectrum of the peak at 1.6 min from an EP)
triggered PI scan of m/z 179.
194
6~ 3113 '''.0
60H H.O
~ !>04 :!.1e6
2.0
~- :.2e5
• !>04
2.Ge6
.- .... 6
~
3 !>04
~ U.o
f 30H f U.62_ '.:Iee
=-
• Ge6
I.OH
.-
'~Jj 6.OH.-50000
~ 11£l.Mi.I..... ./U .f.I~• •~.111a00 _L_. ___,\,~ .aUA
• 2 3 • ~ 6 7 • t '0 "
'2 .3 ,. '5 .1
~.-
~O
.b...u..._~,...u._-;:k- __22_7Lt---:C __~..L°_L__ . _
~ 300 350
mil.• mu
Figure 5.33 Extracted ion chromatogram of m/z 279 and EPI spectrum of the peak at 3.6 min from an EPI
triggered PI scan of mlz 179.
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Figure 5.35 Extracted ion chromatogram of mlz 307 and EPI spectrum of the peak at 5.3 min from an EPI
triggered PI scan of mlz 179.
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triggered PI scan of mlz 179.
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Figure 5.37 Extracted ion chromatogram of mlz 310 and EPI spectrum of the peak at 6.9 min from an EPI
triggered PI scan of mlz 179.
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Figure 5.38 Extracted ion chromatogram of mlz 365 and EPI spectrum of the peak at 6.6 min from an EPI
triggered PI scan of mlz 179.
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Figure 5.39 Extracted ion chromatogram of m/z 358 and EPI spectrum of the peak at 6.8 min from an EPI
triggered PI scan of mlz 179.
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Figure 5.40 Extracted ion chromatogram of m/z 375 and EPI spectrum of the peak at 7.6 min from an EPI
triggered PI scan of mlz I79.
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triggered PI scan of mlz 179.
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5.4.3 Overall Discussion and Conclusions
Previous analytical studies on human apocrine sweat have predominantly focused on
individual 'odour profiles' which are detectable via GC·MS analysis often in
combination with perceived odour intensity, rated by human volunteers. The work
presented herein was more focused on the chemical precursors to 'body odour'.
To my knowledge this is the first NMR study on apocrine sweat samples, in which 25
metabolites could be tentatively identified. Furthermore, inter-person variation could
be identified from both the NMR and LC·MS techniques, which is consistent with the
reported literature in regards to the analysis of the volatile components (Bernier et al.,
1999; Curran et al., 2005; Natsch et al., 2006; Penn et al., 2007; Sommerville et al.,
1994).
In total, 12 odour precursors have been identified across all LC·MS techniques with a
further 20 being partially identified through the use of the targeted approach, due to
the increase in sensitivity over both the Exactive and QTOF systems. Definitive
identification was not always possible due to the lack of synthetic standards, however,
strong evidence for identity has been provided via LC·MS/MS fragmentation as well
as accurate mass identification.
Retention times of each of the amino acid odour precursors are expected to differ
when comparing against different HPLC columns, due to the differences in the
composition of the stationary phase, column length and particle size dimensions.
However, in the case of RP columns, the order in which these odour precursors elute
are expected to be consistent with one another. In regards to the HILIC column, the
elution odour is considered to be opposite to that of RP systems.
The glutamine conjugates, 3M2H·Gln and HMHA·Gln as well as the 3M3SH·Cys·
Gly conjugates, have been described as the key precursors to body odour (Emter and
Natsch, 2008; Natsch et al., 2006; Natsch et al., 2003; Starkenmann et al., 2005). All
three conjugates were detectable across all samples, with HMHA being the most
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dominant odour precursor detected. In previous reports, the 3M3SH-Cys-Gly
precursor has been shown to vary between individuals, as reported here, however. in a
recent paper by Trocas and co-workers; they reported a 2: I ratio between males and
females over a three year study (Troccaz et al., 2009). Furthermore, they showed that
the same microflora can generate distinctively different body odours with respect to
the composition of apocrine sweat.
Moreover, these reported odour precursors (Natsch et ai., 2006; Natsch et al., 2003)
have been shown to occur in different ratios between different individuals, but
whether these ratios are stable over time and whether they are genetically fixed has
not been reported. From the work herein, it is shown that the sweat composition of
each individual is consistent from one day to the next. However, it is not certain
whether the sweat composition or in particular, the odour precursors, remain constant
in an individual across the course of a day.
Both NMR and Le-MS showed that there were no side related differences, nor were
there any differences between each 24 h time point. This is consistent with the work
by Ferdenzi and co-workers (Ferdenzi et al., 2009), where they concluded that that
the left and right axillary can be considered as perceptually equivalent in
attractiveness, intensity, or masculinity. However, if handedness is taken into account,
there were reported differences between the left and right axillae in left-handed
people only. It was reported that the odour, masculinity and intensity was more
profound on the more active left side. This was in line with previous observations on
asymmetry of axillary odour (Bird and Gower, 1982) and the rate of sweat production
(Inaba and Inaba, 1992), with the view that side-related differences could be due to
changes in the local environmental conditions caused by the increase in activity,
favouring sweating rate or increased activity of microflora (Ferdenzi et al., 2009).
However, previous reports have shown the skin microflora to be quantitatively and
qualitatively the same in the left and right axillae and not to be affected by
handedness or sex (Leyden et al., 1981). Thus, Ferdenzi's hypothesis "that there
exists an underlying activity-independent asymmetry that makes the left axilla smell
stronger and that the superimposition of the activity-based asymmetry would balance
both sides in right-handers but emphasize the asymmetry in left-handers", can neither
be confirmed nor dismissed from the work presented here due to the limited sample
199
volume and lack of available biometric data. Nonetheless, the results presented herein
are in agreement with the hypothesis that individual odour differences are more likely
to be influenced both by genetics and microflora (Emter and Natsch, 2008; James et
al., 2004; Kuhn and Natsch, 2009; Penn and Potts, 1998b; Troccaz et al., 2009).
There is also evidence that MHC genes can influence microflora composition
(Toivanen et aI., 200 I).
Further examining odour production in relation to the genotype can offer many
practical applications. Firstly, it would be advantageous for researchers if the left or
right side could be used separately as identical stimuli (doubling the amount of
samples) or as a control vs treated. Secondly, there is increasing interest in whether
human odours could be used for forensic research (Roberts et al., 2005), potentially
non-invasive disease diagnostics (Mantini et al., 2000; Penn and Potts, 1998b; Turner
and Magan, 2004; Willis et al., 2004) or reducing the risk of attracting mosquitoes
and other disease vectors (Penn et al., 2007). Finally, understanding of how
chemonsensory individuality in humans is determined in part by MHC or other genes
(Penn and Potts, 1998a; Penn, 2002) would provide rational for both a direct and
indirect approach to mask or eliminate these odours.
The findings of this present study illustrate the complementary nature of these
analytical techniques and demonstrate the potential value of employing both NMR
and LC-MS, in both a global and targeted manner, to the analysis of apocrine sweat
samples. Identification of components detected by IH NMR spectroscopy was aided
by the large body of information already available on metabolites identified in human
biofluids. In comparison, the available data for metabolite identification by LC-MS is
less extensive which reflects the major disadvantage of using LC-MS in
metabolomics, as databases of compounds likely to be encountered in apocrine sweat
have not yet been defined. However, through the use of high mass accuracy
instruments, elemental compositions can be postulated. Nonetheless, further analysis
would be required for structural elucidation of these metabolites via the application of
LC-NMR-MS.
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Chapter 6
6 General Discussion
The main aim of this work was to develop a series of analytical methodologies (NMR,
HILlC-MS, RP-UPLC-MS and RP-LC-MSIMS) that would provide further insight
into the chemical composition of human apocrine secretions, with particular reference
to odour precursors, as well as identifying intra- and inter-subject variation between
six individuals. Although the methods were developed for the use of apocrine gland
secretions, they have the potential to be adapted for the analysis of other biological
fluids such as plasma and urine. Four analytical techniques were developed in
tandem, in order to provide as much information as possible on the composition of
human apocrine sweat. The most significant developments in each chapter are
summarised in Table 6.1.
Analytical methodologies were initially developed with an artificial sweat matrix in
order to test analytical procedures and were therefore not designed to replicate
apocrine secretions per se, due to the current uncertainties about the exact
composition. Firstly, NMR procedures were developed with hypoallergenic infant
formula from Neocate (www.neocate.co.uk) as the exact composition has been fully
characterised and therefore allowed accurate comparison of different NMR
conditions. The data evaluated in chapter two showed that a 1 mm micro-volume
probe coupled to a 400 MHz spectrometer was best suited to handling small samples
volumes typically obtained from human apocrine sweat. The sensitivity enhancement
was -5.3 fold over data acquired using conventional 5mm OD NMR tubes on a 400
MHz spectrometer, and provided similar sensitivity to that of a 500 MHz
spectrometer coupled with a cryo-probe. Secondly. a HILlC-MS method was
developed with blood plasma as the biological matrix in order to provide a novel
global approach for the separation ofthe more polar compounds that would ultimately
complement the NMR data. This was mostly focused on the separation of amino acids
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due to the range of polarities they represent. Finally, two further RP-LC-MS/MS
methods were developed with available standards, providing a more selective and
sensitive approach for screening against odour precursors. Furthermore, there was the
opportunity to analyse the apocrine sweat samples with an orbitrap MS using RP-
UPLC. However, due to time constraints, the LC conditions used were developed by
Dr. Catharine Ortori (University of Nottingham). The orbitrap is more advanced than
the current QTOF instrument, thereby, providing higher mass resolution; which
approaches that of FTICR (~100 000) in comparison to QTOF (~10 000); greater
sensitivity and mass accuracy as well as having the ability of positive and negative
switching during acquisition.
Chapter
Table 6.1 Summary of the main conclusions of the work carried out in each chapter
Development
Two Artificial sweat matrix was used to develop NMR methodologies
I mm micro-volume probe identified as the most suitable for the analysis of apocrine
sweat
Three Developed Global HILlC-MS approach in order to characterise apocrine gland
secretions
Developed semi-targeted LC-MSIMS approach which is capable of screening for
unknown odour precursors.
Developed targeted LC-MSIMS approach for the analysis of known reported odour
precursors.
Four Reviewed analytical methodologies with sweat produced in vitro using an ASG5 cell
line
PCA and PC-DA was used to explore the metabolite differences between hormonal
drug treatments
Both NMR and HILlC-MS data were able to differentiate between the different
treatments, thus, showing complementary information on a different subset of
metabolites
Putatively identified 275 metabolites ranging from amino acids, hydroxy acids, fatty
acids, bile acids, nucleotides, lipids and vitamins
Five PCA was used to explore the metabolite differences between volunteers
All methodologies showed complementary information on a different subset of
metabolites
Left and right secretions were shown to be similar in composition
Identified 12 known odour precursors and possibly identified a further 20 odour
precursors
Putatively identified 473 metabolites ranging from amino acids, hydroxy acids, fatty
acids, bile acids, glucuronides, lipids and vitamins
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To the author's knowledge, this is the first time NMR profiling of human apocrine
sweat has been achieved. However, previous studies on eccrine sweat have been
reported (Harker et al., 2006). Moreover, to the author's knowledge, this was the first
metabolomics study that has used either HILIC or RP-UPLC methodologies for the
global metabolite identification of human apocrine sweat. The majority of the
literature is GC based (Hasegawa et al., 2004; Natsch et al., 2006; Natsch et al., 2004;
Penn et al., 2007; Starkenmann et al., 2005), with some work using targeted RP-LC-
MS (Emter and Natsch, 2008; Natsch et al., 2006; Troccaz et al., 2009) for the
identification of odour precursors. However, the main novelty of the MS/MS data
presented herein, comes from the PI scanning methodology to selectively scan for
unknown odour precursors. Nonetheless, one of the major limitations with the
MSIMS methodology currently reported is the lack of synthetic standards or
isotopically labelled standards to provide absolute identification. Isotopic labelled
standards would have the same chemistry and retention time as their counterpart, but
would be differentiated due to the difference in molecular weight, thus, providing
different MRM transitions. However, under the circumstances, typically for the
MSIMS methodologies, metabolite identification proposed was based on knowledge
of fragmentation profiles of other standards. If time and funds were not placing such
constraints, it may have been possible to organise synthesis of more of the amino acid
conjugates (odour precursors). Presence ofthese compounds would allow the MS/MS
methodology to be validated, allowing absolute quantification of these odour
precursor metabolites.
Spectral variations obtained from global methodologies (NMR, HILlC-MS, and RP-
UPLC-MS) were explored using both PCA and PC-DA, in which the variation was
explained by the first three PCs. It was observed that inter-variation for each
volunteer was greater than intra-variation. Moreover, samples collected from the left
and right arm, as well as 24 h time points, were consistent with one another. This
information was also echoed by RP-LC-MSIMS data, which only monitored the
odour precursors. It is also noted that a 24 h time point is considered to be a long
biological time period, thus, for future studies it would be interesting to identify
whether these odour precursors are secreted at a consistent rate during a 24 h period.
Nonetheless, this potentially has great benefits for future projects, as not only can one
203
double the sample volume obtained from a single volunteer, but there is also the
potential to have a test and control side per individual. Identifying the metabolites
contributing to inter-person variation could not be achieved, partly due to
experimental design (small sample size) and the absence of available meta data for
each volunteer, thereby, identifying a major limitation. Nonetheless, it was possible to
provide further insight into the metabolite composition of human apocrine washes.
contributing to the research area greatly, as well as highlighting the complementary
nature of the developed methodologies.
The NMR data was able to identify 25 metabolites, with lactate being the most
dominant, at -13.2 mM, which is consistent with the literature (Meyer et aI., 2007;
Sato et al., 1989) and that reported in eccrine sweat (Harker et al., 2006).
Furthermore, comparison of the in vitro produced apocrine sweat from AGS cell lines
(Burry et al., 2008), was shown to be of similar composition to that of an in vivo
apocrine sweat collected from human volunteers (see Table 4.1 and Table 5.3 on page
128 and 158 respectively). Thus, it can be concluded that the in vitro sweat would
have provided a good sample type for method development and as a result would be
recommended to use for any further method development. However, when analysing
the in vitro samples by MSIMS, odour precursors were not shown to be present.
Although, 3M2H-Gln has previously been identified through GC-MS with the AGS5
cells (Burry et al., 2008), it is possible that the odour precursors were removed during
the extraction procedure or that these compounds were below the limit of detection
with the instrumentation used.
The biggest challenge in this project was post acquisition, as in metabolomics analysis
there is the requirement of converting an unidentified feature into a known chemical
entity i.e. a metabolite. Currently, both NMR and Le-MS have been developed to suit
high-throughput analysis. However, these have not been developed to provide
automatic identification of the many hundreds of features detected. Thus,
identification is still a manual or semi-automated process, which is typically biased
towards metabolites of interest rather than all metabolites. Currently, many lab groups
quote the number of features, often thousands from LC-MS data, as the number of
metabolites detected. This is expected to be many magnitudes lowers due to many
metabolites producing more than one feature, for example, fragmentation products,
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isotopes, multiply-charged species, or adducts (Brown et al., 2009). Thus. it is not
uncommon for one metabolite to produce 10 or more detectable features. adding to
the complexity of the data (Dunn et al., 20 11b). To overcome these difficulties. a
database of all reported sweat metabolites was sourced from available literature (see
Appendix A), as well as using generic online databases, such as HMDB (see Table
5.2, page 155), to search for M+H as well as common adducts such as Na+. K+ and
NH4+ to generate a putative identification. However, the majority of the reported
literature is GC based, thus, leaving a large gap in identified metabolites via LC. as
well as the available metabolite databases being far from a complete representation.
To overcome these difficulties new MS software would need to be sourced in order to
reduce the new number of detected features into a number of suitable mlz which could
be used to search for hits or potential matches or to construct an accurate chemical
formula based on the accurate mass. Nonetheless, 473 metabolites were putatively
identified from the analysis of human apocrine sweat, with glucuronides, bile acids
and sulphates being readily detected.
LC-MSIMS analyses readily identified 3M2H-Gln and HMHA-Gln, which are
considered as the major odour precursor in apocrine sweat (Zeng et al., 1991), as well
as identifying 10 other known odour precursors, which are known to be present
(Emter and Natsch, 2008; Natsch et al., 2006; Natsch et al., 2004; Starkenmann et al.,
2005; Starkenmann et al., 2008). These odour precursors were also detected on both
the HILIC and RP-LC-MS methodologies adding further evidence to their presence.
Furthermore, the PI scanning approach was able to detect a further 20 metabolites,
which have the potential to be unidentified odour precursors. In order to confirm their
identities, other methodologies would need to be sourced, as the cost of sample
collection, together with limited sample volumes, makes fraction collection followed
by NMR analysis unfeasible in this instance. One approach would be to use an LTQ
Orbitrap-Velos developed by Thermo Scientific, which would provide MS" accurate
mass fragmentation and together with the knowledge that part of the metabolite is
known (i.e. contains an amino acid residue), would allow the molecular formula and
structure to be calculated. Once the structure is determined, a synthetic standard
would need to be synthesised for absolute clarification.
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Appendix A
A list of reported metabolites fuund m human apocrine sweat secretions. For further infonnatiOll see Appendix A on the attached CD
Com~DeDt5 Stroct1lre Molecule Ma .. M+H
l-Hydroxy .cids
3-Hydroxy-3-methylhexanoic acid
~OH
C7HI403 146.0943 147.1021
OH 0
3-Hydroxy-4-methylhexanoic acid
~OH
C7HI403 146.0943 147.1021
3-HYdroxy-3-methylheptanoic acid
~
C8H1603 160.1099 1610628
OH
OH 0
3-Hydroxy-4-methylheptanoic acid
~OH
C8HI603 160.1099 1610621
OH 0
3-Hydroxyoctanoic acid
~OH C8H1603 160.1099 1610621
3-Hydroxy·3·methyloctanoic acid
~OH
C9HI803 174.1256 175.1334
OH 0
3-Hydroxy-4·methyloctanoic acid
~:
C9HIB03 174.12S6 175.1334
3-Hydroxy-4·methylnonanoic acid
~OH
CI0H2003 IBB.1412 189.1491
OH 0
3-Hydroxydecanoic acid
~OH
CI0H2003 IBB.1412 189.1491
V.... lUnled .cid.
(Z}-3·Methylhex·2-enoic acid )J C7HI202 128.0837 129.0916
OH
(E}-3·Methylhex·2-enoic acid
~
C7H1202 128.0837 129.0916
OH
0
4-Methyloct-4-enoic acid
~OH
C9HI602 156.1150 157.1229
0
(Z}-4·Methyloct·3-enoic acid
~OH C9HI602 156.1150 157.1229
0
(E}-4-Methyloct·3-enoic acid
~OH
C9HI602 156.1150 157.1229
(Z}-4·Methylnon.3-enoic acid fOO CIOHIB02 170.1307 171.1385
0
(E}-4.Methylnon-3-enoic acid
~OH
CIOHIB02 170.1307 171.1385
(E}-3·Methyl-2-octenoic acid
~
C9HI602 156.1150 157.1229
M(E}-3·Methyl-2-pentenoic acid 0 C6HIOO2 114.0681 115.0759
(Z}-3.Methylhex-2-anoic acid
~
C7HI202 128.0837 129.0916
236
07-0ctenoic acid
~OH
CSHI402 142.0994 1431072
0
9-Decenoic acid
~OH
CIOHIS02 170.1307 171.1385
0
10-Undecenoic acid
~OH
CIIH2002 IS4.1463 IS5.1542
0
2-Hexenoic acid
~
C6HIOO2 114.06SI 115.0759
"""'" OH
9-Pentadecenoic acid
~OH CI5H2S02 240.2089 241.2168
9-Hexadecenoic acid
~;~
CI6H3002 254.2246 255.2~24
~~9-Heptadecenoic acid , CI7H3202 268.2402 2692481
Oleic acid
~:" CISH3402 282.2559 283.2637
Unsaturated C I I acid (lO-Wl<Iecenoic acid)
~H
CIIH2002 184.1463 185.1542
Steroidal
Sa-Androsl-16-en-3a-01
'D,e&=> C19H300 274.2297 275.2375
Androsta-4. 16-dien-3-one £t5b C19H260 270.1984 271.20620
Sa-Androst-16-en-3-one oDSb C19H280 272.2140 273.2218
Andtosta-4. 16-dien- 3a-ol oo,e&=> C19H280 272.2140 273.2218
Sa-Androst-16-en-3~1 oo£t5b C19H300 274.2297 2752375
Sa-Androsta-S. 16-dien-3~1 DSb C19H280 272.2140 273.2218HO
Androst-S-ene-311-17Cl$-diols ;::&b CI9H3202 292.2402 293.2481
HO
237
Androsta-5. 16-dien-3a-ol
...CtSb C19H280 272.2140 273.2218
HO
Androsta- 5. le-dien- 3-one rt)b CI9H260 270.1984 271.2062
0
Androsta-s, 16-dien-3®-o1
~£t5b C19H280 272.2140 2732218
Cholesterol
-~
C27H460 386.3549 387.3627
Squalene # C30H50 410.3913 411.3991
~
5cx-Dihydrotestosterone CI9H3002 290.2246 291.2324
H
o -
H
.c#5~-Dihydrotestosterone C19H3002 290.2246 291.2324H0
H
0
Dehydrocpiandrosterone
~
C19H2802 288.2089
HO
H
~
Testosterone C19H2802 288.2089 219.2168
H
0
17-Oxo-5a-androstan-3a-yl sulfate
~,.o~
C19H3005S 370.1814 371.1892
o,s...O\\· ~
0
17-Oxo-5-androsten-3a-yl sulfate
~,P cJ5f5 CI9H28OSS 368.1657 369.1736/p",O'\' ~
0
S""anylalkanob
SH
3-Sulfimylhexan-l-ol
~oo
C6HI40S 134.0765 m.O&44
238
SH
2-Methyl-3-sulfanylbutan-I-ol ArOH C5HI20S 120.0609 12106 7
'Ii3-Sulfanylpentan-l-ol
~OH
C5HI20S 120.0609 121.06 7
3-Methyl-3-,ulfanylhexan-I-01
~OH
C7HI60S 148.0922 1491000
0
"Dimethylsulfone -R- C2H602S 94.0089 95.0167
0
Amino acids degradtion products and miseeUaneous acids
0
2-HydtOxypropanoic acid YOH C3H603 90.0317 91.0395OH
3-Methyl-2-oxopentanoic acid J/OH C6HI003 130.0630 I 107
0
0
4-Methyl-2-oxopentanoic acid rrOH C6HIOO3 130.0630 1310700
0
4-Ethylheptanoic acid
~OH
C9HI802 158.1307 I 9"
Phenylacetic acid W C8H802 136.0524 1370601OH
0
4-Ethyloctanoic acid ('goat acid')
~OH CIOH2002 172.1463 173 I 42
0
8-Hydroxyoctanoic acid HO~ C8H1603 160.1099 161 117Ofl
0
Octanedioic acid (suberic acid) HO~ C8HI404 174.0892 17 .091OH
0
0
9-Hydroxynonanoic acid
HO~OH C9H1803 174.1256 17 .1 34
(4-Hydroxyphenyl)acetic acid HOw C8H803 152.0473 IS3'osS2
OH
0 0
Nonanedioic acid (azelaic acid)
HO~OH
C9H1604 188.1049 1891127
HO
2-Ethylhexanoic acid ?J- C8HI602 144.115 14S.1229
2-Pipendinone (}=O C5H9NO 99.0684 100 0762
0
2-Methyihexanoic acid
~OH
C7HI402 130.0994 131 1012
2-Methylheptanoic acid ~\_)_<H C8HI602 144.115 145.1229
2-Methyloctanoic acid ~:H C9HI802 158.1307 I 9138
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2-Methylnonanoic acid ~H C10H2002 172.1463 1731542
2-Methyldecanoic acid ~H
CIIH2202 186.162 187 1698
8-Methyltmdecanoic acid
~OH CI2H2402 200.1776 201 1855
0
9-Methyldodecanoic acid ~: CI3H2602 214.1933 215 2011
10-Methyltridecanoic acid ~OH
CI4H2802 228.2089 2292168
Isovaleric acid MOH CSHIOO2 102.0681 1m 07S9
3-Methylhexanoic acid
~~
C7HI402 1300994 I~I 1072
4-Ethylpentanoic acid MOH C7H1402 1300994 I~I 1072
4-Ethylnonanoic acid A, CIIH2202 186162 1871698HO
4-Ethyldecanoic acid h, C12H2402 200.1776 201 18SS
0
Propanoic acid .._)lOH C3H602 740368 750446
0
Hexanoic acid ~OH C6HI202 1160837 1170'116
Benzoic acid
Q-{H C7H602 1220368 ID O~~6
Dodecanoic acid OH
C12H2402 200.1776 201 IRSS
0
Tetradecanoic acid ~OH
CI4H2802 228.2089 2292168
Pentadecanoic acid ~oo
CISH3002 2422246 2432324
Hexadecanoic acid ~oo
CI6H3202 256.2402 2572481
Heptadecanoic acid
~O. CI7H3402 270.2559 271 2637
2-Methylhexadecanoic acid ~n. CI7H3402 2702559 271.2637
Octadecanoic acid ~~
C18H3602 2842715 285 27'l4
2"0
0
n -Heptanoic acid
~OH
C7H1402 130.0994 131 1072
0
n -Octanoic acid
~OH
C8HI602 144.115 145.1229
0
n -Nananoic acid
~OH
C9HI802 158.1307 1591385
0
n -Decanoic acid
~OH
CIOH2002 172.1463 173.1542
0
n -Undecanoic acid
~OH
CIIH2202 186.162 187.1698
0
n - Methyldodecanoic acid
~OH
CI3H2602 214.1933 215.2011
0
n -Methyltetradecanoic acid
~OH
CI5H3002 242.2246 2432324
Esters
0
7-Hexadecenoic acid methyl ester o~ CI7H3202 268.2402 2692481
t
0
Acetic acid pbenyJmethyl ester ~0'-O C9HIOO2 150.0681 1510759
~ I!
2-Phenylethyl acetate 0y CIOHI202 164.0837 165.0916
~o -
Cyclopentanetridecanoic acid methyl ester
~
CI9H3602 296.2715 2972794
0
1
Dodecanoic acid, 10-methyl, methyl ester
I~
C14H2802 228.2089 229.2168
\
Furancarhoxylic acid methyl ester
~O C6H603 126.0317 127.0395II 0
Hexanedioic acid dimethyl ester
/0'CJ
C8HI404 174.0892 1750970
°I
Methyl 9-methyltetradecanoate V C16H3202 256.2402 257 24 I
0 .......0
Propanedioic acid dimethyl ester
o~O CSH804 132.0423 I ~ 0 01
I0
Hexanoic acid methyl ester o~ C7HI402 130.0994 131 1072
I
0
Octanoic acid methyl ester o~ C91-11802 158.1307 159138S
I
0
Nonanoic acid methyl ester O~ CIOH2002 172.1463 1731542
I
0
Decanoic acid methyl ester O~ CIIH2202 186.162 187169
I
2<11
0Undecanoic acid methyl ester o~ C12H2402 200.1776 201.1855
I
0
Dodecanoic acid methyl ester
o~ C13H2602 214.1933 2152011
I
0
Tridecanoic acid methyl ester o~ CI4H2802 228.2089 2292168
I
0
Tetradecanoic acid methyl ester o~ CISH3002 242.2246 24JB24
I
0
Pentadecanoic acid methyl ester o~ CI6H3202 256.2402 2572481
I
Hexadecanoic acid methyl ester
o~ CI7H3402 270.2559 27126J7
I
Heptadecanoic acid methylester o~ CI8H3602 284.2715 28~ 2794
I
0
9-Hexadecenoic acid methyl ester o~ C17H3202 268.2402 2692481
I
Terpinyl acetate
~-{ CI2H2002 196.1463 197 I ~42
0
Methyl-N -methylanthranilate lb- C9HIIN02 IM.079 166 0868
2-Hexyl 2-pentenoate /:~ CI1H2002 184.1463 185.1542
E-Cinnamyl acetate yo~ CIIHI202 176.0837 177 0916
0
0
)lo
a- Trichlorornethyl-benzyl acetate 0)(0 CIOH9C1302 265.9668 266 9746
I
Isoeugenol acetate
-{~ C12H1403 206.0943 207 1021
Dihydromyrcenol acetate
~-< C12H2002 196.1463 197 1~420
Neryl acetate )-.1 CI2H2002 196.1463 197 1~42
Geranyl acetate
~~
CI2H2002 196.1463 197 1542
(E'
0
Citronellol acetate
~~
C12H2202 198.162 199 1698
Methylcis-dihydrojasrnonate f
0-<:0-0 CI2HI903' 211.1334 2121412
242
HO
Pentyl salicylate
~}--b CI2HI603 208.1099 209 1178
Methyl trans-jasmonate °3~")-/ C12H1803 210.1256 211 IJ:I4a, 0
_ 0
'"
~ HO
l-Hexenyl salicylate
, :K:I C13H1603 220.1099 221 1178
~ HO
l-Hexyl salicylate }--b CI3HI803 222.1256 223 13:14
2-Ethylhexyl salicylate R- CISH2203 250.1 S69 2511M7HO 0 o~
Ethyl tetradecanoate 0 CI6H3202 256.2402 2572411
/'o~
Ethyl pentadecanoate
o C17H3402 2702559 271 26.\7
/'<,~
Ethyl hexadecanoate /',,~ CI8H3602 284.2715 28S 279<4
Benzyl benzoate Oyo_O CI4HI202 212.0837 2IJ 0916
0
2-phenylethyl phenylacetate
~)LO CI6HI602 240.1150 241.1229
Y
Isopropyl dodecanoate
~o
CISH3002 242.2246 243 H24
Dodecyl hexanoate
~,,~
C18H3602 284.2715 285 279<4
Hexadecanoic acid isopropyl ester
y
~o
C19H3802 2982872 2W 29$0
Ethyl heptadecanoate
o
C19H3802 298.2872/',,~ 2W 29$0
Dodecyl benzoate oyO C19H3002 290.2246 2912'14
~o
Tridecyl benzoate 0.,,0 C20H3202 304.2402 3052411
~o
Tetradecyl benzoate oyO C21H3402 318.2559 3192637
~
24]
Deeyl octanoate
~V CI8H3602 284.271S 28S2794
Dodeeyl octanoate
~v C20H4002 312.3028 313.3107
Tetradecyl octanoate
~v C22H4402 340.3341 341.3420
1
2-EthylhexyI4-methoxyeinnamate 0,,\01 C18H2603 290.1882 291 1960
l-Octyl 4-methoxyeinnamate
~O,
C18H2603 290.1882 291 1960
~o
I
2-Ethyl-hexyl 4-methoxycinnamate O~o1 CI8H2603 290.1882 291 1960
Isooctaoedioldibutyrate ~o1. C16H3004 286.2144 2 72222
~oo
Amines
2-Pentylpyrrole
-.» C9HISN 137.1204 13812 3
2-Pbeooxyethylmethylamine
.o C9H13NO IS10997 In.107/~~o
Nicotine 6-0 CIOHI4N2 162.IIS7 163 1235
4-Sec-butylaniline H1N-O-< CIOHISN 149.1204 ISO 12 3
N,N-Dirnethyl-l-dodecylamine I CI4H31N 213.2457 2142535/N~
N,N-Dimethyl-I-hexa<iecylamine 'N" CI8H39N 269.3083 2703161
~
N,N-Dimethyl-I-octadecylamine I C20H43N 297.3396 29 3~74,N~
Amide.
-0
Methyl N,N-diethylthiocarbamate >=8 C6HI3NOS 1470718 14 07%
rN\_
n-Propylbenzamide o-z_/ CIOHI3NO 1630997 164 107
Hydroxy acetanilide
~O
C8H9N02 ISI.0633 I 20712HOHN-Q
Aldehydes
2-Furanearboxaldehyde oJ[) CSH402 96.0211 97029
Benzaldehyde o~ C7H60 106.0419 1070497
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Hexanal O~ C6HI20 100.0888 1010966
Heptanal ~o C7HI40 114.1045 115.1123
Octanal O~ C8HI60 128.1201 1291279
Nonanal o~ C9HI80 142.1358 143.1436
Decanal o~ CIOH200 156.1514 1571592
Undecanal ~o CIIH220 170.1671 171 1749
Dodecanal o~ CI2H240 184 1827 I 5190
Tridecanal ~o CI3H260 198.1984 199 2062
Tetradecanal o~ CI4H280 212.214 213221
Hexadecanal
o~
CI6H320 240.2453 241 2 ~I
(E)-2-Nonenal ~ C9HI60 140.1201 141 12790
Geranial
~
CIOHI60 152.1201 1511279
p-Anisaldebyde o~ C8H802 136.0524 1370 24
~ D \
{l';I
Pentylcinnamaldehyde
~
CI4HI80 202,1358 203.1436
E-2-Hexylcinnamaldehyde
~
CI5H200 216.1514 217 1592(~
0
0
Ketones
6, IO-Dimethyl-5,9-undecadien-2-one
~
CI3H220 194,1671 19 17 9
6-Methyl-5-hepten-2-one
~
C8HI40 126.104 1271123
a-Ionone
~
C13H200 192,1514 1931 92
p-Ionone
~
CI3H200 192.1514 1931 92
Benzophenone 0y0 CI3HIOO 1820732 18 0 10
0
"'"
0
Jasmone 0 CIIHI60 164,1201 16$,1279
245
Acetophenone }-O C8H80 120.0575 12U165J
lsopropylacetophenone 0-0 CIIHI40 162.1045 163104
2-Nonanone
~
C9HI80 142.1358 143.1416
2-Undecanone
~
CIIH220 170.1671 171.1749
2-Dodecanone
~
CI2H240 184.1827 185.1905
2-Tridecanone
~
CI3H260 19S.1984 199 2062
2-Tetradecanone
~
CI4H280 212.2140 213 221
2-Pentadecanone
~
CI5H300 226.2297 227 237
2-Hexadecanone
~
CI6H320 240.2453 241 2 ]1
Alcohols
Tridecan-I-ol HO~ C13H280 200.2140 201221
n -Tetradecanol HO~ CI4H300 214.2297 21 .237
Pentadecanol HO~ C15H320 228.2453 2292531
n -Hexadecanol HO~ C16H340 242.2610 24326
a Hexadecadienol HO~ C16H300 238.2297 292 75
2-Furanmethanol
HO~
C5H602 9S.0368 99 0446
Phenol
HO-O C6H60 94.0419 950497
Benzyl Alcohol HO~ C7H80 108.0575 109 06~]
2-Phenylethanol H0"--O C8HIOO 122,0732 1230 10
p-Menth-I-en-S-ol
-to- CIOH1SO 154.1358 IS .1416
Geraniol
YM_OH
CIOHISO 154.1358 15 14 6
CitroneUol
~OH
CIOH200 156.1514 157 1 92
~OH
Eugenol CIOHI202 164.0837 1650916
~ 0""'"
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~OH
lsoeugenol C10H1202 164.0837 1650916
~ 0/
2-Phenoxyethano1
HO~O~
C8HlOO2 138.0681 1390759
Aliphatic/Aromatic
Nonane ~ C9H20 128.1565 129164
Undecane ~ CIIH24 156.1878 157.1956
Dodecane /VVVVV C12H26 170.2035 171.2113
Tridecane ~ C13H28 184.2191 185.2269
Tetradecane C14H30 1982348 199 2426
Pentadecane CI5H32 212.2504 21' 2~
Hexadecane CI6H34 226.2661 2272739
Heptadecane CI7H36 240.2817 241 2 9
Octadecane CI8H38 2542974 25530 2
Nonadecane CI9H40 268.3130 269320
Eicosane C20H42 282.3287 2833365
Heneicosane C21H44 296.3443 297.l52 1
Docosane C22H46 310.3600 311 67
Tricosane C23H48 3243756 323834
Tetracosane C24H50 3383913 339.'991
3-Methyloctadecane
~ CI9H40 2683130 26<1'20
3-Methylnonadecane
~ C20H42 282.3287 28 3b
4-Methylpentadecane
~ CI6H34 226.2661 227 27 9
Nonane, l-chl oro- CI~ C9HI9C1 1621175 1631254
Pyridine 0I C5H5N 79.0422 80.0500
2'17
a-Pinene
~
C10H16 136.1252 1371HO
Naphthalene (X) CIOH8 128.0626 1290704
~
Cyclotetradecane 0 C14H28 196.2191 197221>9
Toluene 0 C7H8 92.0626 930704
p-Cymene >--0- CIOHI4 134.1096 135 1174
Methyl biphenyl 0-0 CI3HI2 11>8.0939 169 1017
2-Phenylundecane
~
C17H28 232.2191 2H 2269
3-Phenylundecane
~
C17H28 232.2191 2H 2269
4-Phenylundecane
~
C17H28 232.2191 2H 2269
5-Phenylundecane
~
CI7H28 232.2191 1312269
6-Phenylundecane 0< C17H28 232.2191 133221>9
2-Phenyldodecane
~
CI8H30 246.2348 2472421>
5-Phenyldodecane
~
CI8H30 246.2348 2472426
6-Phenyldodecane vs: CI8H30 246.2348 247.2426
2-Phenyltridecane
~
CI9H32 260.2504 261 2512
3-Phenyltridecane
~
C19H32 260.2504 261 2512
4-Phenyltridecane
~
CI9H32 260.2504 2612512
6-Phenyltndecane
~
CI9H32 260.2504 261 2~12
l-Dodecene ~ C12H24 168.1878 16919~
1-Tetradecene ~ C14H28 196.2191 197221>9
l-Nonadecene ~ C19H38 266.2974 267.3052
Famesene
~
CISH24 204.1878 20S.19~
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Precursors
OH
N-a-3-methylhex-2-enoyl-L-glutamine J'~ CI2H20N204 256.1423 257 1501o 0
NH,
1~NN-a-3-hydroxy-3-methylhexanoyl- L-gJutamine o ~ C12H22N205 274.1529 275.1607
H,N
OH
OH H NH'fS-[ 1-(2-hydroxy-I-methylethyl)- 2-methylethyl)- J-vN~S CIIH22N204S 278.1300 279.1379
L-cysteineylglycine o 0
H,N
S-[1-(2-hydroxy-I-methylethyl)-l-ethyl)-L- HO~:C C8HI7N03S 2070929 20 1007
cysteine
OH
OH H J:IH,
S-[I-(2-hydroxyethyl)-l-methylbutyl)-L- o~N~S~OH CI2H24N204S 292.1457 293 I 3
cysteinylglycine
NH,
S-[1-(2-hydroxyethyl)-l-methylbutyl)-L-cystein HO~S~OH CIOH2IN03S 235.1242 B61320
OH H J:IH,
S-[1-(2-hydroxyethyl)-butyl)-L-cysteinylglycine oJ-vN~srOH CIIH22N204S 278.1300 279 I 79
N-a-3-hydroxy-4-methylhept anoyl- L- 01~ C13H24N205 288.1685 2891763glutamine
H,N
l~N-a-3-hydroxy-3-methyloct anoyl- L-glutamine
o ~~
C14H26N205 302.1842 303.1920
.....
N-a-3-hydroxy-4-methyloct anoyl- L-gJutamine ol:~ CI4H26N205 302.1842 303192Q
H,N
N-a-4-methyl-3-oct-enoyl- L-glutamine ol;~ C14H24N204 284 1736 28 I 14
H,'
N-a-3-methyl-2-o"opent-anoyl- L-glutamine ,;rCI! CIIHI8N205 258.1216 259 12901
HI'
N-a-4-methyl-2-oxopent-anoyl- L-glutamine ,l~~ CIIHI8N205 258.1216 2591294
"I'
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N-a-4-ethyl-hept·anoyl- L-glutamine ol;~ CI4H26N204 2861893 271971
""1~Nsu-q-hydroxyphenyl-acetyl- L-glutamine
N~
CI3HI6N205 280.1059 281 1117o I
o .&
H,N 011
N-a-4-ethyl-oct-anoyl- L-gJutamine oJ;uL CI5H28N204 300.2049 301 2127
.....
N-a.-7-carbo>:y-hept-anoyl- L-glutamine 01~~o. CI3H22N206 302.1478 303 I ~6
..,.
N-a-9-hydroxy- non-anoyl- L-glutamine
· l;~o' C14H26N205 302.1842 30~ 1920
'"
Hypothetical Precursors J~N-a-3-hydroxy- 3-methylhept-anoyl- L-
o ~~
C13H24N205 2881685 2 9 176'
glutamine
.....
N-a-3-hydroxy-oct-anoyl- L-glutamine 01~~ C13H24N205 288.1685 291 6'
.."
N-a-8-hydroxy-oct-anoyl- L-glutamine 01;~O" C13H24N205 288.1685 29176.
',N
TCA Cycle Intermediates
Citrate :7)- C6H5073•'0 0 o· 189.0035 1900114
0
hAeonitate C6H306" 170.9930 172.000'0 0
o '0
o·
Isoeitrate
O~O
C6H50r 1890035 1900lU
'0 OH'O
0
a-Ketoglutarate 'O~O' C5H4052• 1440059 I~ om
0 0
0
Succinate ~O' C4H4042•'0 116.0110 11701
0
0
Fumarate ~O' C4H402'· 84.0211 85,0290'0
0
2 0
0Malate Jyyo· C4H40Sl. 13200S9 n~OD7
-0
OH 0
0
Oxaloacetate ~O. C4H20Sl. 129.9902 I ~O99110-0
0 0
0
Pyruvic acid
~OH C3H403 88.0160 890238
0
251
AppendixB
A list ofputitive identification of metabolites present in the in vitro ASG5 cell line sweat samples.
g...mlz nfll ppm error MF Adduct Metabolites
Carbollydrate.
365.105 599.05 1.78 CI2H22011 N. J-alpha-D-Galactosyl-myo-inositol or related compoufll:b Carboh)-drlt
689.2125 682.00 0.73 C24H420Z1 N. 1, l-kestotetreose or related compounds C<rt>oIt'W's1«
291.0692 444.26 2.71 C9HI609 N. 2(alpha-D-Mannosyl)-D-p,lycerate or related compounds Cll'botwdrll
Ami."
232.1532 523.19 4.87 CllH2IN04 H 3-(1-Aminoc:thyl)Nonanedioic Acid;lsobutyryl-L-camitinc;N(alpha)+Buloxycarbonyl -L. Qualcmll'Y Atru.oet
leucine.O'Buteecylcamitine
282.2785 108.51 2.23 CI8H35NO H Olcamide j:.nvanud.:li
131.1175 48298 2.97 C6HI4N20 H c:psilon-aminocaproamide or related compounds IlohlmlrK»
137.0708 576.19 1.02 C7H8N20 H N-Methylniootinamide or related compounds Cycloc"""","
Ami.oAdd.
291.1288 658.24 3.81 CIOHI8N406 H Arginincsuccinic acid;N(omep;aHL-Arginino)succinatc AnunoAad
294.2411 113.38 2.58 C16H33N02 N. z-amino-hexadccenoic acid or related compounds Ammo f.ttv kidl126.0222 606.65 1.98 C2H7N03S H Taurine AmlnoAad
90.0544 613.64 6.22 C3H7N02 H L~A1lllline AmmoM..u134.0454 625.87 4.55 C4H7N04 H L~Aspartale Anuno Aad
133.0608 639.57 0.23 C4H8N203 H L~Asparagine AnunoAQd,
132.0764 613.03 2.73 C4H9N302 H Creatine Amino Actd.t
120.0651 617.18 3.50 C4H9N03 H L'Ihreoeine AnunoAad.
147.0759 626.82 3.54 C5HION203 H L-Glutam.ine AnunoAad.
150.0577 532.21 4.20 C5HIIN02S H L~Methionine AmU1Oi\a4f
116.0703 585.59 2.67 C5H9N02 H LcProline I\nuoo Aad.
148.0602 621.57 1.62 C5H9N04 H L-Glutamate AmIOOI\o4l
130.0861 593.70 1.15 C6HIIN02 H Na-Acctyleminobutenal or related compounds AmU10Aad
132.1017 504.56 1.51 C6H13N02 H Ltsoteucme.t-Leocme An\lno,I\QJ.J
147.1125 597.33 2.04 C6HI4N202 H Ld.eucyl-Hydrcxylamine AnunoAodo
175.1183 637.50 3.71 C6HI4N402 H L~Arlrinine A,mIM,.\aJ
139.0495 556.97 5.11 C6H6N202 H Urocanic acid or related oompound AnunoAadf
146.117 700.58 3.83 C7HI5N02 H z-emmo-hepunoic acid or related compounds A.rtuoo latt, AciJ.
138.0551 564.84 1.01 C7H7N02 H z-rutrorcluene or related compounds AnunoAA.:::tdi:_'IlI\
152.0702 214.03 2.70 C8H9N02 H (E)-4-Hydroxyphenylacelaldchyde-oximeorrelalcd compound AnuM ""ob
182.0805 553.37 3.68 C9HIIN03 H L'Ivrosine Anunolll>
220.117 523.81 0.59 C9H17N05 H Pantothenic acid A.rumQAttd.
BUeAdd.
433.248 512.78 0.30 C24H3803 NaCl (20S}-3beta·Hvdroxychol.5-en-24-oic Acid or related compounds BlleiOld" MlJdo"II.,'.
391.284 103.24 0.69 C24H3804 H (22E}-3a1pha.12alpha·Djhydroxy~5beta--chol~22~~24-01C Acid or rclated compoundj aile ICI~ uW den, .Ii\.
516.3008 174.38 3.60 C26H45N07S H Taurallocholic acid or related compounds aile tcadl anJda-".\l,
549.341 118.52 2.24 C32H41N304 NH3 3-Amino-N.( 4.[2-(2,6.Dimcthyl.Phenoxy}AoctylaminoJ~3.II)'droxy-1.lsobul)"I.S. Bile IQdJ anddo'\\ltl\
Pbenyl-Pemylj-Benzamlde or related compounds
Glycerol.
482.3598 466.40 1.43 C24H52NQ6P H I~O-He.xadecyl·lyso·sn·!Uycero~3~phosphocholine OI"".""hooooIIod>oIw<508.3765 464.47 0.71 C26H54N06P H PC(0·18: I (1IZ)lO:O) or related compounds Oh""""hooob<><IIOl_575.3111 503.62 4.94 C27H5308P K PA(l2:0/12:0) 01, oc:rorbolf\h.tc.
606.3647 46969 2.23 C29H58N06P NaCl PC(0·3:I(lEYO-I81(9Z))IS) or related compounds Ol,~_
665.4133 471.96 0.83 C32H58NO IOP NH3 I-Palmiloyl-2 -(5-keto-8 -oxo-6-octenoyl)-sn·lZlycero-3~ phospheudvlchohee Oh·~.\694.4177 481.95 1.12 C33H66NOSP NaCl PC(10:0/15:0)[UJ or related oomponds GI""""oo."h"""'hn ..704.5168 130.30 4.61 C35H74N06P HCOONa PE·NMe2(0-14 :0/0·14:0) OI\'OCtOflhosrhoc:hollncl647.4851 112.18 0.93 C36H6605 HCOONa DG(15:0/18:2(9Z.12Z}IQ:O) or related compounds Glyoc:rohP1~
676.4928 38312 2.42 C36H70N08P H PC(10:0/18: 1(9Z» or related compounds OI,.oor""l_hodlol_678.5077 394.42 1.31 C36H72N08P H PC(10:0/18:0) ()["related compowuis OI,'tO""OJI~oebotlnef718.5324 129.42 4.59 C36H76N06P HCOONa PC(0·14:0/0·14:0)
Gh""""~hodlol_610.5413 103.58 1.34 C37H6805 NH3 DG(14:Dn:0:2(IIZ, 14Z)IO:O)or related compounds OlvaroliPlw754.5299 382.13 4.49 C37H78N06P Na_HCOONa PE(0·16:0/0·16:0) Oh'OCt(lpho"t'hodh0111l1\lJ"1Cf663.4711 113.23 2.19 C38H6805 NaCI 00(l5:0120:3(5l,8l,IIZ)IO:0) or reloled compounds GI\'Ca'Ohl'lldJ704.5228 380.02 3.90 C38H74N08P H PC(12:O/J8:1(9Z» or related compowlds
Ol""·""hooorh"""-'l ....706.5389 390.41 1.12 C38H76NOSP H PC(l1 :0/19:0) or related compounds Ol'·~t706.5414 441.72 4.66 C38H76NOSP H PC(IO:0120:0) or related compounds Oh""",,~ .....692.5574 395.09 2.08 C38H78N07P H PC(O~14:0116:0) Ol\~ll638.5733 104.49 2.38 C39H7205 NH3 DG(14:0122:2(1 3Z.16Z)1O:0) or related compounds Oh'ccrohpkb701.5597 448.85 0.74 C39H74N06P NH3 l.tetradecanyl.2-{8-f31-1addcnne-octanyl}-sn~jitlyccrophosphoctJlanolamlne Ol'~tnl"-.nar718.5387 219.08 4.18 C39H76NOSP H 16:0~18: I-PE or related compounds Oh~728.5542 420.27 3.06 C39HSON07P N. PE(0·18:0116:0)IUl OI,~O«h_"1IbUQ766.5288 190.92 1.33 C39H82N06P KCI PE·NMe2(0-16:0/0·16:0) Oh~ ..~782.5612 402.65 4.32 C39H82N06P Na_HCOONa PE·NMe2(0-16:0/0·16·0) OI,~'hJt~709.4405 475.27 4.92 C40H64QS HCOOK 00(17:2(9Z, 12Z)l20:5(5Z,8Z, 111., 14Z, 17Z)IO:0)1;",21 OhOll"OlIl)hb730.5351 399.98 0.82 C4OH76NOSP H PC(14:0/18:2(11 Z,14Z» or related oompounds Oh ....... m."!'b< ~780.5472 342.59 4.83 C40H84N06P KCI PC(O·12:0/0-20:0)[U] or related compounds Oh~742.5404 197.93 4.77 C41H76N08P H 18:0·18:3-PE or related compounds Oh_"" ...770.5654 361.64 2.08 C41H82NOSP N. PC(10;0I23:0) or related compoUnds
Oh~""~824.4862 252.37 2.89 C42H76NOIOP K 18:0·18:3.PS or related compounds Oh_""__
788.5418 32467 0.79 C42H78NOIOP H 18:0-18:2~PS or relatoo oompounds 01'·~l~826.4996 497.21 0.16 C42H78NOIOP K PS(18:0/18:2(9Z.12Z» or relaled oompowlds 01'~UCl1Ii770.5506 366.21 1.43 C42H79NOS NI_Na Galliclosylceramide (dI8:1118: 1(9Z»;Oluoosyloc:rarnidc (d 18 1!9Z.18 I) OI,«'otI~I~
784.5799 406.43 3.49 C42H84N08P N. PC(I 0:0124:0) or related compOWlds
Oh"'_"""''''''~_776.5909 398.33 041 C42H86N06P NI_Nil PC(0·16:/0-18: I (9Z))[UJ or ",I ,ted compound. Oh""""",,,,,,I,,,*~
772.5976 385.56 058 C42H88N06P K PC(0·16:0I0·18:0) O"_"",,,*"~,753.4658 48016 2.44 C43H6605 Na_HCOONa DG(18:3(6Z.9Z.12Z)I22:6(4Z,7Z, 10Z,13Z,16Z, 19Z)IO;O)or relflted oompound:! Oh·¢CmllrltoU775.4798 481.19 2.17 C43H7306P NaCI DG(17,0122:4(7Z, IOZ.13Z,16Z)IO:O)[i302) or related oompounds Ohoollf'tldl763.5828 35545 266 C43H8205 HCOOK 00(16: 1(9Z)I24:0A>:0) or related oompounds Oh'OlJ'l)ill'll763.5885 364.87 4.81 C43H8205 HCOOK DG(16:0124: 1(15Z)IO:0) or related compounds GI,,,,,,,hr'oJ.824.5581 385.15 3.52 C44l184NOSP K PC(14:0122:2(13Z.16Z) or relatod compounds
01,,· .. """"""""""' ....774.5427 179 II 2.48 C45H76N07P H PE(22:6(4l,7Z,IOZ,13l,16Z, 19Z)ldm 18: I (II Z)) or rel,tcd oompow.WI Oh ___ fDOI_
763.6 360.23 2.96 C45H8405 NaCI 00(l8,1(lIZ)I24:1(l5Z)IO:0) orrdoled oompoWld, GhlJl;.'mhl'ltb806.5843 136.27 2.36 C45H86N06P K I-{l O·melhylhex.adecanyl)- 2-(8-[JHaddcranc-octanyl)·sn-g1yoerophosphoohoh ne 01 CI1'O(>oo."hod>oh ...
822.5794 143.75 2.53 C45H86N07P K PE(22:1(13Z),dm18 1(11Z») orrclatai oomPQlIDru
1""",,,-_.8085851 336.63 3.04 C46H82NOSP H PC(16:0122:5(4E, 7E, IOE, 13E, 16E))IU) or related oompound. Oh_""',hodlol812.6202 340.75 2.45 C46HS6N08P H PC(16:0/22:3(13Z.16Z,19Z))fUl or relared oompoww. GI'·~hochollnes763.6155 364.36 4.13 C46H8605 NII_Na DG(21 :0I22:2(13Z, 16Z)IO:0)1;,02) OI\CG"OItPl.JJ730.5395 36407 1.90 C47H6805 NH3 DG(22:6(4Z, 7Z.1 Oz, 13Z, 16Z, 19Z)I22:6(4Z,7Z, IOZ, 13Z, 16l, 19Z)IOO)'
Oh""""'~'1l<834.6022 329.38 231 C48H84N08P H PC(18:0122:6(4E,7E,l OE,13E, 16E, 19E»[Ul or related compounds
Ol, .. ""h<~~894.6423 146.39 0.86 C48H91NOS HCOOK Oalaclosylceramide (dIS'1124: 1(15Z») or related compounds Oh·oohplds792.7049 124.71 332 C49H9006 NH3 TO(16: 1(9Z)/14 ·0/16: 1{9Z»[iso31 Oll'Jtroillll.JJ915.6705 102.32 4.93 C53H9206 Na_HCOONa TO(l6: I (9Z)l16J (9Z)l18.3(9Z, 12Z, 15z))1 ,.. 3) or related ooo,poww. TnlC\l.I~.929.6858 102.78 4.47 C56H9206 HCOON. TO(16, 1(9Z)l17:2(9Z,I2Z)I20S(5Z,8Z,IIZ, 14Z, 17Z))I'!I06) or reI"ed oompoull<h
rnlk.~I"\'ilI:rul.a
F.ttyAdd.
184.1325 193.79 380 CIOHI402 NH3 1-(3,4~imethvlphenyl)ethane~1 ,2-<1.iolor related oolnpound, huvAadt tnJ ~l&I{Itci202.1799 492.63 1.24 CIIH2002 NH3 II·Undecanolactoneor related OOrnpOunds I;.lty A4.:1da anJ "\111~'_
208.1328
229.1535
241.1542
239.1049
235.206
268.2271
254.2471
256.263
261.2201
258.2781
274.2733
288.2889
275.1998
298.2727
284.2942
300.2906
304.262
302.3048
302.3048
316.3203
330.3358
340.32
342.3362
358.3678
480.3083
677.5591
704.5297
782.4773
87.0443
89.0595
160.1325
156.1376
155.106
172.1325
146.0594
HydfOlyadd.
250.0928 166.87
223.1071 510.95
239.1047 605.62
226.1438 435.97
304.2852 148.51
304.2858 187.96
310.2375 115.40
332.3145 181.15
387.2633 112.88
137.045 294.53
133.0855 160.75
219.0051 638.54
hopre.oIdJ
368.4239 22063
447.3383 114.34
489.3617 113.79
489.35 114.72
Pha.plloUpid.
468.3079 465.94
494.3238 464.08
480.3443 456.83
496.3401
520.3404
544.3384
692.4062
688.4941
674.5119
690.5069
675.5451
736.4311
738.4443
702.S098
700.5287
716.5237
702.5441
702.5408
702.5442
728.5561
728.526
716.5567
732.554
732.5537
732.5549
7325547
718.5741
722.5098
782.4689
724.5276
726.5429
728.5606
744.5539
744.5557
744.5551
756.5543
7565S05
775.5495
742.5756
758.5702
744.5895
760.585
760.583
746.6046
780.4597
750.5424
768.5906
784.5877
770.6083
436.45
680.98
555.30
691.73
113.43
J 10.85
312.60
109.00
11522
254.89
263.19
239.09
112.20
115.34
273.47
297.59
109.01
255.27
314.89
229.21
248.00
241.l8
239.30
241.70
429.95
446.20
441.47
493.77
657.38
161.09
718.21
111.09
119.97
120.17
496.09
463.31
461.86
461.39
212.33
208.14
197.75
210.44
450.32
223.45
488.35
372.47
193.51
204_02
19847
42L81
S07.59
520.51
348.01
438-82
371.08
408,42
44306
503.26
37S.11
186.64
493.25
184.40
189.44
191.66
166.55
202.25
395.76
353.49
438.70
109.36
342.73
358.48
352.48
365.23
428.20
373.88
237.21
IS4.27
335.00
347.40
344.05
1.92 CI2HI7N02
1.61
1.95
2.09
1.57
0.00
2.87
I.S7
4.71
3.99
2.73
2.77
CI2H240
C13H240
C14HI602
C16H260
CI6H2602
CI6H280
C16H300
C16H300
C16H320
CI6H3202
C17H3402
2.73
4.53
2.04
3.00
3.06
1.82
1.82
2.IS
C18H2602
CISH3202
CI8H340
CI8H3402
CI8H35NO
CI8H3602
CISH3602
C19H3802
2.54
2.91
1.29
0.39
0.31
C20H4002
C21H3802
C21H4002
C22H4402
C25H43N02
0.12
2.19
4.95
2.76
2.36
4.31
4.42
4.19
4.07
4.38
C38H7609
C40H7JNJ04
C41H73N08
C4H602
C4H802
CSHI402
C9HI40
C9HI402
C9HI402
C9H7NO
0.80
2.78
1.25
0.13
1.94
3.91
0.52
424
0.85
C IOH19N02S2
CIIHIIN03
C11H2003
C12HI603
C17H3403
CI7H3403
C18H2803
C19H3803
C20H4003
4.01
3.16
1.46
C4HS05
C6H I203
C9H804
:U5 C25H50
4.25
1.37
1.74
C30H4S
C30H54
C35H46
1.11
0.61
1.12
0.71
1.25
1.95
4.87
4.27
0.00
3.62
2.32
0.39
3.71
4.26
1.66
1.73
1.30
3.40
144
C22H46N07P
C24H48N07P
C24H50N06P
C24HSON07P
C26HSON07P
C28HSON07P
C33H64N06P
C37H70N06P
C37H72N07P
C37H72N06P
C37H75N206P
C38H68N06P
C38H70N06P
C38H72N06P
C39H74N07P
C39H74N08P
C39H76N07P
C39H76N07P
C39H76N07P
045
4.86
2.99
3.62
3.21
485
4.57
0.54
3.78
0.51
341
2.92
2.42
0.19
261
1.80
3.90
1.12
150
4.74
1.04
0.86
310
0.47
1.59
2.69
2.16
3.73
3.38
3.26
C39H80N07P
C40H74N08P
C40H78N07P
C4OH7SN06P
C4OH78N08P
C4OH78N06P
C40H78N06P
C4OH80N07P
C41H72N07P
C41H72N06P
C41H74N07P
C41H76N07P
C41H78N07P
C4IH78N06P
C41H78NOSP
C41H78N08P
C42H78N08P
C40H80N06P
C42H790IOP
C42HSON07P
C42H80N06P
C42H82N07P
C42H82N08P
C42H82N06P
C42H84N07P
C43H68N08P
C43H76N07P
C44H82N07P
C44H82N08P
C44HS4N07P
H
Na_Na
N._Na
N.
H
NH3
NH3
NH]
N.
NH]
NH3
NH3
H
NH3
NH3
NH3
N.
NH3
NH3
NH3
NH3
NH3
NlH
NH3
Na_HCOONa
H
Na_Na
KCI
H
H
NH3
NH3
H
NH3
H
H
NH3
K
NH3
NH3
NH3
NH3
NH3
NaCI
H
H
K
NH3
K
KCI
N.
H
H
H
H
H
H
NaCI
H
H
H
H
K
K
H
H
H
H
H
H
N.
H
H
H
H
H
H
H
H
Na_Na
H
H
H
H
H
H
H
N.
H
H
H
H
H
H
H
N.
H
H
H
H
z-sec-Burylpbenyl N·methylcarbamate;3·(Dimethylamino)propyl balzOlIC,-3,4.
Methylencdioxy.N-dhylamphctaminc:
Iu-docecea-l-ol or related compounds
2-tridc:cenal
IOE,12E-letradecadienc-4,6-diynoic acid
4,6.ll·hexadecatrimal
4,7,IO·hexadecatrimoic acid or related compounds
10, 12-hexadecedienal or rei ated compounds
6E, lil-hexadccadicn-I-ol or rereted compounds
IO-propyl-5,9-tridecadial-I-ol or related compounds
I .z-Eposvbexedecane; II Zchexedecen-I-ol or related compounds
13-methyl-pentadecanoic acid or related compounds
(+)-14-methyl palmitic ecid.Io-metbyl-bexedecenoic acid or related compOUnds
13E-ootadecene--9, ll-diynoic acid or related compounds
1OE.I lE-OClaclccadienoic acid or related comccends
ll-octedecenel or related compounds
(1IE)-Octadeoenoic acid or related compounds
Oleamide
(+)-Isostearic acid; IO-methyl-heptadccanoic acid or related oompouncb
15.methyl-heptadecanoic acid or related compounds
(+)·16-methyl stearic ecid.Ll-metbyl-octedecenoic acid or related compounds
17.mcthyl-nonadecanoic acid or related compounds
12Z, ISZ-heneicosadienoic acid or related compounds
12Z-hcncic:oscnoic acid 0.- related compounds
19-melhyl-hoteicosanoic acid or related compounds
(.)N-(IR-methyl-2-hydroxy~yl) alpha,alpha-dimcthylarachidonoyl'll1Ineor rel.ted
compocads
1·(O-alpha·D-g1ucopyranosyl}-(l ,3R,29S,31 R)-dotnaoontanetdraOl
N-ornithinyl-35-aminobactcriohopane-32,33,34.lriol
bllCteriohopane-,32,33,34-triol-35-C)Clitol;bacteriohopanctClrOl cwhto!
I ,4-Lactone or related compounds
2-Methylpropanoate or matoo compounds
2-ethyl-3E-hexenoic acid or related compounds
(3Z,6Z)-nonadienal or relaled compounds
2,6-nonadienoic acid or related compounds
2.6.nonadicnoic acid or related oompounds
1{2H)·lsoquinolinonc or related compounds
S·AceJ.yldihydrolipoamide
5-Mcthoxyindoleacct.lllc;lndolc.lactate
2-hydroxy·1 O-Wldec:.:enoicacid or related oompounw
12-o)(o-SE,8E,IOZ4xlocalrienoic acid or related compound.!
17·hyclro:l:y·heptadccanoic acid or related compounds
2-hydroxy·heptadccanoic acid or related compounds
(·)-8-hydroxy·l JE,17-octadecadICll-9-ynolc acid or related oompoW1ds
19-hydroxy·nonadccanoic acid; 2-hydroxy·nonadccanoic wd
20-hydroxy-cicosanoic acid;2-hydroxy-ciOOSlUlOlc aCld,]·hydroxY<'lcosanolc ICId).-2-
hydroxyph)tanate
D·threonic acid
(R)-3-Hydroxvbexanoic acid or related compounds
2,4-Dihydroxy-Trans Cinnamic Acid or related oompounds
4-pentacosc:oe;&-penlaoosene;9-pentacoscne;C25 Monoc:ycllc highly branched
isoprenoid;C25: I Hi¢l1y branched isoprenoid
4,4'-Diapophytoene;-4,4'.Diapophytoenel DenydJ'osqualenc-
Tetrahydrosqualme
4' -Apo-3,4-<lidohydrolycopenoi (4-Apo-3 ',4'-<lideh)'droI_)
LysoPC(14;0);PC(O:O/14:0) or related compounds
1-16:1·lysoPC or related compounds
LysoPC(dmI6:0);PC(0-16:1(IIZ)IO'O) or related oompound,
LysoPC(16:0) or related compounds
LysoPC(18:2(9Z,I2Z» or related COII1pOLmds
LysoPC(20:4{5Z,8Z,11 Z, 14Z» or related oompowxls
PE{14:0I14: I (9Z» or related compounds
PE{14:0118:2(9Z, 12Z» or related compoWlds
PE(14:0/dm18:1(IIZ» or related compounds
PE(l4:0118:1(IIZ)) ... related compounds
SM(dI8:1114:0)
PE(IS:O/18:4{6Z,9Z,12Z, 15Z» or relaled compoW1ds
PEn S:O/18:3(6Z,9Z,12Z» or related compounds
PC(14: 1(9ZYI6: I(9Z» or rdated COIllP"""'"
PE(16:1(9ZYdmI8:1(IIZ» or related compow,ds
16:0-IS:2-PE orrel.led compounds
PE{18: 1(IIZYdmI6:0) or relaled compoWKb
PE( 16:0/dm 18: I (9Z» or related compounds
I-Hcxadecanoyl-2 -(9Z~adeocooyl)·sn-8Iyoero-3- phosphonocthll"lOl anune or rclltod
compounds
PE(O-18:0116:0)[UJ
PC(14:0118:3(6Z,9Z,12Z» or related oompow1<b
PC(14:0/dmI8: I(9Z» orrelalcd compoWlds
PC(l6:0116: I(9Z» or related compoun'"
PC(14:OJI8:1(9Z» or rel.ted compounds
PC(14:OJI8:1(9E»fUl or reI"ed compounds
PC(14:0118: I(IIZ» or related compoun'"
PC(14:0IdmI8:0) or related compounds
PE(18:4(6Z,9Z,1lZ, 15ZYdm18: I(IIZ» or reI.ted compounds
PE(14:0I22:5(4Z,7Z, IOZ.13Z, 16Z» or related compounds
PE(18:3(6Z.9Z,12ZYdmI8:1 (II Z» or relett., ompound,
PE<18:2(9Z, I2Z)ldml8: I(lIZ» or re1ated c:ompoun£b
PE(18:1(IIZYdmI8:1(IIZ».PE(18.1(IIZ)ldmIS·I(9Z» or rel.ted _pound,
PE(14'0I22:2(13Z,16Z» or related ",mpounds
18:O-j8:2-PE or rehuw oompounds
PC(l5:0118:2(9Z,12Z» or "I.ted compounds
PC(l4:0/20:3(SZ,SZ, lIZ» or reJlllw oompound
PC(l 0:0122:0) or related compounds
PG(18'0118:2(9Z,12Z» or "I.ted oompoun'"
PC(16:1(9ZYdmI8:1(IIZ» orreloted compounds
PC(14:0120:2(11Z,14Z» or related compoun'"
PC(J6:0/drnI8:1(IIZ» or relatod compounds
PC(14: I(9Z)I20:0) or ,.j.ted compounds
PC(14:01Z0.1(IIZ» or related compounds
PC(16:0/dm 18:0) or related compounds
PE(18:4(6Z,9Z,12Z,15ZY2D:5(5Z,8Z,IIZ,14Z,I7Z» or ,..IOIedcompounds
PE(20:4(5Z,8Z,IIZ,14Z)ldmlS'I(IIZ» orrel.tcd~
PC(18,2(9Z,llZ)ldmIS:I(IIZ» or "Iated compoun'"
PC(l4: I(9ZY22:2( I3Z,16Z» or ",I"", oon>pO<m<b
PC(18:1(lIZYdmI8:1(IIZ» orreilled compounds
I-llIval~lJ
1-1", a1dd1", ...
}-'any Aclolu end COI\I""
"'llt, aldch"daI
h,,\ Mdt! ~ C:~ua-
hlWllldcb\Jd
Fau\'lI00h0.\liI
Fill' aloohol.
"'IU\, .looholl
F.IIY Aads ark! C(II\t\t&l
P.tty Aads ond eon, ....
Fatty Aads and COOIU• • (CI
FallV AoW!
Flllvllooht:llJ
Fenv AadJi.oo Con,,,,-.tc.!S
.... uyllrud
Fauv ACids end Con,U.• •*
fauv Aadl and Coo,uit.leII
F.1t Aadl and C(IQ,I\If!'
hit' "cua and COOt\IA.lct
FallY AadlanJ Ct\nIua-
..-.11, AeuD and Cdf\l\laa.
FillY Aadllrkt v'W\I"J.'
....It\ anudaI
tim 1C,1 ."".~
IIOJ)&OOI!.M
II""""",..
FIII¥AoIiI
hltlAad;:
hit' Aa,.. -.I c.a;
hu" aldch,_
".U)'k4J.
... ~" ..........tnJ .'ftNj
".,tl aI..wa,
LI~endOal\alt\
lndoka..-.d In&llltl \ .1\.
11\\11\", lat"
thor"., ..."J\lI
'''*',' j.tt, ..
HvdI~ , ratl\ LidI
Ih'*'''\1'(III\ khU
,,,...bu\VI.u\
11,...b~r'll'eciJII
Ih~\lall".a..s.
Ih-dro, Acida
11\u.m, ,.._
PboJl'holl~ldJ
Pbo..rlboh~ldt
Phoephohpnbi
Photpoohouu
Pbo 1)~lrllil
l)oo.l'hollPlJII
I)OOKIv.nlll"dI
IloJ\OIPholtl1ldl
Phc)Il!'hollPldI
l)oo.rooh~\I,b
P~lriJa
1~lklll(l1
~lrHb
l'boot,Iooh",,..
Pho~rhnoIlrl
~INdI
l'bootlhol",,010
11k~hJ1l\b
1'h<"'I'I>~'1"
1'tM'mI'hut1rlJ.
f'to,.l~tJ_\1
l_p"""p,oIo
l"""'t"""IP''''
l'1\ooO""Jllloio
1'ho.""""~I<lo
I~PbntlDI
l)oo..'hoIlrlda
1)"""'hohpl<lo
I~Mh~ldf
PhoaJlholtrub
Pbost'hoh~l.JI
')hoapl"-llipld.
Phoirrhi.,hpIJI
Pboe:OhollPldi
Vho.irt\ollJ)loU
Phoirboll pub:
I'bo.phohrld&
PhotJrbolloldt
1}llOSJ'lholJuldi
PhoIt>hohold.l
I)MsPMhrIJl
Phoi;f'ohoilPIJi
P~hrub
Phoitloohplo.1l
l'bo<phohr''''
IlhoItlOOht'oldi
Pho ....hoIltllJi
PhoIiI>I>oIJr''''
11\oatl~llrl.s.
824.5595 342.49 3.54 C44H84N08P K PC(14:0/22:2( 13Z,16Z» or related compounds Pho.rho!.l('old,!
786.5984 381.69 2.92 C44H84N08P H PC(14: 1(9Z)l22:1(13Z» or related compounds I~phollf'ltdl
786.6028 427.54 2.67 C44H84N08P H PC(16:0120:2(11 E,14E))ruJ or related compounds I'boll'lbohrlJil
786.5982 451.86 3.18 C44H84N08P H PC(IS: 1(IOZY18:1(10Z» or related compounds PboIDholtPldfi
786.6026 505.34 2.42 C44H84N08P H PC(18:OJI8:2{2E,4E)) orrclated compounds PhosrhollPldii
786.6042 594.01 445 C44H84N08P H PC(18:0/18:2(6Z,9Z» or related compounds PhospboIlPldi
786.6028 675.87 2.67 C44H84N08P H PC(18:0I18:2(IOZ,12Z» or related compounds Phodpboh !'lIeU
772.618 360.33 4.45 C44H86N07P H PC(18:0/dm18: 1(11Z» or relatod compounds l'hosflhoh PIW
776.5602 182.06 4.66 C45H78N07P H PE(22:5(4z,n,loz,13Z.16Z)ldm 18: 1(11 Z») or related compounds Phosflholl1lldi
810.6021 33387 4.70 C46H84N08P H 20:2-18:2-PC or related compounds I>hostlhohpldi
836.596 141.97 362 C46H88N07P K PC(20:I(llZYdm18:1(1IZ» or related oompounds PhofphollPlI,U
814.634 426.34 2.46 C46H88N08P H PC(14: 1(9Z)'24:1(15Z» or related compounds PhoJl~bohOl(b
8506111 140.03 292 C47H90N07P K PE(24:1(15ZYdmI8:1(IIZ)) or related compounds PbosphohplI,b
8&0.6235 146.68 2.25 C48H92N08P K PC(16: 1(9ZY24: 1(15Z» or related compounds PhoI"pbohpaoJi
924.7379 103.23 1.34 C52HI04N08P N. PC(18:0I26:0) or related compounds Phoirhohpuil
188. !75 580.12 3.88 C9H2I NlO H N l-Acerylsoermidine or related compounds Polnnunel
188.175 623.03 3.93 C9H21N30 H N8-AcetylspemUdine or related compounds Po1"amanCl
Polypeptides
273.0825 294.95 1.25 CIOHI6N204 NI_Na (S}ATPA;Prolylhyrlrox:yprolinc POh11Qlhdai
308.0904 615.60 2.21 CIOH17N306S H Glutathione.Reduced glutathione l)oh'PCPhr.sc:.
229.1539 541.82 3.36 CIIH20N203 H L-isolcucvl-L-prolinc;L-lcucyl-L-proline 1)~,1)C:rtadCli
4270954 664.31 4.40 C 13H22N408S2 H Cysteineglutethione disulfide PohTICCHIJ
613.1595 649.09 0.16 C20H32N60 12S2 H Glutathionedisulfide;Oxidized glutathione l)ol'l'J1q)tI~
681.1999 294.13 3.21 C22H42N408S2 NICI_HCOONa D-Pantetrune Poh_kkw
179.0482 614.98 1.62 C5HION203S H Cys-Glv.Cvsteine-SiAcetemide l'oI\'DQ)l"*
188.1751 477.34 3.40 C9H21N30 H NI-Acctylspennidine;N8-Acctylspcmidine Polvemn ..
Nucleotida aDd Derivative.
275.0738 250.68 4.62 CIOHI2N404 N. Decxyinosine.Nebulerine.Purine Riboside Nud .... dcMII_
306.0804 507.19 1.57 CIOHI3N50S N. 8-Hydroxy-2'-Dooxyguanosinc;8-Hydroxy-dcoxyguanosine;Crotoooslde,GulnOSar'le, Nud_dcAMI_
338.0497 548.33 0.12 CIOHIlN506 K 8·Hydroxvguanosine Nud_dcAnoi
364.0643 642.29 2.69 CIOH14N508P H 8-Oxo·2' -Dc:oxy-Ouanos:ine-5'-Monophosphate or retered compounds NucltiX...w.
298.0957 156.40 3.82 CIlHl5N503S H 5'-Methylthioadmosine or related compounds Nud_dcAMI,
565.0832 696.81 0.30 CI6H26N2016P2 H dIDP-D-p;aJactosc or related compounds Nud",,1dcI
608.0896 610.25 1.23 C 17H27N30 17P2 H UDP-GlcNAc or related compounds
664.1178 617.75 0.72 C21H27N7014P2 H Nicotinamide adenine dinucleotide or related compound!
113.0341 185.11 4.07 C4H4N202 H Uracil
129.0765 524.80 4.57 C4H5N30 NH3 Cytosine
152.0561 508.74 4.93 C4H605 NH3 3-Dehydro-L-threonate;Malate
152.056 642.92 4.27 C4H605 NH3 3-Dchydro-L·thrc:onate;Malate
137.0454 446.55 2_85 C5H4N40 H Hypoxanthine
153.0412 314.70 3.27 C5H4N402 H 6,8-Dihydroxypurine;.Alloxanthine;Oxypunnol
136.0617 615.68 0.51 C5H5N5 H Adenine
136.0615 252.64 1.98 C5H5N5 H Adenine
136.0612 229.73 4.19 C5H5NS H Adenine
136.0621 157.31 2.43 CSHSN5 H Adenine
152.0561 461.72 4.93 C5H5N50 H 2-Hydroxyadcnine;8-Hydroxyadenine;Guanine
"'"129.0657 629.63 1.24 C5H8N202 H 5,6-Dihydrothymine or related compounds l~nnudlnCll aM t)cn, 1\.1\
405.0095 616.31 4.07 C9HI4N2012P2 H UDP Nud~l&.
Q.. ttrDU)' Amiael
244.1538 126.45 2.17 CI2H2IN04 H Tiglylcamitine Q\alc.marv An\lIQ
246.1694 499.59 2.36 CI2H23N04 H 2-Methylbut)TOylcamitine;Isovalerylcamitine Ouatcrn"" Amlnct
330.2638 119.83 3.03 CI8H35N04 H 4,8 dimcthylnonaooyl carnitine Qu.tcrnan Amn'lCf
398.3262 440.68 2.59 C23H43N04 H treas-Hexedec-z-enoyl carnitine Oualcman MuncI
400.3418 440.34 0.80 C23H45N04 H L-Palmitoylcamitine QuaICl11It\' Amu.a
426.357 436.45 1.81 C25H47N04 H Elaidic camitine.octedecenoyl carnitine; Vacccnyl carnitine;; Qullcman Ami
162.1119 653.66 3.52 C7Hl5N03 H L-Camitine Qullcmll)' Amara
204.1222 590.80 4.07 C9HI7N04 H L-Acetylcamitine Qu'lemll'VAn\l1)Cf
Splll.lold bue.
252.2303 113.30 2.10 Cl4H31NO N. Leurvl Dimcthvlamme-N-Oxide:Xestoaminol C;; Spl\ltlJllMdbueJI
310.1746 712.63 4.93 C15H23N304 H Polyproline SphU\jl(H~ "
442.1864 609.22 4.95 CI7H38N05P KCI C 17 Sphinganinc-I-phosphate Srru_~_
318.2399 110.04 1.38 CI8H33N02 N. (4E,8E,1 OE-d18:3)sphingosine;; SphmllOld bt-.:I
320.2555 111.94 153 C18H35N02 N. (4E,8E,dI8:2) sphin~osme or related COffipC)W1ds SI)hlnlOld bucw
648.38 200.39 387 C32H63N05S KCI N-(tetradecanoyl)«oxysphinR-4-minc-l-sulfonale Sphmaolll'ldI
703.575 449.57 026 C39H79N2Q6P H SM(dI8:1116:0) SI'huUtohp,,'"
785.6536 446.72 067 C45H89N206P H SM(dI8:1122:1(l3Z)) 'I,hl_arld;
Vlt.wau
417.2769 274.31 0.86 C27H3802 N. 25·hydroxy-16.17 ,23.23,24,24-hexadchydrovitamm D3 125-hydro'{y-16,17,23.23.204,2.~ Vnlfru.n 01 N1dden,,,,,
hexa<iehydrocholeealclfc-ol or related compounds
447.3106 115.06 1.45 C27H4205 H (23R}-1 alpha,23.2S-trihydroxy-24-oxovitamin 03 I (23R} illph.,23,25-t.nhydroxy.24. Vll-.un 1.)1and dm, iii\:
oxocholecaldfcrol or related oompounds
433.3304 103.54 3.67 C27H4404 H (20S} I aJpha,20,25-trihydroxyvitamin 03 f (20S}-1 aiphll,20,2S· VIt.ln"lln0 and.", eh'
trih)'rlroxycholecalcifcrol or relata:! compounds
447.3466 103.15 0.60 C28H4604 H (20S} I alphl.20,2S·trihydroxy·24a-homovital1un 03 I (20S)-lalpha,20,2S-1nh)"dI\)",· , Vltllm1n1)liNtJcn\1l1
24a-homocllolecalcifrrol or related compounds
503.3072 19J.93 3.93 C29H4802 KCI (22alpha}hydroxy·isofucosterol or related oompoWlds Vilinun Ol..-J .Ja1\.J'
461.3626 103.90 0.17 C29H4804 H (20S)-14a1ph.,20,25-trihydroxy-26.27 -dimethylvltUUUl D31 (20S)-I.lph .. 20.2S- Vilinun I)l ...... .s." .. ,
trihydroxy-26,27..dimd.hylcholoc:alciferol or related CODipound.:t
601.3268 506.60 4.31 C36H500 K 11-(4-""'oxymethylphcnyl)-I.lph.,25-dJhydroxy.9,II-<hddl)'lroVlt"",n 03/11-(4- Vlt6nUl\ Dl ..... Jol".b\'ft
~toxymt:thylphenyl} 1alpha,25-dJhydroxy-9,1 \.(hdehydroeholecalclfrrol 01 rrl..taJ
oompoWlds
725.4475 131.38 0.65 C39H64012 H I-Hyd:ro:-;yvitamin 03 cellobioside;; VlI&It\lnOJ and 1ktl,.cJ\
MiIK:eU .. eHl
224.125 19391 3.17 CIOH19N03 N. Clpryloylglycine
~1allO""
188.0704 496.37 1.12 CIIH9N02 H lndoleacrylic acid tndr.'4 .nd 1",,",<1 "Ill\
275.1412 408.38 153 CI5H2402 K Capsldiol;dlhydroArtemislOate;Famcsoic acid,lle1nunthosporol,llemandulcm.lalll AIOOOOI• • nd Polloi
lucirerln;Lubimin;Sirmin;;
289.1792 103.80 2.14 CI8H2403 H 16, 17-Epicstriol or related compounds SlautlU and '~J I,." .. ,
300.3246 260.32 4.93 C19H380 NHl 2-nonadccanoneJTistana\ AJ.Xb1
3572622 113.06 3.75 C20H3605 H 13, 14-dihydro POEI or related compounds I)rolllno«b
478.3214 198.74 4.41 C21H43N507 H Gmtamicin DnIa
142.026\ 697.79 1.90 C2H8N04P H I-Hydro:\),-2-aminoethylphrnJphonatc;Ethanolamme phosphate;;
""'I Phoorbako
604.354 189.84 2.25 C30H5207P2 NH3 all-trans-Hcxaprt:nyl diphosphate AI""",II!<lAl
790.5238 186.10 2.76 C46H73N304 NaCI N-lryplopbanyl-35-arninob.ctenobopanc-32,33.34·triol Ilol",,,,,da
104.1064 573.42 5.67 C5HIlNO H Choline Aldeh\"det
123.0549 152.27 317 C6H6N20 H NICOlInlUllide C'"Qh~Am.I~
107.0492 483.94 0.56 C7H60 H Benzaldehyde AJ.Xb,dcs
187.1076 646.46 0.64 C8HIIN03 NH3 5-Hydm.'(vdopamine or relaltd eompoWids C.tochol~ arl!J 1.)m\1IlJ' ..
2040861 610.01 2.55 C8H13N05 H N2·acetyl-alpha-aminoadipate or related oompounds
"'''''''1470436 552.77 2.72 C9H602 H Phcnylpropiolic acid A1~1 Chk'<1dcs
Appendix C
A listofputitive identification of metabolites in hwnan apocrine sweat Bold text represents matches found in the HM08 urine database.
mh rtlll pem f'rJ'OJ" MP AddKt Met-bolitel Clall1
Ami., Add.
249.0615 84.30
369.1512 469.14
369.1531 S04.14
543.1576 "-4.30
199.9543 804.54
172.0120 67.20
18399)4 80.16
164.0296 68.46
252.0148 66.48
191.0406 68.46
169.0583 38S.80
138.0142 63.84
177.0612 64.56
191.0768 64.56
185.9932 76.80
23t.9888 66.48
220.0669 64.54
200.0408 64.56
240.0486 81.12
144.1019 430.92
252.9794 81.12
226.0454 74.28
307.0345 81.00
DVPoIypeptides
293.1468 404.58
319.1248 87.96
319.1240 146.64
273.1454 169.86
273.1452 200.76
273.1453 232.32
277.1224 682.08
363.1782 414.48
533.2586 383.58
581.2786 418.26
177.OJ31 46.:1.98
187.0716 424.98
233.0509 191.58
PoIy.ml_,
239.1647 428.52
301.1766 388.14
331.2094 422 16
Qua1erury Amllttl
33ti.2300 465.90
330.26]9 444.30
344.1793 457.86
372.3106 478.02
398.3263 485.88
430.3164 425.28
400.3421 SOI.54
414.3581 S08.68
424.3422 491.70
448.3396 508.68
428.3739 518.04
584.4885 696.00
356.0420 66.54
C.rbobydnlH
36S.I06O 70.44
382.1343 45882
485.1127 587.46
20).0374 83.46
253.0140 169.44
F.tty Acids .ad Co-.lIII.1Iu
173.1535 604.14 0.58
173.1536 64806 0.23
173.1536 703.80 0.23
173.1536 739.08 0.29
185.1535 440.52 0.43
213.1848 461.64
195.1885
311.1974
251.2005
1SS.lJ18
253.2169
197.1817
274.2739
2SS.D1S
267.2326
3111427
279.2318
311.2215
341.2444
347.1200
l1S.11lS
19!5.1176
313.2371
183.1631
281.1483
183.2Ul
327.2173
317.2286
399.1968
325.2373
374.2539
327.2529
369.1955
3392286
601.20
459.72
446.22
476.16
61S.9O
447.96
448.20
656.88
641.82
561.86
438.66
466.44
488.82
6J3.JO
634.44
443.04
474.30
499.50
......
.... 66
667.62
479.10
4TI.06
48186
400.68
485.88
443.70
488.81
1.73
....
4.47
0.31
1.00
4.48
3."
1.22
0.16
1.41
0.35
4.58
1..11
0.84
3.71
1.64
0.05
0.95
2.91
0.21
2.10
1.86
2.41
CIIHUN102
CUH24N208
CUH24N1OO
CIBlD4N1013
ClH'7NOlS
C1H1NOl
C3H7N06S
C4H9NOJ
C4H9N05S:
C5HIONIOJ
CSHION2OJ
CSHILNOlS
CSHI1N10l
C6H14N102
C5H7NOJ
C5119NOl
C6HUNJOJ
C6IDN10l
C7H1IN04
C7H13NOl
C8H8N203
C9HIIN03
~H16 lOSS
4.09
2.38
0.03
0.73
l.n
0."
1.30
1.82
4.01
372
4.69
4.17
3."
ClOH17N306
CIIHlONIOJ
CIIHlONIOJ
CIIHlONI03
CIlH20NIOJ
CIlHlONI03
CIIH22N104S
C}6HllN604
C22H40N805
C22H40N805
C5HIONIOJS
C7HIlNI04
Cm12N204
us
3.31
4.29
Ct0H26N4 K
CIIHl8N40 N.CI
C14H30N402 N._N.
047
]J9
058
0.64
0.45
0.33
0.05
O.TI
016
0.25
1.05
).71
0.42
CI7H33N04
CI8H35N04
CI9H37N04
C21H41N04
C23H43N04
C23H43N06
Cl3H45N04
C24H47N04
C2SH45N04
C2SH47N04
C25H49N04
C33H65N04
C9H1SN302S
4.41
2.25
3.59
l.38
4.58
Cl2H22011
CI4H23NOIl
CI5H26N2012
C6H1206
C7H1405S
CIOH2002
CIOl{lOO2
CI0H2002
CI0H2002
CIIH2002
042 C13H2402
1.05
0.64
C14H280l
C16tU5N04
020
0."
1.66
1.01
O.SS
1.92
L27
267
0.25
0.58
CI6H1602
CI6H3001
Cl6H300l
C16HJOOl
CI6lDIOl
C16WIOl
Cl7H3202
CI8H2602
CIII1:I3OO1
CI8H3004
0.64
1.04
2.03
0.'15
0.67
C19H3802
C18KJ201
C18H3101
CI8W2OJ
CI8H3204
O.ll
1.07
al2
1.74
C18H3402
C18Rl402
Ct8H3402
Ct8H3402
1.59
208
0,0]
Ct8H3602
C18H3602S
C19H3204
0.53 CI9H3206
0,15 C19H34001
1.65
0,91
C19H3602
C19H3602
N._N.
HCOOH
BCOOB
N.CI
KO
DCOON.
H
N._N. (HCOON.)
HCOONa
"-'._N.
N.
N. HCOON.
N.=N. (HCOON.)
N._N.
N.CI
N.Chl
N. N.
N.:N. (HCOON.)
HCOONa
H
KCI
N._N.
N._N.
NH3
N. HCOON. (HCOOH)
N.:HCOONa (HCOOH)
HCOOH
HCOOD
ncooa
H
H
K
HCOOK
H
H
N._Na
N.
H
H
H
H
H
H
N.
H
HCOOH
HCOON.
N.
H
NoCl
N.
N._N.
H
H
H
H
HCOON.
NHJ
H
H
H
N. N.
NH3(N._N.)
H
H
K
B
H
N._N.
HCOONa
N._N.
U
H
H
H
H
N._Na (II)
N._N.
HCOOK
H
NH3
H
KCI
N._N.
lrTryptop~aD
Cal.c1Oly1"ydroIY!yliDe
C.I.ctosylhydrosyl}'Ii_
Glucosy~.lactosyl "ydroxylysiH
TlIlri.H
L-SeriH
L-Saine O-sulfate
lrAllotllreotiDe;lrHomoJeriDe; L.T"reo.hte
L-Methionine sulfone
L-GI.ca.miM
l-UreidoiJOb.lynte
.....Medroio.iJle
L-Or.itWJte
L-LYliae
Pyl'O!itlucamic.cid
lrProIiue
L-Citr.Ui.
L-Hislidhte
(2s,5s}5-Carboxymethylproline or related compound!
ProIiue Betai.
Nicotinurate
L-Tyrotiae
N-AcetylCYltathioDiee
Norophthalmicacid
1A50lncyl-L-prolllM!!;L4ellcy~""'proUae
L-le1tCY~L-proUDe
L-isolucyl-L-proUIlt;L-1eacy~""'proUae
L-le.cyl-L-proliae
L-Ie.cyl-L-proliae
Pantetheine
Tllyrotropi. rele.siUl bormo_
Postin
Postin
Cys-Cly;Cysteiae-S-Acet.mlde
L1tlycy~lr.ydroxyprolillt;N-AcetyltlucamiK
L-.R;tvcyl-L-h~-droxyproline;N-Acetyl.R;lul8.mine
Spermiee
NI-AcetybpermiR
NI,NI2-Diacety1$pCfIOine
DecanoyJcarnitiIlC',O-Declllloyl-~arnitine
4,8 dimethylnonanoyJ carnitine
Dodccanoykamitine
Tetradecanoylcamitine
trans-Hexadec-2-eJoyl carnitine
Hexadecanedioic acid mono-L-amitine ester
L-PahaitoyiClrlltt.e
Hepta.decanoyl carnitine
LinoeI.aidyl camitineJ.,inoleyl carnitine
Elaidic carnitine or related compounds
Stearoylcamitine
HexacoslUloyi carnitine
ErJ,othiooeine
Alp"a-LaclOsc;D-MalloR;Meliblole;Sacrose
N-Acetyl-9..Q...lacto}lneul'fllllinicacid
Chitobiose
D-Fructose;D-G.I.ctose;D-GI.cOleiD-M • • ao.e;MyoiDCMltoi
4-Methylthio-Alpha-D-Mannose;OI-Mcthyl-4-Deoxy-4_ Thin-Alpha-
D-G1ucose.O I-Mcthyl-4-Deoxy-4- Thin- Bcta-O-Gluoose
2-methyl nonaoic aCid or related compounds
3-methyl-nonanoic acid or related compounds
7-melhyl-nonanoie acid or related eompounds
2-methyl nonaoic acid or relatOOeompouncb
II-Undecanolaclone:2-hendecenoic acid Ol" related compound.
AmlooAddJ
S r A.mluo Add"
S rAmIIlOAcld.
S r Amluo Acid.
AmluoAddJ
AmlllOAcid.
Ammo Acidl
AmluoAcid.
Ammo Acicb
Am.IItOAcidl
Aml.oAdd.
AmlltOAcld.
AmlltOAdd.
AmlllOAcid.
AmluoAcld.
AmluoAddl
AmlllOAcld.
Am.IItOAdd.
Amino ACids
Am.I.oAcid.
C~hcAmlJ'lOAct(b
AmlllOAdd.
AmluoAcid.
Pol'r1)q)lldel
POilpeptldtJ
PoIl'peptidu
Polypeptidet
Polypeptidu
Polypeptides
Poh'J)e1)tJdei
Polypepllikf
Poi)-peptJdeI
PoIVPCPtldes
PoIypeptldu
PoilpepUcks
l'olypeplJdct
PoIy.ml.u
Poly.ml • •
Polyalllu\CI
Quaternary AnUneI
Quatc:marvAnuMi
QuattmarY Amlt\el
MonOlCyl",lyecrophoephatCil
QunternaryAmtnol
QuaterruuyArnu)CI
Q • •tr.n.ry AmlDtl
Quaternary AnnnCl
Qualernary AmLnCit
Quaternary Amu\CII
QuatcmaryAnllncl
Quaternary AmlnCl
QualernaryAminCl
ClrbohydnlU
CatbohydralCl
Carbohydra.1Cl
Carbo~'dnlel
Ammokctonca
Fatty AClw and Conlua.ICl
Fatty ACLdi and COOluallCf
F.lty A~I<b and Conlu" ....
F.lly ACldJi and COIlIu,..lat
F.tty AClcU and CCIfV"I.'.
12·tridocenOic acid;.2-methyl-2-dodecenok. acid or reI.ted coLllpoundl F.tty ACIc.illtLd ConJu,;.t
Myri.dc.cid
10E-hcptadeccnolc acid; IO-methyl-9-hexada:CSLoic IICldor n:18Itd
compounds
4,7,IO-hexadecatrienoic .cld or related compound.
P.lmilD~l", .tld
10-ltu.decuoic acid or rel.ted compo.Dd.
P.lmilOleic.cld
P.lmiiicadd
tJ-metilyl-pe.tadK'SIaic add or rellted compo .. d.
IOE-heptado!!Cel'loic acid or rdated cnmpound!
13E-octadeccne-9,11-di}noic acid orrelatcd compound.
Alp ... -Lluoleulc.cid
(9Z,IIE,14Z}{I3S}hydroperoxyoctadeca-(9,11.14}-tneno&te c.-
rellted compounds
(+ }16-methyl !l.tarit;: ac.id or rdilled compound.
IOE,tlE-octadec.d5e.ok .cld or rel.ted compolld,
Liuokic.cld
13S-hydroll'occadICCldie~c .cid
(9Z,IIE){i3S}13-Hydroperoxyoctadeca-9,II..wCflOic acid or reiato:l
.,,_-
Oleic add
(1IE)-OttidectltOtc .tld or rel.led compou.dl
Oleic.dd
(11 E)-Occadecuok acid;(6Z)-(kbdecuoic .cld or rel.led
compou.adt
Ste.ricacld
2-merc8pto-ocl8.dccIU\OIC acid
methyl 15-hydropcroXY-9Z,12Z, 16E~tadc:catrienoate or reI.led
oompounds
meth)'IIO.12-dihydroperoxy-8E.13E.15~tadecatriwoote OI't!:ialod
compounds
Il-methoxy-12.13-epo>''Y-9«tadocenoic lllcidor related compound!
IOE-nonadece:noic acid or related compounds
10E-nonadecenoic acid; IO-methylme-octadecanoic acid or re.laiM
oompounds
r.uyAcld,;
Filly ACIc.illtLd COD,IUfala
FallY Addt Uld Conl~.1aI
'.'IY Add • • act c.-.I .... tI!.
F.tty Add • • ad COaJIliUtJ
r.lty Add, .. cI .
F.lty Add, .. d CO~"11t
'.tty Acld ... d CO-.J .... "l
F.lty ACldt and eonll.lll.at.
FattY AClw 'ltd Coft'U&.lc:f
F.ttyAc1dJ
fatty ACIIU ll'd COI\Jua.1tc»
FallyAladt
'.tty Acids ..... Collj ".
F.lty Ac1d~ .. d C.-.I tet
'.ttyAcld.;
Fatty ACldJ
F.ttyAdd.
'.ttyAdd
ratty Acldl
F.ttyAcid.
r.ttyAddl
F.tty ACid. and Conl~.ICS
F.Il)! ACIds ~d Corulllalat
Fatty ACl(1I and COIlJUI.IC»
hI'" ACId. and Contu,..t.
Flit)' ACids and COC\JL.II~.
",..,
...
...
...
-...
...
...
-
...
...
...
...
--...
...
...
...
--...
...
...
...
...
".
-
......
...
...
...
...
...
...
...
...
...
-...
....
,
...
...
,
...
...
...
...
""'...
...
...
...
...
...
...
...
...
...
,.
....
...
...
...
...
...
...
...
...
...
....
...
...
...
...
...
~
".
-...,..,...
...
...
"'.
...
...
297.2790
371.2116
316.3212
3&.5.2473
307.26<0
]11.2943
357.2644
369.2069
329.1473
381.1754
383.2911
465.3456
425.2574
409.3039
187.0717
187.0717
187.0710
187.0709
187.0717
271.0246
271.0245
271.0247
F.tly .IMkyda
167.1430 440.52
209.1898 466.44
240.2321 462.54
270.2794 458 88
309.2431 561.06
367.2159 57672
169.0609 16944
F.tty.lcoltob
205.1587 430.92
253.2139 56202
2972398 599.22
258.2794 454.92
311.2554 626.88
343.1316 555.12
325.2711
313.2494
371.2705
371.2895
143.0452
145.0609
Bydrol}~IO f.tty .dd..
263.1618 430.91 0.04
285.1414 SOl.S4 105
287.1611
301.1410
265.1806
265.1804
337.1985
291.1929
313.1767
269.2119
269.2119
315.1924
271.12T7
355.2097
309.2043
367.2106
369.2253
369.2254
]47.1828
293.2121
319.224! 548.:51
341.2080 450.36
297.2411
299.2588
315.25]5
385.1562
383.2413
337.2357
J99.2373
371.2407
371.2320
369.17.51
372.3476
400.3789
lJ3.086S
licouaoid.
303.2317
51318
465.72
41802
448.14
686.28
528.90
484 86
488.34
455.88
53184
533 82
80142
592.38
460.80
7s,90
169.44
'OJ.»
234.24
388.14
1'9.86
100.76
374.12
58746
480.78
465.72
465.n
463.98
424.98
374.22
SS818
442.20
549.78
444.30
446.22
404.40
510.30
570.84
424.98
598.16
l67.90
627.54
467.94
443.70
487.26
430.92
4]5.36
572.82
565.02
518.10
536.70
588.42
67998
571.86
495.60
46171
518.10
S05.38
S36.70
577.68
448.14
0.64 C19H3602
2.S1 CI9H3802
0.76 C19H3802
C20RJl:Ol:
ClOH3602
ClOH3802
C20H38OS
OS7
all
Oi7
112
CUH2802
ClllU201
CllH4202
C22H4402
101 C23H49N205P
463
3 ..
1.17
·4.11
UI
2.46
4.'1
... 2
C23H4402
C24H4402
C1IHI601
C1IHI601
ClBI602
C1IHI601
C8HI602
C9HI602
.... C9H1602
J.n ('9H1602
0.30
011
037
096
1.l0
4.49
0.71
C11H180
C14H240
CI5IU6O
CI7H320
C18H320
C20H380
C8Hl40
0.24
0.43
0.74
112
CI4H200
C14H3002
C15H320
C16H320
090 CI6H34Q
294 CI1H2202
065
1.6]
li3
3.21
CI7H360
CI8H380
C2OH4202
C21H4402
1.47
124
C6H120
C6HI40
CI4H240]
CI4H2403
223
0.53
C14Hl803
C16H2204
1.28 CI6H2603
196 CI6H260]
068 CI6H2803
041 CI6H2803
0.57 C16H3003
II.
108
057
0.70
1.32
13.
UO
I..
119
331
0.34
CI6HlOO3
C16IDOO3
C16H3203
C16H3203
CI6H3204
CI6H3204
CI7H3204
Cl7H3404
Cl7H3404
C18H2805
C18H3003
1.19 C18HlIOJ
1.85 C18H3403
1.45
130
178
0.39
C18H3403
CUID603
C18H3604
C1RH3604
OlO
383
2.3'
C18H3604
CI&H3604
C18H3605
0.78
3&l
C18H3606
CI9H3803
0.16 C21H4201
113
092
C211l4203
Cl4H460]
4.S1
0.3 CI0H3002
H
KCI
NHJ
H
H
H
H
HCOOH
H
Na_Na
Na_N.
H
KCI
NI_NI
NI_ I
NI_NI
NI_N.
NI_NI
NI_NI
N.CIx2
NIClxl
H
H
NHJ
NH3
HCOOH
KCI
NI_N.
H
N.
HCOONa
NH3
HCOON.
HCOOK
HCOON.
N. NI
NaCl
NI_NI
NI_Na
NI_Na
N.
Na_N.
Na_Na
N.
H
H
HCOONa
N.
Na_Na
H
H
Na_Na
H
HCOON.
N.
HCOON.
HCOON.
HCOONa
N.
H
N. (H)
Na_Na
H
H
H
HCOON.
HCOON.
N.
HCOON.
N.
NoCl
NHJ
NH3
H
H
10E·nonadecmoic acid; IQ.mcthylene-ocladecanolc acid, I Oz,..
nonadocmolC acid Cl' related compounds
(+}I6--methy\ stearic acid;·(2R,6S,IOS}pnstanate·~II.meth}'l-
octadecanmc acid or related compounds
(+}I6-methyl stearic acid;·(2R,6S,IOS}pristanlle";II-methyl-
octadecanoic acid or related compounds
Ancllido.k .dd
1 1,14-ctcosadienoicICtd or related compounds
lj-eicosenoic acid or related compounds
11.13-dimethoxy-12-hydroxy-9-octadcccnoic acid; "13, 14-Dihydro
PGF-la"; er related compounds
4, 7,IO,13-Docosatetntynoic acid or related compounds
Doro .. lteueaolc .cld
(13Z}Docosenoic acid or related compound!
19-mcthyl-heneicosanoic acld;3·mcthyl-hencu:osanolc
acid;Docosanoic acid; lsobehenic acid
Sphinl!osyl-phosphocholine-,~ "2,4 ,6-tnmethyl-2,1 5-tetracosadlenoic
acid";;
14E--lncosenoic.ad or related GOmpounds
:5,9-letl'acosadienoic acid
Clpl')·lic.cid
C.pl')·Uc add
C.prylic .cid
C.prylicadd
Caprylic.cld
2· .... yll-butuoic lcid;2E-.o.aoIc .cid or rel.led cotnpo .. d.
F.ltyAdd.
Fltty ACI<it and Cocuu,a ..
F.tty ACIds and CoqJutalcll
Fatty Ac.uq lind eoa"",.tCII
Fitly AciciJ and C0I11u,:atea
Fauy Acid ... d Co-.l .. alrCl
Fatly ACldi and COI1IUA.tCII
Fatty ACldI and Con.)\li.tea
Fatly Ac,ds and COI1I~atc::t
Fatly ACId! Md Corllua.tea
F.lt)' Add. ... d Co~ .....
F.ltr Addl .. d. Co~ .. a"l
r.,1y Adds .. 41Co ........
F.lty MIIIs .. d o~"'."t
r.uy Add, lad Co-J ... ".
'.'1y Add, .. d aJ • • • •
2,5·undecadien.al.
l 8-teUad<adienal
"CIE,4S,5E.7R)-Gcnnacra.l( 10) or related compounds
14-Melhvl-8E-hcxadeoenaJ or related compounds
9,12-ot:ladeudic:nal
llZ-Eioosenai
2-octCflAIor related compounds
Il.tc:tnwcccn.2.4-diyn.I-01
2,2,9,9-tetremethyl-undec8ll-1,10-diol
3S,7S-dimethyl-2S-trideclIlol
1 ).-Epoxyhexadecane; IIz..hexadccen-I-01 or related compoW'lds
f.ttyalJch\~
Fatty.~\-dct
Fattytkkh,-det
Flttyalddl,-dc:I
fatty .ldehvdel
Fattvl~'_
r.ttvaldd1Wet
F'attyl.k:o~.
FauYllcohol.
Falty Ilcohol.
Fal1Ylk:ohol.
14-methyl-I-pcntada:anol,I-HexadtQOOl,"3S,7S-<JUllcthyl-2S- Fatty alcohol.
tetndec:anol'
·I,9Z,I6-hq)tadecatrim-4,6-di}TI-3,8-diol·~·:5,8, II-hcptadOCltn)nolC Fltty .kohof.
IO-hydroxy-tetndc:canoic acid or related compounds
2-Elhylha •.-ylphthalatc;3·~xy·a1pha-d\romanol;4-
prenylpblorisova1~lpha-CEHC-,Dibutyl
phth.alate;Dii9ObutyJ phthalate
(2E,6E}{IOR,IIS}IO,II-Epoxy.3,7.ll-trimethylll'ldoca-2,6-dlcoolC Hydro,), ratly alad!
acid or related compounds
(9R,1 ]R}-la,lb-dinor·10,11-dlh~12-oxo-IS-phytoalOicacld or Ilydto),)' ratty feCldJ
related compounds
(IR,2.R}J~so--2-pentyl~yclopentanehc::unolC acld·."(IS,2S}-3-o~2- Ilydre\')' ratty 1C1<it
pallykyclopc:n\.anl:hexanott acid
(IS,2S}3-oxo-2-pcntyl-cyclopc:ntanehexanotc aCid or related
compounds
(+ }12-hydroxy-9Z-hexadecenoic .dd;IO-k.eto palmitic acid or related II)dro\'y rallY klliI
compowtds
IO-keto palrniIK.,.id or related i;OlUpounWi
IO-oxo-I4-methvl.pcntadecanoic aCid or rclat& compounds
II-hvdrolCY .,Ihmbc acid or related compounds
14-hydroX)' palmibc acid or related compound.
IO,I6-Oihydroxybc.-.adccaooic acKi or related compoundJ
3,ll-dihydro).y palmitic acMlor rclated oornpoundJ
2-rnethyl.beudccanedJOlc acid or related compounds
MG(0:0I14:QIO:0}.MG(14:0I0·0.(J'0)
MG(MII.,01O,0),MG(14.0i0.OollO)
12.(00).14, lS-dihydroxy·9l.,13E.l SZ-octadocall'lenolc acid
(9R,13R}IO,II~ihydR)-12-())(O-IS·pbytoenolc aCid or rdaled
-..-
add-;Cicutoxin;;
14-mcthyl-l-ho:adecanol
3S,7S-dimethyl---2-bc:x.adccanol,Oct.ldc:l;anol
1.2-eicos.nediol: 13-meth)i--1.2-non.d8CInedloi
1.2-hc:ne:.cosanc:dio~·13-mcthyl·I.2-acosanedlOl-; -IS-methyl-I)-
ocosaned.iol";;
2E-he.xenol,2-Oxohexane; Cl' Unsaturated alcohol
3·Methylpcntan-l-ol;Hexan-I-o1
(IR,2R}3-o:\_'()-2-pentyl~yclopelltancbutano}c acid or related
compounds
6(R)-hydroxy-tctradeca-2E,8Z-dicnoatc or related compoundt
F,u"lleoholJ
Fatty.k:ohol.
F.ttylkx)holt
Fattyalcoholl
FanYlk:ohol1
F.ltvak:ohol.
Hydroxy ratty acldJ
Hydro')' rilly "I<it
Hydro1\')' ratty 1C1<it
Ilydro!r()'ratlykldl
1hliroxv fall'! kl<it
II,droW ral'" IK-w.
I hdroqo (.ttv __1da
~hUro"<Y rltlv acll,la
1I)UI'OWr.ttvar..uJ,
I hdn:", r.ttv.cllia
Ih-dro" fatty acKk
lIydto" r.tty __kif
II\,Jm (IItv .. 11II
Oxo (att'!· 1C1.u
Ilydroxy r.ltv .... ,'"
(J R,2R~r.()-2-pulykyclope.t .. eot'l .. l)h: add or rel.ted Hydro~ '.ny uld.
oompou.d.
(6R,7S)-6,7-Eposyuc.ladecanoic acid,(9ZHI2S }llydroxyoctadoccnOic Il)'dJ'O"<)II'IItty atldl
acid; lQ.hydroxy-8-«tadecmoic acKi or related «>nlpounds
IOR-hvdmxy-8E-octadecmoK: Kid or relaloo compounds
(R}-2.Hydroxystearate or reI.ted oompouncb
(9R.lOR)-Dih~fUlOic. acid orrd,.ted compounds
(9S,IOS}9.1Q.Dlhydroxycx:t.decanoaLe or related (:QffIpouMs
10.l1~\'droxv Ileanc acid or related compoundi
1l,12-dihydroxv Ilcwic aead or related oompounds
18-~ydrolY"9s..IOR~I~ydroIy","ric .cld; 9,10..11-
tri~)·dro~·.'_.nte or reI • • d co.potIacU
SativlCactd
19·hydro.xy.nonadecanolC acld;2·hydroX).nooadecarwuc acid
(+}-I8-.meckyi-eicf» • .c:Mcacld;19-me"Yl-eiconlOlc acMl;"1,6-
dl~III)·I-IW).adec .. olc .dd";Huelto .. .ok: uid;Homoplaynak
.cld
1O-oxo-docosanoic aCid or reI.ted COOlpowwil
24-hydroxy-10Z.Cc:tracOIlCflOIC Ilad-,l-hydroxy·1 SZ--tetnM;O!JCr\ole
acid,J-oxo-tetracosanoic acid;Jlydroxynervoruc .cld
So-Hydror.yller. .... dd;Hydf'OJ:)ilOt.proic .dd
(-+}Pmun: Kid orrelatodcompounds
I h...h-oxy 1'11lIy IKllU
1 h-dto).'V 1II1t\l kid.
Ihu.'O.~r.ltvlCl(l'
Ilych", ratty klcU
H\'dro),,,,r.ttv.cl.H
Ilydro'q' r.tt\l KiJI
tI)drolyf.ltr·cl41
Ilydro,,, rail>,'acl~
II)droxy fatty .ddt
Oxof.itt\'.c«.b
Il)Jr'OxyratayICl(u
Hydro~ Adcll
...
..
...
...
...
...
...
..
-
-...
...
...
...
...
..
...
..
...
...
...
-....
....
...
...
...
...
...
...
...
..
..
"""""
..
...
...
...
...
...
...
...
pol
...
..
...
..
...
...
..
...
...
...
...
...
..
...
-...
..
...
..
....
...
'"...
...
....
...
...
...
319.1276 451.82
]21.2431 ,U5n
356.279] 459n
]]9.2530 489.78
5U 1303 463.56
369.2634 443.70
369.2634 490.74
Faltya.leSe.
1S6.2631 448 14
294.2405 552.24
282.2790 474.30
348.2874 610.02
]74}()31 597.24
382.3063 494 88
430.2857 511.26
504.2398 419.n
512.3043 483.78
510.252] 469.80
Fattyaqrl,IyCOlklt.
545.366] 542.58
671.].632 571.62
691.3669 S99.21
655.4203 600.24
CarboX}11t add.
307.1836 592.38
299.2215 464 46
369}()13 44370
393.2978 757.68
402.3517 499.50
416.3137 51318
444.4049 554.22
543.2937 61590
4493599 78894
1'3.0351 &4.56
339.1573
3S5.1SltI
357.1473
117.2161
371.1626
273.1113
373.UI6
361.234'
311.2007
383.1636
383.18)7
385.1787
401.2197
417.2148
384.2743
367.24'"
377.1968
S04 2750
455.3346
511.2906
417.3455 513.18
454 3897 S44.56
497.29)7 52788
466.3895 548 52
459.3559 526.92
541.3406 61920
55].2842 549.78
693.5314 712.62
73) .S092 S04 lA
Bile adda
473.151l 51804
414.3210 46-4.46
367.2293 467.94
383.2216 58842
399.2181 571.86
355.2630 474.30
369.1441 44370
3732735 474.30
449.2541 51002
571.44
S62.02
566.9.
04.82
573.84
441.~
.. 2.38
48S.SI
,.....
429.00
SSI.58
583."
455.88
438.66
<63.56
... .30
430.92
467.9.
56796
47610
659.76
44796
4.J9 CIOfDlOJ
0 .. ClOH3403
073 Cl0H3404
012 ClOH3404
065 ClOH36Qll
us
HI
C2OI!3603
C20li36O]
094
0.37
0.60
037
0.45
016
200
010
C16H33NO
CI6H33NOl
C18H35NO
Cl0H39NOl
C22H4INOl
C22H4SNO
CllH4SNOl
Cl5H43NOl
4.57
SOO
ClSHSINOl
Cl9H43OOl
064
1.16
C26HSI07
C32H58013
294 C32H6206
1.57 C34H6609
ISO C16H3004
070
017
019
010
06S
036
.s.
0.56
0.05
CI7I!3OO4
C22H4204
=H4204
C2.1H4<04
CW!4604
C26HSOO<
Cl6HS004
Cl6HSOO4
C'H807
3.45
'.63
2."
0.14
4.58
0.11
o..,
C18Hl201
C18H2200
C18K2401
CI8K2801
CI9Hl601
C19H21O
CI9Hl8OJ
0.17
4.37
431
1.77
l.06
0.77
034
CUHl102
ClIHl801
C21H2804
C2tIUB05
CllH3004
ClIHJ20J
ClUD204
0.67
0.17
C211D4OJ
ClIR3404
0.39
4.93
244
0.67
015
1.21
ClIRl405
CllH360S
ClIH2806
Cl6H45NO
C26H4606
C27H4409
307
1.21
Cl7H41
C27H4804
418 C30H480
0..
...,
4"4"
4.19
2,13
ClIH4lO4
CHH500
C19HS20
C33ID8N404
C44H7402
C46H7602
363 CllH33N09
084 CllH400S
389
042
C24H3203
Cl4H3104
0.80 C24H320S
0.42
1.65
C24HJ402
C24ID403
0.56 Cl4H3603
0'2 C24H3605
H
H
NH3
H
NaCl~
HCOOH
HCOOH
H
N.
H
N.
N.
Ha_N.
KC.
N.cba
NoCW
KC.
HCOON.
N.
K
N.
H
H
N.
NlI3
NH3
NlI3
N.cb<2
N.
H
HCOON.
"COONa (HCOOJq
HCOOl(
H
HCooK
H
HCOON.
"COON.
H
K
N.
"HCOON.
HCOONa
HCOON.
HCOON.
N1IJ
H
H(IICOOII)
N.cba
H
H
Na_N.
NH3
KC.
NH3
Na_l'ia
NaCl HCOONa
H -
N.c.
XCI
NH3
NlI3
H
H
H
H
H
H
HCOOH
(ISS)-IS.Uydroxy--5,8,11.dJ.13.1n • • -elcOIa1e1n1eltOak or ~la1ed Elco .. lcMd.
COlIIpo • • dl
12.HET~I2R.HETrE; lS~xI>IIZ.13E-acosadienotcacid orrela1cd Elcoaaooldl
0'''''''''""",
IO,ll-dihydro-I2<pi.leukotricne 84;"11.12-DHET".II-dooxy. Eicou.notds
PG-EI;II~xy_PGF2a;II~xy.PGF2beta,12.keto-tetrahydro-
Lc:ukotrimc 84:14,1 5-DHET"';"15·hydrnpcroxycioosa-SZ,ll ZonE-
trienoate-;~5,6-DHET";·5,6-dihydroX)'-8,11.I4--eicosalrienoic
acid~;·6,7~~12-qH-leukotnene B4 ........ 9.DHET";·S.9-dihydtolC)'
5.1I,14-acosatrienolc ecid'~phidicolin;S 1033;Zoapatanol;;
IO,ll4ihydro-I2-cpi-lcukOCric:nc B4;"II,12-DHET";11-dco)()"- Ei<:osanoWI
PGE); II ~xy-PGF2a;.II«Oxy·PGF2beta;12-keto-tetrahydJt).
Latkotriene 84;·14,1 S-DHEr';"1 S_hydroperoxyeteoaa_8Z.IIZ,13E-
tneooatc"; "5.6-DHEr';"S,6-dlhydroxy-8.11.14-etc:osatrienolc
actd·;·6.7~~11-q:n-leukOlnene B4 ....·S.9-DHET";·8,9·<hhydroxy
5.ll.l4-elcosatricnoic acid";Aphidicolin;S 1033;Zoapatanol
3'~N-Octanoy1--a-D-Gtucop)'nmosyl-B-~Frudofinnolide;"N-
Octanoyl.B-D-Fructofuranosyl-a.O-Olucopynnolide,Sucmse
Mooocaproylate"
II(R}-HEDE or related compounds
II S·HEOE or related compounds
Palmiticanude
N~etradocanoyl}dhanolamindl-amino-hcudecanoic acid
Elatdoylamide;OIc:amide
N~leoylethano1amine
AnandAmide(20·2. n-6)
!)orowwrude
Eicosanoyl-EA
"( _)N-{ 1R -methyl-2·hydroxy-ethyl) alpha,alpha~hmethylant.chidonoyl
amine" or rdate:d compounds
Tricosano\'I·EA
(+1_ )N -( l_methyl·2_hydro".:y.2·phetyl<thyl) uactudonyl amine
Elcounoldi
ElCOSlOOIW
Fat1y.nlldet
FAtty amldea/Amlno fauv kid
Fat1yamlcb
Fat1Y.mldet
F.ttyllUldc:I
Fat1YamJdcI
Fatty anudea
Felly.mutes
Fattvamub
Fatly,ntides
II£...eicosenoic acid
I-(O-alpha-~glucopyranos)'l}- 3-kdo-{ 1 ,25R}-hc:xacoaancdlOl
l.Q.alpha.J)..A)UCOP'tT8JXl5yl-l,l-eH:MIlltdK>1 Fat1Y .~I.~daI
25-O-(2"_bcta_~glucopyranosyl_beta_~gluc:opyBOOl)'l)-25_hydrolq'. Fatty acylll)'eolideil
I-(O-alpha.I)..glucopynmosyl}-25-keto-( 1.3R,27R}octaooWlCtnol or F.tty acyl ,1)'COildei
related compounds
l().hydrolql-I6--<lxo-hexadecanoic ac~"2.3·
Diliydrox),cyclopc:ntaneundocanoic tctd~;9.hydroX)'.I6-0xo--
bexad«.anoic acid;Bexadecanedioic acid
8E-Heptadcw;:c:ocdioicacn
D(2-cthylhc.xyl) adipate:,Docosancdto)C acid
D(2-cthylhexyl) adlpatt',Docosanedioic acid
TricosanedJoicacn
Tetracosanedioicaad
Hc:xacosanedioic acid
Hc:xacosancdioic acid
Hexacosanedioic acid
Citric acld;bodtric acid
E.lrotte
2-lIydrol)-'utrMe
17a-Elll'lldioI; E.1ndial
I9-Nora.dros1ero.e; l'_Noretioc~a.olo.e
Aadro.teKdto.e
3-Oxo-dcltal.stero~ Sa·Andro!lt-3-en-17-one
ll-KLloetiocllola.ok>_;16a-Hydroq'dt-_'·droi.o .. drollero,I!;:;
A.doros .. diol
16-Dellydropl"Olr.~lel'OKor relaRd compo • • cll
II·Dehydrocorticosterone or related compounds
AklOIIe~;Cortbo_
Conu:cMo-t
16-a-Hydl"Olyprea_aokI_;11-Hydrosyprta.eloiOltl!;;;
Ilb,2I-Dih)'droxy-Sb-pregnane-3,lO-dlooe or related compounds
Tctnl~'drodtos)'cortiCOItero_
Sa-Tetra-_'·drooordC06kl'O_:"Sbtl ... Prq.a.-
3alplla, 17alpb,l0aIph-lrioI--l t-oM":'~eoJ)'-9-atetll)'lt __
PGE1;Te1nllydrocortiCOIliero.
5a-Tetn-.,.drorortlJOl;Corto1o_;TetrallydrocordJOl
Bet • ...cor.,.;Corlol
18'())"'OCOrtooi
25-Azacholesterol
11-DOC'Cbolcstanehexot
(24R)-I'oIpha,20)4-lrihydroX)<Cdysone;"(2SR)-Ilalpha)0)6-
trihydroxyecdysonc·;"(25S)-llalphl,20,26-trihydrox'Yccd)'lOIIe~;
OaclJboxyhc KW
o.tarbo""hc well
OtCaJboxyhc aCid.
Dicarbo~hc acld8
Dtearboxyhc ,clds
OaclJboxyhc ICldi
DtCaJboxyhc aCldi
Otcarboxylacacub
Tr1e.rbos)'lk AcJdJl
Steroids .. d Sierold Dt:rtud\t':I
Skrold • • .d Slerold l)e.rh'ad\u
SlerolcllA-d Steroid [)em.d\'eI
Steroid d Skmd Dertvad"a
Skrold tI Sieroid De.rh'.d'h
Steroids and Steroid I):nvatlvoa
Sterold ... d Steroid Dt:m adH~'
Sieroid • • .cI Slerold ))em-a.het;
Steroid. a.cl Skmd Oem .dl ell
Steroid. and Steroid Denvatl".
Steroid. ,lid Steroid Derh-Ad'h
Skrold. ,lid Steroid Otrhad,a,
Slt.roId. a.d krold Der1vad, ..
S1UOidJ Ind SlcroId OC","11".
S1erold • • id Steroid Derhad, __
S1erold. a.cl Slerold Ikrtud\1I
SluoldJl .. d krolct o..mAd'eII
Skrold.J a.do krold Ik.rtulh"
Stc:roll.bInd SlcrolJ I)m",ll'.
SleroidJ anJ S~ld t)CI1\4ItI,.
Stcrom.od Slc:rotti OaWatl\'.
Cholea1aol and cUnvIIHU
...
...
...
-...
"..
.-
"..
po
...
...
...
...
...
...
...
...
...
...
....
...
...
...
"""...
...
...
....
--
...
....
...
...
,..
...
...
...
...
....
...
....
...
...
-...
I'_
...
..
5beta~1estane CholClicrol and dCI""II\'.
3alpha,7Illpha,12alpha,26- Tetmhydroxy·5bela-cholcstanc or related Steroids and St.trolJ IJrcrw.II'.
compounds
4alpha.14alpha-dimdhyi-24-mdhylenc<holesl-7 ,9(11 )-dIt:n·3bc:ta.o1 F..raocteroll and Cl4·mdJ\)1 d.wI"'''''
Tc:uterone.Typha~1
8eta-Si.,.,.roI
23R,24R-dunethYlcholestan-3b-ol or related compound.
lntegc:mssine
eplstCf)1 pahrutoIClt~f~1 paln1l1oIeet~;
ClJl,osttrvlok:ate
F~OI1Q'OIIIU'od C24--md)t,'1 ~"'~~
Slerold • • 1IdS~""d Otrh.d'ltfj
r'.I"K0I1a-ol. and Cl4-n\l:th" duwlu\1l
Steroids and SttrolJ I)(:m'all".
"::"'OflCl'OII and Cl4-i11d.h,tdu".tn ..
r'.lR,o.tCJ'ois.nd Cl~·U\dh\1 dlll\ .. lIV111
(23R)-23-H)'dro"1'-3,7-d!oso-5belB-cholan-24~ic ACid or related Bile leldllJ\d dalVahv
compo""",
24-Nor-5~\au>3a1pha,7alpha,l2alpha,22,l3~ Bile acw and dtn\'all\'GI
pentol~PGF2alpha i!lOJXOP)'lester
3-OxochoLa·1 ,4.6-tnc:o-24~IC Acid Bile leads IU\d dc:nVJl1vea
(22E)-I2a1pha-Hydrolql-3-oxochol ... I,4,22-tnen-2~ic ACid or Blit AClw
related compounds
3.1.12-TnoXO--5beu.-chol-I<I1-24-oic ACid OI'relaloJ compounds llileAcilb
5beta-ChoJa.3,8(14).II-trien-14-Olc Acid Bile acads and dcnVJ;hva
(20S,22E)-3beta.llydroxythola-5.16,22-trien-24-oic Acid or rclated Bile Acidl
com'''''' ....
(20S}-3beta-Hydrox)'Chola-5,16-d1e11-14~lCAcld or related Bile IClds and d.,v.l1v.
compounds
(23R)-23-~'droxy-3.7-dtoxo-Sbela-cholan-24~lc ACid or related Bile ACId.
compouncil
...
...
...
-...
...
...
...
...
...
...
...
...
413~662
445~SS8
391.2847
431.2766
407.2796
4~.J209
494.2848
5J6.2936
464.JC1JO
488.2986
482.3475
468.3681
484.3633
686.3416
Vic.mlu .. dderlndns
39]2099 86,04 1,04
415.1918 44],04 ].78
597.]108 56106 1.19
469.3142 620.76
5012882 476.70
453.2883 612.96
422.3263 481 86
452.3368 464 46
460.2728 429.00
455.2678 58).50
509.2575 390.90
464.3367 463,56
511.2728 S45.52
485~726 714.22
466.3525 470,34
452.3735 518,04
409,3103 7SO,12
55).2653 57570
487.2m 575.70
499.2940 585.48
492.3680 478 02
497.3147 61704
479,3195 66252
509.3297 662.52
597.3098 398 76
Pro&tagl .. dllS
3491986 42708
365.1939 410...'
375.2142 446.22
373.1998
J9Ll089
393.2247
341.2686
353.2385
368.2793
351.2529
426.2052
517.2413
428.3008
554.2462
Le.kotrit.a
440.1449 431.66
462.2284 440.52
442.2621 446.22
517.2]51 429.72
752.82
453,96
512.22
474.30
477.06
457.86
476.10
476.70
447.54
449.16
45]96
4n02
45972
488.34
465.71
429.00
425.18
50340
568.92
459.72
487.80
58194
S20,02
42900
445.32
OJl C2AH3804
2,31 C2AH38()(j
1.69 C14R4004
u.
4.31
1.11
....
CUH4JN05
C16H4JNOS
1.3.
I...
U)
<.73
C26H4JNOS;
C26H4JN06
Cl6H4JN06
C21H4406
0.58 C27H4605
006 C27H4606
3.26 C32H5IN012
C22H3204S
C22H3404S
C37H4803
1.26
3.49
C23H4405
C29H4802
1.32 C28H440
0.43
0.49
C25H4004
C26H4205
3.17
4.70
C26H43NO
Cl7H4202
328 C26H4304P
0,67 C27H420S
1.55
124
Cl7H43F
C27H4404S
0.39 C27H4405
0,11 C27H4604
3.35
4.57
Cl&1i420l
081-145001
410 Cl8H4602
4.27 C29H4603
0.73 C29H4605
0.72 C30H4802
0.69 Cl'7H43F03
4.59 C31H4605
1.64 C"H5004
0.32
....
4.34
CI8H300S
ClInD~
C20HJ2OS
.... ClOHJ2OS
0.92
0.13
ClOHll'"
C20HJ'OO
0.12 C20H3604
ClOH.o
C2tH1404
CIIRl404
1.13
3.4g
0.37
097
Cl3H33N()4
C2lH4007
C23H41N06
C23H41N06
Ll2
8.1.
N.
N.
8
N.
H
H
N._N.
HCOONa
H
N.
NH3
NH3
NH3
HCOOH
H
N.
Noel
HCOONa
KCI
Noel
NH3
NH3
KCI
Noel
Noel
NH3
NaCI_HCOON.
N.
NH3
NH3
H
Na_HCOON.
KCI
Noel
NH3
Noel
HCOOH
H
KCI
N.
N.
N.
N.
N.
N.
H
KC!
NHl
H
K
Na_HCOONa
H
NaC-l_HCOON.
0.18
2.20
C231l39NOSS H
C25H40N206S Na
ClJID7NOSS H
C13R37NOSS N. (Na)
(22E)-3alpha, 12.lpha·Dihydroxy·Sbet.I~ol-22--cn-24-o;c ACid or
related compounds
(lr,5r)- 7 -« I r ,2r ,6s,8r,Su}2 ,6-Dimethyl-8- U (2 r)--2-
Methylbutanoyl}Oxy }.l .2.6.7 .8.8a-Hexahydrot1llphthalcn-l- YI)-l.5-
Oihydroxybeptanoic Acid or related compounds
Ctleeodeosydtolic .dd;l)eo.lyellolle .c1d;Hyodeox),elaolle
acid;Iso.nodeo.lJehoik .dd;UrsodMq·clloilc .dd
(llR)-J.lp ... 7.lp .... 21-Tri~droJ:y~beta-cIilol .... l'-ok Acid or
rti.tecltoaIpo .. ds
tb,J .. U.-Tri")'droIY-~b-cItol .. ole acld;CltoIk .dd;l:Iyoc.,lle
• dd;Unocliolic .dd
Clteeocieoryeltolk .dd J[lyd. collJ ... ae
3.lp ... ll.lp".-Dillydroly~beta-cldas-2.okJylllydM or rei. led
comPOllltdS
Clluodeo.lydlolie .dd Rlyehle CO-.!UiR''''
Glycoc.botic.cld
GtycoclioHc .dd
3alpha,6a1pha. 7alfi\a, 12alpha- Tetrahydro"\)'-Sbeta~olell-14.cn_16-
ole acid;3-Epiecdysone,Ecdysone-,Ponutcrone A
3a,7a,12a-Trihydrol>.)'-5b-cholestanoic actd orrelatc:d compounds
Ibeta.3.1pba,7.lpha.llalpm- Tetzah)'drol>.)'-5bcta--clxllcstan-26-o.c
sed or related compounds
(3a,5h,7a,12a}-24-[(carboxymcthyl)amino)-I,11-dihydroxy-24.
oxochoIM-J-yl-b-D-Glucop)-TaIloslduroruc acid
8UeAddJ
BUeAddJ
AC')I Clycll6:BUe Acid.
Aq-I CI)'d.,;8Ue Add,
AC}'ICI)d.,;8I1e Add.
Acyl Cl}cllH;8Ue Add.
AC)I Clyciaet;811e Add.J
Bile leW and dan.lIVOI
(6RS}22-oxo-23,24,2S.l6,27-pcntanorvitamlO DJ 6,19-lulfurdioXldc vnemm Ol ~ dc","ln'.
adduct I {6RS)-22-oxo-23,24,2S,26,27-pc:ntanorcholccalclferol 6,19-
sulfur dioxide adduct
(6RS)-22-hydroxy-23,24,l5,26,27-pcnwwfVll4mln D) 6,19-lUlfur Vllamln 01 an.J den ... tl"'"
dIOXide adduct I (6RS)-1l-hydroxy-23,24,lS,26,27-
pentanorcbolccalc:lfcroI6,19-sulfur dioxide adduct
lalpha,25-dlhydro),:y-2S,lS·,hphc:llyl-26.27-dtnorVlwmn 031 VII.Jlun 1)2 anJ Iko\ltl\
lalpha,l5-dihydro"y-25.2S4.iphcnrl-26,17-dlnoreholecaklfcrol
1,2-Didecanoyialycerol vuenun 02 and demtll\CI
(22alpha}-hydroxy-isofucosterol;M{24R.24'R)-Fucostcrol qKI~t1e or Vluunm 02 and dcrWlti\'ct
related compmmds
(5E)-iJovitamin 021 (SE)-isocrgocakifcrol «related COIIlPOWUU V,UUllln 02 and drtI".ll\"
II'-<:arboxv-p,amml-chromanol or related compoWlds Vltamm 02 and dcl\'lll\W
(24R}'alpba,24,2S-trih)'Urox-y-ll-oUVlt.amUl D3/(24R)- Vitamin D2 an.J den"'tl~
lalpha,l4 ,25-trihydroxy·22-OXllCholccalcuc:rol or reI.ted compoondJ
25-az.avitamin D3/25-az.acholec.lciferol~, Vitamin D2 ant! claw.1I
(22E}lalpha-hydroxy-22,23-chdehydrovil4mm D3/(12EH.lph.- VII.mln D1 and dtn''IlI''
hydroxy-11,23-didchydrocholecalcifcrol or related compouncb
14-(dimethoxyphosphoryl}2S,l6.27-trinorvitamin 03/24- Vllanlln 011ttJ ,.kn\"dll'
(dimcthoxyphosphoryl)-lS,26.27-trinorcholecalcifcrol or rel.ted
"'ml"""","
(23R)-lalpha.23,25-lrihydrnxy.24-OXOVltamDl D3/(23R} Vll.Imm 02 and den, .. lIva
lalpha,23,25-trihydroxy.14-oxocholccalcifcrol or related compoondJ
3-F1u~9,IO-secocholesta.5,7,10(19}tnene Vitamin 03 and ckn''''lI'W
(6R)-25-bydro:\)'Viwnin 03 6,19-sulfur dioXldc adduct I (6R)-2S· Vlwiln 01 1M den\'lll''OI
hyd.ro")'Chokcalciferol 6.19-sulfur dKIXlde adduct or related
"'-""'"(23S.25R)-lalpha,23,25,25.tetnhydroxyvitamin D3/(23S,2SRr Vitamin 02 and dolVlllwt
la!pha,2),2S,26-tetrahydro~olccalcifc:rol or related compourn:b
(IOR}lalpha,19.lS-trihydroxy·10,19-dihydroviwnin 031 (IOR)- VltamIQ Dl and de.n .. ll\
I alpha,I9 ,25·trihyaroxy-1 0, 19--dihydrocholccalciferol or related
"'-ca.hcofcrol 0 or related compounds Vlwnan 03 and dc:rW.ll\'elIhlpha-(chloromcthyl)-lalpha,25-dJhydroX)'Vltamin D3/11alphl- VIWtl.ln 03 and cknVltlVeI(chlororuethyl}I.Ipha,lS-dthydroxycholecalcifcrol:,
(l2a1pha)-hydroXY~pelt-4~-3-one or !'dated compound. Vltamlll OJ and dcnnllYOI
(l2E} lalpha,25-dihydroxy-26,27--dimcthyl-22,23-didch}'drovltAmlfl VIWl\ln Dl and .JcnvtllYei
031 (22E)-lalpha,25.ditaydroxy-26,27.ctimethyl-12,l3-
didehydroc:holecakifcrol or related compounds
Ig-accto:\)'-lalpha,l5-dihydroxyvltAmin D3/18-acctoxy.lalpba,lS- Vitamin 01 and dcnVlt!,
dihydroxychotccaJ~ircrol
16,27-DibolOO-lalpha-hydroxy-24~lvltamlfl D2:26,17-Dihomo- Vilanuo 02 and dernallvel
Ialpha-bydro:,:}'vitanun m-;-4,4-.[)uncthyl-14a-form)'I-S-.c.holclt&-
8,24-d)e:n..] b-ol-; -4 ,4khmethyl-141Ipha.formyl-5alpha-cholesta-Il,24_
dien-lbeui-ol"
(IOE}19-fluoro-IaJpha,2S-ditaydroX)'VltamlU D3/(10l~rl9-nuoro-- VllllTlan 01 and dc:r'Ivam..
lalph.,25-dihydro,,),choloc:alclfcrol or reI.ted compow!.dI
1'-(3~etoxy-l-propynyl}lalpha,lS-dihydroxy-9,11_ V,tan\ln Oland lk'rwIllvCf
didchydrovitamin Ol/II-(3..acetox-y-I-propynyl)-llilpha.25_
chhydroxy-9,II.wdehydrocholecalcirerol
Ia1pha-hydro.xy.18-(m-(l-bydroxy-l<tbylpropyl)-benl)-loxy}- V,tl.lnln 01 Jnd dct!\'.,,,
23)4,25,26)7- ...... om"'1U0 D3/1a1pha-hydnlI<Y-18-lm{l-
bydroxy·l-c:thylpropyl)-bcwylo"Y).21,l4,lS,l6,27-
pcntanon:bolccalcifcrol
2,34inor-6-kelo-prosI&jI;landlnFI • or related compounds
l,J-di.o .., 6-keckM'GFlaJpll.; ..l,l-DI.or--TXBl
13,I4--Di"ydro-l5-ke~PGE1;lo.-HydrOl:y--Ie.kotrie ..
84;PrOlt~.ltd.i. EliTllrombou_ Al
(13E}-11.lp_·H)'drosy."l~.diolOPN*t-tJ...ellO.te or relattd
cOatpo .. dJ
ll-DellydnMUoinbonlCl Bl
10,1 t-di"ydro-1O-dI~droxy_L TB4; 1'(R}ollydroxy.p(j:EI or
.-eI.ted~po .. cb
11~x)-PGFI .. ll-dcoxy-PGFI b, 15S-HpEDE,POEl
alcohol,PGF2aJphIi alcohol
8-ltoprwtue
11.deo:ly-l t __ et~k ... PGDl or- rel.tltd «*lpo ... d.
3.1p .... 1t beta,17.lplla-Trlllydrory-5bet,-prcs • • • -lD-ollt or
rel.ted composad.
17-phcnyl-trinor--PGF2alph. amide
1(3}.Rlyceryl-PGF2alpha,2-glyccryI-POf2.lpha
PGFlaIph.a-dihydroxypropanYiamine
PGFl.lpha-dihydroxypropl.lwlamlne
ProICl.nO"lJ
Prw&ll;I • • dl..
Pl"Olta.o6d.
Pl'OIt .. okh
P..,.tacl .. dlti
Pr'OIt"oicli
Prwtlll .. dl ..
Proat.al .. diu
ProstaalanduUl
1>rosttglandu\I
1'1O'1allatkiull_I......
II·tn ... L n4;Le.kotrie_ £;& Lukotrk ..
(7£,9£, J lZ.14Z)-{SS.6R}-&--(cystd....s..yl}-5~·droJ:)"C'O&._7.9,II, t..e.kotrle ..
14-1ecr.e..,.te .. ;11 .. r.... LTE4;Luk.olrit_14;
Leukotric:nc El Le.kobit. • •
II.tnlns-LlD4;·14,IS·LTD4·~Leukotricne D4 Lcuk:OlnCllel
...
....
...
-
...
...
...
-1"-
..
...
...
,..
...
...
...
OIl
-OIl
OIl
OIl
OIl
...
...
...
...
"'~
....
...
...
....
I
...
...
...
-,..,...
-
Porp~yri ..
580.1019 468.66
5892993 585.48
569.)151 377.16
567.2999 551.40
IJopruoid.
2852210 448.14
653.3361 379.14
679.3389 -417.72
655.3396 41171
657.3676 38700
641.3521 571.62
637.4115 657.8-4
6433900 614.88
623.3976 613.92
7894253 572.34
S.lp~.tHlSlllpboH.
321.0765 384.06
413.1l70 464.40
367.1576 467.94
735.3234 467.94
425.1174 468.66
435.US4 471.30
435.1451 SOl.46
367.1519 StW.24
367.1581 535.74
383.1531 388.44
383.1531 420.60
3831528 466.86
437.16M "42.08
369.1734 "87.26
437.1609 490.08
369.1735 520.02
369.17.l4 679.98
445.1200
395.1893
512.2681
5062895
498.2893
522.28&4
498.2887
514.2834
552.2413
465.3037 648.36
519.2527 484 80
4812987 568.92
Gl.~U'OIlidn
465.1494 573.78
465.2487 456.71
481.2436 42324
467.2646 443.16
554.2581 76.J2
563.2459 455.88
6133206 561.06
609 3400 486.84
SplllllgOldlSplll-colipld
226.2170 50424
266.2093 51324
310.23>4 S07.36
3682192 577.68
288.2898 458.88
322.2719 474.3C.1
321.2716 597.14
322.1719 474.30
311.2716 597.14
338.2665 4SO 12
286,3106 476.10
301.3051 468.41
302.3052 468.42
3183001 448.14
314.3418 499.56
402.2855 41046
4383545 528.24
552 3096 648.06
414.2999 476.10
5633770
5343213
560.5014
5625176
7225523
722.5523
722.S522
722.5523
734.16
509.04
495.66
38424
444.18
476.10
476.70
444.18
75.11
489.78
402.66
775.32
73908
653.88
687.24
717.>4
748.86
090
'-63
'99
'00
C25H27N306 N.cb:2
C33H40N406 H
C34H40N404 H
C34H40N404 H
0.9:5
2n
2"
237
012
C20fU80
C40HS004
C40H5204
C40H5205
C401IS404
I.93 C40H5601
l.M
176
C401B601
C40HS603
273
0.10
C41HS&O
C46H6106
acoon CIOHt6N205S HCOOH
0.19 C19Hl8035 N._N.
1.37 CI9Hl805S H
CI9H2805S
....
1.13
1.70
CI9Hl105S
CI9Hl8OSS
C19H28OSS
~11
1.72
CI9H2805S
CI9Hl805S
0,68 CI9H2S06S
0.60
1.41
2.ll
0.57
CI9H2S06S
C191U806S
C19H3005S
CI9H3005S
1-53 CI.9H3005S
Ut C191DOOSS
0.41 Ct9l13OOSS
1.16
0.68
1.29
3.02
l.U
at,
Ct9HJ0()3S
C21H320SS
Cl6H43N07S
C26H45NOSS
C26H45N06S
C26H4~N06S
....
UJ
3.71
Cl6H45.N06S
Cl6B4SN07S
Cl6R4!5N07S
099
'10
U3
C27H4604S
C27H460SS
C27H460SS
2.36
1.53
0.46
086
C25HJ608
ClSHJ801
C2SH3809
C2SH4008
Hl
0.64
016
Cl7HJ601I
C29H38011
C30H48010
1.36 C34H5208
261
094
0.42
44S
CI4H29NO
C14H29N02
CI6lilJN03
Cl7H3SN02
O'S
0.78
0.03
0.78
• . 03
0.11
042
0."
0.46
038
022
"'1.92
411
'66
CI7H37N02
Ct8lD7NOl
Cl8HJ7N01
C18lD7NOl
Ct8HJ7NOl
C18H37N03
ClRHJ9NQ
CI8HJ9N01
CI8H39NOl
C181D9N03
C20H43NO
C2JID9N06
C23H47N02
C24H47N07
C26HJ603
4.:53
4.32
0.20
II.
1.57
ClOH52N201
C31H45N0:5
C34H67NOJ
C34H69N03
C40H77N08
2.57 C4OH77NOI
266 C4OH77NOI
217 C40H77N08
H
N.cl
HCOOK
N._N.
N.cl
KCI
HCOON.
N.cl
N.cl
KCI
H
H
H
H
H
H
HCOON.
H
HCOON.
H
H
KCI
H
H
Na{HCOONa)
H
N.
H
H
K
H
K
II
H
H
II
H
NDJ
H
HCOOH
N.
H
N.
N.
HCooK
H
N.
N.
N.
N•
N.
H
H
H
H
H
II
HCOON.
N._HCOON.
NH3
N._HCOONa
N.
N.
NI
NI
N.
NI
N.
Biotripymn--a.;Biotnpyrrin-b
D-Uroblbn
Adouetine Y;Crmatine A;Protoporl)hyrinogen IX
Adoucline Y;Crmatine A.Protopotl>hyrinoSaJ IX
retinal; ll-cis-3,4-di.ddtydroretmol or related compounds
4-Kct0-4'-h~lIoxanthm. 7,8-Didehydroutaxanthm
3R,3'S-utaxanthin or related compounds
4-Oxomytiloxanthin
4.4'-Dihydroxydiatoxanthin;4-Ketomyxol;7-
Mcth}·lhypoxanthine,HalotynlhiaxanlhlD~ytiloxanlhln
(JR.l'R,13-ci,)-b..b-C.rote--.J,J'-dk)l or rel.ted ~ompo • .cI.
L.tel.
AntheraxlUltlun;Caloxanthin;Capsanlhin;Cucurbitaxanthln
A,Deepoxysalmoxanlhin.Flavo:ocanUun,Lornxanthmll9-
Hydroxvlut~-t.utein 5.6-epo~eo;M1cromona1;M'(XOI;;
Anhydnwbodovibnn
I'-Hydroxy-sunma--carotcne glUCOSIde or related compow'ld.
itopRnOtdj
lJoora>o,do
_do
_,do
lsoprcoouil
I.opn:ncnd.
lJoora>o,do
BiodlllRlfo.e Biod • • 1td Otrh.chtt
OREA ... ,.lei Tet~kro.e • • I'.1Ie SlcroidJi .MI $kmd Dr:m-l1t~--ft
Jbetll-Hydroxy .. dro,I-s.e .. 17--o.e3 ... K.le; TeJIo.tel"OM • •tt • • Sterold ... d S.roid (km .i,...
OHEA .III,.te; Tesllol.ro_."'.. SkroldJl.MI Skrold Ik.rl\.ch~
OHEA ,llIf.",; TeslOllitro.e .. If.1Ie Sterohb." Skrohl fkrh-,.~ft
(1~S}l5-H)'droxy-5,Il,II"'"'I ...13-ln .. -eICOll.llecne_te or ,-eJ • • d SkroIdJl.1NI Steroid Derl\ 'Ihe.,
compo • • d,
OHEA ,llIfate;TelCOILleroH ,111,.. Steroid • • ad Skrold IH-ri\ _ehti.
3beca-Hydroxy • • df'Olt~ ... 17--o.e3"IIf'te; Te.IoI.,.,..lttlte Skrold. 1M Skroid Deri\lchft
3b.I6a-Dihydroxyandrostel\Ol1e lul(.te'.~·(llZ)--8,I8-cthanorctu\Jol·.I.'_ St«'OdI and SWOtJ o.w'Iilt".
apo-beta.c.rotenal;Deso!l.estrel,.
3b,16.-0ihydroxyandrostmone lulfale leI'O!dI and SIerOtd Dannt.l\
3b.I6a-Dihydroxyandrostooone sulf.te S\croadl &nd Sk:r0t4 o..,~\.
ARf"OIl1ero.e ,.K,te Sterold ... 4 krohll'Hrh.a,ti.
5.-DI~ydrotestOllero.e • • I'lte;5,lphi-dUlydrolltJtoIlerolle Skrold. IMI Sk~d o.rl\.ihft
,lIIf.IIt;AltdrosllerOMI.Jr.1e
51-0i~drotesI0l"'1'OH • • f.Ie;~.lp~.-dI~ydroflt'lOI.rolle Skroidt 1.cI lerold IH~."~
• "'.te;A.cIro.:kro_ ... f.te
5.-01~ydroteJtclIleroee,"f.k;5.1pb--dI~·droluto"eroee Sterold ... 11 w.rotd O,-,*'.thft
.. Jf.I1e:AHrocllero_ ,"'.Ie
S.-DI"ydroteslOltel'Olle .!d(.1e;5.lpb--dI~·drolHeo..ro_
,!df.te;Attclrostr.ro.e ,!dr.1e
A.oro.tel1*e • •w,.
Prq;tnenoione sulfate
SalfOlJy~oIlti1ocltol.te:S.lfoiltilocIM>lyltlydH::
Lithocholyltaurine; TsW'Olithocholale
Steroid, .Itd SkNid I'k-rlulh~
Stcrowh Ind Siaoid l)o,U!t\
BUeAdd.
BI1eAt.ldt
BUeAdei.
c.M.odeoxy~ImIoyII • • riM:T • • ~~llOdeosy~W ... ;T • • rodeos)~ IUIe .dd, .1Id Ikri\ .d,ft
ltoIit .dd;T .. ro.rsodeosydlOlk .dd
T • • roc.~104etolYcldlt .dd BUll Add.
T .. roc.ltoIk .dd BUe AddJ
BUeAdd.
• cid;T • • roclloil.",; T • • ro"yoc~oI. "'-:T • • rollnoc:lIoIlc:
.dd;;AldCMItero_ 18--CI.ul'OIIlde
Cholesterol sulfate
26--hydroxyc.holesterolJ-sulfate
26--hydtm)"CboiesteroJ 3~ulfate
Sierow.. and StftOIJ Oenv.u,.
Steroids and SktOlJ Dennin'.
Stc:rokil and Stcro&JDerwJtI\-.
THtotl1ero.e ttl.nro.kk
A.cIroswl'OK .1.uro.IOe
llbeta-hydro)(yandrostcrone-3~lucurorude
17·hydroJrYandrostane-J-,lucuroMle; 18-acctoxy_PGF1alpha_ll_
acetate methyl ester, oJ, 17-AndrostanedlOlglucurorude°;3_llphl_
IUldrostancdiol ~Iucurorude
AWOIl1ero. 18-cI.nro.ide ClltC.ro.Idu
Enocupin OlucW'OnIdc.
"(3a,Sb,7.}-13~xy-7-hydro~;y ..24-norcholan-3-)'1_~D- Olucumrudt.
Glucopynmosiduroruc aCldo;6aJpha-
GlucurooosylhyodeoxycholateJ)o::lxycholic acKi 3-glucuroftlJe
CIKI""'''
ChKII'04Ihlq
Olucw'omiJd
Olucw'On.l~
2S-hydroX}'Vltamin 02 2S-(bcta-81ucuronide) 125 Glucuronu*
hydroxyergocakafcroI2S-{beta~8Iucuronlde);2S-h}'droX)'VILInun 02-
1S-glucW"Ollide-.25-hydroxyvllamll\e 01 2S-(bc:tIi-,llK:uronJde)
HalaminolA
(4E,d 14: I) sphingosJne;2-amtn~tetndacUlolI; ICld
Pro.'Iopinine
Antoso (4E, 14-mcthyl-<l17: I) sphin8osme";CI7 Sphmaosll)e~ *110
(4E.I 5-methyl-d17: I) sphil\llosme"
C 17 Sphin,:arUne
Sp ..hll .. l_
SpW i_
S,W I_
S'W i_
4-hydroxySIJhmAOIine;6-hydJ'OX\'!phmaosine
SPlsulcwne
SpW .... i_
SplUlIl • •I.
4-hydroll.-y~aninc-.Ph,1OIPhU'lllOJme
2-amino-I4,16--duneth)'locladecan-J--01
M'T1OC~SllhinAo~in F
Cbohne stente",Pa\al.ebdine A
Gaiactos}ls:phingosme;OI\lCOlYbphang~ne
EstradK:JI l7betl.-cyclopenlylproploMle;Estndlol C)plOMte (USP)
l..aicettamolA
Scyphostaun A
N-Pahnltoylsphingosme
Cer(dI8.0116:0)
Galactosykcramide
(diS: IfI6~OhGlcCa-(d1V~lfI60);Gluool}'lcc.r'llllde(dI8 1/160)
GalICtOS)'k:enrnldt
(d18 II16~0);GlcCer(dI8.lfI6'O~.Giucosy1cer.nude(dI8 11160)
Galactosykemntde
(d 18'lfl6:0);GlcCc:r(d 18.11l6:0);Gluco~·Ic:ef.,mdc (dIS'1/16,0)
Glliactosyl~enunide
(d18 1I16:0);GlcCcJ{dI8;11l6~O);G1ucosy1cc:ramlde(d18 1/160)
S"I" ._S..., _
SphlQAoid bu4IIS...,...... _
St>l\lIojoo .. bu«
SpW-aokI ... _.
,WIllOW MM.
SDWMOW .... _
S,WIIItOId kJ,t.S..., .... oJbu«
SphUl.aotd ....
$'WtllloW ,
SDW.oW ...
Sphmaoid bu.-
sptUlI,ItollJ buoJ
SpblAAoJd tuo.
Sutuaaotd buat
phll'lAola.",dIS..., _
S"I"", _
S"III",."'_
SphlAlollPldI
SphlllAollplda
SptnnaollJllIU
SphllllObpIIH
Sphmaohpub
...
"'"...
...
...
...
..
...
...
...
..
...
-..
...
..
....
...
...
..
...
...
...
...
...
...
...
...
...
...
..
...
...
...
...
...
...
...
...
...
...
..
...
...
...
..
...
...
...
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...
..
..
...
...
...
...
..
...
...
...
..
....
I"
..
...
...
...
roo
906.6986 739.08
Clycerollpkb
381.2979 691.03
396.3105 47!02
401.2661 57378
430.3891 528.90
471.3659 694.98
599.4249 679.32
613.4246 656,88
669.4655 790.86
701.3729 569,76
697.3989 582.54
713.4774 464.94
72],5552 696.72
780.5947 700.86
780.5947 736.14
780.5950 767.46
795.5443 550.38
795500 636.36
795.5431 775.32
781.597B 769.44
791 5926 550.38
911.6167 630.54
9116167 710.70
945.7081 775.32
963.7382 771.36
Pltolp'-oHpldl
443.2405 448.14
454.2930 751.80
531.2572 575.70
516.2876 444.18
617.2943 55728
616.2625 189.54
543,3197 586.44
691.3055 566.94
557.]354 598.26
625.3041 420.18
710.3937 603.)2
712.3601 408.24
745.3991 571.62
752.4725 679.32
752.5147 542.64
729.3889 567.90
765.3679
733.5494
760,5789
7904674
796.4550
842.4243
909.4085
7534823
774.5945
738.5050
743.5705
796.5443
816,6057
838.4536
789.6122
839.5638
820.5991
830.6205
830.6209
817.4409
83]4513
834 6154
S44 6361
8685003 477.06
846.6154 65784
8096154 699.90
809.6156 748.86
905.5129 492.72
908.7015 739.08
848.6309
848.6313
899 6350
921.6165
888.6621
904.6939
8666684
980.6476
964.7150
MbccUncou
1:51.0478 385.80
1670198 73.98
255.9781 66 54
85].5855 53868
853.5854 636.36
853.5857 712.62
627.3831 611.94
511.2729 54072
310.9307 6558
765.3972 443.04
463.14
587.46
648.12
682.08
426.06
550.44
551.34
681.30
683.22
775.32
741.00
54264
701.88
476.94
675.42
474.30
585.48
63444
737.10
571.86
57318
612.84
699.90
567.00
644.16
476.10
47610
659.76
769.38
805,50
803.46
60216
2.01 C50H95N08
0.97
0.76
0.57
000
4.50
1.52
1.09
3.17
4.65
1.23
1.37
2.28
C21H4204
C23H3801
Cl3H3801
Cl5H4801
C27H5006
C33H6206
C.HHWOS
C36H6605
C37H6205
C40H6405
C4OH7005
C40H7805
1,59
1.59
1.28
445
2.84
2.99
3.33
0.19
C42HBIN07
C42H8IN07
C42H8IN07
C43H8205
C43H8205
<:43H8205
C46Hl!OOS
C49H8405
2.72 CS4H9206
2.72 CS4H9206
0.73
0.56
C56HI0206
C62HI00Cl6
0.02
0.48
1.36
2.79
0,16
0.47
CI9H3909P
C2IH44N07P
C22H43012P
Cl4H50N06P
Cl5H49012P
C21H44N07P
1.36
2.10
1.26
1.28
1.77
0.48
114
4.28
3.89
LOO
C27H46N07P
C27HS3012P
C28H48N07P
C28HS508P
C33H66N08P
C34H62NOIOP
C37H6908P
C37H76N01P
C38H78N08P
C39H6508P
3.71
0.50
489
478
C39H6508P
C39H74N08P
C39H82N06P
C40H70NOSP
3.06
4.96
C40H12NOIOP
C40H74N08P
4.39
1.0S
C40H7SOI3P
C4{)H750&P
4.92 C40HS4N06P
0.81
1.02
0.58
3.93
3.05
0.73
0.64
4.16
4.78
4.41
3.56
C41H72NOiP
C41H76N07P
C41H78N07P
C42H86N07P
C43ID6NO&P
C43H82N08P
C43H83013P
C43H88N07P
C43H&8N07P
C43H88N07P
C44IDI09P
1.82 C44ID309P
0.74 C44H90N07P
4.87 C44H90N07P
HCOONa
N.
NII3
N.
NII3
H
N._Na (NaCW)
K
N._HCOONa
NoClx2
KCl
HCCOK
HCOOK
HCOON.
HCOON.
HCOONa
NoClx2
NoClx2
NoCb<2
HCOON.
K
KCl
KCl
KCl
N.
H
K
HCOOH
Na_HCOON,
NH3
N'_HCOONa (HCOOH)
NH3
KCI
KCl
K
KCl
KCI
N._Na
K
KCl
NH3
HCOQNa
HCOON.
K
N.c1x2
N.clx2
K
HCOON.
H
NII3
HCOON.
HCOON.
KCl
NH3
H
N.cl
HCOON.
HCooNa
N'_N'
N.cl
NoCl
HCOONa
3.15
4.80
157
1.35
LlO
4.28
C45H82N08P KCI
C45H90N07P HaCl
C46H82N07P NH3
C46H82N07P NH3
C47H81013P N.
C48HlOON06P Na_HCOONa
4.61 C48H92N06P K
2.29 C48H92N06P K
0.23 C48H9301IP Na
017 C48H930IIP Na_N.
4.29
470
463
407
2.02
C48H96N07P NIlC)
C49HIOON07P NaCl
CSOH94NQ1P H
CSOH98N07P NaC)_HCOON.
C54HI04N08P K
nu
2.51
3.52
196
2.10
1.7S
3.63
201
l.80
C5H8N202 Na
C6H8N20 Na_Na
C7H8NOSP K
CS4H82a... NaCl
CS4H8204 HaCl
CS4H8204 NaCl
C39H5804 K.
C30I14402 KCl
C3H707P; HaCl_ HCOON.
4.49 C40H6807P2 Na_Na
Galactosylceramide (d 18: 1126: 1(17Z»;Glucosyleerlllllde
(dI8:1126:1(17Z»
Sph""ohpo'"
MG(18010:01'O:0) GI)"ccrolLfW.II
I-Aracbidonoylglycerol or relatc:d compounds Glycerohpull
2-Aractudo!lOYlal>,~1 or related compounds Ghurohplti..l
MG(0:0Il2:1(13ZYO:0);MG{22:1(13Z-,.u:0~:0) G1ycerollpull
Tricaprilin Glyca-ohl)ida
TG(IO:Of1O:OIIO:O~I!IOl Glyccrohlmb
DG(15:0I18:3(6Z,8Z,12Z)IO:O) or rel8tIId compounds Otyc • .rollpld.
OG(I 50118:2(9l.,12ZYQ:0) or related Compoundl Ghw-ohmda
DG(14~0f20~5(SZ,&Z,11Z.14Z,17ZyO:0) or related comJ)OUllda Glyc:oilpkil
DG(17:2(9Z,I2ZYlO: 5(SZ.8Z.11Z.14Z,17Z)IU~0~ls021 1)"c'I'I ...lvccroll
DO(I5:0I22:4(7Z,10Z,13Z,16Z)'O:0) or retated compoundl Olyc:ohpKla
DG( 1S:om:OIO:O):.IX1( 16 0121 :OA>:OX1502 JJ)O( 17:0120010:0~ lIOll. Glyterohpidl
IXi( 18~OII9:CW:Ol 1m2 1;00(22:011 S:M:O)
OGTS{16:0I16:0)
OGTS{160116:0)
DGTS(16:0I16:0)
DG{16:0J24: 1(1SZ}'U:O)Of related compounds
DG(16: 1(9Z)"24:00:0) 01' related compoWKiI
00(13:0/22: 1(13Z)"O:0) Of related compounds
00(21,0I22,5(7Z,1OZ,13Z.16Z.19Z)I)OX""'1
00(22:5(42, 7Z,IOZ.13Z,16Z)'24: 1(15Z)IOO) CW' related COIl\poundt
GIYtCI'OllJ)l(iI
GlyccrohPlIli
GlyccrohpHli
Glyccrohpl(b
Olyccrohpida
GlyceroilpHlI
Oaacylalvccro1l
Glyccsohpldi
TU( 16: I (9Z ),I17:2(9Z, 122),118:3(92, 12Z.1 5Z)~ is06l; Tnac)'lal)'usoll
1'O(17.2(9Z.12Z)l17:2(9Z,12Z.),I17:2(9Z,121.»
TG(161(9ZY17,2(9Z,I2ZYI8.3(9Z,12Z, ISZ)X,006l, TN<ylll" .. · .1J
TG(l U(9Z,I2ZYI7:2(9Z.12ZYI7,2(9Z,12Z»
TO(I6:0/17:0f20:3{8Z.IIZ,14Z»)fi8061 or rdated compounds Trw:yl ...IV(CIl)I.
TG(17'0120'4(5Z.8Z.IIZ.14Zyn'6(4Z.7Z.IOZ.IJZ.16Z.19Z)X .... 1 Tno<,l.~·""'l.
orrelated compounds
PG(13:0~:0)
1-16:()..lysoPE;.PC( 13:OIOO);PE( 16:010'0)
PI(1301O:0)
LysoPC(dmI6:0);pc{0-16: 1(IIZ)tU:O) orrelatcd I:OmPQwWI
PI'6'0I0:0)
LysoPE(0:0I22:6(4Z, 7Z.IOZ.1 ]Z,16Z,19Z»;
L,..PE(",6(4Z,7Z.IOZ.IJZ.16Z.19Z}Il.0)
L,1IoPE(0.0n.2..S(4Z,7Z,IOZ.13Z,16Z» or related compounda
Pl(18,01ll,0)
L,..pc(20·5(5Z.8Z,IIZ,14Z,17Z»
PA(12:0/13:0}
PE(16:0I12:0), pc(10:0I15:0)fUl or related compounds
ps(14.1(9Z)l14: 1(9Z»
16:0-18:2-PA; 'PA(16:0/18:2(9Z,12Z}); Phosphaudyl ethanol
PE(0-16:OJI6:0)' PC(0-14:0/1 5:0) or related compounds
ps(0--16:QIO..I6:0)IU1 or related compounds
PA(18 3(9Z.12Z,ISZYI8.l(9Z,1lZ,15Z»Of related compounda
ah-..:cn:JflholP'lat.al
JlI~lhaICli
",1~hOIphal.
.IVCU'OI)hoI)1hOlJ:\l\h.MI
ah~1
al,«rorllolrhOd.hlYaoa.m_
.IVC<:tOI'hOIItlhOdllanG ......
aIVCCf'Ol'l\Npha\
&h""",,_oo.ho"-
.1~lGI
Il~_
al~~
al~hoIphat.
,,1'JU"OfIhocphoc.thant'lt.nllfW
.I~~'"
II~ICI
18:3-18:3-PA arrelated compowxls "hurorohocphatel
PE(14:0J20:2(IIZ,14Z» cr reteied compounds Jl"'tCf'OP~lhodhIt.notaml,*
PE-NMe2(0-16:01O-16.0) .1~lh~\OIao'Iu.
pc(14.1(9Z)Il8,4(6Z,9Z,12Z, 15Z»,'PC( 18 4(6Z,9Z,12Z.15ZYI4 1(9 Il""""''' • • pl..'',bo .....
Z»~"PE(IS:0I20:S(5Z,8Z,11Z.14Z.17Z»~~·PE(20 S(SZ,8Z,11z..147~
17ZYI50)
16:0-18:3-PS "lycerop~OICIlnCI
pc(14:0118:3(6Z.9Z,l2Z.»; PE(15:0flO:l(Sl,8Z,11 Z» or related al)-'CCl'OphOilphOCholu1C.
oompowxh
PI(17OJI4:1(9Z» ,Iyceropholphomllinob
PA(18.2(9Z,I2ZYI90).I-"' ......... '1-2{8-{31-1............., .... ,I}<n-ll""""'booph ....
glyccro--3-phospho-{l '--sn-glyc:crol)
pc«().12:01O-20:0)(Ul;PC(Q..14:0,o..18:0)(U];pc{0-16:01O--- a1ycerophocphothohnct
16:0);PC(0--20:01O-12:0)fUl
PE(14.0122:5(4Z,7Z,IOZ,13Z,16Z» or related compounds II)Ul'QpholJ"ulC(lIanollmtl*
PE(18:2(9Z,12Z)ldmI8.1(IIZ» or rdated compounds IlyceropholphOl.'tMno\lmlNl
PE(18'1(lIZYdmI8:1(1IZ» or related compounds IlIVCCt'OPhoIohocthMolam~
pc(18:0JO..I6:0) or related wmpounds "lyccropholphOChOb ...
20:2-18.3-PE ()('related compound!! "lyeerophoephO((hanoLNnl.ACl
PC(l S:0120:2(IIZ, 14Z» or relalcd compounds II,lycerophOlphOdhanotamll'lW
PI( 16:0I18.0);PI( I8.0/16:0) h·ceropholphOI-nlMI\OtJ
pc(0-16:0Il9:0) or related compoUnds I\UfOPhotphOdhanoiam"*
PE(()..16:0Il2:0) or related compounds IlI~ocdIannWnUMII
PE(0--18:0flO:O) or related compounds ...h'CuovholohocthMollm"*
1{6-[51-lodd"' .... """'no,I~2{8-IJJ-I_0«tan)1~ ... _.ly«ro-J·II __ .. It«t<>lt
phospho-(l'-sn-JI,lyccl'Ol)
1{6-[JJ-lodd<nO»hcx.onoyl~2{8-13J-l __ .... yl~ .. -.ly«ro-3·ll_"""""I_
pbospbG--{I'-sn-",lycerol)
PC(0-14,0I22,0~pc(0-16MOm,pc(0-1l 0118 O~pc(0-200l16 0) 11)""",,~h_
PC(0-14:0122:0},PC(O-16:0flO:0);PC(0-18.0I18.0);PC(0--10 01160) 11)'CCtOpholpt\octIolu_
PC( I 5:0121:4(7Z,10Z,13Z, 16Z»« related compoundi
PE(",OIdmI8·0~PE(24.O/dmI6,0~.
PC(20:4{5l.,sz,IIZ,14ZYdrnI8.I(llZ)) or relltcdcompow\Jl
PC(204(5Z.8Z.ltZ,14Z)ldmI8:1(IIZ») or rd.led compound.
PI( 16:0n.2:5(4Z.7Z.10Z, 13Z, 16Z» or related C<'lmpounda
1.2-diphytanyl-sn-8Iycero-3-pholIphochohne~Q..20.()IO..20·0)
Ilvc:erophoIph~_ ....
.,,""""---Ilhuropholpil<k.holuMl
...1~lhoIa'lhOl..bob_
.1~lholuholntJt,llIl\J
a1yccl'Ophol,;tmdllJhnCI
l"E.6E-phyto<b",yl~2"E.6E-phyta<l'''')I}o.-gly<_3-
pbosphocholinc
I-(lE,6E-phytadicnyl}-2-(2E.6E---poyt.dlct} I}-sn·glyccro-)-
pholPhocholinc
I,l-ditetradccanoyl---$ft-.Iyc:~3+phospho-(l'-tyso-3'-tetl'td«anoyl_1 '. a1y«rophotptW'lfht.«UU
sn-Kh,c:erol)
1,l-dltetmdcc:anoyl+su-&Iyecro- 3-phol!pho-{l' -1yso-3'-lCcndecano) 1-I '- II)\;CNpholphoal~t
SD-al\.urol)
PC(22:0/dmI8'0): PC(24·OJdmI6.0)
PC(0-19·0122.0)
pc(18'2(9Z,12Z)Il4'1(15Z»or related compounds
PC(24:0IdmlS'I(IIZ» «related compounds
PC(22 1(13Z}'24:1(15Z)}or related compounds
Jllyca-opJM.phcx.holuWl
.1'I'CCf(lpl.o.phoc:that\o.,'l1I*
,l"""",boophoo.ho_
alyccropholpbodJo~
II"""",boophoo.hoh ...
5.,6-0Ik),drodlyml.
Mc:thylunWazole r.cetaldebyde;N+Propanoyhmida20le
l{Phoaphooomc:thyl)Pynd.ine-l-Carbo.~llc Acid
UbIQuinonc--9
UbiqlU.l\OO~9
UbiQumone---9
Coenzvmtl Q6;lIbIQUmone--6
2-Pbvtvl·I,4-naphthoQuinonc;demdhylptwIlOQUloooc
2-Phospboglycenc ac.id,3·Pbospho-[).a1ycaatc:;D-Gb'CCftIO 2-
......... '"
all-trans-Octaprcnyl diphosphate;oclapmlyl dlpbosphale; P'rq)h)1oent A~'ll'hotphlICi
wphoe:phate
Pyrjmldl .. aid Dtri, a'''6
Aklehydelimulazolcl
P\nooulJ and Dcn\'lbWII
QulAOnCland OmYWIllVt!I
Quinonesan.) Ocnvatn'.
Quloonettnd OcnVIIll'"
UblqUlnofIotN""'.... _
,A,yl Pbo'l''''''''
...
...
-l"
...
...
..
-...
...
...
...
...
..
...
...
...
...
...
...
...
..
..
...
..
...
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